Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy

ABSTRACT

Disclosed herein are methods of gene editing, or endogenous suppression, of cytokines/chemokines/transcription factors secreted from chimeric antigen receptor (CAR)-bearing immune effector cell such as CAR-T cells for the mitigation of cytokine release syndrome and/or CAR-T associated neuropathy. These methods involve insertion of the CAR into a locus of a cytokine gene, blocking its expression. Also disclosed herein are (CAR)-bearing immune effector cells with CARs inserted into a locus of a cytokine gene, and methods of treatment of diseases with immunotherapy with a reduced incidence of cytokine release syndrome and/or CAR-T associated neuropathy.

This application claims the benefit of United States ProvisionalApplication No. 62/679,597, filed Jun. 1, 2018, the disclosure of whichis hereby incorporated by reference in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Aug. 6, 2019, isnamed WGN0003-401-PC SL.txt and is 956,834 bytes in size.

CAR-T cells have emerged as a promising therapy for the treatment ofhematological malignancies. Despite remarkable clinical efficacy againstB cell malignancies, the success of CAR-T therapy has been limited bysevere, life-threatening toxicities, observed in over 50% of patients.These toxicities have resulted in several deaths leading to earlytermination of clinical trial. Toxicities primarily manifest as cytokinerelease syndrome (CRS, also referred to as “cytokine storm”)characterized by high elevations of cytokines including INFy,granulocyte-macrophage colony-stimulating factor, IL-10, and IL-6. Thesecytokine elevations result in a plethora of clinical symptoms includingfever, hypotension, organ dysfunction, respiratory failure andcoagulopathy. CRS can be fatal. Additionally, neurotoxicity oftenpresents even after the initial symptoms of CRS have subsided. Thepathogenesis of CRS and associated neurotoxicity is poorly understoodand further understanding of the mechanism would be useful for thesuccessful translation of CAR-T therapy. In the meanwhile, disruptingthe pathogenesis of CRS by reducing the level of cytokine genesavailable for expression is one way to mitigate the condition.

Disclosed herein are methods of gene deletion and endogenoussuppression, of cytokines/chemokines/transcription factors secreted fromchimeric antigen receptor (CAR)-bearing immune effector cell, such asCAR-T cell, for the mitigation of cytokine release syndrome and/or CAR-Tassociated neuropathy. These gene deletion methods may include, but arenot limited to, insertion of the CAR into a locus of acytokine/chemokine/transcription factor gene, blocking its expression;gene editing with Transcription Activator-like Effector Nucleases(TALENs), Zinc Finger Nucleases (ZFNs), or CRISPR; expression of an scFvwith an endoplasmic reticulum (ER) binding tether to bind the cytokinein the ER and prevent secretion; and transfection of small hairpin RNAs(shRNAs) or small interfering RNAs (siRNAs). Also disclosed herein areCAR-bearing immune effector cells modified with these describedcytokine/chemokine/transcription factor gene deletion methods, andmethods of treatment of diseases with immunotherapy with a reducedincidence of cytokine release syndrome (CRS) and/or CAR-T associatedneuropathy (CAN).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1—Illustrates the concept of inserting a CAR into the gene for acytokine in order to block its translation, thereby deleting it orreducing its level, thus preventing or reducing cytokine releasesyndrome and/or CAR-bearing immune effector cell associated neuropathy(CAR-T associated neuropathy).

FIG. 2—Shows a timeline for a method of treatment of hematologicmalignancies using the CAR-T cells disclosed herein. Those of skill inthe art will appreciate that some flexibility is possible in the timeframes shown.

FIG. 3—Shows the AAV donor construct for insertion of CD34 into theGM-CSF locus.

FIG. 4—Shows the WC40 plasmid vector for use in inserting GFP into theCD3c locus.

FIG. 5—Shows the AAV donor construct for insertion of GFP into the CDRlocus.

FIG. 6—Shows a CAR19-GM-CSF PEBL-trCD34 construct.

FIG. 7—Shows IL-6 expression in T cells, iDC cells, T cells+iDC, Tcells+beads, and iDC+beads+T cells for GM-CSF knock-out, wild-type, andcontrols at 24 hours.

FIG. 8—Shows IL-6 expression in CAR19, iDC only, Act MQ only, MC only,RAMOS only, CAR19+iDC, CAR19+ActMQ, CAR19+MQ, CAR19+RAMOS,iDC+RAMOS+CAR-T, ActMQ+RAIVIOS+CAR-T, and MQ+RAMOS+CAR-T for CAR19GM-CSF knock-out, CAR19, and controls at 24 hours.

FIG. 9—Shows IL-6 expression in T cells, iDC cells, T cells+iDC, Tcells+beads, and iDC+beads+T cells for GM-CSF knock-out, wild-type, andcontrols at 48 hours.

FIG. 10—Shows IL-6 expression in CAR19, iDC only, Act MQ only, MC only,RAMOS only, CAR19+iDC, CAR19+ActMQ, CAR19+MQ, CAR19+RAMOS,iDC+RAMOS+CAR-T, ActMQ+RAIVIOS+CAR-T, and MQ+RAMOS+CAR-T for CAR19GM-CSF knock-out, CAR19, and controls at 48 hours.

FIG. 11—Shows a set-up of an ELISA plate for detecting specific markersof CAR-T cells.

FIG. 12a and FIG. 12b —Shows the results for an ELISA assay detectingspecific markers of the CAR-T cells. FIG. 12a shows the top half of theELISA plate, and FIG. 12b shows the bottom half of the plate. In each ofrows A-H, from top to bottom, the sub-rows indicate [450] test, [540]ref, Pathlength, 450, 540, Corrected [450], and Corrected [540].

DETAILED DESCRIPTION

Accordingly, disclosed herein as Embodiment 1 is a chimeric antigenreceptor (CAR)-bearing immune effector cell that is deficient in acytokine or in a chemokine or in a transcription factor that is involvedin cytokine release syndrome.

The following disclosure will detail embodiments, alternatives, and usesof the cytokine-deficient cells, as well as the use of such cells in,for example, immunotherapy and adoptive cell transfer for the treatmentof diseases. Accordingly, provided herein are the following additionalembodiments.

Embodiment 2—The cell as recited in embodiment 1, wherein the cytokineor chemokine or transcription factor deficiency is effected by deletionor suppression of a gene encoding the cytokine or chemokine ortranscription factor.

Embodiment 3—The cell as recited in any of embodiments 1 or 2, whereinthe deletion or suppression is effected by inserting the CAR into alocus of the cytokine or chemokine or transcription factor gene.

Embodiment 4—The cell as recited in any of embodiments 1 to 3, whereinthe CAR is part of a construct that also includes a selectable marker.

Embodiment 5—The cell as recited in any of embodiments 1 to 4, whereinthe selectable marker comprises a green fluorescence (GFP) gene, ayellow fluorescent (YFP) gene, a truncated CD34 (tCD34) gene, or atruncated EGFR (tEGFR) gene.

Embodiment 6—The cell as recited in any of embodiments 1 to 5, whereinthe cytokine or chemokine or transcription factor deficiency is effectedby deletion or suppression of the cytokine or chemokine gene, byTranscription Activator-like Effector Nucleases (TALENs), Zinc FingerNucleases (ZFNs), or Clustered Regularly Interspaced Short PalindromicRepeats (CRISPR) editing.

Embodiment 7—The cell as recited in any of embodiments 1 to 6, whereindeletion or suppression is effected using CRISPR.

Embodiment 8—The cell as recited in any of embodiments 1 to 7, whereindeletion or suppression is effected using Cas9-CRISPR.

Embodiment 9—The cell as recited in any of embodiments 1 to 8, whereinthe Cas9 is delivered into the cell as mRNA or protein.

Embodiment 10—The cell as recited in any of embodiments 1 to 9, whereinthe Cas9 is delivered into the cell as mRNA.

Embodiment 11—The cell as recited in any of embodiments 1 to 10, whereinthe Cas9 is delivered into the cell as protein.

Embodiment 12—The cell as recited in any of embodiments 1 to 11, whereina guide RNA (gRNA) targeting the gene to be deleted or suppressed isdelivered contemporaneously with the Cas9.

Embodiment 13—The cell as recited in any of embodiments 1 to 12, whereinthe delivery is by electroporation.

Embodiment 14—The cell as recited in any of embodiments 1 to 13, whereinthe cytokine or chemokine or transcription factor deficiency is effectedby suppression of the cytokine or chemokine or transcription factor genetranscript by transfection of one or more types of small interferingRNAs (siRNA).

Embodiment 15—The cell as recited in any of embodiments 1 to 14, whereinthe cytokine or chemokine or transcription factor deficiency is effectedby suppression of the cytokine or chemokine or transcription factor genetranscript by transduction of one or more types of short hairpin RNAs(shRNA).

Embodiment 16—A chimeric antigen receptor (CAR)-bearing immune effectorcell expressing at least one CAR, wherein:

the at least one CAR is inserted into a locus of a cytokine or chemokineor transcription factor gene or transcription factor gene;

the cytokine or chemokine or transcription factor gene is deleted orsuppressed by a method chosen from Transcription Activator-like EffectorNucleases (TALENs), Zinc Finger Nucleases (ZFNs), and ClusteredRegularly Interspaces Short Palindromic Repeats (CRISPR) editing;

the cytokine or chemokine or transcription factor is suppressed byexpression of an scFv with an endoplasmic reticulum (ER) binding tetherto bind the cytokine or chemokine in the ER and prevent secretion;

the cytokine or chemokine or transcription factor gene transcript issuppressed by transfection of small interfering RNAs (siRNAs); or

the cytokine or chemokine or transcription factor gene transcript issuppressed by transduction of short hairpin RNAs (shRNAs).

Embodiment 17—The cell as recited in any of embodiments 1 to 16, whereinthe cell is chosen from a chimeric antigen receptor T cell (CAR-T), aCAR-bearing iNKT cell (iNKT-CAR), and a CAR-bearing natural killer (NK)cell (NK-CAR), or a CAR-bearing macrophage.

Embodiment 18—The cell as recited in any of embodiments 1 to 17, whereinthe cell is a CAR-T.

Embodiment 19—The cell as recited in any of embodiments 1 to 18, whereinthe cell is a dual or tandem CAR-T.

Embodiment 20—The cell as recited in any of embodiments 1 to 17, whereinthe cell is an iNKT-CAR.

Embodiment 21—The cell as recited in any of embodiments 1 to 20, whereinthe cell is a dual or tandem iNKT-CAR.

Embodiment 22—The cell as recited in any of embodiments 1 to 17, whereinthe cell is a CAR-macrophage.

Embodiment 23—The cell as recited in any of embodiments 1 to 22, whereinthe cell is a dual or tandem CAR-macrophage.

Embodiment 24—The cell as recited in any of embodiments 1 to 23, whereinthe cytokine or chemokine or transcription factor contributes to thedevelopment of cytokine release syndrome.

Embodiment 25—The cell as recited in any of embodiments 1 to 24, whereinthe cytokine or chemokine or transcription factor is selected from amongthose recited in Table 10.

Embodiment 26—The cell as recited in any of embodiments 1 to 25, whereinthe cytokine or chemokine or transcription factor is produced by T cellsthat activate or localize myeloid cells.

Embodiment 27—The cell as recited in any of embodiments 1 to 26, whereinthe cytokine or chemokine or transcription factor is a T cell surfacereceptor gene that activates myeloid or CAR-T cells.

Embodiment 28—The cell as recited in any of embodiments 1 to 27, whereinthe gene that is deleted or suppressed is a T cell surface receptor thatis integrated into CAR-T cell signaling.

Embodiment 29—The cell as recited in any of embodiments 1 to 28, whereinthe cytokine or chemokine or transcription factor drives T cell/CAR-Tcell differentiation.

Embodiment 30—The cell as recited in any of embodiments 1 to 29, whereinthe cytokine or chemokine is a transcription factor that drives Tcell/CAR-T cell differentiation.

Embodiment 31—The cell as recited in any of embodiments 1 to 30, whereinthe cytokine or chemokine or transcription factor is chosen from MCP1(CCL2), MCP-2, GM-CSF, G-CSF, M-CSF, 11-4, and IFNy.

Embodiment 32—The cell as recited in any of embodiments 1 to 31, whereinthe cytokine or chemokine or transcription factor is GM-CSF.

Embodiment 33—The cell as recited in any of embodiments 1 to 32, whereinthe cell is a GM-CSF deficient CAR-T cell.

Embodiment 34—The cell as recited in any of embodiments 1 to 33, whereinthe cell is a GM-CSF deficient iNKT-CAR cell.

Embodiment 35—The cell as recited in any of embodiments 1 to 34, whereinthe immune effector cells to be used are harvested from a healthy donor.

Embodiment 36—The cell as recited in any of embodiments 1 to 35, whereinthe donor is a human.

Embodiment 37—The cell as recited in any of embodiments 1 to 36, whereinthe chimeric antigen receptor(s) specifically binds at least one antigenexpressed on a malignant cell.

Embodiment 38—The cell as recited in any of embodiments 1 to 37, whereinthe one or more antigens expressed on a malignant cell is chosen fromBCMA, CS1, CD38, CD138, CD19, CD33, CD123, CD371, CD117, CD135, Tim-3,CD5, CD7, CD2, CD4, CD3, CD79A, CD79B, APRIL, CD56, and CD1a.

Embodiment 39—The cell as recited in any of embodiments 1 to 38, whereinthe chimeric antigen receptor specifically binds at least one antigenexpressed on a malignant T cell.

Embodiment 40—The cell as recited in any of embodiments 1 to 39, whereinthe antigen is selected from CD2, CD3c, CD4, CD5, CD7, TCRA, and TCRβ.

Embodiment 41—The cell as recited in any of embodiments 1 to 38, whereinthe chimeric antigen receptor specifically binds at least one antigenexpressed on a malignant B cell.

Embodiment 42—The cell as recited in any of embodiments 1 to 41, whereinthe antigen is selected from CD19, CD20, CD21, CD22, CD23, CD24, CD25,CD27, CD38, and CD45.

Embodiment 43—The cell as recited in any of embodiments 1 to 42, whereinthe antigen is selected from CD19 and CD20.

Embodiment 44—The cell as recited in any of embodiments 1 to 38, whereinthe chimeric antigen receptor specifically binds at least one antigenexpressed on a malignant mesothelial cell.

Embodiment 45—The cell as recited in any of embodiments 1 to 44, whereinthe antigen is mesothelin.

Embodiment 46—The cell as recited in any of embodiments 1 to 38, whereinthe chimeric antigen receptor specifically binds at least one antigenexpressed on a malignant plasma cell.

Embodiment 47—The cell as recited in any of embodiments 1 to 46, whereinthe antigen is selected from BCMA, CS1, CD38, and CD19.

Embodiment 48—The cell as recited in any of embodiments 1 to 47, whereinthe chimeric antigen receptor expresses the extracellular portion of theAPRIL protein, the ligand for BCMA and TACI, effectively co-targetingboth BCMA and TACI.

Embodiment 49—The cell as recited in any of embodiments 1 to 48, whereinthe CAR-T cell further comprises a suicide gene.

Embodiment 50—The cell as recited in any of embodiments 1 to 49, whereinendogenous T cell receptor mediated signaling is negligible in the cell.

Embodiment 51—The cell as recited in any of embodiments 1 to 50, whereinthe cell does not induce alloreactivity or graft-versus-host disease.

Embodiment 52—The cell as recited in any of embodiments 1 to 51, whereinthe cell does not induce fratricide.

Embodiment 53—A method of treatment of cancer in a patient, which has areduced incidence of cytokine release syndrome and/or CAR-T associatedneuropathy, comprising the administration of cells as recited in any ofembodiments 1 to 52.

Embodiment 54—The method as recited in embodiment 53, wherein the canceris a hematologic malignancy.

Embodiment 55—The method as recited in any of embodiments 53 to 54,wherein the hematologic malignancy is a T-cell malignancy.

Embodiment 56—The method as recited in any of embodiments 53 to 55,wherein the T cell malignancy is T-cell acute lymphoblastic leukemia(T-ALL).

Embodiment 57—The method as recited in any of embodiments 53 to 56,wherein the T cell malignancy is non-Hodgkin's lymphoma.

Embodiment 58—The method as recited in any of embodiments 53 to 57,wherein the hematologic malignancy is multiple myeloma.

Embodiment 59—The method as recited in any of embodiments 53 to 58,wherein the hematologic malignancy is AML.

Embodiment 60—The method as recited in any of embodiments 53 to 59,wherein the cancer is a solid tumor.

Embodiment 61—The method as recited any of embodiments 53 to 60, whereinthe cancer is cervical cancer, pancreatic cancer, ovarian cancer,mesothelioma, and lung cancer.

Embodiment 62—A method of prevention or reduction of cytokine releasesyndrome or CAR-T associated neuropathy in a patient receiving chimericantigen receptor T cell (CAR-T), CAR-bearing iNKT cell (iNKT-CAR),CAR-bearing natural killer (NK) cell (NK-CAR), or CAR-bearing macrophage(CAR-macrophage) immunotherapy, comprising the administration of cellsas recited in any of embodiments 53 to 61 as the immunotherapy.

Embodiment 63—The method of any of embodiments 53 to 62, wherein thepatient is being treated for cancer.

Embodiment 64—The method as recited in any of embodiments 53 to 63,wherein the cancer is a hematologic malignancy.

Embodiment 65—The method as recited in any of embodiments 53 to 64,wherein the hematologic malignancy is a T-cell malignancy.

Embodiment 66—The method as recited in any of embodiments 53 to 65,wherein the T cell malignancy is T-cell acute lymphoblastic leukemia(T-ALL).

Embodiment 67—The method as recited in any of embodiments 53 to 66,wherein the T cell malignancy is non-Hodgkin's lymphoma.

Embodiment 68—The method as recited in any of embodiments 53 to 67,wherein the hematologic malignancy is multiple myeloma.

Embodiment 69—The method as recited in any of embodiments 53 to 68,wherein the hematologic malignancy is AML.

Embodiment 70—The method as recited in any of embodiments 53 to 69,wherein the cancer is a solid tumor.

Embodiment 71—The method as recited in any of embodiments 53 to 70,wherein the cancer is cervical cancer, pancreatic cancer, ovariancancer, mesothelioma, and lung cancer.

Embodiment 72—A method of blocking the expression of a cytokine gene orchemokine gene or transcription factor gene in a chimeric antigenreceptor T cell (CAR-T), CAR-bearing iNKT cell (iNKT-CAR), CAR-bearingnatural killer (NK) cell (NK-CAR), or CAR-bearing macrophage(CAR-macrophage) comprising the insertion of a CAR into a locus of thecytokine gene or chemokine gene or transcription factor gene.

Embodiment 73—The method of any of embodiments 53 to 72, whereinblocking the expression of the cytokine gene or chemokine gene ortranscription factor gene does not reduce CAR-T cell-mediated killing.

Embodiment 74—A method of making a CAR-T (immune effector) cell thatdoes not cause or contribute to CRS or CAR-T-associated neuropathy (CAN)comprising deleting or suppressing a cytokine or chemokine ortranscription factor gene.

Embodiment 75—The method of any of embodiments 53 to 74, whereindeleting or suppressing the cytokine or chemokine or transcriptionfactor gene does not reduce CAR-T cell-mediated killing.

Embodiment 76—The method as recited in any of embodiments 53 to 75,wherein the deletion or suppression is effected by inserting the CARinto a locus of the cytokine or chemokine or transcription factor gene.

Embodiment 77—The method as recited in any of embodiments 53 to 76,wherein the CAR is part of a construct that also includes a selectablemarker.

Embodiment 78—The method as recited in any of embodiments 53 to 77,wherein the selectable marker comprises a green fluorescence (GFP) gene,a YFP gene, a tCD34 gene, or a tEGFR gene.

Embodiment 79—The method of any of embodiments 53 to 78, wherein theinsertion of a CAR with a selectable marker into the cytokine orchemokine or transcription factor gene allows a single-step purificationof TCR-negative cells.

Embodiment 80—The method of any of embodiments 53 to 79, wherein theinsertion of a CAR with a selectable marker into the cytokine orchemokine or transcription factor gene allows a single step purificationof CAR+ cytokine negative cells.

Embodiment 81—The method as recited in any of embodiments 53 to 80,wherein the deletion or suppression is effected using TranscriptionActivator-like Effector Nucleases (TALENs), Zinc Finger Nucleases(ZFNs), or Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) editing.

Embodiment 82—The method as recited in any of embodiments 53 to 81,wherein the deletion or suppression is effected using CRISPR.

Embodiment 83—The method as recited in any of embodiments 53 to 82,wherein the deletion or suppression is effected using Cas9-CRISPR.

Embodiment 84—The method as recited in any of embodiments 53 to 83,wherein the Cas9 is delivered into the cell as mRNA or protein.

Embodiment 85—The method as recited in any of embodiments 53 to 84,wherein the Cas9 is delivered into the cell as mRNA.

Embodiment 86—The method as recited in any of embodiments 53 to 85,wherein the Cas9 is delivered into the cell as protein.

Embodiment 87—The method as recited in any of embodiments 53 to 86,wherein a guide RNA (gRNA) targeting the gene to be deleted orsuppressed is delivered contemporaneously with the Cas9.

Embodiment 88—The method as recited in any of embodiments 53 to 87,wherein the delivery is by electroporation.

Embodiment 89—The method as recited in any of embodiments 53 to 88,wherein the deletion or suppression is effected by suppression of thecytokine or chemokine or transcription factor gene transcript bytransduction of one or more types of short hairpin RNAs (shRNA).

Embodiment 90—The method as recited in any of embodiments531 to 89,wherein the deletion or suppression is effected by transducing aconstruct encoding a protein expression blocker (PEBL).

Embodiment 91—The method of any of embodiments 53 to 90, wherein theconstruct encodes an antibody-derived single-chain variable fragmentspecific for the cytokine, chemokine or TF gene.

Embodiment 92—The method of any of embodiments 53 to 91, whereindeletion of the cytokine, chemokine, or transcription factor gene doesnot reduce CAR-T-mediated killing.

Embodiment 93—The method of any of embodiments 53 to 92, wherein the CARto be inserted comprises a donor template.

Embodiment 94—The method of any of embodiments 53 to 93, wherein donortemplate comprises an adeno-associated virus (AAV), a single-strandedDNA, or a double-stranded DNA.

Disclosed herein is a chimeric antigen receptor (CAR)-bearing immuneeffector cell that is deficient in a cytokine.

In certain embodiments, the cytokine deficiency is effected by ablationof a cytokine gene or a chemokine gene, or a transcription factor gene.

In certain embodiments, the ablation is effected by inserting the CARinto a locus of the cytokine/chemokine/transcription factor gene.

In certain embodiments, the CAR is part of a construct that alsoincludes a selectable marker.

In certain embodiments, the cytokine deficiency is effected by deletionor suppression of the cytokine/chemokine/transcription factor gene, byTranscription Activator-like Effector Nucleases (TALENs), Zinc FingerNucleases (ZFNs), or Clustered Regularly Interspaces Short PalindromicRepeats (CRISPR) editing.

In certain embodiments, the cytokine deficiency is effected bysuppression of the cytokine/chemokine/transcription factor genetranscript by transfection of small interfering RNAs (siRNAs).

Also disclosed herein is a chimeric antigen receptor (CAR)-bearingimmune effector cell expressing at least one CAR, wherein:

-   -   the at least one CAR is inserted into a locus of a        cytokine/chemokine/transcription factor gene;    -   the cytokine/chemokine/transcription factor gene is deleted or        suppressed by a method chosen from Transcription Activator-like        Effector Nucleases (TALENs), Zinc Finger Nucleases (ZFNs), and        Clustered Regularly Interspaces Short Palindromic Repeats        (CRISPR) editing;    -   the cytokine is suppressed by expression of an scFv with an        endoplasmic reticulum (ER) binding tether to bind the cytokine        in the ER and prevent secretion; or    -   the cytokine/chemokine/transcription factor gene transcript is        suppressed by small interfering RNAs (siRNAs) transfection.

In certain embodiments, the cell is chosen from a chimeric antigenreceptor T cell (CAR-T), a CAR-bearing iNKT cell (iNKT-CAR), and aCAR-bearing natural killer (NK) cell (NK-CAR).

In certain embodiments, the cell is a CAR-T.

In certain embodiments, the cell is a dual or tandem CAR-T.

In certain embodiments, the cell is an iNKT-CAR.

In certain embodiments, the cell is a dual or tandem iNKT-CAR.

In certain embodiments, the cytokine contributes to the development ofcytokine release syndrome.

In certain embodiments, the cytokine is chosen from MCP1 (CCL2), MCP-2,GM-CSF, G-CSF, M-CSF, IL-4, and IFNy.

In certain embodiments, the cytokine is GM-CSF.

In certain embodiments, the cell is a GM-CSF deficient CAR-T cell.

In certain embodiments, the cell is a GM-CSF deficient iNKT-CAR cell.

In certain embodiments, the chimeric antigen receptor specifically bindsat least one antigen expressed on a malignant T cell.

In certain embodiments, the antigen is selected from CD2, CDR, CD4, CD5,CD7, TCRA, and TCRβ.

In certain embodiments, the chimeric antigen receptor specifically bindsat least one antigen expressed on a malignant B cell.

In certain embodiments, the antigen is selected from CD19 and CD20.

In certain embodiments, the chimeric antigen receptor specifically bindsat least one antigen expressed on a malignant mesothelial cell.

In certain embodiments, the antigen is mesothelin.

In certain embodiments, the chimeric antigen receptor specifically bindsat least one antigen expressed on a malignant plasma cell.

In certain embodiments, the antigen is selected from BCMA, CS1, CD38,and CD19.

In certain embodiments, the chimeric antigen receptor expresses theextracellular portion of the APRIL protein, the ligand for BCMA andTACI, effectively co-targeting both BCMA and TACI.

In certain embodiments, the CAR-T cell further comprises a suicide gene.

In certain embodiments, endogenous T cell receptor mediated signaling isnegligible in the cell.

In certain embodiments, the cell does not induce alloreactivity orgraft-versus-host disease.

In certain embodiments, the cell does not induce fratricide.

Also disclosed herein is a method of treatment of cancer in a patient,which has a reduced incidence of cytokine release syndrome and/or CAR-Tassociated neuropathy, comprising the administration of chimeric antigenreceptor (CAR)-bearing immune effector cells as disclosed herein.

In certain embodiments, the cancer is a hematologic malignancy.

In certain embodiments, the hematologic malignancy is a T-cellmalignancy.

In certain embodiments, the T cell malignancy is T-cell acutelymphoblastic leukemia (T-ALL).

In certain embodiments, the T cell malignancy is non-Hodgkin's lymphoma.

In certain embodiments, the hematologic malignancy is multiple myeloma.

In certain embodiments, the cancer is a solid tumor.

In certain embodiments, the cancer is cervical cancer, pancreaticcancer, ovarian cancer, mesothelioma, and lung cancer.

Also disclosed herein is a method of prevention or reduction of cytokinerelease syndrome, CAR-T associated neuropathy in a patient receivingchimeric antigen receptor T cell (CAR-T), CAR-bearing iNKT cell(iNKT-CAR), or CAR-bearing natural killer (NK) cell (NK-CAR)immunotherapy, comprising the administration of chimeric antigenreceptor (CAR)-bearing immune effector cells as disclosed herein as theimmunotherapy.

Also disclosed herein is a method of blocking the expression of acytokine/chemokine/transcription factor gene in a chimeric antigenreceptor T cell (CAR-T), CAR-bearing iNKT cell (iNKT-CAR), orCAR-bearing natural killer (NK) cell (NK-CAR), comprising the insertionof a CAR into a locus of the cytokine/chemokine/transcription factorgene.

CAR-Bearing Immune Effector Cells

A chimeric antigen receptor (CAR), is a recombinant fusion proteincomprising: 1) an extracellular ligand-binding domain, i.e., anantigen-recognition domain, 2) a transmembrane domain, and 3) asignaling transducing domain.

Methods for CAR design, delivery and expression, and the manufacturingof clinical-grade CAR-T cell populations are known in the art. See, forexample, Lee et al., Clin. Cancer Res., 2012, 18(10): 2780-90. Anengineered chimeric antigen receptor polynucleotide that encodes for aCAR comprises: a signal peptide, an antigen recognition domain, at leastone co-stimulatory domain, and a signaling domain.

The antigen-specific extracellular domain of a chimeric antigen receptorrecognizes and specifically binds an antigen, typically asurface-expressed antigen of a malignancy. An “antigen-specificextracellular domain” (or, equivalently, “antigen-binding domain”)specifically binds an antigen when, for example, it binds the antigenwith an affinity constant or affinity of interaction (KD) between about0.1 pM to about 10 μM, preferably about 0.1 pM to about 1 μM, morepreferably about 0.1 pM to about 100 nM. Methods for determining theaffinity of interaction are known in the art. An antigen-specificextracellular domain suitable for use in a CAR of the present disclosuremay be any antigen-binding polypeptide, a wide variety of which areknown in the art. In some instances, the antigen-binding domain is asingle chain Fv (scFv). Other antibody based recognition domains (cAbVHH (camelid antibody variable domains) and humanized versions thereof,lgNAR VH (shark antibody variable domains) and humanized versionsthereof, sdAb VH (single domain antibody variable domains) and“camelized” antibody variable domains are suitable for use. In someinstances, T-cell receptor (TCR) based recognition domains such assingle chain TCR (scTv, single chain two-domain TCR containing VαVβ) arealso suitable for use.

A chimeric antigen receptor of the present disclosure also comprises an“intracellular domain” that provides an intracellular signal to theCAR-bearing immune effector cell upon antigen binding to theantigen-specific extracellular domain. The intracellular signalingdomain of a chimeric antigen receptor of the present disclosure isresponsible for activation of at least one of the effector functions ofthe T cell in which the chimeric receptor is expressed. The term“effector function” refers to a specialized function of a differentiatedcell, such as an iNKT cell. An effector function of an iNKT cell, forexample, may be NK transactivation, T cell activation anddifferentiation, B cell activation, dendritic cell activation andcross-presentation activity, and macrophage activation. Thus, the term“intracellular domain” refers to the portion of a CAR that transducesthe effector function signal upon binding of an antigen to theextracellular domain and directs the iNKT cell to perform a specializedfunction. Non-limiting examples of suitable intracellular domainsinclude the zeta chain of the T-cell receptor or any of its homologs(e.g., eta, delta, gamma, or epsilon), MB 1 chain, 829, Fe Rill, Fe R1,and combinations of signaling molecules, such as CD3ζ and CD28, CD27,4-1 BB, DAP-1 0, OX40, and combinations thereof, as well as othersimilar molecules and fragments. Intracellular signaling portions ofother members of the families of activating proteins may be used, suchas FcγRIII and FcεRI. While usually the entire intracellular domain willbe employed, in many cases it will not be necessary to use the entireintracellular polypeptide. To the extent that a truncated portion of theintracellular signaling domain may find use, such truncated portion maybe used in place of the intact chain as long as it still transduces theeffector function signal. The term intracellular domain is thus meant toinclude any truncated portion of the intracellular domain sufficient totransduce the effector function signal.

Typically, the antigen-specific extracellular domain is linked to theintracellular domain of the chimeric antigen receptor by a“transmembrane domain.” A transmembrane domain traverses the cellmembrane, anchors the CAR to the T cell surface, and connects theextracellular domain to the intracellular signaling domain, thusimpacting expression of the CAR on the T cell surface. Chimeric antigenreceptors may also further comprise one or more costimulatory domainand/or one or more spacer. A “costimulatory domain” is derived from theintracellular signaling domains of costimulatory proteins that enhancecytokine production, proliferation, cytotoxicity, and/or persistence invivo. A “peptide hinge” connects the antigen-specific extracellulardomain to the transmembrane domain. The transmembrane domain is fused tothe costimulatory domain, optionally a costimulatory domain is fused toa second costimulatory domain, and the costimulatory domain is fused toa signaling domain, not limited to CD3ζ. For example, inclusion of aspacer domain between the antigen-specific extracellular domain and thetransmembrane domain, and between multiple scFvs in the case of tandemCAR, may affect flexibility of the antigen-binding domain(s) and therebyCAR function. Suitable transmembrane domains, costimulatory domains, andspacers are known in the art.

Engineered CARs may be introduced into CAR-bearing immune effector cellsusing retroviruses, which efficiently and stably integrate a nucleicacid sequence encoding the chimeric antigen receptor into the targetcell genome. Other methods known in the art include, but are not limitedto, lentiviral transduction, transposon-based systems, direct RNAtransfection, and CRISPR/Cas systems (e.g., type I, type II, or type Illsystems using a suitable Cas protein such Cas3, Cas4, Cas5, Cas5e (orCasD), Cash, Cas6e, Cas6f, Cas7, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9,Cas10, Cas1 Od, CasF, CasG, CasH, Csy1, Csy2, Csy3, Cse1 (or CasA), Cse2(or CasB), Cse3 (or CasE), Cse4 (or CasC), Csc1, Csc2, Csa5, Csn2, Csm2,Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2,Csb3,Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csz1, Csx15, Csf1, Csf2,Csf3, Csf4, and Cu1966, etc.). Zinc finger nucleases (ZFNs) andtranscription activator-like effector nucleases (TALENs) may also beused. See, e.g., Shearer RF and Saunders DN, “Experimental design forstable genetic manipulation in mammalian cell lines: lentivirus andalternatives,” Genes Cells 2015 January; 20(1):1-10.

Manipulation of PI3K signaling can be used to prevent altered CAR-T celldifferentiation due to constitutive CAR self-signaling and fosterlong-lived memory T cell development. pharmacologic blockade of PI3Kduring CAR-T manufacture and ex vivo expansion can abrogate preferentialeffector T cell development and restore CAR-T effector/memory ratio tothat observed in empty vector transduced T cells, which can improve invivo T cell persistence and therapeutic activity. Inhibition of p110δPI3K can enhance efficacy and memory in tumor-specific therapeutic CD8 Tcells, while inhibition of p110α PI3K can increase cytokine productionand antitumor response.

This is proposed to be because the presence of a CAR on a T cell'ssurface can alter its activation and differentiation, even in theabsence of ligand. Constitutive self-signaling through CAR, related toboth the scFv framework and the signaling domains, can lead to aberrantT cell behavior, including altered differentiation and decreasedsurvival. This is significant as the effectiveness of CAR-T cells inpatients is directly associated with their in vivo longevity. Thepresence of the CD28 costimulatory domain increased CAR-T cellexhaustion induced by persistent CAR self-signaling; the 4-1BBcostimulatory domain had a lesser effect. Furthermore, CD3-zetasignificantly enhances the constitutive activation of the PI3K, AKT,mTOR, and glycolysis pathways, and fostered formation of short-livedeffector cells over central/stem memory cells. See, e.g., Zhang W. etal., “Modulation of PI3K signaling to improve CAR T cell function,”Oncotarget, 2018 Nov. 9; 9(88): 35807-35808.

CAR Antigens. Suitable antigens to be genome-edited in the iNKT cellsdisclosed herein, and to be recognized by the CARs of iNKT-CARsdisclosed herein, include antigens specific to hematologic malignancies.These can include T cell-specific antigens and/or antigens that are notspecific to T cells. The antigen may be specifically bound by thechimeric antigen receptor of an iNKT-CARs cell, and the antigen forwhich the iNKT-CARs cell is deficient, is an antigen expressed on amalignant T cell, preferably an antigen that is overexpressed onmalignant T cell (i.e., a T cell derived from a T-cell malignancy) incomparison to a nonmalignant T cell. Examples of such antigens includeCD2, CD3ε, CD4, CD5, CD7, TRAC, and TCRβ.

T-cell malignancies comprise malignancies derived from T-cellprecursors, mature T cells, or natural killer cells. Examples of T-cellmalignancies include T-cell acute lymphoblastic leukemia/lymphoma(T-ALL), T-cell large granular lymphocyte (LGL) leukemia, human T-cellleukemia virus type 1-positive (HTLV-1 +) adult T-cell leukemia/lymphoma(ATL), T-cell prolymphocytic leukemia (T-PLL), and various peripheralT-cell lymphomas (PTCLs), including but not limited toangioimmunoblastic T-cell lymphoma (AITL), ALK-positive anaplastic largecell lymphoma, and ALK-negative anaplastic large cell lymphoma.

Suitable CAR antigens can also include antigens found on the surface ofa multiple myeloma cell, i.e., a malignant plasma cell, such as BCMA,CS1, CD38, and CD19. Alternatively, the CAR may be designed to expressthe extracellular portion of the APRIL protein, the ligand for BCMA andTACI, effectively co-targeting both BCMA and TACI for the treatment ofmultiple myeloma.

Additional examples of suitable antigens to be genome-edited in the iNKTcells disclosed herein, and to be recognized by the CARs of iNKT-CARsdisclosed herein, are given below in Tables 1-10. These include CD2,CD3ε, CD4, CD5, CD7, TRAC, TCRβ, BCMA, CS1, and CD38.

Fratricide Resistance. The CAR-T, iNKT, NK and other CAR-bearing immuneeffector cells encompassed by the present disclosure are optionallydeficient in one or more antigens to which the chimeric antigen receptorspecifically binds and are therefore fratricide-resistant. In someembodiments, the one or more antigens of the cell is modified such thechimeric antigen receptor no longer specifically binds the one or moremodified antigens. For example, the epitope of the one or more antigensrecognized by the chimeric antigen receptor may be modified by one ormore amino acid changes (e.g., substitutions or deletions) or theepitope may be deleted from the antigen. In other embodiments,expression of the one or more antigens is reduced in the cell by atleast 50%, at least 60%, at least 70%, at least 80%, at least 90% ormore. Methods for decreasing the expression of a protein are known inthe art and include, but are not limited to, modifying or replacing thepromoter operably linked to the nucleic acid sequence encoding theprotein. In still other embodiments, the cell is modified such that theone or more antigens is not expressed, e.g., by deletion or disruptionof the gene encoding the one or more antigens. In each of the aboveembodiments, the CAR-bearing immune effector cell may be deficient inone or preferably all the antigens to which the chimeric antigenreceptor specifically binds. Methods for genetically modifying a cell tobe deficient in one or more antigens are well known in art, andnon-limiting examples are provided above. In an exemplary embodiment,CRISPR/cas9 gene editing can be used to modify a cell to be deficient inone or more antigens. Zinc finger nucleases (ZFNs) and transcriptionactivator-like effector nucleases (TALENs) may also be used. See, e.g.,Shearer RF and Saunders DN, “Experimental design for stable geneticmanipulation in mammalian cell lines: lentivirus and alternatives,”Genes Cells 2015 January; 20(1):1-10.

Avoidance of Allogenicity. CAR-T, iNKT, NK and other CAR-bearing immuneeffector cells encompassed by the present disclosure may further bedeficient in endogenous T cell receptor (TCR) signaling as a result ofdeleting a part of the T Cell Receptor (TCR)-CD3 complex. In variousembodiments it may be desirable to eliminate or suppress endogenous TCRsignaling in CAR-bearing immune effector cells disclosed herein. Forexample, decreasing or eliminating endogenous TCR signaling in CAR-Tcells may prevent or reduce graft versus host disease (GvHD) whenallogenic T cells are used to produce the CAR-T cells. Methods foreliminating or suppressing endogenous TCR signaling are known in the artand include, but are not limited to, deleting a part of the TCR-CD3receptor complex, e.g., the TCR receptor alpha chain (TRAC), the TCRreceptor beta chain (TRBC), CD3ε CD3γ CD3δ, and/or CD3ζ. Deleting a partof the TCR receptor complex may block TCR mediated signaling and maythus permit the safe use of allogeneic T cells as the source of CAR-Tcells without inducing life-threatening GvHD.

Suicide Genes. Alternatively, or in addition, CAR-bearing immuneeffector cells encompassed by the present disclosure may furthercomprise one or more suicide genes. As used herein, “suicide gene”refers to a nucleic acid sequence introduced to a cell by standardmethods known in the art that, when activated, results in the death ofthe cell. Suicide genes may facilitate effective tracking andelimination of the CAR-bearing immune effector cells in vivo ifrequired. Facilitated killing by activating the suicide gene may occurby methods known in the art. Suitable suicide gene therapy systems knownin the art include, but are not limited to, various the herpes simplexvirus thymidine kinase (HSVtk)/ganciclovir (GCV) suicide gene therapysystems or inducible caspase 9 protein. In an exemplary embodiment, asuicide gene is a CD34/thymidine kinase chimeric suicide gene.

Components that may be included in a CAR as described herein areprovided below in Tables 1 and 2.

TABLE 1 Amino acid sequences of different CAR components. SEQ IDFunctional domains NO: Amino acid sequence CD8α signal peptide SEQ IDMALPVTALLLPLALLLHAARP NO: 1 CD8α hinge SEQ IDTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGA NO: 2 VHTRGLDFACD CD28 TransmembraneSEQ ID FWVLVVVGGVLACYSLLVTVAFIIFWV (T_(m)) domain NO: 3Surface glycoprotein CD8 SEQ ID MALPVTALLLPLALLLHAARPSQFRVSPLDRTalpha chain isoform 1 NO: 4 WNLGETVELKCQVLLSNPTSGCSWLFQPRGAA precursorASPTFLLYLSQNKPKAAEGLDTQRFSGKRLGDT (NP_001139345.1)FVLTLSDFRRENEGYYFCSALSNSIMYFSHFVP VFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLL LSLVITLYCNHRNRRRVCKCPRPVVKSGDKPSL SARYV4-1BB costimulatory SEQ ID KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFP domainNO: 5 EEEEGGCEL CD28 costimulatory SEQ IDRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAP domain NO: 6 PRDFAAYRS CD3 zeta (ζ)SEQ ID RVKFSRSADAPAYKQGQNQLYNELNLGRREEY NO: 7DVLDKRRGRDPEMGGKPRRKNPQEGLYNELQ KDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR P2A peptide SEQ ID GSGATNFSLLKQAGDVEENPGP NO: 8(GGGGS)₄ linker SEQ ID GGGGSGGGGSGGGGSGGGGS NO: 9 hCD34 SEQ IDMPRGWTALCLLSLLPSGFMSLDNNGTATPELP NO: 10TQGTFSNVSTNVSYQETTTPSTLGSTSLHPVSQ HGNEATTNITETTVKFTSTSVITSVYGNTNSSVQSQTSVISTVFTTPANVSTPETTLKPSLSPGNVSD LSTTSTSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLEQNKTSSCAEFKKDRGEGLARV LCGEEQADADAGAQVCSLLLAQSEVRPQCLLLVLANRTEISSKLQLMKKHQSDLKKLGILDFTEQ DVASHQSYSQKTLIALVTSGALLAVLGITGYFLMNRRSWSPI Human-Herpes Simplex SEQ ID MPRGWTALCLLSLLPSGFMSLDNNGTATPELPVirus-1 (HSV)-thymidine NO: 11 TQGTFSNVSTNVSYQETTTPSTLGSTSLHPVSQkinase (TK) HGNEATTNITETTVKFTSTSVITSVYGNTNSSVQSQTSVISTVFTTPANVSTPETTLKPSLSPGNVSD LSTTSTSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLEQNKTSSCAEFKKDRGEGLARV LCGEEQADADAGAQVCSLLLAQSEVRPQCLLLVLANRTEISSKLQLMKKHQSDLKKLGILDFTEQ DVASHQSYSQKTLIALVTSGALLAVLGITGYFLMNRRSWSPTGEGGGGGDLGGVKLPHLFGKRL VEARMASYPCHQHASAFDQAARSRGHSNRRTALRPRRQQEATEVRLEQKMPTLLRVYIDGPHG MGKTTTTQLLVALGSRDDIVYVPEPMTYWQVLGASETIANIYTTQHRLDQGEISAGDAAVVMTS AQITMGMPYAVTDAVLAPHVGGEAGSSHAPPPALTLLLDRHPIAVMLCYPAARYLMGSMTPAV LAFVALIPPTLPGTNIVLGALPEDRHIDRLAKRQRPGERLDLAMLAAIRRVYGLLANTVRYLQGGG SWWEDWGQLSGTAVPPQGAEPQSNAGPRPHIGDTLFTLFRAPELLAPNGDLYNVFAWALDVLAK RLRPMHVFILDYDQSPAGCRDALLQLTSGMVQTHVTTPGSIPTICDLARTFAREMGEAN

TABLE 2Amino acid sequences of the variable heavy (V_(H)) and variable light (V_(L)) chainsof the scFvs. SEQ ID ScFv sequences NO: Amino acid sequenceCD2 heavy chain variable SEQ ID EVKLEESGAELVKPGASVKLSCRTSGFN1KDTIregion (35.1 ATCC ® HB- NO: 12 HWVKQRPEQGLKWIGRIDPANGNTKYDPKFQ 222^(TM))DKATVTADTSSNTAYLQLSSLTSEDTAVYYCV TYAYDGNWYFDVWGAGTAVTVSSCD2 light chain variable SEQ ID DIKNITQSPSSMYVSLGERVTITCKASQDINSFLregion (35.1 ATCC ® HB- NO: 13 SWFQQKPGKSPKTLIYRANRLVDGVPSRFSGS222^(TM)) GSGQDYSLTISSLEYEDMEIYYCLQYDEFPYTF GGGTKLEMKRCD2 heavy chain variable SEQ ID EVQLEESGAELVRPGTSVKLSCKASGYTFTSYregion (OKT 11 NO: 14 WMHWIKQRPEQGLEWIGRIDPYDSETHYNEK ATCC ®CRL-8027^(TM)) FKDKAILSVDKSSSTAYIQLSSLTSDDSAVYYCSRRDAKYDGYALDYWGQGTSVTVSS CD2 light chain variable SEQ IDDIVMTQAAPSVPVTPGESVSISCRSSKTLLHSN region (OKT 11 NO: 15GNTYLYWFLQRPGQSPQVLIYRMSNLASGVP ATCC ® CRL-8027^(TM))NRFSGSGSETTFTLRISRVEAEDVGIYYCMQHL EYPYTFGGGTKLEIERCD3 heavy chain variable SEQ ID GSQVQLQQSGAELARPGASVKMSCKASGYTFregion (OKT 3) NO: 16 TRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSA VYYCARYYDDHYCLDYWGQGTTLTVSSCD3 light chain variable SEQ ID QIVLTQSPAIIVISASPGEKVTMTCSASSSVSYMregion (OKT 3) NO: 17 NWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPF TFGSGTKLEINR CD3 heavy chain variableSEQ ID EVQLVESGGGLVQPGGSLRLSCAASGYSFTGY region (UCHT1) NO: 18TMNWVRQAPGKCLEWVALINPYKGVSTYNQ KFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS CD3 heavy chain variable SEQ IDDIQMTQSPSSLSASVGDRVTITCRASQDIRNYL region (UCHT1) NO: 19NWYQQKPGKAPKLLIYYTSRLESGVPSRFSGS GSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGCGTKVEIK CD7 heavy chain variable SEQ IDEVQLVESGGGLVKPGGSLKLSCAASGLTFSSY region NO: 20AMSWVRQTPEKRLEWVASISSGGFTYYPDSV KGRFTISRDNARNILYLQMSSLRSEDTAMYYCARDEVRGYLDVWGAGTTVTVS CD7 light chain variable SEQ IDDIQMTQTTSSLSASLGDRVTISCSASQGISNYL region NO: 21NWYQQKPDGTVKLLIYYTSSLHSGVPSRFSGS GSGTDYSLTISNLEPEDIATYYCQQYSKLPYTFGGGTKLEIKR FTL3 heavy chain SEQ ID EVQLVQSGAEVKKPGASVKVSCKASGYTFTSvariable region (EB10) NO: 22 YYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVY YCARGVGAHDAFDIWGQGTTVTVSSFTL3 light chain variable SEQ ID DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNregion (EB10) NO: 23 GNNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSDTDFTLQISRVEAEDVGVYYCMQG THPAISFGQGTRLEIK FTL3 heavy chainSEQ ID EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSY variable region (NC7) NO: 24AISWVRQAPGQGLEWMGGIIPIFGTANYAQKF QGRVTITADKSTSTAYMELSSLRSEDTAVYYCATFALFGFREQAFDIWGQGTTVTVSS FTL3 light chain variable SEQ IDDIQMTQSPSSLSASVGDRVTITCRASQSISSYLN region (NC7) NO: 25WYQQKPGKAPKLLIYAASSLQSGVPSRFSGSG SGTDFTLTISSLQPEDLATYYCQQSYSTPFTFGPGTKVDIK FTL3 heavy chain SEQ ID EVQLVQSGAEVKKPGASVKVSCKASGYTFTSvariable region (D3-D4) NO: 26 YYMHWARQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVY YCARVVAAAVADYWGQGTLVTVSSFTL3 light chain variable SEQ ID DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNregion (D3-D4) NO: 27 GYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQS LQTPFTFGPGTKVDIKCS1 heavy chain variable SEQ ID QVQLQQPGAELVRPGASVKLSCKASGYSFTTY regionNO: 28 WMNWVKQRPGQGLEWIGMIHPSDSETRL NQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCARSTMIATRAMDYWGQGTSVTVSS CS1 light chain variable SEQ IDDIVMTQSQKSMSTSVGDRVSITCKASQDVITG region NO: 29VAWYQQKPGQSPKLLIYSASYRYTGVPD RFTGSGSGTDFTFTISNVQAEDLAVYYCQQHYSTPLTFGAGTKLELK CD33 heavy chain SEQ ID QVQLQQPGAEVVKPGASVKMSCKASGYTFTSvariable region NO: 30 YYIHWIKQTPGQGLEWVGVIYPGNDDISYNQKFQGKATLTADKSSTTAYMQLSSLTSEDSAVYY CAREVRLRYFDVWGQGTTVTVSSSGCD33 light chain variable SEQ ID GSEIVLTQSPGSLAVSPGERVTMSCKSSQSVFFregion NO: 31 SSSQKNYLAWYQQIPGQSPRLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQPEDLAIYYCHQ YLSSRTFGQGTKLEIKR

Mono CAR-T Cells

In certain embodiments, the disclosure provides an engineered T cellcomprising a single CAR, that specifically binds an antigen or cellsurface protein, wherein the T cell is optionally deficient in thatantigen or cell surface protein (e.g., CD7CARTΔCD7 cell). Innon-limiting examples, the deficiency in the antigen or cell surfaceprotein resulted from (a) modification of antigen or cell surfaceprotein expressed by the T cell such that the chimeric antigen receptorsno longer specifically binds the modified antigen or cell surfaceprotein (e.g., the epitope of the one or more antigens recognized by thechimeric antigen receptor may be modified by one or more amino acidchanges (e.g., substitutions or deletions) or the epitope may be deletedfrom the antigen), (b) modification of the T cell such that expressionof antigen or cell surface protein is reduced in the T cell by at least50%, at least 60%, at least 70%, at least 80%, at least 90% or more, or(c) modification of the T cell such that antigen or cell surface proteinis not expressed (e.g., by deletion or disruption of the gene encodingantigen or cell surface protein). In each of the above embodiments, theCAR-T cell may be deficient in one or preferably all the antigens orcell surface proteins to which the chimeric antigen receptorspecifically binds. The methods to genetically modify a T cell to bedeficient in one or more antigens or cell surface proteins are wellknown in art and non-limiting examples are provided herein. Inembodiments described below, the CRISPR-Cas9 system is used to modify aT cell to be deficient in one or more antigens. Any of these may beaccomplished by the methods disclosed herein. In further embodiments,the T cell comprises a suicide gene.

For example, the CAR for a CD7 specific CAR-T cell may be generated bycloning a commercially synthesized anti-CD7 single chain variablefragment (scFv) into a 3rd generation CAR backbone with CD28 and/or4-1BB internal signaling domains. An extracellular hCD34 domain may beadded after a P2A peptide to enable both detection of CAR followingviral transduction and purification using anti-hCD34 magnetic beads. Asimilar method may be followed for making CARs specific for othermalignant T cell antigens.

CAR-T cells encompassed by the present disclosure may further bedeficient in endogenous T cell receptor (TCR) signaling as a result ofdeleting a part of the T Cell Receptor (TCR)-CD3 complex. In variousembodiments it may be desirable to eliminate or suppress endogenous TCRsignaling in CAR-T cells disclosed herein. For example, decreasing oreliminating endogenous TCR signaling in CAR-T cells may prevent orreduce graft versus host disease (GvHD) when allogenic T cells are usedto produce the CAR-T cells. Methods for eliminating or suppressingendogenous TCR signaling are known in the art and include, but are notlimited to, deleting a part of the TCR-CD3 receptor complex, e.g., theTCR receptor alpha chain (TRAC), the TCR receptor beta chain (TCRβ) orsubtypes thereof, TCRδ, TCRγ, CD3ε, CD3γ, and/or CD3δ. Deleting a partof the TCR receptor complex may block TCR mediated signaling and maythus permit the safe use of allogeneic T cells as the source of CAR-Tcells without inducing life-threatening GvHD.

In addition, the CAR-T cells encompassed by the present disclosure mayfurther comprise one or more suicide genes as described herein.

In a similar manner, other mono-CAR-T cells may be constructed and aregiven below in Table 3.

TABLE 3 Mono CARs and CAR-Ts Antigen Antigen Target of Deletion/ CAR-TSuppression Example cells cells M1 APRIL — M2 APRIL APRIL M3 APRILAPRIL + TRAC M4 APRIL APRIL + CD3ε M5 APRIL CD3ε M6 BCMA — M7 CD117 — M8CD117 CD117 M9 CD123 — M10 CD123 CD123 M11 CD135 — M12 CD135 CD135 M13CD138 — M14 CD19 — M15 CD1a — M16 CD1a CD3ε M17 CD1a TRAC M18 CD1aCD1a + TRAC M19 CD1a CD1a + CD3ε M20 CD2 — M21 CD2 CD2 M22 CD2 CD2 +TRAC M23 CD2 CD2 + CD3ε M24 CD20 M25 CD21 M26 CD22 M27 CD23 M28 CD3 —M29 CD3 CD3ε M30 CD3 CD3ε + TRAC M31 CD33 — M32 CD33 CD33 M33 CD371 —M34 CD371 CD371 M35 CD38 — M36 CD38 CD38 M37 CD4 — M38 CD4 CD4 M39 CD4CD4 + TRAC M40 CD4 CD4 + CD3ε M41 CD5 — M42 CD5 CD5 M43 CD5 CD5 + TRACM44 CD5 CD5 + CD3ε M45 CD56 — M46 CD56 CD56 M47 CD56 CD56 + TRAC M48CD56 CD56 + CD3ε M49 CD56 CD3ε M50 CD56 TRAC M51 CD7 — M52 CD7 CD7 M53CD7 CD7 + TRAC M54 CD7 CD7 + CD3ε M55 CD79A — M56 CD79B — M57 CS1 — M58CS1 CS1 M59 Tim-3 — M60 Tim-3 Tim-3 M61 Tim-3 Tim-3 + TRAC M62 Tim-3TRAC M63 Tim-3 CD3ε M64 Tim-3 Tim-3 + CD3ε

Disclosed are embodiments of CAR amino acid sequences that can beexpressed on the surface of a genome-edited CAR-T cell derived from acytotoxic T cell, a memory T cell, or a gamma delta (γδ) T cell.

TABLE 4 Amino Acid Sequences of Mono Chimeric Antigen Receptors (CARs).Mono CAR Constructs SEQ ID NO: Amino acid sequence CD7-CAR-4- SEQ IDMALPVTALLLPLALLLHAARPDIQMTQTTSSLSASLGDRVT 1BB_CD34 NO: 32ISCSASQGISNYLNWYQQKPDGTVKLLIYYTSSLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCQQYSKLPYTFGGGTKLEIKRGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLKLSCAASGLTFSSYAMSWVRQTPEKRLEWVASISSGGFTYYPDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCARDEVRGYLDVWGAGTTVTVSPRASTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRRTDGSGATNFSLLKQAGDVEENPGPVSEAMPRGWTALCLLSLLPSGFMSLDNNGTATPELPTQGTFSNVSTNVSYQETTTPSTLGSTSLHPVSQHGNEATTNITETTVKFTSTSVITSVYGNTNSSVQSQTSVISTVFTTPANVSTPETTLKPSLSPGNVSDLSTTSTSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLEQNKTSSCAEFKKDRGEGLARVLCGEEQADADAGAQVCSLLLAQSEVRPQCLLLVLANRTEISSKLQLMKKHQSDLKKLGILDFTEQDVASHQSYSQKTLIALVTSGALLAV LGITGYFLMNRRSWSPI CD7-CAR-4-SEQ ID MALPVTALLLPLALLLHAARPDIQMTQTTSSLSASLGDRVT 1BB_CD34_TK NO: 33ISCSASQGISNYLNWYQQKPDGTVKLLIYYTSSLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCQQYSKLPYTFGGGTKLEIKRGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLKLSCAASGLTFSSYAMSWVRQTPEKRLEWVASISSGGFTYYPDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCARDEVRGYLDVWGAGTTVTVSPRASTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRRTDGSGATNFSLLKQAGDVEENPGPVSEAMPRGWTALCLLSLLPSGFMSLDNNGTATPELPTQGTFSNVSTNVSYQETTTPSTLGSTSLHPVSQHGNEATTNITETTVKFTSTSVITSVYGNTNSSVQSQTSVISTVFTTPANVSTPETTLKPSLSPGNVSDLSTTSTSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLEQNKTSSCAEFKKDRGEGLARVLCGEEQADADAGAQVCSLLLAQSEVRPQCLLLVLANRTEISSKLQLMKKHQSDLKKLGILDFTEQDVASHQSYSQKTLIALVTSGALLAVLGITGYFLMNRRSWSPTGEGGGGGDLGGVKLPHLFGKRLVEARMASYPCHQHASAFDQAARSRGHSNRRTALRPRRQQEATEVRLEQKMPTLLRVYIDGPHGMGKTTTTQLLVALGSRDDIVYVPEPMTYWQVLGASETIANIYTTQHRLDQGEISAGDAAVVMTSAQITMGMPYAVTDAVLAPHVGGEAGSSHAPPPALTLLLDRHPIAVMLCYPAARYLMGSMTPQAVLAFVALIPPTLPGTNIVLGALPEDRHIDRLAKRQRPGERLDLAMLAAIRRVYGLLANTVRYLQGGGSWWEDWGQLSGTAVPPQGAEPQSNAGPRPHIGDTLFTLFRAPELLAPNGDLYNVFAWALDVLAKRLRPMHVFILDYDQSPAGCRDALLQLTSGMVQTHVTTPG SIPTICDLARTFAREMGEAN CD7-CAR-SEQ ID MALPVTALLLPLALLLHAARPDIQMTQTTSSLSASLGDRVT CD28_CD34 NO: 34ISCSASQGISNYLNWYQQKPDGTVKLLIYYTSSLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCQQYSKLPYTFGGGTKLEIKRGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLKLSCAASGLTFSSYAMSWVRQTPEKRLEWVASISSGGFTYYPDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCARDEVRGYLDVWGAGTTVTVSPRASTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRRTDGSGATNFSLLKQAGDVEENPGPVSEAMPRGWTALCLLSLLPSGFMSLDNNGTATPELPTQGTFSNVSTNVSYQETTTPSTLGSTSLHPVSQHGNEATTNITETTVKFTSTSVITSVYGNTNSSVQSQTSVISTVFTTPANVSTPETTLKPSLSPGNVSDLSTTSTSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLEQNKTSSCAEFKKDRGEGLARVLCGEEQADADAGAQVCSLLLAQSEVRPQCLLLVLANRTEISSKLQLMKKHQSDLKKLGILDFTEQDVASHQSYSQKTLIALVTSGALLAV LGITGYFLMNRRSWSPI CD7-CAR-SEQ ID MALPVTALLLPLALLLHAARPDIQMTQTTSSLSASLGDRVT CD28_CD34_TK NO: 35ISCSASQGISNYLNWYQQKPDGTVKLLIYYTSSLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCQQYSKLPYTFGGGTKLEIKRGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVKPGGSLKLSCAASGLTFSSYAMSWVRQTPEKRLEWVASISSGGFTYYPDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCARDEVRGYLDVWGAGTTVTVSPRASTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRRTDGSGATNFSLLKQAGDVEENPGPVSEAMPRGWTALCLLSLLPSGFMSLDNNGTATPELPTQGTFSNVSTNVSYQETTTPSTLGSTSLHPVSQHGNEATTNITETTVKFTSTSVITSVYGNTNSSVQSQTSVISTVFTTPANVSTPETTLKPSLSPGNVSDLSTTSTSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLEQNKTSSCAEFKKDRGEGLARVLCGEEQADADAGAQVCSLLLAQSEVRPQCLLLVLANRTEISSKLQLMKKHQSDLKKLGILDFTEQDVASHQSYSQKTLIALVTSGALLAVLGITGYFLMNRRSWSPTGEGGGGGDLGGVKLPHLFGKRLVEARMASYPCHQHASAFDQAARSRGHSNRRTALRPRRQQEATEVRLEQKMPTLLRVYIDGPHGMGKTTTTQLLVALGSRDDIVYVPEPMTYWQVLGASETIANIYTTQHRLDQGEISAGDAAVVMTSAQITMGMPYAVTDAVLAPHVGGEAGSSHAPPPALTLLLDRHPIAVMLCYPAARYLMGSMTPQAVLAFVALIPPTLPGTNIVLGALPEDRHIDRLAKRQRPGERLDLAMLAAIRRVYGLLANTVRYLQGGGSWWEDWGQLSGTAVPPQGAEPQSNAGPRPHIGDTLFTLFRAPELLAPNGDLYNVFAWALDVLAKRLRPMHVFILDYDQSPAGCRDALLQLTSGMVQTHVTTPG SIPTICDLARTFAREMGEAN CD79B-CAR-SEQ ID MALPVTALLLPLALLLHAARPGSDIQLTQSPSSLSASVGDR CD28_CD34 NO: 36VTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIKRGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSSPRASTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRRTDGSGATNFSLLKQAGDVEENPGPVSEAMPRGWTALCLLSLLPSGFMSLDNNGTATPELPTQGTFSNVSTNVSYQETTTPSTLGSTSLHPVSQHGNEATTNITETTVKFTSTSVITSVYGNTNSSVQSQTSVISTVFTTPANVSTPETTLKPSLSPGNVSDLSTTSTSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLEQNKTSSCAEFKKDRGEGLARVLCGEEQADADAGAQVCSLLLAQSEVRPQCLLLVLANRTEISSKLQLMKKHQSDLKKLGILDFTEQDVASHQSYSQKTLIALVTSGALLAVLGITGYFLMNRRSWSPTGEGGGGGFKRDLGGVKLPHLFGKRLVEARMASYPCHQHASAFDQAARSRGHSNRRTALRPRRQQEATEVRLEQKMPTLLRVYIDGPHGMGKTTTTQLLVALGSRDDIVYVPEPMTYWQVLGASETIANIYTTQHRLDQGEISAGDAAVVMTSAQITMGMPYAVTDAVLAPHVGGEAGSSHAPPPALTLLLDRHPIAVMLCYPAARYLMGSMTPQAVLAFVALIPPTLPGTNIVLGALPEDRHIDRLAKRQRPGERLDLAMLAAIRRVYGLLANTVRYLQGGGSWWEDWGQLSGTAVPPQGAEPQSNAGPRPHIGDTLFTLFRAPELLAPNGDLYNVFAWALDVLAKRLRPMHVFILDYDQSPAGCRDALLQLTSGMVQTHVTTPGSIPTICDLARTFAREMGEAN CD2-CAR- SEQ IDMALPVTALLLPLALLLHAARPDIVMTQAAPSVPVTPGESVS CD28_CD34 NO: 37ISCRSSKTLLHSNGNTYLYWFLQRPGQSPQVLIYRMSNLASGVPNRFSGSGSETTFTLRISRVEAEDVGIYYCMQHLEYPYTFGGGTKLEIERGGGGSGGGGSGGGGSGGGGSEVQLEESGAELVRPGTSVKLSCKASGYTFTSYWMHWIKQRPEQGLEWIGRIDPYDSETHYNEKFKDKAILSVDKSSSTAYIQLSSLTSDDSAVYYCSRRDAKYDGYALDYWGQGTSVTVSSPRASTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALFIMQALPPRRTDGSGATNFSLLKQAGDVEENPGPVSEAMPRGWTALCLLSLLPSGFMSLDNNGTATPELPTQGTFSNVSTNVSYQETTTPSTLGSTSLHPVSQHGNEATTNITETTVKFTSTSVITSVYGNTNSSVQSQTSVISTVFTTPANVSTPETTLKPSLSPGNVSDLSTTSTSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLEQNKTSSCAEFKKDRGEGLARVLCGEEQADADAGAQVCSLLLAQSEVRPQCLLLVLANRTEISSKLQLMKKHQSDLKKLGILDFTEQDVASHQSYSQKTLIA LVTSGALLAVLGITGYFLMNRRSWSPICD2-CAR-4- SEQ ID MALPVTALLLPLALLLHAARPDIVMTQAAPSVPVTPGESVS 1BB_CD34NO: 38 ISCRSSKTLLHSNGNTYLYWFLQRPGQSPQVLIYRMSNLASGVPNRFSGSGSETTFTLRISRVEAEDVGIYYCMQHLEYPYTFGGGTKLEIERGGGGSGGGGSGGGGSGGGGSEVQLEESGAELVRPGTSVKLSCKASGYTFTSYWMHWIKQRPEQGLEWIGRIDPYDSETHYNEKFKDKAILSVDKSSSTAYIQLSSLTSDDSAVYYCSRRDAKYDGYALDYWGQGTSVTVSSPRASTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALFIMQALPPRRTDGSGATNFSLLKQAGDVEENPGPVSEAMPRGWTALCLLSLLPSGFMSLDNNGTATPELPTQGTFSNVSTNVSYQETTTPSTLGSTSLHPVSQHGNEATTNITETTVKFTSTSVITSVYGNTNSSVQSQTSVISTVFTTPANVSTPETTLKPSLSPGNVSDLSTTSTSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLEQNKTSSCAEFKKDRGEGLARVLCGEEQADADAGAQVCSLLLAQSEVRPQCLLLVLANRTEISSKLQLMKKHQSDLKKLGILDFTEQDVASHQSYSQKTLIA LVTSGALLAVLGITGYFLMNRRSWSPICD3-CD28-CD34 SEQ ID MALPVTALLLPLALLLHAARPGSQVQLQQSGAELARPGAS NO: 39VKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGGSGGGGSGGGGSQIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEINRPRASTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRRTDGSGATNFSLLKQAGDVEENPGPVSEAMPRGWTALCLLSLLPSGFMSLDNNGTATPELPTQGTFSNVSTNVSYQETTTPSTLGSTSLHPVSQHGNEATTNITETTVKFTSTSVITSVYGNTNSSVQSQTSVISTVFTTPANVSTPETTLKPSLSPGNVSDLSTTSTSLATSPTKPYTSSSPILSDIKAEIKCSGIREVKLTQGICLEQNKTSSCAEFKKDRGEGLARVLCGEEQADADAGAQVCSLLLAQSEVRPQCLLLVLANRTEISSKLQLMKKHQSDLKKLGILDFTEQDVASHQSYSQKTLIALV TSGALLAVLGITGYFLMNRRSWSPI

Tandem CAR-T Cells

A tandem CAR-T cell (tCAR-T), is a T cell with a single chimeric antigenpolypeptide comprising two distinct extracellular ligand-binding(antigen/protein recognition) domains capable of interacting with twodifferent cell surface molecules (e.g., antigen/protein), wherein theextracellular ligand-binding domains are linked together by one or moreflexible linkers and share one or more costimulatory domains, whereinthe binding of the first or second extracellular ligand-binding domainwill signal through one or more the costimulatory domains(s) and asignaling transducing domain.

In certain embodiments, the T cell is deficient in one or more antigensor cell surface proteins (e.g., CD7 and CD2 for a CD7*CD2-tCARΔCD7ΔCD2cell, or CD2 for a CD3*CD2-tCARΔCD3ΔCD2 cell). In non-limiting examples,the deficiency in the antigen(s) or cell surface protein(s) resultedfrom (a) modification of antigen or cell surface protein expressed bythe T cell such that the chimeric antigen receptor no longerspecifically binds the modified antigen(s) or cell surface protein(s)(e.g., the epitope of the one or more antigens recognized by thechimeric antigen receptor may be modified by one or more amino acidchanges (e.g., substitutions or deletions) or the epitope may be deletedfrom the antigen), (b) modification of the T cell such that expressionof antigen(s) or cell surface protein(s) is/are reduced in the T cell byat least 50%, at least 60%, at least 70%, at least 80%, at least 90% ormore, or (c) modification of the T cell such that antigen(s) or cellsurface protein(s) is/are not expressed (e.g., by deletion or disruptionof the gene encoding antigen or cell surface protein). In each of theabove embodiments, the CAR-T cell may be deficient in one or preferablyall the antigens or cell surface proteins to which the chimeric antigenreceptor specifically binds. The methods to genetically modify a T cellto be deficient in one or more antigens or cell surface proteins arewell known in art and non-limiting examples are provided herein. Inembodiments described below, the CRISPR-Cas9 system is used to modify aT cell to be deficient in one or more antigen(s) or cell surfaceprotein(s). Any of these may be accomplished by the methods disclosedherein. In further embodiments, the T cell comprises a suicide gene.

A tCAR for a genome-edited, tandem CAR-T cell, i.e.,CD2*CD3-tCARTΔCD2ΔCD3ε, may be generated by cloning a commerciallysynthesized anti-CD2 single chain variable fragment (scFv) and ananti-CD3 single chain variable fragment (scFv), separated by a peptidelinker, into a lentiviral vector containing, e.g., a 2^(nd) or 3^(rd)generation CAR backbone with CD28 and/or 4-1BB internal signalingdomains. An extracellular hCD34 domain may be added after a P2A peptideto enable both detection of CAR following viral transduction andpurification using anti-hCD34 magnetic beads. A similar method may befollowed for making tCARs specific for other malignant T cell antigens.

Tandem CARs may have different linker structures, i.e., be linear orhairpin, and the hairpin linker may optionally comprise a (Cys=Cys)double-stranded bond (DSB).

A linear tandem CAR-T cell comprises a chimeric antigen receptor (CAR)polypeptide comprising a first signal peptide, a first extracellularligand-binding domain, a second extracellular ligand-binding domain, ahinge region, a transmembrane domain, one or more co-stimulatorydomains, and a signaling transducing domain, wherein the firstextracellular ligand-binding antigen recognition domain and the secondextracellular ligand-binding antigen recognition domain have affinitiesfor different cell surface molecules, i.e., antigens on a cancer cell,for example, a malignant T cell, B cell, or plasma cell; and wherein thelinear tandem CAR-T cell possesses one or more genetic modifications,deletions, or disruptions resulting in reduced expression of the cellsurface molecules in the linear tandem CAR-T cell.

In another embodiment, the signal peptide is the signal peptide fromhuman CD8α.

In a third embodiment, the first extracellular ligand-binding domaincomprises a single chain antibody fragment (scFv), comprising the light(V_(L)) and the heavy (V_(H)) variable fragment, designated V_(H)1 andV_(L)1 and joined by a linker (e.g., GGGGS (SEQ ID NO: 3065)). In someembodiments, this linker peptide is repeated 2, 3, 4, 5 or 6 times. Insome embodiments, the first antigen recognition domain can be selectedfrom: I) V_(H)1—(GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(L)1 or 2)V_(L)1—(GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(H)1.

In some embodiments, the second extracellular ligand-binding domaincomprises a single chain antibody fragment (scFv), comprising the light(V_(L)) and the heavy (V_(H)) variable fragment, designated V_(H)2 andV_(L)2 and joined by a linker (e.g., GGGGS (SEQ ID NO: 3065)). In someembodiments, this linker peptide is repeated 2, 3, 4, 5 or 6 times. Insome embodiments, the first antigen recognition domain can be selectedfrom: 1) V_(H)2—(GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(L)2 or 2)V_(L)2—(GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(H)2.

In further embodiments, the first antigen recognition domain and secondantigen recognition domain are connected by a short linker peptide of 5amino acids (GGGGS (SEQ ID NO: 3065)). In some embodiments, this linkerpeptide is repeated 2, 3, 4, 5, or 6 times.

Tandem CAR Constructs

In one embodiment, the first extracellular ligand-binding domain antigenrecognition comprises a single chain antibody fragment (scFv),comprising the heavy (V_(H)) and the light (V_(L)) variable fragment,designated V_(H)1 and V_(L)1, and joined by a linker (e.g., GGGGS (SEQID NO: 3065)), targets a cell surface molecule, i.e., an antigenexpressed on a malignant cell.

In certain embodiments, the heavy (V_(H)) and the light (V_(L)) variablefragment, designated V_(H)1 and V_(L)1, targeting an antigen expressedon a malignant T cell is selected from BCMA, CS1, CD38, CD138, CD19,CD33, CD123, CD371, CD117, CD135, Tim-3, CD5, CD7, CD2, CD4, CD3, CD79A,CD79B, APRIL, CD56, and CD1a.

In certain embodiments, the second extracellular ligand-binding domainantigen recognition comprises a single chain antibody fragment (scFv),comprising the heavy (V_(H)) and the light (V_(L)) variable fragment,designated V_(H)2 and V_(L)2, and joined by a linker (e.g., GGGGS (SEQID NO: 3065)), and targets a cell surface molecule, i.e., an antigen,expressed on a malignant cell.

In certain embodiments, the heavy (V_(H)) and the light (V_(L)) variablefragments, designated V_(H)2 and V_(L)2, targeting an antigen expressedon a malignant T cell is selected from BCMA, CS1, CD38, CD138, CD19,CD33, CD123, CD371, CD117, CD135, Tim-3, CD5, CD7, CD2, CD4, CD3, CD79A,CD79B, APRIL, CD56, and CD1a and differs from the variable heavy(V_(H)1) and light sequences (V_(L)1) of the first extracellularligand-binding domain of the CAR molecule.

Additional examples of tandem CARs are given below in Table 5.

TABLE 5 Tandem CARs and CAR-Ts Example Antigen Target CAR-T cell AntigenDeletion/Suppression T1 APRILxBCMA — T2 APRILxCD19 — T3 APRILxCD38 — T4APRILxCD38 CD38 T5 APRILx CS1 — T6 APRILx CS1 CS1 T7 BCMAxCD19 — T8BCMAxCD38 — T9 BCMAxCD38 CD38 T10 BCMAxCS1 — T11 BCMAxCS1 CS1 T12CD138xAPRIL T13 CD138xBCMA T14 CD138xCD19 T15 CD138xCD38 T16 CD138xCD38CD38 T17 CD138xCD79A T18 CD138xCD79B T19 CD138xCS1 T20 CD138xCS1 CS1 T21CD19xCD38 — T22 CD19xCD38 CD3ε T23 CD2xCD3ε — T24 CD2xCD3ε CD2 T25CD2xCD3ε CD3ε T26 CD2xCD3ε CD2 and CD3ε T27 CD2xCD4 — T28 CD2xCD4 CD2T29 CD2xCD4 CD4 T30 CD2xCD4 CD2 and CD4 T31 CD2xCD4 CD2 and TRAC T32CD2xCD4 CD4 and TRAC T33 CD2xCD4 CD2 and CD4 and TRAC T34 CD2xCD5 — T35CD2xCD5 CD2 T36 CD2xCD5 CD5 T37 CD2xCD5 CD2 and CD5 T38 CD2xCD5 CD2 andTRAC T39 CD2xCD5 CD5 and TRAC T40 CD2xCD5 CD2 and CD5 and TRAC T41CD2xCD7 — T42 CD2xCD7 CD2 T43 CD2xCD7 CD7 T44 CD2xCD7 CD2 and CD7 T45CD2xCD7 CD2 and TRAC T46 CD2xCD7 CD7 and TRAC T47 CD2xCD7 CD2 and CD7and TRAC T48 CD3εxCD4 — T49 CD3εxCD4 CD3ε T50 CD3εxCD4 CD4 T51 CD3εxCD4CD3ε and CD4 T52 CD3εxCD5 — T53 CD3εxCD5 CD3ε T54 CD3εxCD5 CD5 T55CD3εxCD5 CD3ε and CD5 T56 CD3εxCD7 — T57 CD3εxCD7 CD3ε T58 CD3εxCD7 CD7T59 CD3εxCD7 CD3ε and CD7 T60 CD4xCD5 — T61 CD4xCD5 CD4 T62 CD4xCD5 CD5T63 CD4xCD5 CD4 and CD5 T64 CD4xCD5 CD4 and TRAC T65 CD4xCD5 CD5 andTRAC T66 CD4xCD5 CD4 and CD5 and TRAC T67 CD4xCD7 — T68 CD4xCD7 CD4 T69CD4xCD7 CD7 T70 CD4xCD7 CD4 and CD7 T71 CD4xCD7 CD4 and TRAC T72 CD4xCD7CD4 and TRAC T73 CD4xCD7 CD4 and CD7 and TRAC T74 CD5xCD7 — T75 CD5xCD7CD5 T76 CD5xCD7 CD7 T77 CD5xCD7 CD5 and CD7 T78 CD5xCD7 CD5 and TRAC T79CD5xCD7 CD7 and TRAC T80 CD5xCD7 CD5 and CD7 and TRAC T81 CD79AxAPRILT82 CD79AxBCMA T83 CD79AxCD19 T84 CD79AxCD38 T85 CD79AxCD38 CD38 T86CD79AxCD79B T87 CD79AxCS1 T88 CD79AxCS1 CS1 T89 CD79BxAPRIL T90CD79BxBCMA T91 CD79BxCD19 T92 CD79BxCD38 T93 CD79BxCD38 CD38 T94CD79BxCD79A T95 CD79BxCS1 T96 CD79BxCS1 CS1 T97 CS1xCD19 — T98 CS1xCD19CS1 T99 CS1xCD38 — T100 CS1xCD38 CS1 T101 CS1xCD38 CD38 T102 CS1xCD38CS1 and CD38 T103 TCRβxCD2 — T104 TCRβxCD2 TCRβ T105 TCRβxCD2 CD2 T106TCRβxCD2 TCRβ and CD2 T107 TCRβxCD3ε — T108 TCRβxCD3ε TCRβ T109TCRβxCD3ε CD3ε T110 TCRβxCD3ε TCRβ and CD3ε T111 TCRβxCD4 — T112TCRβxCD4 TCRβ T113 TCRβxCD4 CD4 T114 TCRβxCD4 TCRβ and CD4 T115 TCRβxCD5— T116 TCRβxCD5 TCRβ T117 TCRβxCD5 CD5 T118 TCRβxCD5 TCRβ and CD5 T119TCRβxCD7 — T120 TCRβxCD7 TCRβ T121 TCRβxCD7 CD7 T122 TCRβxCD7 TCRβ andCD7 T123 TRACxCD2 — T124 TRACxCD2 TRAC T125 TRACxCD2 CD2 T126 TRACxCD2TRAC and CD2 T127 TRACxCD3ε — T128 TRACxCD3ε TRAC T129 TRACxCD3ε CD3εT130 TRACxCD3ε TRAC and CD3ε T131 TRACxCD4 — T132 TRACxCD4 TRAC T133TRACxCD4 CD4 T134 TRACxCD4 TRAC and CD4 T135 TRACxCD5 — T136 TRACxCD5TRAC T137 TRACxCD5 CD5 T138 TRACxCD5 TRAC and CD5 T139 TRACxCD7 — T140TRACxCD7 TRAC T141 TRACxCD7 CD7 T142 TRACxCD7 TRAC and CD7

In some embodiments, hairpin tandem CAR constructs may be providedherein, such as including, but not limited to, a construct incorporatingthe V_(H) and V_(L) domains of CD2 and CD3 scFvs (Table 6).

TABLE 6 Hairpin Tandem CAR Constructs Targeting CD2 and CD3. Clone 5Clone 6 Clone 7 Clone 8 Clone 13 Clone 14 Clone 15 Clone 16 CD8a CD8aCD8a CD8a CD8a CD8a CD8a CD8a CD3-V_(L) CD3-V_(L) CD3-V_(L) CD3-V_(L)CD2-V_(L) CD2-V_(L) CD3-V_(L) CD3-V_(L) GGGGS₄ GGGGS₄ GGGGS₄ GGGGS₄GGGGS₄ GGGGS₄ GGGGS₄ GGGGS₄ (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID(SEQ ID (SEQ ID (SEQ ID NO: 9) NO: 9) NO: 9) NO: 9) NO: 9) NO: 9) NO: 9)NO: 9) CD2-V_(L) CD2-V_(L) CD2-V_(L) CD2-V_(L) CD3-V_(L) CD3-V_(L)CD2-V_(L) CD2-V_(L) (GGGGS)₁₀ (GGGGS)₄ (GGGGS)₁₀ (GGGGS)₄ (GGGGS)₁₀(GGGGS)₄ (GGGGS)₁₀ (GGGGS)₄ (SEQ GGGG (SEQ GGGG (SEQ GGGG (SEQ GGGGID NO: P(GGGGS)₄ ID NO: P(GGGGS)₄ ID NO: P(GGGGS)₄ ID NO: P(GGGGS)₄3067) (SEQ 3067) (SEQ 3067) (SEQ 3067) (SEQ ID NO: ID NO: ID NO: ID NO:3068) 3068) 3068) 3068) CD2-V_(H) CD2-V_(H) CD2-V_(H) CD2-V_(H)CD3-V_(H) CD3-V_(H) CD2-V_(H) CD2-V_(H) GGGGS₄ GGGGS₄ GGGGS₄ GGGGS₄GGGGS₄ GGGGS₄ GGGGS₄ GGGGS₄ (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID(SEQ ID (SEQ ID (SEQ ID NO: 9) NO: 9) NO: 9) NO: 9) NO: 9) NO: 9) NO: 9)NO: 9) CD3-V_(H) CD3-V_(H) CD3-V_(H) CD3-V_(H) CD2-V_(H) CD2-V_(H)CD3-V_(H) CD3-V_(H) CD28 CD28 CD28 CD28 CD28 CD28 CD28 CD28 Tm Tm Tm TmTm Tm Tm Tm CD28 CD28 CD28 CD28 CD28 CD28 CD28 CD28 CD3z₍₁₋₂₎ CD3z₍₁₋₂₎CD3z₍₁₋₂₎ CD3z₍₁₋₂₎ CD3z₍₁₋₂₎ CD3z₍₁₋₂₎ CD3z₍₁₋₂₎ CD3z₍₁₋₂₎ P2A P2A P2AP2A P2A P2A P2A P2A CD34 CD34 CD34 CD34 CD34 CD34 CD34 CD34

Dual CAR-T Cells

In certain embodiments, the disclosure provides an engineered T cellwith two distinct chimeric antigen receptor polypeptides with affinityto different antigen(s) or cell surface protein(s) expressed within thesame effector cell, wherein each CAR functions independently. The CARmay be expressed from single or multiple polynucleotide sequences thatspecifically bind different antigen(s) or cell surface protein(s),wherein the T cell is deficient in the antigen(s) or cell surfaceprotein(s) to which the CARs bind (e.g., CD7*CD2-dCARΔCD7ACD2 cell). Innon-limiting examples, the deficiency in the antigen(s) or cell surfaceprotein(s) resulted from (a) modification of antigen or cell surfaceprotein expressed by the T cell such that the chimeric antigen receptorno longer specifically binds the modified antigen(s) or cell surfaceprotein(s) (e.g., the epitope of the one or more antigens recognized bythe chimeric antigen receptor may be modified by one or more amino acidchanges (e.g., substitutions or deletions) or the epitope may be deletedfrom the antigen), (b) modification of the T cell such that expressionof antigen(s) or cell surface protein(s) is/are reduced in the T cell byat least 50%, at least 60%, at least 70%, at least 80%, at least 90% ormore, or (c) modification of the T cell such that antigen(s) or cellsurface protein(s) is/are not expressed (e.g., by deletion or disruptionof the gene encoding antigen or cell surface protein). In each of theabove embodiments, the CAR-T cell may be deficient in one or preferablyall the antigens or cell surface proteins to which the chimeric antigenreceptor specifically binds. The methods to genetically modify a T cellto be deficient in one or more antigens or cell surface proteins arewell known in art and non-limiting examples are provided herein. Inembodiments described below, the CRISPR-Cas9 system is used to modify aT cell to be deficient in one or more antigen(s) or cell surfaceprotein(s). Any of these may be accomplished by the methods disclosedherein. In further embodiments, the T cell comprises a suicide gene.

A dCAR for a genome-edited, dual CAR-T cell, i.e.,CD2*CD3ε-dCARTΔCD2ΔCD3ε, may be generated by cloning a commerciallysynthesized anti-CD2 single chain variable fragment into a lentiviralvector containing, e.g., a 2^(nd) or 3^(rd) generation CAR backbone withCD28 and/or 4-1BB internal signaling domains and cloning a commerciallysynthesized anti-CD3ε single chain variable into the same lentiviralvector containing an additional 2^(nd) or 3^(rd) generation CAR backbonewith CD28 and/or 4-1BB internal signaling domains resulting in a plasmidfrom which the two CAR constructs are expressed from the same vector. Anextracellular hCD34 domain may be added after a P2A peptide to enableboth detection of CAR following viral transduction and purificationusing anti-hCD34 magnetic beads. A similar method may be followed formaking tCARs specific for other malignant T cell antigens.

In a similar manner, other dual CARs may be constructed and are givenbelow in Tables 5-7.

In one embodiment, a dual CAR-T cell comprises (i) a first chimericantigen receptor (CAR) polypeptide comprising a first signal peptide, afirst antigen recognition domain, a first hinge region, a firsttransmembrane domain, a first co-stimulatory domain, and a firstsignaling domain; and (ii) a second chimeric antigen receptorpolypeptide comprising a second signaling peptide, a second antigenrecognition domain, a second hinge region, a second transmembranedomain, a second co-stimulatory domain, and a second signaling domain;wherein the first antigen recognition domain and the second antigenrecognition domain have affinities for different target antigens; andwherein the dual CAR-T cell possesses one or more genetic disruptionsresulting in reduced expression of the target antigen in the dual CAR-Tcell.

In a second embodiment, the first signal peptide is a CD8a signalsequence.

In a third embodiment, the first antigen recognition domain is fusionprotein of the variable regions of immunoglobulin heavy and lightchains, designated V_(H)1 and V_(L)1, for the first antigen recognitiondomain, connected by a short linker peptide of 5 amino acids (GGGGS)₃₋₄(SEQ ID NO: 3065)). In some embodiments, this linker peptide is repeated3 or 4 times. In some embodiments, the first antigen recognition domaincan be selected from V_(H)1—(GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(L)1 orV_(L)1—(GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(H)1.

In some embodiments, the first hinge region comprises CD8a.

In some embodiments, the first transmembrane domain is CD8 or CD28.

In some embodiments, the first co-stimulatory domain comprises 4-1BB,CD28, or a combination of both, in either order, i.e., 4-1BB-CD28 orCD28-4-1BB.

In some embodiments, the first signaling domain is CD3ζ or a CD3ζbi-peptide., i.e., CD3ζ-CD3ζ.

In some embodiments, the second signal peptide is a CD8a signal sequenceof SEQ NO:1.

In some embodiments, the second antigen recognition domain is fusionprotein of the variable regions of immunoglobulin heavy and lightchains, designated V_(H)2 and V_(L)2, for the second antigen recognitiondomain, connected by a short linker peptide of 5 amino acids (GGGGS (SEQID NO: 3065)). In some embodiments, this linker peptide is repeated 3 or4 times. In some embodiments, the second antigen recognition domain canbe selected from V_(H)2—(GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(L)2 orV_(L)2—(GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(H)2.

In some embodiments, the second hinge region comprises CD8a.

In some embodiments, the second transmembrane domain is CD8 or CD28.

In some embodiments, the second co-stimulatory domain comprises 4-1BB,CD28, or a combination of both, in either order, i.e., 4-1BB-CD28 orCD28-4-1BB.

In some embodiments, the second signaling domain is CD3ζ or a CD3ζbi-peptide, i.e., CD3ζ-CD3ζ.

In some embodiments, the CAR polypeptide comprises a first antigenrecognition domain fusion protein of V_(H)1—(GGGGS)₃₋₄ (SEQ ID NO:3066)—V_(L)1 and a second antigen recognition domain fusion protein ofV_(H)2—(GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(L)2.

In some embodiments, the CAR polypeptide comprises a first antigenrecognition domain fusion protein of V_(L)1—(GGGGS)₃₋₄ (SEQ ID NO:3066)—V_(H)1 and a second antigen recognition domain fusion protein ofV_(L)2—(GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(H)2.

In some embodiments, the CAR polypeptide comprises a first antigenrecognition domain fusion protein of V_(H)2—(GGGGS)₃₋₄ (SEQ ID NO:3066)—V_(L)2 and a second antigen recognition domain fusion protein ofV_(H)1—(GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(L)1.

In some embodiments, the CAR polypeptide comprises a first antigenrecognition domain fusion protein of V_(L)2—(GGGGS)₃₋₄ (SEQ ID NO:3066)—V_(H)2 and a second antigen recognition domain fusion protein ofV_(L)1—(GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(H)1.

In some embodiments, the CAR polypeptide comprises a first antigenrecognition domain fusion protein of V_(H)1—(GGGGS)₃₋₄ (SEQ ID NO:3066)—V_(L)I and a second antigen recognition domain fusion protein ofV_(L)2 (GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(H)2.

In some embodiments, the CAR polypeptide comprises a first antigenrecognition domain fusion protein of V_(L)1—(GGGGS)₃₋₄ (SEQ ID NO:3066)—V_(H)1 and a second antigen recognition domain fusion protein ofV_(H)2—(GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(L)2.

In some embodiments, the CAR polypeptide comprises a first antigenrecognition domain fusion protein of V_(H)2—(GGGGS)₃₋₄ (SEQ ID NO:3066)—V_(L)2 and a second antigen recognition domain fusion protein ofV_(L)1—(GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(H)1.

In some embodiments, the CAR polypeptide comprises a first antigenrecognition domain fusion protein of V_(L)2—(GGGGS)₃₋₄ (SEQ ID NO:3066)—V_(H)2 and a second antigen recognition domain fusion protein ofV_(H)1 (GGGGS)₃₋₄ (SEQ ID NO: 3066)—V_(L)1.

In some embodiments, the CAR polypeptide comprises at least one highefficiency cleavage site, wherein the high efficiency cleavage site isselected from P2A, T2A, E2A, and F2A.

In some embodiments, the CAR polypeptide comprises a suicide gene.

In some embodiments, the CAR polypeptide comprises a mutant cytokinereceptor.

In some embodiments, the dual CAR-T cell targets two antigens selectedfrom CD5, CD7, CD2, CD4, CD3, CD33, CD123 (IL3RA), CD371 (CLL-1;CLEC12A), CD117 (c-kit), CD135 (FLT3), BCMA, CS1, CD38, CD79A, CD79B,CD138, and CD19, APRIL, and TACI.

Additional examples of dual CARs are given below in Table 7.

TABLE 7 Dual CARs and dCAR-Ts Antigen Targets of CARs Antigen Deletion/Example in dCAR-T cell Suppression D1 APRILxBCMA — D2 APRILxCD19 — D3APRILxCD38 — D4 APRILxCD38 CD38 D5 APRILxCS1 — D6 APRILxCS1 CS1 D7BCMAxCD19 — D8 BCMAxCD38 — D9 BCMAxCD38 CD38 D10 BCMAxC S1 — D11 BCMAxCS1 CS1 D12 CD138xAPRIL D13 CD138xBCMA D14 CD138xCD19 D15 CD138xCD38 D16CD138xCD38 CD38 D17 CD138xCD79A D18 CD138xCD79B D19 CD138xCS1 D20CD138xCS1 CS1 D21 CD19xCD38 — D22 CD19xCD38 CD38 D23 CD2xCD3ε — D24CD2xCD3ε CD2 D25 CD2xCD3ε CD3ε D26 CD2xCD3ε CD2 and CD3ε D27 CD2xCD4 —D28 CD2xCD4 CD2 D29 CD2xCD4 CD4 D30 CD2xCD4 CD2 and CD4 D31 CD2xCD4 CD2and TRAC D32 CD2xCD4 CD4 and TRAC D33 CD2xCD4 CD2 and CD4 and TRAC D34CD2xCD5 — D35 CD2xCD5 CD2 D36 CD2xCD5 CD5 D37 CD2xCD5 CD2 and CD5 D38CD2xCD5 CD2 and TRAC D39 CD2xCD5 CD5 and TRAC D40 CD2xCD5 CD2 and CD5and TRAC D41 CD2xCD7 — D42 CD2xCD7 CD2 D43 CD2xCD7 CD7 D44 CD2xCD7 CD2and CD7 D45 CD2xCD7 CD2 and TRAC D46 CD2xCD7 CD7 and TRAC D47 CD2xCD7CD2 and CD7 and TRAC D48 CD3εxCD4 — D49 CD3εxCD4 CD3ε D50 CD3εxCD4 CD4D51 CD3εxCD4 CD3ε and CD4 D52 CD3εxCD5 — D53 CD3εxCD5 CD3ε D54 CD3εxCD5CD5 D55 CD3εxCD5 CD3ε and CD5 D56 CD3εxCD7 — D57 CD3εxCD7 CD3ε D58CD3εxCD7 CD7 D59 CD3εxCD7 CD3ε and CD7 D60 CD4xCD5 — D61 CD4xCD5 CD4 D62CD4xCD5 CD5 D63 CD4xCD5 CD4 and CD5 D64 CD4xCD5 CD4 and TRAC D65 CD4xCD5CD5 and TRAC D66 CD4xCD5 CD4 and CD5 and TRAC D67 CD4xCD7 — D68 CD4xCD7CD4 D69 CD4xCD7 CD7 D70 CD4xCD7 CD4 and CD7 D71 CD4xCD7 CD4 and TRAC D72CD4xCD7 CD7 and TRAC D73 CD4xCD7 CD4 and CD7 and TRAC D74 CD5xCD7 — D75CD5xCD7 CD5 D76 CD5xCD7 CD7 D77 CD5xCD7 CD5 and CD7 D78 CD5xCD7 CD5 andTRAC D79 CD5xCD7 CD7 and TRAC D80 CD5xCD7 CD5 and CD7 and TRAC D81CD79AxAPRIL D82 CD79AxBCMA D83 CD79AxCD19 D84 CD79AxCD38 D85 CD79AxCD38CD38 D86 CD79AxCD79B D87 CD79AxCS1 D88 CD79AxCS1 CS1 D89 CD79BxAPRIL D90CD79BxBCMA D91 CD79BxCD19 D92 CD79BxCD38 D93 CD79BxCD38 CD38 D94CD79BxCD79A D95 CD79BxCS1 D96 CD79BxCS1 CS1 D97 CS1xCD19 — D98 CS1xCD19CS1 D99 CS1xCD38 — D100 CS1xCD38 CS1 D101 CS1xCD38 CD38 D102 CS1xCD38CS1 and CD38 D103 TCRβxCD2 — D104 TCRβxCD2 TCRβ D105 TCRβxCD2 CD2 D106TCRβxCD2 TCRβ and CD2 D107 TCRβxCD3ε — D108 TCRβxCD3ε TCRβ D109TCRβxCD3ε CD3ε D110 TCRβxCD3ε TCRβ and CD3ε D111 TCRβxCD4 — D112TCRβxCD4 TCRβ D113 TCRβxCD4 CD4 D114 TCRβxCD4 TCRβ and CD4 D115 TCRβxCD5— D116 TCRβxCD5 TCRβ D117 TCRβxCD5 CD5 D118 TCRβxCD5 TCRβ and CD5 D119TCRβxCD7 — D120 TCRβxCD7 TCRβ D121 TCRβxCD7 CD7 D122 TCRβxCD7 TCRβ andCD7 D123 TRACxCD2 — D124 TRACxCD2 TRAC D125 TRACxCD2 CD2 D126 TRACxCD2TRAC and CD2 D127 TRACxCD3ε — D128 TRACxCD3ε TRAC D129 TRACxCD3ε CD3εD130 TRACxCD3ε TRAC and CD3ε D131 TRACxCD4 — D132 TRACxCD4 TRAC D133TRACxCD4 CD4 D134 TRACxCD4 TRAC and CD4 D135 TRACxCD5 — D136 TRACxCD5TRAC D137 TRACxCD5 CD5 D138 TRACxCD5 TRAC and CD5 D139 TRACxCD7 — D140TRACxCD7 TRAC D141 TRACxCD7 CD7 D142 TRACxCD7 TRAC and CD7

Cytokine/Chemokine/Transcription Factor Gene Deletion or Suppression

Cytokine release syndrome (CRS) is caused by a large, rapid release ofcytokines from immune cells in response to immunotherapy (or otherimmunological stimulus). Accordingly, reducing the level of cytokinesreleased would prevent or reduce the development and/or maintenance ofCRS. As disclosed herein, this can be accomplished by modifying,disrupting, or deleting one or more cytokine/chemokine/transcriptionfactor genes. One method to accomplish this is genetic ablation (genesilencing) in which gene expression is abolished through the alterationor deletion of genetic sequence information. This can be accomplishedusing known genetic engineering tools in the art such as TranscriptionActivator-like Effector Nucleases (TALENs), Zinc Finger Nucleases(ZFNs), CRISPR, and also by transfection of small interfering RNAs(siRNAs).

Another technique is expression of an scFv with an endoplasmic reticulum(ER) binding tether to bind the cytokine in the ER and preventsecretion. Specific constructs, named protein expression blockers(PEBLs), prevent transport of targeted proteins to the cell membrane.PEBL constructs can be readily combined with other gene modificationsystems for ex vivo cell processing of immune cells. A short hairpin RNAor small hairpin RNA (shRNA/Hairpin Vector) is an artificial RNAmolecule with a tight hairpin turn that can be used to silence targetgene expression, i.e., of antigens, via RNA interference (RNAi).Expression of shRNA in cells is typically accomplished by delivery ofplasmids or through viral or bacterial vectors.

Cytokines or chemokines that can be deleted from immune effector cellsas disclosed herein, e.g., by targeted transduction of a CAR into thegene sequence of the cytokine, include without limitation the following:XCL1, XCL2, CCL1, CCL2, CCL3, CCL4, CCLS, CCL7, CCL8, CCL11, CCL13,CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23,CCL24, CCL25, CCL26, CCL27, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6,CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CX3CL1,IL-1α, IL-1β, IL-1RA, IL-18, IL-2, IL-4, IL-7, IL-9, IL-13, IL-15, IL-3,IL-5, GM-CSF, IL-6, IL-11, G-CSF, IL-12, LIF, OSM, IL-10, IL-20, IL-14,IL-16, IL-17, IFN-α, IFN-γ, CD154, LT-β, TNF-α, TNF-β, 4-1BBL, APRIL,CD70, CD153, CD178, GITRL, LIGHT, OX40L, TALL-1, TRAIL, TWEAK, TRANCE,TGF-62 1, TGF-β2, TGF-β3, Epo, Tpo, Flt-3L, SCF, M-CSF, MSP, A2M, ACKR1,ACKR2, ACKR3, ACVR1, ACVR2B, ACVRL1, ADIPOQ, AGER, AGRN, AIMP1, AREG,BMP1, BMP10, BMP15, BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8A, BMP8B,BMPR2, C10orf99, C1QTNF4, C5, CCL28, CCR1, CCR2, CCR3, CCR5, CCR6, CCR7,CD109, CD36, CD4, CD40LG, CD74, CER1, CHRD, CKLF, CLCF1, CMTM1, CMTM2,CMTM3, CMTM4, CMTM5, CMTM6, CMTM7, CMTM8, CNTF, CNTFR, COPS5, CRLF1,CSF1, CSF1R, CSF2, CSF3, CSF3R, CTF1, CX3CR1, CXCL16, CXCL17, CXCR1,CXCR2, CXCR3, CXCR4, CXCR6, EBI3, EDN1, ELANE, ENG, FAM3B, FAM3C, FAM3D,FAS, FASLG, FGF2, FLT3LG, FZD4, GBP1, GDF1, GDF10, GDF11, GDF15, GDF2,GDF3, GDF5, GDF6, GDF7, GDF9, GPI, GREM1, GREM2, GRN, HAX1, HFE2, HMGB1,HYAL2, IFNA10, IFNA14, IFNA16, IFNA2, IFNA5, IFNA6, IFNA8, IFNAR1,IFNAR2, IFNB1, IFNE, IFNG, IFNGR1, IFNK, IFNL1, IFNL3, IFNW1, IL10RA,IL11RA, IL12A, IL12B, IL12RB1, IL17A, IL17B, IL17C, IL17D, IL17F,IL18BP, IL-19, IL1F10, IL1R1, IL1R2, IL1RAPL1, IL1RL1, IL1RN, IL20RA,IL20RB, IL21, IL22, IL22RA1, IL22RA2, IL23A, IL23R, IL24, IL25, IL26,IL27, IL2RA, IL2RB, IL2RG, IL31, IL31RA, IL32, IL33, IL34, IL36A, IL36B,IL36G, IL36RN, IL37, IL6R, IL6ST, INHA, INHBA, INHBB, INHBC, INHBE,ITGA4, ITGAV, ITGB1, ITGB3, KIT, KITLG, KLHL20, LEFTY1, LEFTY2, LIFR,LTA, LTB, LTBP1, LTBP3, LTBP4, MIF, MINOS1-, MSTN, NAMPT, NBL1, NDP,NLRP7, NODAL, NOG, NRG1, NRP1, NRP2, OSMR, PARK7, PDPN, PF4, PF4V1,PGLYRP1, PLP2, PPBP, PXDN, SCG2, SCGB3A1, SECTM1, SLURP1, SOSTDC1,SP100, SPP1, TCAP, TGFBR1, TGFBR2, TGFBR3, THBS1, THNSL2, THPO, TIMP1,TNF, TNFRSF11, TNFRSF1A, TNFRSF9, TNFRSF10, TNF SF11, TNFSF12, TNFSF12-,TNFSF13, TNFSF13B, TNFSF14, TNFSF15, TNFSF18, TNFSF4, TNFSF8, TNFSF9,TRIM16, TSLP, TWSG1, TXLNA, VASN, VEGFA, VSTM1, WFIKKN1, WFIKKN2, WNT1,WNT2, WNTSA, WNT7A, and ZFP36.

In some embodiments, the cytokine is chosen from cytokine is chosen fromMCP1 (CCL2), MCP-2, GM-CSF, G-CSF, M-CSF, Il-4, and IFNγ.

In certain embodiments, transcription factors that can be deleted fromimmune effector cells as disclosed herein include AHR, BCL6, FOXP3,GATA3, MAF, RORC, SPI1, and TBX21.

The sequences of these genes are known and available in the art and caninclude, for example, those provided in Table 10.

Selection of Priority Target Genes

Cytokine/chemokine gene targets of specific interest for deletion orsuppression (e.g., ablation, knock-out, KO) in CAR-T cells for themitigation of CRS have been categorized into groups based on biologicalfunction. CRS development is dependent upon CAR-T cell activation andsubsequent cytokine release, which initiates a dysregulated immunesystem in the recipient of the CAR-T cell therapy. Several studies haveindicated that recipient myeloid activation is necessary for thedevelopment of CRS.

The first group of potential genes to KO in CAR-T are surface receptorsthat, when engaged with myeloid cells in normal immunological responsesactivate the myeloid cells (e.g., CD40L). The second group are cytokinesthat are released from CAR-T cells that activate myeloid cells (e.g.,GM-CSF). In both these categories, the goal is to prevent CAR-T cellsignaling, which will activate recipient myeloid cells and initiate CRS.

The third category of targets are endogenous T cell receptors thatincrease T cell activation (potentially in the absence of tumor target)that are integrated into the CAR-T receptor (e.g., endogenous CD28). Theaim is to curtail activation of the CAR-T from non-tumor interactions,such as activated myeloid cells that could engage with CD28 on activatedT cells, thus amplifying T cell cytokine production and subsequentmyeloid activation.

The fourth and fifth categories of gene KO targets are transcriptionfactors and cytokines that drive CAR-T cell differentiation andsubsequent functional characteristics. CAR-T cells that arephenotypically similar to normal cytotoxic T cells (CTL, typicallyidentified by CD8 expression) are capable of direct tumor killingthrough T cell mediated effector functions. CTL are supported andmaintained by T helper cells (expressing CD4). Importantly, subsets of Thelper cells can support CTL (i.e., Thl cells) or inhibit (i.e., Th2cells). Other T cells, such as Tregs can also inhibit CTL developmentand function. The aim is to target cytokines or transcription factors inthe CAR-T population that would lead to CAR-T differentiation intonon-cytotoxic T cell populations. Additionally, Th2 cells producecytokines (such as GM-CSF and IL-4), which are indicative markers ofCRS. It is likely that CAR-T phenotypes, which cannot optimally killtumor cells, will be activated via CAR-T receptors, produce signals thatdrive CRS in the host, increase the time required for tumor killing, andrequire higher CAR-T cell doses than optimized “killing” products. Thus,knocking out or ablating (or suppressing) transcription factors (such asGATA3) or cytokines (such as IL-4) will prevent (or reduce) Th2 bias andreduce CRS.

Of additional interest regarding both myeloid activating cytokines andoptimized CAR-T cell differentiation is the potential to mitigate CAR-Tneurotoxicity. Neurotoxicity occurs in a small population of CAR-Trecipients with CRS. Research has shown that CRS patients that progressto develop neurotoxicity have increased IL-5 and ferritin levels(Santomasso et al., 2017 and Philip et al., 2019). These two biomarkersindicate that mast cell activation may be involved with CNScomplications. IL-5 is a key cytokine produced by Th2 cells, eosinophilsand mast cells. Excessive levels of ferritin are observed inmastocytosis and several diseases involving mast cell dysregulation.Additionally, many mast cell diseases include neurologicaldysregulation. Given raised levels of IL-5, ferritin, and neurologicaltoxicity in some patients, reducing mast cell activation by cytokinessuch as IL-5, or preventing Th2 cell development which drivesIL-5-dependent mast cell activation, may also mitigate neurologicalcomplications seen in CRS recipients. With respect to CNS complications,CX3CR1 and OX40 were also highlighted, due to previously demonstratedhigh T cell burden in the CNS. CX3CR1 is a T cell chemokine receptorthat principally directs T cells and potentially CAR-T cells into theCNS. OX40 is the T cell receptor which facilitates activation bycell-cell interaction with OX40L on eosinophils and mast cells.

Thus, in certain embodiments, the cytokine is chosen from CCL2 (MCP1),MCP-2, GM-CSF, G-CSF, M-CSF, Il-4, and IFNγ.

Indications and Standards of Care in CAR-T Therapy

In some embodiment, the genome-edited immune effector cells disclosedherein, and/or generated using the methods disclosed herein, express oneor more chimeric antigen receptors (CARs) and can be used as amedicament, i.e., for the treatment of disease. In many embodiments, thecells are CAR-T cells.

Cells disclosed herein, and/or generated using the methods disclosedherein, may be used in immunotherapy and adoptive cell transfer, for thetreatment, or the manufacture of a medicament for treatment, of cancers,autoimmune diseases, infectious diseases, and other conditions.

The cancer may be a hematologic malignancy or solid tumor. Hematologicmalignancies include leukemias, lymphomas, multiple myeloma, andsubtypes thereof. Lymphomas can be classified various ways, often basedon the underlying type of malignant cell, including Hodgkin's lymphoma(often cancers of Reed-Sternberg cells, but also sometimes originatingin B cells; all other lymphomas are non-Hodgkin's lymphomas), B-celllymphomas, T-cell lymphomas, mantle cell lymphomas, Burkitt's lymphoma,follicular lymphoma, and others as defined herein and known in the art.

B-cell lymphomas include, but are not limited to, diffuse large B-celllymphoma (DLBCL), chronic lymphocytic leukemia (CLL)/small lymphocyticlymphoma (SLL), and others as defined herein and known in the art.

T-cell lymphomas include T-cell acute lymphoblastic leukemia/lymphoma(T-ALL), peripheral T-cell lymphoma (PTCL), T-cell chronic lymphocyticleukemia (T-CLL) Sezary syndrome, and others as defined herein and knownin the art.

Leukemias include Acute myeloid (or myelogenous) leukemia (AML), chronicmyeloid (or myelogenous) leukemia (CML), acute lymphocytic (orlymphoblastic) leukemia (ALL), chronic lymphocytic leukemia (CLL) hairycell leukemia (sometimes classified as a lymphoma), and others asdefined herein and known in the art.

Plasma cell malignancies include lymphoplasmacytic lymphoma,plasmacytoma, and multiple myeloma.

In some embodiments, the medicament can be used for treating cancer in apatient, particularly for the treatment of solid tumors such asmelanomas, neuroblastomas, gliomas or carcinomas such as tumors of thebrain, head and neck, breast, lung (e.g., non small cell lung cancer,NSCLC), reproductive tract (e.g., ovary), upper digestive tract,pancreas, liver, renal system (e.g., kidneys), bladder, prostate andcolorectum.

In another embodiment, the medicament can be used for treating cancer ina patient, particularly for the treatment of hematologic malignanciesselected from multiple myeloma and acute myeloid leukemia (AML) and forT-cell malignancies selected from T-cell acute lymphoblastic leukemia(T-ALL), non-Hodgkin's lymphoma, and T-cell chronic lymphocytic leukemia(T-CLL).

In some embodiments, the cells may be used in the treatment ofautoimmune diseases such as lupus, autoimmune (rheumatoid) arthritis,multiple sclerosis, transplant rejection, Crohn's disease, ulcerativecolitis, dermatitis, and the like. In some embodiments, the cells arechimeric autoantibody receptor T-cells, or CAAR-Ts displaying antigensor fragments thereof, instead of antibody fragments; in this version ofadoptive cell transfer, the B cells that cause autoimmune diseases willattempt to attack the engineered T cells, which will respond by killingthem.

In some embodiments, the cells may be used in the treatment ofinfectious diseases such as HIV and tuberculosis.

In another embodiment, the CAR-T cells of the present disclosure canundergo robust in vivo T cell expansion and can persist for an extendedamount of time.

In some embodiments, the treatment of a patient with CAR-T cells of thepresent disclosure can be ameliorating, curative or prophylactic. It maybe either part of an autologous immunotherapy or part of an allogenicimmunotherapy treatment. By autologous, it is meant that cells, cellline or population of cells used for treating patients are originatingfrom said patient or from a Human Leucocyte Antigen (HLA) compatibledonor. By allogeneic, is meant that the cells or population of cellsused for treating patients are not originating from the patient but froma donor.

The treatment of cancer with CAR-T cells of the present disclosure maybe in combination with one or more therapies selected from antibodytherapy, chemotherapy, cytokine therapy, dendritic cell therapy, genetherapy, hormone therapy, radiotherapy, laser light therapy, andradiation therapy.

The administration of CAR-T cells or a population of CAR-T cells of thepresent disclosure of the present disclosure be carried out by aerosolinhalation, injection, ingestion, transfusion, implantation ortransplantation. The CAR-T cells compositions described herein, i.e.,mono CAR, dual CAR, tandem CARs, may be administered to a patientsubcutaneously, intradermally, intratumorally, intranodally,intramedullary, intramuscularly, by intravenous or intralymphaticinjection, or intraperitoneally. In one embodiment, the cellcompositions of the present disclosure are preferably administered byintravenous injection.

The administration of CAR-T cells or a population of CAR-T cells canconsist of the administration of 10⁴-10⁹ cells per kg body weight,preferably 10⁵ to 10⁶ cells/kg body weight including all integer valuesof cell numbers within those ranges. The CAR-T cells or a population ofCAR-T cells can be administrated in one or more doses. In anotherembodiment, the effective amount of CAR-T cells or a population of CAR-Tcells are administrated as a single dose. In another embodiment, theeffective amount of cells are administered as more than one dose over aperiod time. Timing of administration is within the judgment of a healthcare provider and depends on the clinical condition of the patient. TheCAR-T cells or a population of CAR-T cells may be obtained from anysource, such as a blood bank or a donor. While the needs of a patientvary, determination of optimal ranges of effective amounts of a givenCAR-T cell population(s) for a particular disease or conditions arewithin the skill of the art. An effective amount means an amount whichprovides a therapeutic or prophylactic benefit. The dosage administeredwill be dependent upon the age, health and weight of the patientrecipient, type of concurrent treatment, if any, frequency of treatment,and the nature of the effect desired.

In another embodiment, the effective amount of CAR-T cells or apopulation of CAR-T cells or composition comprising those CAR-T cellsare administered parenterally. The administration can be an intravenousadministration. The administration of CAR-T cells or a population ofCAR-T cells or composition comprising those CAR-T cells can be directlydone by injection within a tumor.

In one embodiment of the present disclosure, the CAR-T cells or apopulation of the CAR-T cells are administered to a patient inconjunction with, e.g., before, simultaneously or following, any numberof relevant treatment modalities, including but not limited to,treatment with cytokines, or expression of cytokines from within theCAR-T, that enhance T-cell proliferation and persistence and, includebut not limited to, IL-2, IL-7, and IL-15.

In a second embodiment, the CAR-T cells or a population of CAR-T cellsof the present disclosure may be used in combination with agents thatinhibit immunosuppressive pathways, including but not limited to,inhibitors of TGF-β, interleukin 10 (IL-10), adenosine, VEGF,indoleamine 2,3 dioxygenase 1 (IDO1), indoleamine 2,3-dioxygenase 2(IDO2), tryptophan 2-3-dioxygenase (TDO), lactate, hypoxia, arginase,and prostaglandin E2.

In another embodiment, the CAR-T cells or a population of CAR-T cells ofthe present disclosure may be used in combination with T-cell checkpointinhibitors, including but not limited to, anti-CTLA4 (Ipilimumab)anti-PD1 (Pembrolizumab, Nivolumab, Cemiplimab), anti-PDL1(Atezolizumab, Avelumab, Durvalumab), anti-PDL2, anti-BTLA, anti-LAG3,anti-TIM3, anti-VISTA, anti-TIGIT, and anti-KIR.

In another embodiment, the CAR-T cells or a population of CAR-T cells ofthe present disclosure may be used in combination with T cell agonists,including but not limited to, antibodies that stimulate CD28, ICOS,OX-40, CD27, 4-1BB, CD137, GITR, and HVEM

In another embodiment, the CAR-T cells or a population of CAR-T cells ofthe present disclosure may be used in combination with therapeuticoncolytic viruses, including but not limited to, retroviruses,picornaviruses, rhabdoviruses, paramyxoviruses, reoviruses,parvoviruses, adenoviruses, herpesviruses, and poxviruses.

In another embodiment, the CAR-T cells or a population of CAR-T cells ofthe present disclosure may be used in combination with immunostimulatorytherapies, such as toll-like receptors agonists, including but notlimited to, TLR3, TLR4, TLR7 and TLR9 agonists.

In another embodiment, the CAR-T cells or a population of CAR-T cells ofthe present disclosure may be used in combination with stimulator ofinterferon gene (STING) agonists, such as cyclic GMP-AMP synthase(cGAS).

Immune effector cell aplasia, particularly T cell aplasia is also aconcern after adoptive cell transfer therapy. When the malignancytreated is a T-cell malignancy, and CAR-T cells target a T cell antigen,normal T cells and their precursors expressing the antigen will becomedepleted, and the immune system will be compromised. Accordingly,methods for managing these side effects are attendant to therapy. Suchmethods include selecting and retaining non-malignant T cells orprecursors, either autologous or allogeneic (optionally engineered notto cause rejection or be rejected), for later expansion and re-infusioninto the patient, after CAR-T cells are exhausted or deactivated.Alternatively, CAR-T cells which recognize and kill subsets ofTCR-bearing cells, such as normal and malignant TRBC1⁺, but not TRBC2⁺cells, or alternatively, TRBC2⁺, but not TRBC1⁺ cells, may be used toeradicate a T cell malignancy while preserving sufficient normal T cellsto maintain normal immune system function.

Definitions

As used herein, the terms below have the meanings indicated. Otherdefinitions may occur throughout the specification.

When ranges of values are disclosed, and the notation “from n₁ . . . ton₂” or “between n₁ . . . and n₂” is used, where n₁ and n₂ are thenumbers, then unless otherwise specified, this notation is intended toinclude the numbers themselves and the range between them. This rangemay be integral or continuous between and including the end values. Byway of example, the range “from 2 to 6 carbons” is intended to includetwo, three, four, five, and six carbons, since carbons come in integerunits. Compare, by way of example, the range “from 1 to 3 μM(micromolar),” which is intended to include 1 μM, 3 μM, and everythingin between to any number of significant figures (e.g., 1.255 μM, 2.1 μM,2.9999 μM, etc.).

The term “about,” as used herein, is intended to qualify the numericalvalues which it modifies, denoting such a value as variable within amargin of error. When no particular margin of error, such as a standarddeviation to a mean value given in a chart or table of data, is recited,the term “about” should be understood to mean that range which wouldencompass the recited value and the range which would be included byrounding up or down to that figure as well, taking into accountsignificant figures.

The term “activation” (and other conjugations thereof) in reference tocells is generally understood to be synonymous with “stimulating” and asused herein refers to treatment of cells that results in expansion ofcell populations. In T cells, activation is often accomplished byexposure to CD2 and CD28 (and sometimes CD2 as well) agonists, typicallyantibodies, optionally coated onto magnetic beads or conjugated to acolloidal polymeric matrix.

The term “antigen” as used herein is a cell surface protein recognizedby (i.e., that is the target of) T cell receptor or chimeric antigenreceptor. In the classical sense antigens are substances, typicallyproteins, that are recognized by antibodies, but the definitions overlapinsofar as the CAR comprises antibody-derived domains such as light(V_(L)) and heavy (V_(H)) chains recognizing one or more antigen(s).

The term “cancer” refers to a malignancy or abnormal growth of cells inthe body. Many different cancers can be characterized or identified byparticular cell surface proteins or molecules. Thus, in general terms,cancer in accordance with the present disclosure may refer to anymalignancy that may be treated with an immune effector cell, such as aCAR-T cell as described herein, in which the immune effector cellrecognizes and binds to the cell surface protein on the cancer cell. Asused herein, cancer may refer to a hematologic malignancy, such asmultiple myeloma, a T-cell malignancy, or a B cell malignancy. T cellmalignancies may include, but are not limited to, T-cell acutelymphoblastic leukemia (T-ALL) or non-Hodgkin's lymphoma. A cancer mayalso refer to a solid tumor, such as including, but not limited to,cervical cancer, pancreatic cancer, ovarian cancer, mesothelioma, andlung cancer.

A “cell surface protein” as used herein is a protein (or proteincomplex) expressed by a cell at least in part on the surface of thecell. Examples of cell surface proteins include the TCR (and subunitsthereof) and CD7.

The term “combination therapy” means the administration of two or moretherapeutic agents to treat a therapeutic condition or disorderdescribed in the present disclosure. Such administration encompassesco-administration of these therapeutic agents in a substantiallysimultaneous manner, such as in a single capsule having a fixed ratio ofactive ingredients or in multiple, separate capsules for each activeingredient. In addition, such administration also encompasses use ofeach type of therapeutic agent in a sequential manner. In either case,the treatment regimen will provide beneficial effects of the drugcombination in treating the conditions or disorders described herein.

The term “composition” as used herein refers to an immunotherapeuticcell population combination with one or more therapeutically acceptablecarriers.

The term “disease” as used herein is intended to be generallysynonymous, and is used interchangeably with, the terms “disorder,”“syndrome,” and “condition” (as in medical condition), in that allreflect an abnormal condition of the human or animal body or of one ofits parts that impairs normal functioning, is typically manifested bydistinguishing signs and symptoms, and causes the human or animal tohave a reduced duration or quality of life.

The term “donor template” refers to the reference genomic material thatthe cell uses as a template to repair the a double-stranded breakthrough the homology-directed repair (HDR) DNA repair pathway. The donortemplate contains the piece of DNA to be inserted into the genome(containing the gene to be expressed, CAR, or marker) with two homologyarms flanking the site of the double-stranded break. In someembodiments, a donor template may be an adeno-associated virus, asingle-stranded DNA, or a double-stranded DNA.

The term “fratricide” as used herein means a process which occurs when aCAR-T cell (or other CAR-bearing immune effector cell) becomes thetarget of, and is killed by, another CAR-T cell comprising the samechimeric antigen receptor as the target of CAR-T cell, because thetargeted cell expresses the antigen specifically recognized by thechimeric antigen receptor on both cells. CAR-T comprising a chimericantigen receptor which are deficient in an antigen to which the chimericantigen receptor specifically binds will be “fratricide-resistant.”

The term “genome-edited” or “gene-edited” as used herein means having agene or potion of the genome added, deleted, or modified (e.g.,disrupted) to be non-functional. Thus, in certain embodiments, a“genome-edited T cell” is a T cell that has had a gene such as a CARrecognizing at least one antigen added; and/or has had a gene such asthe gene(s) to the antigen(s) that are recognized by the CAR deleted,and/or has had the gene to the TCR or a subunit thereof disrupted.

A “healthy donor,” as used herein, is one who does not have a malignancy(particularly a hematologic malignancy, e.g., a T-cell malignancy).

As used herein, an “immature dendritic cell” or “iDC” refers to animmature dendritic cell.

The term “therapeutically acceptable” refers to substances which aresuitable for use in contact with the tissues of patients without unduetoxicity, irritation, and allergic response, are commensurate with areasonable benefit/risk ratio, and/or are effective for their intendeduse.

The term “therapeutically effective” is intended to qualify the amountof active ingredients used in the treatment of a disease or disorder oron the effecting of a clinical endpoint.

The term “patient” is generally synonymous with the term “subject” andincludes all mammals including humans.

A “malignant B cell” is a B cell derived from a B-cell malignancy. Bcell malignancies include, without limitation, (DLBCL), chroniclymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and Bcell-precursor acute lymphoblastic leukemia (ALL).

The term “exposing to,” as used herein, in the context of bringingcompositions of matter (such as antibodies) into intimate contact withother compositions of matter (such as cells), is intended to besynonymous with “incubated with,” and no lengthier period of time incontact is intended by the use of one term instead of the other.

A “malignant T cell” is a T cell derived from a T-cell malignancy. Theterm “T-cell malignancy” refers to a broad, highly heterogeneousgrouping of malignancies derived from T-cell precursors, mature T cells,or natural killer cells. Non-limiting examples of T-cell malignanciesinclude T-cell acute lymphoblastic leukemia/lymphoma (T-ALL), humanT-cell leukemia virus type 1-positive (HTLV-1+) adult T-cellleukemia/lymphoma (ATL), T-cell prolymphocytic leukemia (T-PLL), AdultT-cell lymphoma/leukemia (HTLV-1 associated), Aggressive NK-cellleukemia, Anaplastic large-cell lymphoma (ALCL), ALK positive,Anaplastic large-cell lymphoma (ALCL), ALK negative, AngioimmunoblasticT-cell lymphoma (AITL), Breast implant-associated anaplastic large-celllymphoma, Chronic lymphoproliferative disorder of NK cells, Extra nodalNK/T-cell lymphoma, nasal type, Enteropathy-type T-cell lymphoma,Follicular T-cell lymphoma, Hepatosplenic T-cell lymphoma, IndolentT-cell lymphoproliferative disorder of the GI tract, Monomorphicepitheliotrophic intestinal T-cell lymphoma, Mycosis fungoides, Nodalperipheral T-cell lymphoma with TFH phenotype, Peripheral T-celllymphoma (PTCL), NOS, Primary cutaneous α/β T-cell lymphoma, Primarycutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma,Primary cutaneous acral CD8+ T-cell lymphoma, Primary cutaneous CD4+small/medium T-cell lymphoproliferative disorders [Primary cutaneousanaplastic large-cell lymphoma (C-ALCL), lymphoid papulosis], Sezarysyndrome, Subcutaneous, panniculitis-like T-cell lymphoma, Systemic EBV+T-cell lymphoma of childhood, and T-cell large granular lymphocyticleukemia (LGL).

A “malignant plasma cell” is a plasma cell derived from a plasma cellmalignancy. The term “plasma-cell malignancy” refers to a malignancy inwhich abnormal plasma cells are overproduced. Non-limiting examples ofplasma cell malignancies include lymphoplasmacytic lymphoma,plasmacytoma, and multiple myeloma.

As used herein, “suicide gene” refers to a nucleic acid sequenceintroduced to a CAR-T cell by standard methods known in the art, thatwhen activated result in the death of the CAR-T cell. If requiredsuicide genes may facilitate the tracking and elimination, i.e.,killing, of CAR-T cells in vivo. Facilitated killing of CAR-T cells byactivating a suicide gene can be accomplished by standard methods knownin the art. Suicide gene systems known in the art include, but are notlimited to, several herpes simplex virus thymidine kinase(HSVtk)/ganciclovir (GCV) suicide gene therapy systems and induciblecaspase 9 proteins. In one embodiment, the suicide gene is a chimericCD34/thymidine kinase.

As used herein, an “immune effector cell” is a leukocyte that canmodulate an immune response. Immune effector cells include T cells, Bcells, natural killer (NK) cells, iNKT cells (invariant T-cell receptoralpha natural killer T cells), and macrophages. T cell receptor(TCR)-bearing immune effector cells include, of course, T cells, butalso cells which have been engineered to express a T cell receptor.Immune effector cells may be obtained or derived/generated from anyappropriate source, such as including, but not limited to, healthydonors, peripheral blood mononuclear cells, cord blood, and inducedpluripotent stem cells (iPSC).

As used herein, a “CAR-bearing immune effector cell” is an immuneeffector cell which has been transduced with at least one CAR. A “CAR-Tcell” is a T cell which has been transduced with at least one CAR; CAR-Tcells can be mono, dual, or tandem CAR-T cells. CAR-T cells can beautologous, meaning that they are engineered from a subject's own cells,or allogeneic, meaning that the cells are sourced from a healthy donor,and in many cases, engineered so as not to provoke a host-vs-graft orgraft-vs-host reaction.

A “chimeric antigen receptor” or “CAR” as used herein and generally usedin the art, refers to a recombinant fusion protein that has anextracellular ligand-binding domain, a transmembrane domain, and asignaling transducing domain that directs the cell to perform aspecialized function upon binding of the extracellular ligand-bindingdomain to a component present on the target cell. For example, a CAR canhave an antibody-based specificity for a desired antigen (e.g., tumorantigen) with a T cell receptor-activating intracellular domain togenerate a chimeric protein that exhibits specific anti-target cellularimmune activity. First-generation CARs include an extracellularligand-binding domain and signaling transducing domain, commonly CD3ζ orFcεRIγ. Second generation CARs are built upon first generation CARconstructs by including an intracellular costimulatory domain, commonly4-1BB or CD28. These costimulatory domains help enhance CAR-T cellcytotoxicity and proliferation compared to first generation CARs. Thethird generation CARs include multiple costimulatory domains, primarilyto increase CAR-T cell proliferation and persistence. Chimeric antigenreceptors are distinguished from other antigen binding agents by theirability both to bind MHC-independent antigens and transduce activationsignals via their intracellular domain.

The term “CAR-iNKT cell” (equivalently, iNKT-CAR) means an iNKT cellthat expresses a chimeric antigen receptor. A dual iNKT-CAR cell(equivalently, iNKT-dCAR) is an iNKT-CAR cell that expresses twodistinct chimeric antigen receptor polypeptides with affinity todifferent target antigens expressed within the same effector cell,wherein each CAR functions independently. The CAR may be expressed froma single or multiple polynucleotide sequences. A tandem iNKT-CAR cell(equivalently, iNKT-tCAR) is an iNKT-CAR cell with a single chimericantigen polypeptide containing two distinct antigen recognition domainswith affinity to different targets, wherein the antigen recognitiondomains are linked through a peptide linker and share commoncostimulatory domain(s), and wherein binding of either antigenrecognition domain will signal though a common costimulatory domains(s)and signaling domain.

The term “chimeric antigen receptor T cell” (equivalently, CAR-T) meansan T cell that expresses a chimeric antigen receptor.

The term dual CAR-T (dCAR-T), means a CAR-T cell that expresses cellstwo distinct chimeric antigen receptor polypeptides with affinity todifferent target antigen expressed within the same effector cell,wherein each CAR functions independently. The CAR may be expressed fromsingle or multiple polynucleotide sequences.

The term tandem CAR-T (tCAR-T) means a single chimeric antigenpolypeptide containing two distinct antigen recognition domains withaffinity to different targets wherein the antigen recognition domain islinked through a peptide linker and share common costimulatorydomain(s), wherein the binding of either antigen recognition domain willsignal through a common co-stimulatory domains(s) and signaling domain.

As used herein, a chimeric antigen receptor natural killer (NK) cell(equivalently, NK-CAR) would have a meaning analogous to the definitionsof CAR-T and iNKT-CAR.

As used herein, a chimeric antigen receptor macrophage (equivalently,CAR-macrophage) would have a meaning analogous to the definitions ofCAR-T, iNKT-CAR, and NK-CAR.

As used herein, the term “cytokine release syndrome” refers to acondition that may occur after treatment with some types ofimmunotherapy, such as monoclonal antibodies and CAR-T or otherCAR-bearing immune effector cells. Cytokine release syndrome is causedby a large, rapid release of cytokines into the blood from immune cellsaffected by the immunotherapy. Symptoms of CRS include fever, fatigue,loss of appetite, muscle and joint pain, nausea, vomiting, diarrhea,rashes, fast breathing, rapid heartbeat, low blood pressure, seizures,headache, confusion, delirium, hallucinations, tremor, and loss ofcoordination. CRS can manifest along a spectrum of mild to fatal, andcan be ranked by severity as follows:

-   -   Grade 1: Mild reaction, infusion interruption not indicated;        intervention not indicated    -   Grade 2: Therapy or infusion interruption indicated but responds        promptly to symptomatic treatment (e.g., antihistamines, NSAIDS,        narcotics, IV fluids); prophylactic medications indicated for        <=24 hrs    -   Grade 3: Prolonged (e.g., not rapidly responsive to symptomatic        medication and/or brief interruption of infusion); recurrence of        symptoms following initial improvement; hospitalization        indicated for clinical sequelae (e.g., renal impairment,        pulmonary infiltrates)    -   Grade 4: Life-threatening consequences; pressor or ventilatory        support indicated    -   Grade 5: Death        See, e.g., “Common Terminology Criteria for Adverse Events        (CTCAE) Version v4.03,” National Institutes of Health and        National Cancer Institute, Jun. 14, 2010; Lee D W et al.,        “Current concepts in the diagnosis and management of cytokine        release syndrome,” Blood 2014 124(2):188-95.

As used herein, the term “CAR-T associated neuropathy” means neuropathythat arises subsequent to administration of CAR-T therapy to a patient,often after intervening cytokine release syndrome has occurred andsubsided. The term is relatively new, mainly because CAR-T therapy isrelatively new; see, e.g., Vasthie P and Breitbart WS, “Chimeric antigenreceptor T-cell neuropsychiatric toxicity in acute lymphoblasticleukemia,” Palliat Support Care. 2017 August; 15(4): 499-503.Accordingly, CAR-T associated neuropathy should be understood at thistime to be equivalent to the term “CAR-bearing immune effector cellassociated neuropathy,” since similar neuropathy could arise fromtherapy with, e.g., iNKT-CARs or NK-CARs.

As used herein, a “cytokine” is one of a class of small (˜5-20 kDa),soluble signaling proteins that are that are synthesized and secreted bycertain cells of the immune system at variable, and occasionally locallyhigh, concentrations and by binding to receptors on other cells, sendsignals to and have an effect on those cells. A “chemokine” is achemotactic cytokine, i.e., a subspecies of cytokine that is able toinduce chemotaxis in nearby responsive cells.

As used herein, to be “deficient” in a cytokine or protein means to lacksufficient quantity of the cytokine or protein for the cytokine orprotein to elicit its normal effect. A cell that is “deficient” inGM-CSF, for example, (a “GM-CSF deficient” cell) could be entirelylacking in GM-CSF, but it also could express such a negligible quantityof GM-CSF that the GM-CSF present could not contribute in any meaningfulway to the development or maintenance of cytokine release syndrome.

The term “deletion” as used herein in reference to the effect of editingon a gene or its protein product, means alteration or loss of part thesequence of DNA encoding the protein so as to reduce or preventexpression of the protein product. The term “suppression” in the samecontext means to reduce expression of the protein product; and the term“ablation” in the same context means to knock out (KO) or preventexpression of the protein product. Deletion encompasses suppression andablation.

As used herein, a “secretable protein” is s protein secreted by a cellwhich has an effect on other cells. By way of example, secretableproteins include cytokines, chemokines, and transcription factors.

As used herein, a “selectable marker” refers to a marker that allowsdistinguishing between different cell types, such as a cell into which aCAR has been successfully inserted (i.e., a gene-edited or modifiedcell). Selectable markers are well known in the art and materials andmethods for their use are readily available. In some embodiments, aselectable marker appropriate in accordance with the present disclosuremay be a fluorescent protein gene, such as including, but not limitedto, a green fluorescence (GFP) gene or a yellow fluorescent protein(YFP) gene. In some embodiments, a selectable marker may be a splicevariant of a CD34 gene, such as a truncated CD34 (tCD34) gene or atruncated EGFR (tEGFR) gene. In some embodiments, a selectable markerdescribed herein, such as GFP, or others known and available in the art,may be inserted alone into a gene as described herein (i.e., without aCAR), or may be inserted as a component of a construct comprising theselectable marker and a CAR.

As used herein, a “short hairpin RNA” or “small hairpin RNA” (shRNA) isan artificial RNA molecule, often about 80 base pairs in length and witha tight hairpin turn, that can be used to silence target gene expressionvia processing within the cell into siRNA which in turn knocks down geneexpression. ShRNAs can be incorporated into genomic DNA, and providestable and long-lasting expression.

As used herein, “transduction” is the process by which foreign DNA isintroduced into a cell by a virus or viral vector such as a plasmid, forexample by short hairpin RNAs (shRNAs); it often provides long-lastingor permanent silencing of a gene. It may be accomplished by methodsknown in the art, including electroporation.

Transfection is the process of deliberately introducing purified nucleicacids into eukaryotic cells, for example small interfering RNAs(siRNAs); it produces transient silencing of a gene by RNA interferencewith mRNA transcripts. Transduction is the process by which foreign DNAis introduced into a cell by a virus or viral vector such as a plasmid,for example by short hairpin RNAs (shRNAs); it often provideslong-lasting or permanent silencing of a gene. Both may be accomplishedby methods known in the art, including electroporation.

EXAMPLES

The invention is further illustrated by the following examples.

Example 1 Method of Blocking Gene Translation by CAR Insertion

FIG. 1 shows the deletion of a cytokine gene by using Cas9/CRISPR totarget a locus in a cytokine gene, then use homology-directed repair toinsert the CAS construct. Optionally, the CAS construct would contain amarker, such as a selectable marker as described herein. One challengewith this concept is that is hard to select and sort out the cells havebeen edited from those that still express the cytokine/chemokine. Oneway to overcome this is to insert the CAR construct containing a marker,into gene that has been deleted. It has previously been demonstratedthat inserting CAR19 into the TRAC gene allows the selection ofTRAC-negative, CAR-positive cells. This would allow sorting of cellsthat have both expression of the car and have the cytokine deleted.Another alternative would be to express a shRNA from the CAR constructthat would degrade the RNA encoding for the cytokine without alteringthe genome. A marker on the CAR construct (such as the truncated CD34marker) could be used to select cells that downregulate the cytokine andexpress the CAR, i.e., CAR+=Cytokine negative.

As shown in FIG. 2, CAR-bearing immune effector cells (e.g., CAR-T)would be activated for two days prior to gene editing to delete thetarget cytokine gene and transduction of CAR.

Example 2 General Method of Making Genome-Edited CAR-Bearing ImmuneEffector Cells

Further details regarding the manner of making CAR-bearing immuneeffector cells are known in the art, e.g., as disclosed inWO2018027036A1.

The following general steps may be taken to provide CAR-bearing immuneeffector cells. As those of skill in the art will recognize, certain ofthe steps may be conducted sequentially or out of the order listedbelow, though perhaps leading to different efficiency.

Step 1. Cells are harvested, isolated, and purified, for example usingmagnetic selection with a labelled antibody-coated magnetic beads thatbind to a cell-specific protein (available from, e.g., Miltenyi Biotec).For T cells, anti-CD3/CD28 beads could be used. Other purificationtechniques are known in the art and could be used.

Step 3. Cells are thereafter activated. There are several ways toactivate immune effector cells. For example, T cells may be activatedusing antiCD3/CD28 beads for two days prior to bead removal.Alternatively, an antibody could be used.

Step 4. The antigen that is the target of the CAR may be deleted fromthe cell surface or its expression suppressed to prevent subsequentfratricide. Target deletion may be accomplished by electroporation withCas9 mRNA and gRNA against the target(s). Other techniques, however,could be used to suppress expression of the target. These include othergenome editing techniques such as TALENs, ZFNs, RNA interference, andeliciting of internal binding of the antigen to prevent cell surfaceexpression. Deletion of the target may not be required in everycircumstance. Examples of gRNAs that may be used include those shown inTables 8-10, as well as others known in the art.

TABLE 8 Guide RNA sequences for use in removing surface antigens onimmune effector cells Target gene gRNA sequence CD75′_2′OMe(A(ps)U(ps)C(ps))ACGGAGGUCAAUGUCUAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC2′OMe(U(ps)U(ps)U(ps)U_3′ (SEQ ID NO: 40) CD7g105′_2′OMe(G(ps)U(ps)A(ps))GACAUUGACCUCCGUGAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC2′OMe(U(ps)U(ps)U(ps)U_3′ (SEQ ID NO: 41) CD7g45′_2′OMe(A(ps)U(ps)C(ps))ACGGAGGUCAAUGUCUAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC2′OMe(U(ps)U(ps)U(ps)U_3′ (SEQ ID NO: 42) TRACg5′_2′OMe(G(ps)A(ps)G(ps))AAUCAAAAUCGGUGAAUGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC2′OMe(U(ps)U(ps)U(ps)U_3′ (SEQ ID NO: 43) CS15′_2′OMe(G(ps)A(ps)C(ps))CAAUCUGACAUGCUGCAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC2′OMe(U(ps)U(ps)U(ps)U_3′ (SEQ ID NO: 44) CD25′_2′OMe(A(ps)C(ps)A(ps))GCUGACAGGCUCGACACGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC2′OMe(U(ps)U(ps)U(ps)U_3′ (SEQ ID NO: 45) CD2g5′_2′OMe(G(ps)A(ps)G(ps))AAUCAAAAUCGGUGAAUGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC2′OMe(U(ps)U(ps)U(ps)U 3′ (SEQ ID NO: 46) CD3ϵg5′_2′OMe(A(ps)G(ps)G(ps))GCAUGUCAAUAUUACUGGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC2′OMe(U(ps)U(ps)U(ps)U 3′ (SEQ ID NO: 47) CD55′_2′OMe(C(ps)G(ps)U(ps))UCCAACUCGAAGUGCCAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC2′OMe(U(ps)U(ps)U(ps))U_3′ (SEQ ID NO: 48) CD5g5′_2′OMe(C(ps)G(ps)U(ps))uCCAACUCGAAGUGCCAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC2′OMe(U(ps)U(ps)U(ps)U_3′ (SEQ ID NO: 49) RNA; (ps)indicate phosphorothioate. Underlined bases denote target sequence.

Step 5. Cells may then be transduced with a CAR targeted to (i.e., thatrecognizes) one or more antigen or protein targets, for example with alentivirus containing a CAR construct. Any other suitable method oftransduction/transfection may be used, for example transfection usingDNA-integrating viral or non-viral vectors containing transposableelements, or transient expressing of non-DNA integratingpolynucleotides, such as mRNA, or insertion of CAR polynucleotide intosite of nuclease activity using homologous or non-homologousrecombination.

Step 6. CAR-bearing immune effector cells are then cultured to expandtheir population.

Example 3 Method of Making Genome-Edited Tandem CAR-Bearing ImmuneEffector Cells

In a variation of the protocol in the example above, a tCAR cellrecognizing two antigens can be made. In Step 4, the two antigens can bedeleted from the cell surface, or suppressed as described above, butelectroporation with gRNA for each of the two targets and Cas9 mRNA. InStep 5, cells are then transduced with a CAR that recognizes twotargets.

Example 4 Method of Making Genome-Edited Dual CAR-Bearing ImmuneEffector Cells

In a variation of the protocol in the example above, a dCAR celltargeting two antigens can be made. This variation would contain twoseparate CARs, each recognizing a different antigen.

Example 5 Method of Making and Testing a Genome-Edited CAR-T Cell withSuppressed Expression of Cytokine or Chemokine

The following steps may be taken to provide a genome-edited CAR-T cellwith suppressed expression and/or secretion of a specific cytokine orchemokine. This example describes the making of a CD19 targeting CAR-Twhich is deficient in expression of GM-CSF. As those of skill in the artwill recognize, certain of the steps may be conducted sequentially orout of the order listed below, though perhaps leading to differentefficiency.

Tumor is injected into SCID-Beige mice (3e6 Raji containing Luciferase)if performing in vivo CRS experiment. This should be completed 3 weeksprior to infusion of CAR-T into mice.

T Cell Activation (Day 0).

T cells are purified via leukapheresis chamber using a Miltenyi humanPanT isolation kit, then resuspended in media. Cells are counted and thenumber of human T cell activation CD3/CD28 beads required to obtain 3:1bead:cell ratio determined. Beads are washed 2× with T cell media, thencells diluted at 1.256 cells/mL in hXcyte media. Human T cell activationCD3/CD28 beads are added. Into each well of a 6-well plate are aliquoted4 mL/well of 1.256 cell/mL solution. Cells are incubated at 37° C.

CRISPR (Day 2).

Target deletion may be accomplished by electroporating with Cas9 mRNAand gRNA against the target(s). Other techniques, however, could be usedto suppress expression of the target. These include other genome editingtechniques such as TALENs, RNA interference, and eliciting of internalbinding of the antigen to prevent cell surface expression. Examples ofgRNAs that may be used include those shown in Tables 8-10, as well asothers known in the art.

Nucleofection Sample ID gRNA#1 Cas9 Buffer P3 20 μg gGM-CSF 15 μg Cas9mRNA 100 μl

Table 9 GUIDE RNA sequences for use in reducing CRS Target genegRNA sequence GM-CSF 5′_2′OMe(U(ps)A(ps)C(ps))UCAGGUUCAGGAGACGCGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC2′OMe (U(ps)U(ps)U(ps)U_3′(SEQ ID NO: 50) RNA; (ps) indicate phosphorothioate. Underlined basesdenote target sequence.

TABLE 10 Additional guide RNA sequences for use in reducing theincidence of CRS Target Gene SEQ Symbol Guide RNA Sequence ID NO:Location Gene ID No. A2M GACAAAUCAAUCUACAAACC  56 chr12ENST00000318602.11 A2M GGUCCGCUUCUUAAAUUCUU  57 chr12 ENST00000318602.11A2M UCCUCAUUGGAUGAAGACUU  58 chr12 ENST00000318602.11 ACKR1AACUGAGAACUCAAGUCAGC  59 chr1 ENST00000368122.2 ACKR1GAAGGAAUCAUUCACACCAU  60 chr1 ENST00000368122.2 ACKR1ACACUGGUGAGGAUGAAGAA  61 chr1 ENST00000368122.2 ACKR2UCGGCAUCCUCAGUGGCGAG  62 chr3 ENST00000422265.5 ACKR2GCAUGAAGGCCACUUCAUCC  63 chr3 ENST00000422265.5 ACKR2AAAUCAGGCUAUAGAAGACU  64 chr3 ENST00000422265.5 ACKR3UAGAGCAGGACGCUUUUGUU  65 chr2 ENST00000272928.3 ACKR3CGGCAUGAUUGCCAACUCCG  66 chr2 ENST00000272928.3 ACKR3CCCACAGGUCGGCAAUGGCC  67 chr2 ENST00000272928.3 ACVR1UCUUUCCCUGCUCAUAAACC  68 chr2 ENST00000263640.7 ACVR1UCCUCACUGAGCAUCAACGA  69 chr2 ENST00000263640.7 ACVR1CUCUACAUGUGUGUGUGUGA  70 chr2 ENST00000263640.7 ACVR2BCUACAACGCCAACUGGGAGC  71 chr3 ENST00000352511.4 ACVR2BGCCAGAGCUGUUGCGCCAGG  72 chr3 ENST00000352511.4 ACVR2BAUGACUUCAACUGCUACGAU  73 chr3 ENST00000352511.4 ACVRL1AGACCCUGUGAAGCCGUCUC  74 chr12 ENST00000388922.8 ACVRL1GGCCUACCUGCCGGGGGGCC  75 chr12 ENST00000388922.8 ACVRL1GGGGCUGCGGGAACUUGCAC  76 chr12 ENST00000388922.8 ADIPOQGGGCUCAGGAUGCUGUUGCU  77 chr3 ENST00000320741.6 ADIPOQCGUGGUUUCCUGGUCAUGAC  78 chr3 ENST00000320741.6 ADIPOQGGGGGCCUGCACAGGUUGGA  79 chr3 ENST00000320741.6 AGERACGGACUCGGUAGUUGGACU  80 chr6 ENST00000375076.8 AGERCUGUCGGGAUCCAGGAUGAG  81 chr6 ENST00000375076.8 AGERUCCCCAGGGAGGAGGCCCCU  82 chr6 ENST00000375076.8 AGRNCGGGGAAUGCUGUGCGGCUU  83 chr1 ENST00000379370.6 AGRNGAAGAGCCCGUGCCCCAGCG  84 chr1 ENST00000379370.6 AGRNGCAUUCGUUGCUGUAGGUGG  85 chr1 ENST00000379370.6

 86 

 87 

 88 

 89 

AIMP1 AACCAAUUCGAAGAUCCAGA  90 chr4 ENST00000358008.7 AIMP1UAUGUGGAAGAAGUAGAUGU  91 chr4 ENST00000358008.7 AIMP1CAAGAGGAACAUGAUUCACC  92 chr4 ENST00000358008.7 AREGGGUCCAAUCCAGCAGCAUAA  93 chr4 ENST00000395748.7 AREGCCACAGUGCUGAUGGAUUUG  94 chr4 ENST00000395748.7 AREGAGAAGGCAUUUCACUCACAG  95 chr4 ENST00000395748.7 BCL6CUGUAAAGAUGCUAUAGAAC  96 chr3 ENST00000406870.6 BCL6CACUAAGGUUGCAUUUCAAC  97 chr3 ENST00000406870.6 BCL6GAUCUAGAUUGAUCACACUA  98 chr3 ENST00000406870.6 BCL6AAUCCCUCAGGGUUGAUCUC  99 chr3 ENST00000406870.6 BMP1CAGCGGCAGGCGGGCCACGC  100 chr8 ENST00000306385.9 BMP1GGCCGACUACACCUAUGACC  101 chr8 ENST00000306385.9 BMP1GGCGCUCACCCGCCUUGCAG  102 chr8 ENST00000306385.9 BMP10GAAACUCAUCCUUCAUGCUC  103 chr2 ENST00000295379.1 BMP10AGGGACAUAUCUUCUUCCAG  104 chr2 ENST00000295379.1 BMP10CAGAAACCAAGUAAGCUGCC  105 chr2 ENST00000295379.1 BMP15CGUGCUUUUCAUGGAACACA  106 chrX ENST00000252677.3 BMP15CCCUACUUUGCCCCUGAUUG  107 chrX ENST00000252677.3 BMP15AGUGAAUGCCCUAGGAGCCG  108 chrX ENST00000252677.3 BMP2CGCAGGUCGACCAUGGUGGC  109 chr20 ENST00000378827.4 BMP2GGGCCGCAGGAAGUUCGCGG  110 chr20 ENST00000378827.4 BMP2GCCGCAACUCGAACUCGCUC  111 chr20 ENST00000378827.4 BMP3AGGCUGCUCUUUCUGUGGCU  112 chr4 ENST00000282701.2 BMP3GGCACAGCUUUGCGGAGCUC  113 chr4 ENST00000282701.2 BMP3CGAGCUGCAGCCGCAAGACA  114 chr4 ENST00000282701.2 BMP4UUCGUGGUGGAAGCUCCUCA  115 chr14 ENST00000245451.8 BMP4GAAGAGCAGAUCCACAGCAC  116 chr14 ENST00000245451.8 BMP4CACUCUUGCUAGGCUGCGGG  117 chr14 ENST00000245451.8 BMP5ACUGAGUACUCCGACUCUUC  118 chr6 ENST00000370830.3 BMP5AGACCCAGACCAUUUUCACC  119 chr6 ENST00000370830.3 BMP5CGAAAGACGGGAAAUACAAA  120 chr6 ENST00000370830.3 BMP6GAUGCAGAAGGAGAUCUUGU  121 chr6 ENST00000283147.6 BMP6GGCUGUUGGAGGCCGUGCAG  122 chr6 ENST00000283147.6 BMP6CCUCGCGGAGAGCCCCCUCC  123 chr6 ENST00000283147.6 BMP7UCUCAUUGUCGAAGCGUUCC  124 chr20 ENST00000395863.7 BMP7GCCGUGACAGCUUCCCCUUC  125 chr20 ENST00000395863.7 BMP7UCUUCCAGUGGAACAUGACA  126 chr20 ENST00000395863.7 BMP8ACCAGAAGCCAGAGCGGUCCG  127 chr1 ENST00000331593.5 BMP8AUGGCGGUGCUCGGGCUACCC  128 chr1 ENST00000331593.5 BMP8AUGGCGGUGCUCGGGCUACCC  129 chr1 ENST00000331593.5 BMP8BCGGUGCUCGGGCUGCCUGGG  130 chr1 ENST00000372827.7 BMP8BCCCAGGAGCCAGAGCGGGCC  131 chr1 ENST00000372827.7 BMP8BCCCAGGAGCCAGAGCGGGCC  132 chr1 ENST00000372827.7 BMPR2CACUUGCAGCUGAUUGGCCG  133 chr2 ENST00000374580.8 BMPR2UUUCGUUGAUAAAAUUCUGA  134 chr2 ENST00000374580.8 BMPR2CUCAUCUCCAACUAUAAAGC  135 chr2 ENST00000374580.8 C10orf99GGAAAGGACUAGAAGCCUCA  136 chr10 ENST00000372126.3 C10orf99CCUACCUUCUGUGGAGAAGA  137 chr10 ENST00000372126.3 C10orf99CUCUGAUCAGGAUUUGUUGG  138 chr10 ENST00000372126.3 C1QTNF4CCAUCUCCGACGUGCCCUCC  139 chr11 ENST00000302514.3 C1QTNF4CAGCUCAGAGGAUCCCGGGC  140 chr11 ENST00000302514.3 C1QTNF4CCCAGCAGGCCCAGCAGAAG  141 chr11 ENST00000302514.3 C5*UCCAGCACCGUCACUCCAGA  142 chr9 ENST00000223642.2 C5*ACACGUGUUACACUUUUGCU  143 chr9 ENST00000223642.2 C5*GAUUCGCUUGACCAGUUGGU  144 chr9 ENST00000223642.2 CCL1*AGAAACGUGGUCAGCCACUC  145 chr17 ENST00000225842.3 CCL1*CUCUUGCUGUCCACAUCUUC  146 chr17 ENST00000225842.3 CCL1*GCAGAUCAUCACCACAGCCC  147 chr17 ENST00000225842.3 CCL11AGGUCUCCGCAGCACUUCUG  148 chr17 ENST00000305869.3 CCL11CUGGCCCAGCGAGCCCCUGG  149 chr17 ENST00000305869.3 CCL11UAACCACCUCCAGAGCUACU  150 chr17 ENST00000305869.3 CCL13*AUGUGAAGCAGCAAGUAGAU  151 chr17 ENST00000225844.6 CCL13*CUUCUGGGGACACCUGCUGG  152 chr17 ENST00000225844.6 CCL13*AACUUUGGAUUGGGGAAUGU  153 chr17 ENST00000225844.6 CCL14CAGGAGUGAGGUUGGGGCUC  154 chr17 ENST00000618404.4 CCL14GGCAUUGCACUCACGUGAGG  155 chr17 ENST00000618404.4 CCL14CCACAGCAUGAAGAUCUCCG  156 chr17 ENST00000618404.4 CCL15*UCCCAGAGCUUGAGUUACCA  157 chr17 ENST00000617897.1 CCL15*CACCAUUUGUGAACUGGGCC  158 chr17 ENST00000617897.1 CCL15*CACCAUUUGUGAACUGGGCC  159 chr17 ENST00000617897.1 CCL16GGACGUGCUUACAUGAUUGC  160 chr17 ENST00000611905.1 CCL16GUUGCCAAGGAGACUAGUGG  161 chr17 ENST00000611905.1 CCL16UCCUUCAGAAGUUCCUGAGU  162 chr17 ENST00000611905.1 CCL17GCUCCUCUCCCUGCAGCUCG  163 chr16 ENST00000219244.8 CCL17UGGCUCCCUUGAAGUACUCC  164 chr16 ENST00000219244.8 CCL17UGGAGCAGUCCUCAGAUGUC  165 chr16 ENST00000219244.8 CCL18GAGGCAGCAGAGCUCUUUGU  166 chr17 ENST00000616054.1 CCL18UGGCUUGGGGCACUGGGGGC  167 chr17 ENST00000616054.1 CCL18CCAUCCUCCCUCCCGAGGGG  168 chr17 ENST00000616054.1 CCL19CCCACAACUCACACUACAGC  169 chr9 ENST00000311925.6 CCL19AAGUUCCUCACGAUGUACCC  170 chr9 ENST00000311925.6 CCL19CAUUGGUGCCACUCAGAGUU  171 chr9 ENST00000311925.6 CCL2GUUAUAACAGCAGGUGACUG  172 chr17 ENST00000225831.4 CCL2UUCUUUGGGACACUUGCUGC  173 chr17 ENST00000225831.4 CCL2GGCUUGUCCCUUGCUCCACA  174 chr17 ENST00000225831.4 CCL20CAAACUCUUGGUACAGCACA  175 chr2 ENST00000358813.4 CCL20CACCUCUGCGGCGAAUCAGA  176 chr2 ENST00000358813.4 CCL20CAGUUGAGCUCAAGGCUAAA  177 chr2 ENST00000358813.4 CCL21CCCUGCAGGCAGUGAUGGAG  178 chr9 ENST00000259607.6 CCL21CCUCCCUGCCUUGGUACCUU  179 chr9 ENST00000259607.6 CCL21GGCUCUGAGCCUCCUUAUCC  180 chr9 ENST00000259607.6 CCL22ACCCCUCCCCUAGGCCCCUA  181 chr16 ENST00000219235.4 CCL22GACGGUAACGGACGUAAUCA  182 chr16 ENST00000219235.4 CCL22AGGCCUCGGGCAGGAGUCUG  183 chr16 ENST00000219235.4 CCL23*UCGUUUCAAAGUAACUCUCC  184 chr17 ENST00000615050.1 CCL23*AGCAGUCAGCACUAGUAGCA  185 chr17 ENST00000615050.1 CCL23*GUGCUCUGGAGGAGAAAGAU  186 chr17 ENST00000615050.1 CCL24CCUCAAGGCAGGAGUGAUGU  187 chr7 ENST00000222902.6 CCL24GAGAAUUCCUGAGAACCGAG  188 chr7 ENST00000222902.6 CCL24CUCUCCUCUUCUAGGCUCUG  189 chr7 ENST00000222902.6 CCL25UGUGGUUGCAGGUGUCUUUG  190 chr19 ENST00000390669.7 CCL25GGGCUGUGCUCCGGCGCGCC  191 chr19 ENST00000390669.7 CCL25GGCCCCACUCACAUCGCAGC  192 chr19 ENST00000390669.7 CCL26CCAUCCUGUUGCAUGACUGA  193 chr7 ENST00000005180.8 CCL26CCAGUAACAGCUGCUCCCAG  194 chr7 ENST00000005180.8 CCL26GUAUUGGAAGCAGCAGGUCU  195 chr7 ENST00000005180.8 CCL27GAGCUCACACGAAAGCCUGG  196 chr9 ENST00000259631.4 CCL27ACUGAGGAAGGUCAUCCAGG  197 chr9 ENST00000259631.4 CCL27AGGCAGUGCUGGGUGGCAGU  198 chr9 ENST00000259631.4 CCL28AAUCCUUCCAGCACAGAUUU  199 chr5 ENST00000361115.4 CCL28GUGCCCCCACUCACCUUCUG  200 chr5 ENST00000361115.4 CCL28CAGGCAGGAAUGCAGCAGAG  201 chr5 ENST00000361115.4 CCL3GCCACAAGAAAAGAUUGAUG  202 chr17 ENST00000613922.1 CCL3ACUCACGUGAUGCAGAGAAC  203 chr17 ENST00000613922.1 CCL3UCACCUGCUCAGAAUCAUGC  204 chr17 ENST00000613922.1 CCL4*UGAGAGCGCUGGAGAGCAGA  205 chr17 ENST00000615863.1 CCL4*UGAGAGCGCUGGAGAGCAGA  206 chr17 ENST00000615863.1 CCL4*UGAGAGCGCUGGAGAGCAGA  207 chr17 ENST00000615863.1 CCL5GACUCACACGACUGCUGGGU  208 chr17 ENST00000603197.5 CCL5UGAUGUGGGCACGGGGCAGU  209 chr17 ENST00000603197.5 CCL5CUUUCCUCUUCCAGAUUCCU  210 chr17 ENST00000603197.5 CCL7AUUGAUAAAUCUGUAGCAGC  211 chr17 ENST00000378569.2 CCL7CCACAUACAUUACAGCUUCC  212 chr17 ENST00000378569.2 CCL7CUAGUCCUAUUCCCUGCCCA  213 chr17 ENST00000378569.2 CCL8*AAAGCAGCAGGUGAUUGGAA  214 chr17 ENST00000394620.1 CCL8*CACCAACAUCCAAUGUCCCA  215 chr17 ENST00000394620.1 CCL8*CCCCCAUUCAAAAGUUCUGA  216 chr17 ENST00000394620.1 CCR1CCUGGUUGGAAACAUCCUGG  217 chr3 ENST00000296140.3 CCR1AGGCCCUCUCGUUCACCUUC  218 chr3 ENST00000296140.3 CCR1UCAUAGUCCUCUGUGGUGUU  219 chr3 ENST00000296140.3 CCR2GAUAAACCGAGAACGAGAUG  220 chr3 ENST00000445132.2 CCR2ACCUUUUUUGAUUAUGAUUA  221 chr3 ENST00000445132.2 CCR2GUAGAGCGGAGGCAGGAGUU  222 chr3 ENST00000445132.2 CCR3CUAGAUACAGUUGAGACCUU  223 chr3 ENST00000357422.2 CCR3UAUCAGCUUUUUCACAGAGC  224 chr3 ENST00000357422.2 CCR3GGUGUUCACUGUGGGCCUCU  225 chr3 ENST00000357422.2 CCR5UUUUGCAGUUUAUCAGGAUG  226 chr3 ENST00000292303.4 CCR5AAAACAGGUCAGAGAUGGCC  227 chr3 ENST00000292303.4 CCR5UGUAUUUCCAAAGUCCCACU  228 chr3 ENST00000292303.4 CCR6UUGUUCUUACUCUCCCAUUC  229 chr6 ENST00000341935.9 CCR6GCCUUUUAGCAACUUGCACG  230 chr6 ENST00000341935.9 CCR6CCGGUACAUCGCCAUUGUAC  231 chr6 ENST00000341935.9 CCR7GGCCGCGCUGUAGGCCCAGA  232 chr17 ENST00000246657.2 CCR7GAGCAGGUAGGUAUCGGUCA  233 chr17 ENST00000246657.2 CCR7UAGGCCCACGAAACAAAUGA  234 chr17 ENST00000246657.2 CD109UCCGGGCCUGAUGAUCCCUG  235 chr6 ENST00000287097.5 CD109GCCUUCACAGUCACCUGUGA  236 chr6 ENST00000287097.5 CD109CAAAGACUCCUUCUGCUUCC  237 chr6 ENST00000287097.5 CD27**CCUUCACGAGGAAUGUUCCU  238 chr12 ENST00000266557.3 CD27**UCCUUCACGAGGAAUGUUCC  239 chr12 ENST00000266557.3 CD27**GCUGGUCACAGUCCUUCACG  240 chr12 ENST00000266557.3 CD27**ACUGAGCAGCCUUUCUAUGC  241 chr12 ENST00000266557.3 CD28***CACCAAAAUCUUGUUUCCUG  242 ch2 ENST00000458610.6 CD28***UCACCAAAAUCUUGUUUCCU  243 ch2 ENST00000458610.6 CD28***UUGUCGUACGCUACAAGCAU  244 ch2 ENST00000458610.6 CD28***AUUGUCGUACGCUACAAGCA  245 ch2 ENST00000458610.6 CD36CAAGAAAAAUGGGCUGUGAC  246 chr7 ENST00000309881.11 CD36GGUGCUGUCCUGGCUGUGUU  247 chr7 ENST00000309881.11 CD36UAUCCAGAAGACAAUUAAAA  248 chr7 ENST00000309881.11 CD4**AGUGCAAUGUAGGAGUCCAA  249 chr12 ENST00000011653.8 CD4**CUGGAGCUCCAGCUGAGACA  250 chr12 ENST00000011653.8 CD4**UUUUGAACUCCACCUUCUUC  251 chr12 ENST00000011653.8 CD40LG**CAAAAUAGAUAGAAGAUGAA  252 chrX ENST00000370629.6 CD40LG**ACGAUACAGAGAUGCAACAC  253 chrX ENST00000370629.6 CD40LG**CCAGUUUGAAGGCUUUGUGA  254 chrX ENST00000370629.6 CD70AGCGCUGGAUGCACACCACG  255 chr19 ENST00000245903.3 CD70AGCCCGCAGGACGCACCCAU  256 chr19 ENST00000245903.3 CD70CGCCGCGGCGAUGCCGGAGG  257 chr19 ENST00000245903.3 CD74UGCUCACACAUACCUCUCCG  258 chr5 ENST00000009530.11 CD74UGUUGGAGAUAAGGUCGCGC  259 chr5 ENST00000009530.11 CD74AGAUGCACAGGAGGAGAAGC  260 chr5 ENST00000009530.11 CD8A**CCGGAACUGGCUCGGCCUGG  261 ch2 ENST00000409511.6 CD8A**CACCCGGAACUGGCUCGGCC  262 ch2 ENST00000409511.6 CD8A**GGCGACACCCGGAACUGGCU  263 ch2 ENST00000409511.6 CD8A**CGCCAGGCCGAGCCAGUUCC  264 ch2 ENST00000409511.6 CER1GGCACUGCGACAAACAGAUC  265 chr9 ENST00000380911.3 CER1AAAGAGAACUCUGAUUCUGG  266 chr9 ENST00000380911.3 CER1CUGCUGGUACUCCUGCCUCU  267 chr9 ENST00000380911.3 CHRDGCCGGCGGGGCCGGGAGGCU  268 chr3 ENST00000204604.5 CHRDUCCCGGCCGGCCCGCGGCGC  269 chr3 ENST00000204604.5 CHRDCUGCCCGUUCGGGGAGCGGC  270 chr3 ENST00000204604.5 CKLFGUGAUAACAAUAUAUGGUUC  271 chr16 ENST00000264001.8 CKLFGACUUGAUCGAUUAAUGAAG  272 chr16 ENST00000264001.8 CKLFGUAGGAAAAAGUAAAAUUUA  273 chr16 ENST00000264001.8 CLCF1CAUAGGUCCCAGCCAAGCUG  274 chr11 ENST00000312438.7 CLCF1CAUAGGUUUUCUGGAUGGAG  275 chr11 ENST00000312438.7 CLCF1GGUGCCAGAGCACCGUGCAC  276 chr11 ENST00000312438.7 CMTM1GACUCAGGUUUGGCGUGUUC  277 chr16 ENST00000379500.6 CMTM1UACGCUGCCGCUACUUGCCA  278 chr16 ENST00000379500.6 CMTM1UGCGGGGUGCUUCCGGGGUG  279 chr16 ENST00000379500.6 CMTM2CGAGUCAGUCAUGGCACCUA  280 chr16 ENST00000268595.2 CMTM2UCCACCCGGGGCCAAACCCG  281 chr16 ENST00000268595.2 CMTM2AAAGGCGGUGCAGGACCAUA  282 chr16 ENST00000268595.2 CMTM3CCGGACCCCGAGCCUGCCGG  283 chr16 ENST00000361909.8 CMTM3GGAAAGCCCGCGCCGGCAGC  284 chr16 ENST00000361909.8 CMTM3UCCCGCCGCACUCACCGACU  285 chr16 ENST00000361909.8 CMTM4CCGCCCGGCACCUACCACUU  286 chr16 ENST00000394106.6 CMTM4GGUAGUCGGGGUCGCAGCGC  287 chr16 ENST00000394106.6 CMTM4GCUGCUGGCGCCCGAGAUCA  288 chr16 ENST00000394106.6 CMTM5GCUCAGUGCUCGAGAUCGCC  289 chr14 ENST00000359320.7 CMTM5CCAGGGCUUCGCGGUGGACA  290 chr14 ENST00000359320.7 CMTM5UUACCAGCUCGGUUUCCAGC  291 chr14 ENST00000359320.7 CMTM6UUGAGAACGCGCCGGAGCAA  292 chr3 ENST00000205636.3 CMTM6CGCUCCGGGGGCCUCUGGCG  293 chr3 ENST00000205636.3 CMTM6CGGCCCGAGGCGAUGGAGAA  294 chr3 ENST00000205636.3 CMTM7GGAGCUCCGCACACAGAUGA  295 chr3 ENST00000334983.9 CMTM7AAUGAUCCUCGCCUUUUACC  296 chr3 ENST00000334983.9 CMTM7CGACAGGGGCCAGCUGAUAC  297 chr3 ENST00000334983.9 CMTM8GUGUGCGAGCGGGCGCGCUG  298 chr3 ENST00000307526.3 CMTM8CAGCAGCUUCGCCUACGACC  299 chr3 ENST00000307526.3 CMTM8CCCGUCGGCACUCACGAUCU  300 chr3 ENST00000307526.3 CNTFAUCAACCUGGACUCUGCGGA  301 chr11 ENST00000361987.5 CNTFGGAAGGUACGAUAAGCUUGA  302 chr11 ENST00000361987.5 CNTFGUGCAUUUUACCCCAACCGA  303 chr11 ENST00000361987.5 CNTFRCCAGCUGAGAGCCGUUGAGC  304 chr9 ENST00000351266.8 CNTFRGGGAUGCUGCGGUGACGUGG  305 chr9 ENST00000351266.8 CNTFRCAGGCGCUCGUACUGCACAU  306 chr9 ENST00000351266.8 COPS5UAGUCCAGGGCUUCGCCGCC  307 chr8 ENST00000357849.8 COPS5CUGAGCUUCCUGCAUGUUGU  308 chr8 ENST00000357849.8 COPS5CCUCGGCGAUGGCGGCGUCC  309 chr8 ENST00000357849.8 CRLF1CCAGCGUGAGUACAUCGGAG  310 chr19 ENST00000392386.7 CRLF1CAUAGGGCGUAAAGAGAGCC  311 chr19 ENST00000392386.7 CRLF1ACUCCUCACAUGUGUUGUCC  312 chr19 ENST00000392386.7 CSF1*GCCUUCUUAAGGUAGCACAC  313 chr1 ENST00000329608.10 CSF1*GGUGUUAUCUCUGAAGCGCA  314 chr1 ENST00000329608.10 CSF1*GUCAUGCUCUUCAUAAUCCU  315 chr1 ENST00000329608.10 CSF1RCACCUUUCUGCACUUUCAGC  316 chr5 ENST00000286301.7 CSF1RCAAUGCAGUGCCCUGAUGGG  317 chr5 ENST00000286301.7 CSF1RCCAGGGCGAGAAGGAGUAGU  318 chr5 ENST00000286301.7 CSF2*CCACAGUGCCCAAGAGCAGC  319 chr5 ENST00000296871.3 CSF2*CAGGGCUGCGUGCUGGGGCU  320 chr5 ENST00000296871.3 CSF2*UAGAGACACUGCUGCUGAGA  321 chr5 ENST00000296871.3 CSF3UGUGCCACAGCAGCAGCUGC  322 chr17 ENST00000225474.6 CSF3GAAGCUCUGGGGCAGGGAGC  323 chr17 ENST00000225474.6 CSF3GGGCGAUGGCGCAGCGCUCC  324 chr17 ENST00000225474.6 CSF3RGCAAUAGCAACAAGACCUGG  325 chr1 ENST00000361632.8 CSF3RAUAGCCCUGAGGCCAUGGAU  326 chr1 ENST00000361632.8 CSF3RGCAUGGAGUCUGGUCAGAGC  327 chr1 ENST00000361632.8 CTF1UCUCCGCAGGUGCAGCUCCA  328 chr16 ENST00000279804.2 CTF1CCGGCCACCGGCAGCCGCGG  329 chr16 ENST00000279804.2 CTF1AGCCGCAGCCGCUCGUGCAC  330 chr16 ENST00000279804.2 CX3CL1GUGCCGACCCGAAGGAGCAA  331 chr16 ENST00000006053.6 CX3CL1CUUCGAGAAGCAGAUCGGCG  332 chr16 ENST00000006053.6 CX3CL1CGCCUGUGGCUUCGGGCUCC  333 chr16 ENST00000006053.6 CX3CR1**CUACCAACAAAUUUCCCACC  334 chr3 ENST00000399220.2 CX3CR1**UUGGGGACAUCGUGGUCUUU  335 chr3 ENST00000399220.2 CX3CR1**AAGUUUUCUGUCACUGAUUC  336 chr3 ENST00000399220.2 CXCL1GGAGAGAGCAGCGCGGGCCA  337 chr4 ENST00000395761.3 CXCL1CUGGCCGGCGCGCAGCAGGU  338 chr4 ENST00000395761.3 CXCL1GUGCCUACCCCAGCCGCGUC  339 chr4 ENST00000395761.3 CXCL10UACAGUAUAUAAUUACAACC  340 chr4 ENST00000306602.2 CXCL10CGUGGACAAAAUUGGCUUGC  341 chr4 ENST00000306602.2 CXCL10UUGAUUACUAAUGCUGAUGC  342 chr4 ENST00000306602.2 CXCL11GCUGAAGAUGACAAUGGUGC  343 chr4 ENST00000306621.7 CXCL11GUUGUUACUUGGGUACAUUA  344 chr4 ENST00000306621.7 CXCL11AGCGUCCUCUUUUGAACAUG  345 chr4 ENST00000306621.7 CXCL12CUACACCUUUAAUAAGACUC  346 chr10 ENST00000343575.10 CXCL12UCAAGACUUACACAAUCUGA  347 chr10 ENST00000343575.10 CXCL12UGACGUUGGCUCUGGCAACA  348 chr10 ENST00000343575.10 CXCL13AGGUCUAUUACACAAGCUUG  349 chr4 ENST00000286758.4 CXCL13UUCGAUCAAUGAAGCGUCUA  350 chr4 ENST00000286758.4 CXCL13ACUUACAUGAUUUCUUUUCU  351 chr4 ENST00000286758.4 CXCL14AAUUGGCGCUUGGGUUCCCC  352 chr5 ENST00000337225.5 CXCL14CUGUACACCGCGCGUGUGGA  353 chr5 ENST00000337225.5 CXCL14GAGGGGCGCGGCGUGGGAGC  354 chr5 ENST00000337225.5 CXCL16GCGCUGAGUGGACUGCAAGG  355 chr17 ENST00000293778.10 CXCL16UACCAGCCCCCCAAUUUCUC  356 chr17 ENST00000293778.10 CXCL16AAUGUGGACAUGCUUACUCG  357 chr17 ENST00000293778.10 CXCL17AUUGGUCUCAGAGGGGCCCA  358 chr19 ENST00000601181.5 CXCL17GACCUUUGCACUCACAUUCU  359 chr19 ENST00000601181.5 CXCL17CUUCCGACAGGGGUCGCCAG  360 chr19 ENST00000601181.5 CXCL2GCAGUGGCAGCGGCAGCGAU  361 chr4 ENST00000508487.2 CXCL2UUCUUCCCUAGGAGCGCCCC  362 chr4 ENST00000508487.2 CXCL2UUCUUCCCUAGGAGCGCCCC  363 chr4 ENST00000508487.2 CXCL3*UGGCAGCGGAAGCGCGGGGC  364 chr4 ENST00000296026.4 CXCL3*GGGACCUUACAUUCACACUU  365 chr4 ENST00000296026.4 CXCL3*GGGACCUUACAUUCACACUU  366 chr4 ENST00000296026.4 CXCL5CCCUUUAUAGGGCAGGUUGC  367 chr4 ENST00000296027.4 CXCL5GCGCCAUGCGCUCUCACCGC  368 chr4 ENST00000296027.4 CXCL5GAGCUCCUUGUGCGCGCUGU  369 chr4 ENST00000296027.4 CXCL6*GCCCGAAGGACCCGGGACAC  370 chr4 ENST00000226317.9 CXCL6*GGGGCCCCGGCGGCGUCAGC  371 chr4 ENST00000226317.9 CXCL6*UUUUUAUAGGGCAGGUUGCU  372 chr4 ENST00000226317.9 CXCL8CAACAGGUGCAGUUUUGCCA  373 chr4 ENST00000307407.7 CXCL8AAAUUUGGGGUGGAAAGGUU  374 chr4 ENST00000307407.7 CXCL8UACUUACAUAAUUUCUGUGU  375 chr4 ENST00000307407.7 CXCL9*UUUCAAUUUUCUCGCAGGAA  376 chr4 ENST00000264888.5 CXCL9*AUUGUAGGUGGAUAGUCCCU  377 chr4 ENST00000264888.5 CXCL9*GGAACCCCAGUAGUGAGAAA  378 chr4 ENST00000264888.5 CXCR1GAUGGUAAGCCUGGCGGAAA  379 chr2 ENST00000295683.2 CXCR1UUGGUCAAGUUUGUUUGUCU  380 chr2 ENST00000295683.2 CXCR1CUACAGUGGCAUCCUGCUGU  381 chr2 ENST00000295683.2 CXCR2GUGACAGCUUUGAAGAUUUC  382 chr2 ENST00000318507.6 CXCR2AUCUAGUAGAAAAGGGGGCA  383 chr2 ENST00000318507.6 CXCR2UGUGGUCAUUAUCUAUGCCC  384 chr2 ENST00000318507.6 CXCR3{circumflex over( )} GCAGAAAGAGGAGGCUGUAG  385 chrX ENST00000373693.3 CXCR3{circumflexover ( )} UACCUCCCCGCCCUGCCCAC  386 chrX ENST00000373693.3CXCR3{circumflex over ( )} AAGAGCUGAAGUUCUCCAGG  387 chrXENST00000373693.3 CXCR4{circumflex over ( )} CCCAAAGUACCAGUUUGCCA  388chr2 ENST00000409817.1 CXCR4{circumflex over ( )} AGAGGAGGUCGGCCACUGAC 389 chr2 ENST00000409817.1 CXCR4{circumflex over ( )}UGGAUUGGUCAUCCUGGUCA  390 chr2 ENST00000409817.1 CXCR6**GGAAGUCUUGAUGCUCCUCC  391 chr3 ENST00000304552.4 CXCR6**GGUGUUUGUCUGUGGUCUGG  392 chr3 ENST00000304552.4 CXCR6**CCGUCAGGCUCUGCAACUUA  393 chr3 ENST00000304552.4 EBI3CACCCUGUGCAGGCUCGGCA  394 chr19 ENST00000221847.5 EBI3GGAUGUCCAGCUGUUCUCCA  395 chr19 ENST00000221847.5 EBI3AGCUGCUGCUGGAGCCCCAG  396 chr19 ENST00000221847.5 EDN1UUUCUCUCCCCAGCAGUCUU  397 chr6 ENST00000379375.5 EDN1CCACUCCCAGUCCACCCUGG  398 chr6 ENST00000379375.5 EDN1UCUGCCACCUGGACAUCAUU  399 chr6 ENST00000379375.5 ELANECACAAUCUCCGAGGCCAGCG  400 chr19 ENST00000263621.1 ELANEGUGUCCCUGCAGCUGCGCGG  401 chr19 ENST00000263621.1 ELANEGCGGCCGACAUGACGAAGUU  402 chr19 ENST00000263621.1 ENGCCGGGCCACUCGGCCGGGUA  403 chr9 ENST00000344849.4 ENGCGCCUUCCAAGUGGCAGCCC  404 chr9 ENST00000344849.4 ENGCGUGCGGCCCAUGUCCUGGC  405 chr9 ENST00000344849.4 EPOCUGUUCUAGAAUGUCCUGCC  406 chr7 ENST00000252723.2 EPOCCCUCUGGGCCUCCCAGUCC  407 chr7 ENST00000252723.2 EPOCCUGGAGAGGUACCUCUUGG  408 chr7 ENST00000252723.2 FAM3BUUACAGCUCCAGUCCCCAAA  409 chr21 ENST00000357985.6 FAM3BUGUAGGCAUAGGUGUCAGAU  410 chr21 ENST00000357985.6 FAM3BGUUAUCCUCAAAGCAGAUUU  411 chr21 ENST00000357985.6 FAM3CCUGAUAGUGCAUUUUACUUU  412 chr7 ENST00000359943.7 FAM3CAUUGUUCUUACCAUUUGCCA  413 chr7 ENST00000359943.7 FAM3CUCCCCCUUCAGUUUAAUGAG  414 chr7 ENST00000359943.7 FAM3DGUGUCUUAGGUACUUACAUG  415 chr3 ENST00000358781.6 FAM3DUUUGCGUUUAAAAUCUGCAG  416 chr3 ENST00000358781.6 FAM3DGAGGUUAAAAAGUACAAGUG  417 chr3 ENST00000358781.6 FASCACUUGGGCAUUAACACUUU  418 chr10 ENST00000355740.6 FASUACAGUUGAGACUCAGAACU  419 chr10 ENST00000355740.6 FASGUGUAACAUACCUGGAGGAC  420 chr10 ENST00000355740.6 FASLGUGGGGAUAUGGGUAAUUGAA  421 chr1 ENST00000367721.2 FASLGAACUGUGCCUGGAGGGGCCC  422 chr1 ENST00000367721.2 FASLGGGUGGUGGCCUCCUUUGACC  423 chr1 ENST00000367721.2 FGF2CCGCAGGGACCAUGGCAGCC  424 chr4 ENST00000608478.1 FGF2GGGUCCUUGAAGUGGCCGGG  425 chr4 ENST00000608478.1 FGF2ACGGCCGAGUUGACGGGGUC  426 chr4 ENST00000608478.1 FLT3LGCUCUAGGAGGAGCUCUGCGG  427 chr19 ENST00000594009.5 FLT3LGGAGCGGCUCAAGACUGUCGC  428 chr19 ENST00000594009.5 FLT3LGGCUGACCUGAAAGGCACAUU  429 chr19 ENST00000594009.5 FOXP3AGGACCCGAUGCCCAACCCC  430 chrX ENST00000376207.8 FOXP3CCGAGGGCUUGCCAGGCCUG  431 chrX ENST00000376207.8 FOXP3CCGAUGCCCAACCCCAGGCC  432 chrX ENST00000376207.8 FOXP3CCCCAGGCCUGGCAAGCCCU  433 chrX ENST00000376207.8 FZD4UCGUCCCCGAAGCCCCGCGC  434 chr11 ENST00000531380.1 FZD4CAGACUGAGACCGACGCCCC  435 chr11 ENST00000531380.1 FZD4CGAUGCUGGCCAUGGCCUGG  436 chr11 ENST00000531380.1 GATA3GAGCACAGCCGAGGCCAUGG  437 chr10 ENST00000346208.4 GATA3CUGGUCCGCCGUCACCUCCA  438 chr10 ENST00000346208.4 GATA3AGCCGAGGCCAUGGAGGUGA  439 chr10 ENST00000346208.4 GATA3CGAGGCCAUGGAGGUGACGG  440 chr10 ENST00000346208.4 GBP1UCCUCACAUCUUCAUAAUGG  441 chr1 ENST00000370473.4 GBP1CAAGCUGGCUGGAAAGAAAA  442 chr1 ENST00000370473.4 GBP1UUCUGCCAUUACACAGCCUA  443 chr1 ENST00000370473.4 GDF1CGUCCGCCGCGAGCCAGACC  444 chr19 ENST00000247005.7 GDF1GGCCGGUUCCCCCGGUCAUG  445 chr19 ENST00000247005.7 GDF1GGGGCACGGGGGCGCGGGUC  446 chr19 ENST00000247005.7 GDF10CCAUGGCUCAUGUCCCCGCU  447 chr10 ENST00000580279.1 GDF10CGUUGUUUCUGCUGUUGCUC  448 chr10 ENST00000580279.1 GDF10CGCGGGCAGUGCGGACCAGG  449 chr10 ENST00000580279.1 GDF11ACGGGGCAGCCGUCCGGCUC  450 chr12 ENST00000257868.9 GDF11UCUGCGACUUGAUGCUCUCU  451 chr12 ENST00000257868.9 GDF11CACCACCUCGCGGCUGAUGU  452 chr12 ENST00000257868.9 GDF15CACCGUCCUGAGUUCUUGCC  453 chr19 ENST00000252809.3 GDF15GCUCGCCUCGGCCAGAGACA  454 chr19 ENST00000252809.3 GDF15CUCUCGGAAUCUGGAGUCUU  455 chr19 ENST00000252809.3 GDF2GCGGGCCUAAGAUGUGUCCU  456 chr10 ENST00000581492.2 GDF2CUGCAGUGGCUUCCCCUGUA  457 chr10 ENST00000581492.2 GDF2AGGCACCCCCAGUGGGCUGU  458 chr10 ENST00000581492.2 GDF3AAAAUUUUCUUCAAGAUAUA  459 chr12 ENST00000329913.3 GDF3CCUUAUCUAAGCCCAGAAAU  460 chr12 ENST00000329913.3 GDF3GUUAAUUCUGGCUUUGGGCC  461 chr12 ENST00000329913.3 GDF5CCCUGGCCUGAAGACGUUCC  462 chr20 ENST00000374369.7 GDF5UGACUUGGGCCAGAGACCCC  463 chr20 ENST00000374369.7 GDF5GGUACCAAAGCAAGAAAGUG  464 chr20 ENST00000374369.7 GDF6GCGGCUUCGCAUGCCCUUGG  465 chr8 ENST00000287020.6 GDF6GGAUUUGCCCGGUUUCCAGC  466 chr8 ENST00000287020.6 GDF6GCCCGCCAUGGAUACUCCCA  467 chr8 ENST00000287020.6 GDF7AGCGCCUGCCGCCCCCGCGA  468 chr2 ENST00000272224.4 GDF7GCUGGGCCGGUCCGGAGCCC  469 chr2 ENST00000272224.4 GDF7UGCGGGCGCCGCGGCUGUCC  470 chr2 ENST00000272224.4 GDF9AUACCUGUUACCUGGUCUCC  471 chr5 ENST00000378673.2 GDF9AGAGCCGAACAGUGUUGUAG  472 chr5 ENST00000378673.2 GDF9CUAUAAGACAUAUGCUACCA  473 chr5 ENST00000378673.2 GPIGUCCCGGGUGAGAGCGGCCA  474 chr19 ENST00000356487.9 GPIUCAGCUCGGAGCGGUGCUCG  475 chr19 ENST00000356487.9 GPICGGCCCGCCCGCACCUGAAG  476 chr19 ENST00000356487.9 GREM1UAUGAGCCGCACAGCCUACA  477 chr15 ENST00000622074.1 GREM1CCCUUCAGCAGCCGGCAGCA  478 chr15 ENST00000622074.1 GREM1UUGUGCUGGGCCUUGUCUGG  479 chr15 ENST00000622074.1 GREM2CGGUGACCACCAGGGCCUCC  480 chr1 ENST00000318160.4 GREM2GCAGCAACAACUCGGAGAGA  481 chr1 ENST00000318160.4 GREM2GCUUUCCCUGUCCUUGUUCC  482 chr1 ENST00000318160.4 GRNCAGGCAGACCAUGUGGACCC  483 chr17 ENST00000053867.7 GRNGCUGGAACGCGGUGCCCAGA  484 chr17 ENST00000053867.7 GRNAGCUGGCUCCUCCGGGGUCC  485 chr17 ENST00000053867.7 HAX1CACCUUUCUGCAGAACUUCC  486 chr1 ENST00000328703.11 HAX1UACGGGAGGGACAGACACUU  487 chr1 ENST00000328703.11 HAX1CCAGUCUGGUGCUGGUUGGG  488 chr1 ENST00000328703.11 HFE2AGGAGCGGAGGGCUCGACAG  489 chr1 ENST00000336751.10 HFE2UCAUCAGGAGCACUUCGAGG  490 chr1 ENST00000336751.10 HFE2CGUACUCAGCAUUGCAGCGG  491 chr1 ENST00000336751.10 HMGB1*GAUACUCACGGAGGCCUCUU  492 chr13 ENST00000339872.8 HMGB1*GAUACUCACGGAGGCCUCUU  493 chr13 ENST00000339872.8 HMGB1*GAUACUCACGGAGGCCUCUU  494 chr13 ENST00000339872.8 HYAL2GCGUGGGCCACAGUCCUGUG  495 chr3 ENST00000357750.8 HYAL2UGCUGUGGGCUUGAGCUCCA  496 chr3 ENST00000357750.8 HYAL2GCAGCCCCCAGCAUGCGGGC  497 chr3 ENST00000357750.8 ICAM3**UCAUGUUCCUGAAGGUGUCC  498 chr19 ENST00000160262.9 ICAM3**CAUGUUCCUGAAGGUGUCCA  499 chr19 ENST00000160262.9 ICAM3**AUGUUCCUGAAGGUGUCCAG  500 chr19 ENST00000160262.9 ICAM3**UCCUGAAGGUGUCCAGGGGC  501 chr19 ENST00000160262.9 ICOS**UUUUAUGCAGGAGAAAUCAA  502 ch2 ENST00000316386.10 ICOS**GAGAUGUUUAUAUUUCACAA  503 ch2 ENST00000316386.10 ICOS**AUGUUUAUAUUUCACAACGG  504 ch2 ENST00000316386.10 ICOS**UUUAAAAUGCAGUUGCUGAA  505 ch2 ENST00000316386.10 IFNA10CAAACUCCUCCUGGGGGAUU  506 chr9 ENST00000357374.2 IFNA10CAAACUCCUCCUGGGGGAUU  507 chr9 ENST00000357374.2 IFNA10CAAACUCCUCCUGGGGGAUU  508 chr9 ENST00000357374.2 IFNA14CAGGAGGACUUUGAUGCUCA  509 chr9 ENST00000380222.3 IFNA14AAGCAAAGGGCAAUGCCAUU  510 chr9 ENST00000380222.3 IFNA14AAGCAAAGGGCAAUGCCAUU  511 chr9 ENST00000380222.3 IFNA16CAUCUCAUGGAAGGCAGAGA  512 chr9 ENST00000380216.1 IFNA16AUAUGAUUUCGGAUUCCCCC  513 chr9 ENST00000380216.1 EFNA16AUAUGAUUUCGGAUUCCCCC  514 chr9 ENST00000380216.1 IFNA2UCAAGGUCCUCCUGCUACCC  515 chr9 ENST00000380206.3 IFNA2CACCAGUAAAGCAAAGGUCA  516 chr9 ENST00000380206.3 IFNA2CACCAGUAAAGCAAAGGUCA  517 chr9 ENST00000380206.3 IFNA5UUGAUGAUAAUGGCACAAAU  518 chr9 ENST00000610521.1 IFNA5CUUGCCCUUUGUUUUACUGA  519 chr9 ENST00000610521.1 IFNA5CUUGCCCUUUGUUUUACUGA  520 chr9 ENST00000610521.1 IFNA6AGGUCUGCUGAAUCACCUCA  521 chr9 ENST00000380210.1 IFNA6ACAUGACUUCAGAUUUCCCC  522 chr9 ENST00000380210.1 IFNA6UCAUGGUCCUCCUGUGACCC  523 chr9 ENST00000380210.1 IFNA8UACAAGUCAUUCAGCUCUCU  524 chr9 ENST00000380205.1 IFNA8GUUUAUCAUCAAACUCCUCC  525 chr9 ENST00000380205.1 IFNA8GUUUAUCAUCAAACUCCUCC  526 chr9 ENST00000380205.1 IFNAR1UUUACUUUAAAGAACUGGGA  527 chr21 ENST00000270139.7 IFNAR1GAGUGAAGAAAAGUUGCAUU  528 chr21 ENST00000270139.7 IFNAR1AAACACUUCUUCAUGGUAUG  529 chr21 ENST00000270139.7 IFNAR2UAAACCAGAAGAUUUGAAGG  530 chr21 ENST00000342136.8 IFNAR2UGAGUGGAGAAGCACACACG  531 chr21 ENST00000342136.8 IFNAR2UCAGUUGCUCACACAAUUUC  532 chr21 ENST00000342136.8 IFNB1UUGAAUACUGCCUCAAGGAC  533 chr9 ENST00000380232.3 IFNB1GAAAAUUGCUGCUUCUUUGU  534 chr9 ENST00000380232.3 IFNB1AGCACAACAGGAGAGCAAUU  535 chr9 ENST00000380232.3 IFNEUGGCCAGAGUGUGUCCUUUU  536 chr9 ENST00000448696.4 IFNEUAGACACUGCUGAAUUGACA  537 chr9 ENST00000448696.4 IFNECUUGAUUCACUUGUCUUUGC  538 chr9 ENST00000448696.4 IFNG*UUUUUAAUAGUACUUGUUUG  539 chr12 ENST00000229135.3 IFNG*CUUCUUUUACAUAUGGGUCC  540 chr12 ENST00000229135.3 IFNG*GAAAUAUACAAGUUAUAUCU  541 chr12 ENST00000229135.3 IFNGR1**AUUGUACACCCUAAUGUAAC  542 chr6 ENST00000367739.8 IFNGR1**CUCCAUUUACAAAAACUGAA  543 chr6 ENST00000367739.8 IFNGR1**UUUCUGAUAUCCAGUUUAGG  544 chr6 ENST00000367739.8 IFNKUUGUGGCUUGAGAUCCUUAU  545 chr9 ENST00000276943.2 IFNKCGUUCAGUAAGUUACAGUCC  546 chr9 ENST00000276943.2 IFNKUUUUCUCGUAGACAUUCUAC  547 chr9 ENST00000276943.2 IFNL1AUUUAGCCAUGGCUGCAGCU  548 chr19 ENST00000333625.2 IFNL1GUGGCAGCCCUUCCCAGUUG  549 chr19 ENST00000333625.2 IFNL1UAGCGAGCUUCAAGAAGGCC  550 chr19 ENST00000333625.2 IFNL3CGGGCCUGUGUGAGUCGUCA  551 chr19 ENST00000413851.2 IFNL3CCAAGACAUCCCCCAGGGCU  552 chr19 ENST00000413851.2 IFNL3CCAAGACAUCCCCCAGGGCU  553 chr19 ENST00000413851.2 IFNW1CUCCCUUUUACCAUCUCCUG  554 chr9 ENST00000380229.3 IFNW1CAUUUGGUGCAGAAGCACCA  555 chr9 ENST00000380229.3 IFNW1AGAUCCAACAGGGCUAUAGC  556 chr9 ENST00000380229.3 IL10*CGGAGAUCUCGAAGCAUGUU  557 chr1 ENST00000423557.1 IL10*UCAGACUGGGUGCCCUGGCC  558 chr1 ENST00000423557.1 IL10*CUCAGCACUGCUCUGUUGCC  559 chr1 ENST00000423557.1 IL10RA**GGUCUGGCUACAGUUGGAGA  560 chr11 ENST00000227752.7 IL10RA**GGUAGCCAUUGCUGUGGUAC  561 chr11 ENST00000227752.7 IL10RA**GGUGUUGGUGACGGUCCAGU  562 chr11 ENST00000227752.7 IL11CGUGCCGCAGGUAGGACAGU  563 chr19 ENST00000264563.6 IL11CGGCUCUAUCCCCAGCUCCC  564 chr19 ENST00000264563.6 IL11CACUGGGAGCUCUACAGGUA  565 chr19 ENST00000264563.6 IL11RAAGUGUCCUGGUUUCGGGAUG  566 chr9 ENST00000318041.13 IL11RAGCUAGGGCAUGAACUGGUCC  567 chr9 ENST00000318041.13 IL11RAUGCCCCCAAGUGCACCAUCC  568 chr9 ENST00000318041.13 IL12ACCAGGGUAGCCACAAGGAGG  569 chr3 ENST00000305579.6 IL12AGGUCUGGAGUGGCCACGGGG  570 chr3 ENST00000305579.6 IL12AUGACGGCCCUCAGCAGGUUU  571 chr3 ENST00000305579.6 IL12BACUCUUUGACUUGGAUGGUC  572 chr5 ENST00000231228.2 IL12BGGUGAUACCAUCUUCUUCAG  573 chr5 ENST00000231228.2 IL12BUUUAUGUCGUAGAAUUGGAU  574 chr5 ENST00000231228.2 IL12RB1{circumflex over( )} CACUUCCUGCGGUGUUGGUG  575 chr19 ENST00000593993.6IL12RB1{circumflex over ( )} GGAGCACUCGUAACGAUCAC  576 chr19ENST00000593993.6 IL12RB1{circumflex over ( )} AUCUCUUCCAGGCUCGGCCU  577chr19 ENST00000593993.6 IL13* CAUGGCGCUUUUGUUGACCA  578 chr5ENST00000304506.7 IL13* GCCUCCCUCUACAGCCCUCA  579 chr5 ENST00000304506.7IL13* CGACACUCACCUUCUGGUUC  580 chr5 ENST00000304506.7 IL15AUGGAAAUACUUCUCAAAUG  581 chr4 ENST00000296545.11 IL15GGCAUUCAUGUCUUCAUUUU  582 chr4 ENST00000296545.11 IL15AUGGUCAUGAUGAUUGUCCU  583 chr4 ENST00000296545.11 IL16CAAAAUUUCGGUCCAUCUCC  584 chr15 ENST00000302987.8 IL16AGGGCUAGAGCCAUCAUCAC  585 chr15 ENST00000302987.8 IL16GGAAAAUUCCCUCCUUGCCC  586 chr15 ENST00000302987.8 IL17A{circumflex over( )} GCUACUGCUGCUGAGCCUGG  587 chr6 ENST00000340057.1 IL17A{circumflexover ( )} UCAACCUGAACAUCCAUAAC  588 chr6 ENST00000340057.1IL17A{circumflex over ( )} GGAUCGGUUGUAGUAAUCUG  589 chr6ENST00000340057.1 IL17B{circumflex over ( )} GCUCUGAGCUGUUCCUCAGC  590chr5 ENST00000261796.3 IL17B{circumflex over ( )} GAAACCGUAUGCCCGCAUGG 591 chr5 ENST00000261796.3 IL17B{circumflex over ( )}CUCUUGCUUUUGGGGCUCCU  592 chr5 ENST00000261796.3 IL17C{circumflex over( )} UCAGAAACAGGAGGCCGGGG  593 chr16 ENST00000244241.4 IL17C{circumflexover ( )} CGGUACCCCACACUGCUACU  594 chr16 ENST00000244241.4IL17C{circumflex over ( )} GCACCUCGAGCCAGCAGGUG  595 chr16ENST00000244241.4 IL17D{circumflex over ( )} CGGCAGCGCCAGCAGGAAGC  596chr13 ENST00000304920.3 IL17D{circumflex over ( )} GGACCGGCCGGAGGAGCUAC 597 chr13 ENST00000304920.3 IL17D{circumflex over ( )}GUGGAAGGCACUGAGCACGC  598 chr13 ENST00000304920.3 IL17F{circumflex over( )} GGUAGUAUGAAGCUUGACAU  599 chr6 ENST00000336123.4 IL17F{circumflexover ( )} GAAAAAAGUAUGUCCUACUU  600 chr6 ENST00000336123.4IL17F{circumflex over ( )} UACUUGCUGCUGUCGAUAUU  601 chr6ENST00000336123.4 IL18 GGAAAUAAUUUUGUUCUCAC  602 chr11ENST00000280357.11 IL18 UUACAGCCAUACCUCUAGGC  603 chr11ENST00000280357.11 IL18 UUAUUUCAGAUAAUGCACCC  604 chr11ENST00000280357.11 IL18BP GCAGGACCCACAAAGGGCUG  605 chr11ENST00000260049.9 IL18BP UGUGCUUCUAACUGAGGCAG  606 chr11ENST00000260049.9 IL18BP GCUGGACACUGCUUAGCUGC  607 chr11ENST00000260049.9 IL19 AGUUACAGUGUGUUUCCCUU  608 chr1 ENST00000270218.10IL19 CAGUAGACAACCACGGUCUC  609 chr1 ENST00000270218.10 IL19CUUGGAAACUCUCUUCUAUA  610 chr1 ENST00000270218.10 IL1AGGAAGGUUCUGAAGAAGAGA  611 chr2 ENST00000263339.3 IL1AGGUAAGCUUGGAUGUUUUAG  612 chr2 ENST00000263339.3 IL1AGCCAUAGCUUACAUGAUAGA  613 chr2 ENST00000263339.3 IL1B*CAUUCUCCUGGAAGGUCUGU  614 chr2 ENST00000263341.6 IL1B*CAUGGCCACAACAACUGACG  615 chr2 ENST00000263341.6 IL1B*CUCUCCGCAGUGCUCCUUCC  616 chr2 ENST00000263341.6 IL1F10AUCUGCAUACUUCCUAACAG  617 chr2 ENST00000341010.6 IL1F10CCAGGCAGCGGCUCCCUCCC  618 chr2 ENST00000341010.6 IL1F10GGCCUCUCACCUCCAGCUGU  619 chr2 ENST00000341010.6 IL1R1**UCCUUUUAAAGAUAAAUGCA  620 chr2 ENST00000410023.5 IL1R1**CUUAACCCAAAUGAACACAA  621 chr2 ENST00000410023.5 IL1R1**UAUCUACAGAACAAGCCUCC  622 chr2 ENST00000410023.5 IL1R2**CCAGAAGCUGCCGGUUUCGU  623 chr2 ENST00000332549.7 IL1R2**UGUAGCCCUGAGGUGCCCCC  624 chr2 ENST00000332549.7 IL1R2**UAAAAAUGACUCUGCUAGGA  625 chr2 ENST00000332549.7 IL1RAPL1**AAUUCUUAAGGAGCAUCUUG  626 chrX ENST00000378993.5 IL1RAPL1**CUCUGUGGAAGAAGGUGACU  627 chrX ENST00000378993.5 IL1RAPL1**UACACUCACCUCGUUUAUGA  628 chrX ENST00000378993.5 IL1RL1**UUUCUUAUUUCAGAAUUGUC  629 chr2 ENST00000233954.5 IL1RL1**AAUGUGAUGACUGAGGACGC  630 chr2 ENST00000233954.5 IL1RL1**ACCCUUGACCGUGAAGGACC  631 chr2 ENST00000233954.5 IL1RN**UUCCCCAGAAAAGAUAGAUG  632 chr2 ENST00000409930.3 IL1RN**ACAGGCACAUCUUCCCUCCA  633 chr2 ENST00000409930.3 IL1RN**AGCAUGUUUUUACCUCCAGC  634 chr2 ENST00000409930.3 IL2UGUAAUAAUUUUAGUAAGAA  635 chr4 ENST00000226730.4 IL2ACAACUGGAGCAUUUACUGC  636 chr4 ENST00000226730.4 IL2GACUUAGUGCAAUGCAAGAC  637 chr4 ENST00000226730.4 IL20AAGGCUGAAGGCAAGACUAG  638 chr1 ENST00000367096.7 IL20UGGACUGAAGACACUCAAUU  639 chr1 ENST00000367096.7 IL20UUCUGAGAUACGGGGCAGUG  640 chr1 ENST00000367096.7 IL20RACAUCCCCGACCCGCACCUGG  641 chr6 ENST00000316649.9 IL20RAUGUUGCUCCUGGCGGCGCCU  642 chr6 ENST00000316649.9 IL20RACCGCCGCCCAUGCGGGCUCC  643 chr6 ENST00000316649.9 IL20RBAGUGAGUGAGCACCAGCUGC  644 chr3 ENST00000329582.8 IL20RBUGCCAUACAACCUUCGUGUC  645 chr3 ENST00000329582.8 IL20RBUUCUAUUAAAGGGAUGCUUC  646 chr3 ENST00000329582.8 IL21GAAAAAUUAUGUGAAUGACU  647 chr4 ENST00000264497.7 IL21UCAUGUGGCGAUCUUGACCU  648 chr4 ENST00000264497.7 IL21ACAAUCCUCUCCAUGUUGCC  649 chr4 ENST00000264497.7 IL22{circumflex over( )} UGGACUUGUCAAGCCUGCAG  650 chr12 ENST00000328087.5 IL22{circumflexover ( )} UCUCUUGGCCCUCUUGGUAC  651 chr12 ENST00000328087.5IL22{circumflex over ( )} AAGAGCUCACAGAUUUCUGC  652 chr12ENST00000328087.5 IL22RA1{circumflex over ( )} GAUGUCUGGCUGCCCUAAGU  653chr1 ENST00000270800.1 IL22RA1{circumflex over ( )} UCUGGACCCAGGGAGCCCGC 654 chr1 ENST00000270800.1 IL22RA1{circumflex over ( )}CAGGGAUCAGGACGUGCUCC  655 chr1 ENST00000270800.1 IL22RA2{circumflex over( )} UUCUGAGUAGCUCCCAGCCG  656 chr6 ENST00000349184.8 IL22RA2{circumflexover ( )} CUGUAUGUCUGAGGUUUCAC  657 chr6 ENST00000349184.8IL22RA2{circumflex over ( )} ACAGAUAUGGACAGAGACAA  658 chr6ENST00000349184.8 IL23A* CUGCUGCCCUGGACAGCUCA  659 chr12ENST00000228534.5 IL23A* AAGCUGCUGGCACUGAGUCC  660 chr12ENST00000228534.5 IL23A* CUCACCAUGUGUCCCACUAG  661 chr12ENST00000228534.5 IL23R** CUGUUGCACAUAUGUAAAAU  662 chr1ENST00000347310.9 IL23R** GAUGUCAAGAAACAGGCAAA  663 chr1ENST00000347310.9 IL23R** UAAGUACACUCACCUGUUUC  664 chr1ENST00000347310.9 IL24 UGAGAGGCUGUCGCCAGCAA  665 chr1 ENST00000294984.6IL24 CUUCUCUGGAGCCAGGUAUC  666 chr1 ENST00000294984.6 IL24ACAACCCCCUUCACUUGGCA  667 chr1 ENST00000294984.6 IL25CCUACAGGUGGUUGCAUUCU  668 chr14 ENST00000329715.2 IL25GAGGUGUCCUGCCCUUUGCU  669 chr14 ENST00000329715.2 IL25UGCCUCCCCUAGAGCCUGCU  670 chr14 ENST00000329715.2 IL26AUAGAGAGCGUCAACAGCUU  671 chr12 ENST00000229134.4 IL26AGAUUGCUUGUGCUUGGCAA  672 chr12 ENST00000229134.4 IL26UGCUGGUGAAUUUCAUUUUG  673 chr12 ENST00000229134.4 IL27CAUUAGGGGGACUUACAAAG  674 chr16 ENST00000356897.1 IL27GCAGCUCCUGCAGGCUCAGC  675 chr16 ENST00000356897.1 IL27ACCAGCUUGAACCAGGAGCA  676 chr16 ENST00000356897.1 IL2RACAGAGCUUGUGCAUUGACAU  677 chr10 ENST00000379959.7 IL2RAGUGACCCGCUUUUUAUUCUG  678 chr10 ENST00000379959.7 IL2RAAUGGCUUUGAAUGUGGCGUG  679 chr10 ENST00000379959.7 IL2RBUGUGGCCUGGGGACAGCGUC  680 chr22 ENST00000216223.9 IL2RBCCCACAGAUGCAACAUAAGC  681 chr22 ENST00000216223.9 IL2RBGUUGUCUCCAGUUCGCCUGA  682 chr22 ENST00000216223.9 IL2RGCAUACCAAUAAUGCAGAGUG  683 chrX ENST00000374202.6 IL2RGUCGAGUACAUGAAUUGCACU  684 chrX ENST00000374202.6 IL2RGGAAACACUGAGGGAGUCAGU  685 chrX ENST00000374202.6 IL3*GCAGGAGCAGGACGGGCAGG  686 chr5 ENST00000296870.2 IL3*CAACGCCCUUGAAGACAAGC  687 chr5 ENST00000296870.2 IL3*CUACUCACCAGCAAAGGCAA  688 chr5 ENST00000296870.2 IL31CUUUCAAAAGCAUCUUCGAG  689 chr12 ENST00000377035.1 IL31GUAAACGGACGGGCAACGUG  690 chr12 ENST00000377035.1 IL31AGAAAGAGCACAGACGUCGA  691 chr12 ENST00000377035.1 IL31RACAACUUCGCUAAGAACCGUA  692 chr5 ENST00000447346.6 IL31RAAGCUCUGCGAUGUGCGGUCA  693 chr5 ENST00000447346.6 IL31RACAGUCAUUCCCAUUUUUUCU  694 chr5 ENST00000447346.6 IL32CUGCCUCUCUUCACAGCACC  695 chr16 ENST00000325568.9 IL32AGAAUCAGGACGUGGACAGG  696 chr16 ENST00000325568.9 IL32UCAGGGUGAGAAGGAUGAAG  697 chr16 ENST00000325568.9 IL33UUGUUUAGAAUCCCAACAGA  698 chr9 ENST00000381434.7 IL33CUCUGGCCUUAUGAUAAAAA  699 chr9 ENST00000381434.7 IL33UUUCAGUGAAGGCCUUUUGG  700 chr9 ENST00000381434.7 IL34UCUUGGGAUCUUCCUUGGCG  701 chr16 ENST00000288098.6 IL34GCACUCCUCAUUCUGCGUCA  702 chr16 ENST00000288098.6 IL34CAGGAGCCGACUUCAGUACA  703 chr16 ENST00000288098.6 IL36ACACAUGUCGGCAUGAGAUUA  704 chr2 ENST00000259211.6 IL36AGAUUGAGUCCAUUCAGGCCC  705 chr2 ENST00000259211.6 IL36AACUCACCUUCAGCUGCAGUG  706 chr2 ENST00000259211.6 IL36BCAAGCCUACUUUGCAGCUUA  707 chr2 ENST00000327407.2 IL36BUAUGGUUUACCUGGGAAUCA  708 chr2 ENST00000327407.2 IL36BGCUAUUAAAUGAAGAGUGAC  709 chr2 ENST00000327407.2 IL36GUCAGUGUGUAAACCUAUUAC  710 chr2 ENST00000259205.4 IL36GCACAAGGUUCUGACCCUGAA  711 chr2 ENST00000259205.4 IL36GCUGUUUGCACUGCUGUGGCU  712 chr2 ENST00000259205.4 IL36RNCACAGGUGAAGAGAUCAGCG  713 chr2 ENST00000346807.7 IL36RNCACCCAGGAUGACGGGGGAC  714 chr2 ENST00000346807.7 IL36RNGGAGCCGACUCUAACACUAG  715 chr2 ENST00000346807.7 IL37GCUAAUGCAAAGAAGAUCUC  716 chr2 ENST00000263326.7 IL37AUUCUCCUGGGGGUCUCUAA  717 chr2 ENST00000263326.7 IL37AACUCUCACCUUCAGCUGAA  718 chr2 ENST00000263326.7 IL4*CAGAGGGGGAAGCAGUUGGG  719 chr5 ENST00000231449.6 IL4*UGAUAUCGCACUUGUGUCCG  720 chr5 ENST00000231449.6 IL4*UACUCACCUUCUGCUCUGUG  721 chr5 ENST00000231449.6 IL5*CAUAAAGAAAAUUACCUCAU  722 chr5 ENST00000231454.5 IL5*UGCAUUGGUGAAAGAGACCU  723 chr5 ENST00000231454.5 IL5*CAUUUGAGUUUGCUAGCUCU  724 chr5 ENST00000231454.5 IL6*CCCUCCGGCACAGGCGCCUU  725 chr7 ENST00000258743.9 IL6*ACAUCUUUGGAAUCUUCUCC  726 chr7 ENST00000258743.9 IL6*AACGAAUUGACAAACAAAUU  727 chr7 ENST00000258743.9 IL6R**CAGUCCGGCCGAAGACUUCC  728 chr1 ENST00000368485.7 IL6R**UAACUGGCAGGAGAACUUCU  729 chr1 ENST00000368485.7 IL6R**CAGCAAAACUCAAACCUUUC  730 chr1 ENST00000368485.7 IL6STAUUUACCUGGCUCCAAGUUG  731 chr5 ENST00000336909.9 IL6STUUAUAACACUCUUAAUACUU  732 chr5 ENST00000336909.9 IL6STUGAUAAAUUAUGUGGCGGAU  733 chr5 ENST00000336909.9 IL7GGUCAGCAUCGAUCAAUUAU  734 chr8 ENST00000263851.8 IL7AUGCUACUGGCAACAGAACA  735 chr8 ENST00000263851.8 IL7UGUCAAAUUUAGUUUCUUUU  736 chr8 ENST00000263851.8 IL9{circumflex over( )} CUACCUGCAUCUUGUUGAUG  737 chr5 ENST00000274520.1 IL9{circumflexover ( )} UGGACACCCCUGGCCUGCCA  738 chr5 ENST00000274520.1IL9{circumflex over ( )} UGUCAAGAUGCUUCUGGCCA  739 chr5ENST00000274520.1 INHA UCAGCAGCAAGAAGAGCAGU  740 chr2 ENST00000243786.2INHA CCGGGAACUUGUUCUGGCCA  741 chr2 ENST00000243786.2 INHACCGCGGUGACCAGGGAAGGU  742 chr2 ENST00000243786.2 INHBAUGAACUUAUGGAGCAGACCU  743 chr7 ENST00000242208.4 INHBAGAACGGGUAUGUGGAGAUAG  744 chr7 ENST00000242208.4 INHBAGGGUACCGGCUGGGUGACAU  745 chr7 ENST00000242208.4 INHBBGGCGGCGGCGCGGCAGGCGU  746 chr2 ENST00000295228.3 INHBBGUACGUCGUGCGGCGGCUUC  747 chr2 ENST00000295228.3 INHBBUGUGCCGCUUCACCGCCUCC  748 chr2 ENST00000295228.3 INHBCAAAGGCCAGAAGCAAUGAGG  749 chr12 ENST00000309668.2 INHBCUGGACACUGACCGCCAGCUC  750 chr12 ENST00000309668.2 INHBCGCGGGAGCUGCUUCUUGAUC  751 chr12 ENST00000309668.2 INHBEAAAAGUGAGCAGGGAGCUGU  752 chr12 ENST00000266646.2 INHBECAAGCAAAGAGUGCCAGGAA  753 chr12 ENST00000266646.2 INHBECCAGGAGAGUGCGGGACCCU  754 chr12 ENST00000266646.2 ITGA4**CCACCGAGAGCGCAUGGCUU  755 chr2 ENST00000397033.6 ITGA4**GACCGGCCGCCCCUACAACG  756 chr2 ENST00000397033.6 ITGA4**AGCCGAACAGCGUGUUGUGG  757 chr2 ENST00000397033.6 ITGAV**CGGCGAUGGCUUUUCCGCCG  758 chr2 ENST00000261023.7 ITGAV**GUCCCGAGAGAAGAAGCGGG  759 chr2 ENST00000261023.7 ITGAV**GACAGUCCUGCCGAGUACUC  760 chr2 ENST00000261023.7 ITGB1**UGCUGUUCCUUUGCUACGGU  761 chr10 ENST00000302278.7 ITGB1**GAUGACAUAGAAAAUCCCAG  762 chr10 ENST00000302278.7 ITGB1**AUUUAGACAUUUUUACAGGA  763 chr10 ENST00000302278.7 ITGB3**GCGAGGUGAGCCCAGAGGCA  764 chr17 ENST00000559488.5 ITGB3**AGGCCCGAGUACUAGAGGAC  765 chr17 ENST00000559488.5 ITGB3**GGGGACUGACUUGAGUGACC  766 chr17 ENST00000559488.5 KIT**CUCAACCAUCUGUGAGUCCA  767 chr4 ENST00000288135.5 KIT**AUCAGACUUAAUAGUCCGCG  768 chr4 ENST00000288135.5 KIT**AAAGUCCAUUUGACAAAGCC  769 chr4 ENST00000288135.5 KITLGUUUCUUUCACGCACUCCACA  770 chr12 ENST00000228280.9 KITLGAAGUUUUCAAAUAUUUCUGA  771 chr12 ENST00000228280.9 KITLGUCUUGCAGCCAAGUCAUUGU  772 chr12 ENST00000228280.9 KLHL20GCACCGGGAGCUAUGUGAUG  773 chr1 ENST00000209884.4 KLHL20UACUUCCGAGCUAUGUUUAC  774 chr1 ENST00000209884.4 KLHL20UAGCCCUCUCGUCAAUGUCU  775 chr1 ENST00000209884.4 LEFTY1GCUGCAGCAGGGCCACGUAC  776 chr1 ENST00000272134.5 LEFTY1CCUCCAUGUCGGCCCUGUCC  777 chr1 ENST00000272134.5 LEFTY1GUGUUGCCCCUGGCCAGCCC  778 chr1 ENST00000272134.5 LEFTY2AUGUCGGCCCUGUCCAGUAC  779 chr1 ENST00000366820.9 LEFTY2CUCCUCGGUCAGGGCCGCCC  780 chr1 ENST00000366820.9 LEFTY2GCAGCACCAUGUGGCCCCUG  781 chr1 ENST00000366820.9 LIFGUCCCGGGUGAUGUUGCCCA  782 chr22 ENST00000249075.3 LIFUGCCGUUGGCGUGGAAGGGC  783 chr22 ENST00000249075.3 LIFUGUUGGGGAACGGCUCCCCC  784 chr22 ENST00000249075.3 LIFRUGAUGCACUUACCCUUUUUC  785 chr5 ENST00000263409.8 LIFRUAAAUGUUGAUAACAGCCAC  786 chr5 ENST00000263409.8 LIFRGAAACGACCAUCCUGGAUGG  787 chr5 ENST00000263409.8 LTACCCUAGGGGCUCCCUGGUGU  788 chr6 ENST00000418386.2 LTAGAUGCAUCUUGGGGUGCUGA  789 chr6 ENST00000418386.2 LTACAGGUGGAUGUUUACCAAUG  790 chr6 ENST00000418386.2 LTBUAUCACUGUCCUGGCUGUGC  791 chr6 ENST00000429299.2 LTBUCCCUCCUGCUAGCUGUGGC  792 chr6 ENST00000429299.2 LTBUUCAGUCUCAAUGGGGGCAC  793 chr6 ENST00000429299.2 LTBP1AUGGUGGCCAGUGCAGUUCA  794 chr2 ENST00000407925.5 LTBP1GUUUAGGCACGCUGGCACCA  795 chr2 ENST00000407925.5 LTBP1GAGGCAAGGUAUGUGUUGAA  796 chr2 ENST00000407925.5 LTBP3GCCCUCACCCACGCGGAAGC  797 chr11 ENST00000322147.8 LTBP3AUGACGCUCAUCGGAGAGAA  798 chr11 ENST00000322147.8 LTBP3CUGCAAGCGGACCUGUCUCA  799 chr11 ENST00000322147.8 LTBP4CCCUUGAUCUGUCACAAUGG  800 chr19 ENST00000308370.11 LTBP4GGCCGGGGGCCGGGCGCCCG  801 chr19 ENST00000308370.11 LTBP4GUGCUCGUCGUCGCGGUGGU  802 chr19 ENST00000308370.11 MAFCAGGAGAAUGGCAUCAGAAC  803 chr16 ENST00000326043.4 MAFCAGGGGACUGGUGGGCAGGU  804 chr16 ENST00000326043.4 MAFUCCAUGGCCAGGGGACUGGU  805 chr16 ENST00000326043.4 MAFCGACCUGCCCACCAGUCCCC  806 chr16 ENST00000326043.4 MIFUUGGUGUUUACGAUGAACAU  807 chr22 ENST00000215754.7 MIFCAGCAGCUGGCGCAGGCCAC  808 chr22 ENST00000215754.7 MIFGCGCGGAACCCCUCGUCCGG  809 chr22 ENST00000215754.7 MINOS1-GGCCACGGGCAUGAUGCUUC  810 chr1 ENST00000602662.1 MINOS1-GAACAGUGCCAGCUUGUUGA  811 chr1 ENST00000602662.1 MINOS1-AGCCGCUGUGGCCCACGAUC  812 chr1 ENST00000602662.1 MSTNUGACGAUUAUCACGCUACAA  813 chr2 ENST00000260950.4 MSTNUUCCCGGAGUGGAGGAGCUU  814 chr2 ENST00000260950.4 MSTNAAUCCUCAGUAAACUUCGUC  815 chr2 ENST00000260950.4 NAMPTGCUGGGGACGAGCGCGCGGC  816 chr7 ENST00000222553.7 NAMPTCUUUACCUUGUAGGAGUCGG  817 chr7 ENST00000222553.7 NAMPTCCGGCCCGAGAUGAAUCCUG  818 chr7 ENST00000222553.7 NBL1GGCCACGGGCAUGAUGCUUC  819 chr1 ENST00000375136.7 NBL1GAACAGUGCCAGCUUGUUGA  820 chr1 ENST00000375136.7 NBL1AGCCGCUGUGGCCCACGAUC  821 chr1 ENST00000375136.7 NDPUUGAGCUACACUUGUACAAU  822 chrX ENST00000378062.5 NDPCAGCUCAUUCAUAAUGGACU  823 chrX ENST00000378062.5 NDPCAGCAGGGAGAGCAUAGAAA  824 chrX ENST00000378062.5 NLRP7GCCUCUUCCACCUCAGACCA  825 chr19 ENST00000328092.9 NLRP7GAGUUUCAAAUCCCUUUUAU  826 chr19 ENST00000328092.9 NLRP7CUGCAGAGUCCACUCUAGCU  827 chr19 ENST00000328092.9 NODALUGACCAGGCCUCUCUCCAAG  828 chr10 ENST00000287139.7 NODALGGGACAAAGUGACAGUGAAU  829 chr10 ENST00000287139.7 NODALCUGUGUCGGGCUUUGGCUGG  830 chr10 ENST00000287139.7 NOGGACCACCACCAGGGCGUAGA  831 chr17 ENST00000332822.4 NOGGGCGGAUGUGGAGAUAGUGC  832 chr17 ENST00000332822.4 NOGUUGGGGUCAAAGAUAGGGUC  833 chr17 ENST00000332822.4 NRG1GCUACAUCUACAUCCACCAC  834 chr8 ENST00000287842.7 NRG1AAACUUUCUGUGUGAAUGGA  835 chr8 ENST00000287842.7 NRG1UUACUUGCACAAGUAUCUCG  836 chr8 ENST00000287842.7 NRP1UUGCAGAGCAGUGUCUCAGA  837 chr10 ENST00000265371.8 NRP1GCUGUCGGUGUAAAAAACCA  838 chr10 ENST00000265371.8 NRP1CCACAGUAACGCCCAAUGUG  839 chr10 ENST00000265371.8 NRP2CUUUCAGACCCACCGUGCGG  840 chr2 ENST00000357785.9 NRP2UCUGGUGGGAGGGGUAGUCC  841 chr2 ENST00000357785.9 NRP2UUGAGGACAAUCUUCUGGUU  842 chr2 ENST00000357785.9 OSMAGGGCCCAGGUGCUUACAUA  843 chr22 ENST00000215781.2 OSMGAUCUGUCUGCUUCUGGAGC  844 chr22 ENST00000215781.2 OSMGUUUCCAAGCAUGGCGAGCA  845 chr22 ENST00000215781.2 OSMRAUUACAGCACCACUGUGAAG  846 chr5 ENST00000274276.7 OSMRCUUUGUAAGAAUAAAGAGUU  847 chr5 ENST00000274276.7 OSMRGAGCAACUGGAGUUCCUGGG  848 chr5 ENST00000274276.7 PARK7UAGAUUAAGGUCACCGUUGC  849 chr1 ENST00000338639.9 PARK7CAGGACAAAUGACCACAUCA  850 chr1 ENST00000338639.9 PARK7CAUGGAGUUAUUCCUUCAUA  851 chr1 ENST00000338639.9 PDPNCAACUGCAAAGUUUGCUGUC  852 chr1 ENST00000294489.10 PDPNCCCCACCGUCGCGCUCCUCC  853 chr1 ENST00000294489.10 PDPNCAGCUCAGAAUCUUGCUGCU  854 chr1 ENST00000294489.10 PF4UGUGAGGGCUGGCAGCGGCG  855 chr4 ENST00000296029.3 PF4GUGGCAGGAGCAGCAACCCC  856 chr4 ENST00000296029.3 PF4CGCAGCAUGAGCUCCGCAGC  857 chr4 ENST00000296029.3 PF4V1GGCGCGGGUGAGGCGGGACC  858 chr4 ENST00000226524.3 PF4V1AGAGCAGAAACCAGGCUGGG  859 chr4 ENST00000226524.3 PF4V1AGAGCAGAAACCAGGCUGGG  860 chr4 ENST00000226524.3 PGLYRP1CGAUACCACCACAUAGCGUA  861 chr19 ENST00000008938.4 PGLYRP1CAGGGCCUUCCACUCGUUCC  862 chr19 ENST00000008938.4 PGLYRP1GCCGCUCUAUGCUGCUUGCC  863 chr19 ENST00000008938.4 PLP2ACCCUUCCAGAUAUUAUGCC  864 chrX ENST00000376327.5 PLP2ACCGACAGGGAGGAGUAGCC  865 chrX ENST00000376327.5 PLP2GGACCCCUUCUCACACUCCA  866 chrX ENST00000376327.5 PPBPUUGGCGAAAGGCAAAGGUAG  867 chr4 ENST00000296028.3 PPBPGUCAUUGCUGCUGACUGCUC  868 chr4 ENST00000296028.3 PPBPAAGGGGUGGUAUCAAGUCUG  869 chr4 ENST00000296028.3 PXDNACCACAGUUCAGCUCUUCCG  870 chr2 ENST00000252804.8 PXDNGCGUCUGGGAUAUUCACAGA  871 chr2 ENST00000252804.8 PXDNACUGCGACUGUGAAAUCCUG  872 chr2 ENST00000252804.8 RORCCCGCGUUACAGCGCUGGCUC  873 chr1 ENST00000318247.6 RORCAGUAGGCCGCGUUACAGCGC  874 chr1 ENST00000318247.6 RORCCUGCUGACGGGUGCAGGAGU  875 chr1 ENST00000318247.6 RORCGCAGUUCUGCUGACGGGUGC  876 chr1 ENST00000318247.6 SCG2AGCCCUGAUCAUUUCAGGAC  877 chr2 ENST00000305409.2 SCG2CUGGUUCUUUCUGAAGCAGC  878 chr2 ENST00000305409.2 SCG2UGGCUGAAGCAAAGACCCAC  879 chr2 ENST00000305409.2 SCGB3A1CCUCUAUGAGGUGGUUCACG  880 chr5 ENST00000292641.3 SCGB3A1GGUGCCGAGGGGGUUGGCCA  881 chr5 ENST00000292641.3 SCGB3A1UGCAGCUGCUGCUUUCUUAG  882 chr5 ENST00000292641.3 SECTM1ACAGCCCAGCAUGGGAGUCC  883 chr17 ENST00000269389.7 SECTM1CUGGAGCUGCCAGCCGUCCC  884 chr17 ENST00000269389.7 SECTM1CUUGAUGUUGACAUGGGAGA  885 chr17 ENST00000269389.7 SLURP1CCCUGACUCCAGUGCACCCA  886 chr8 ENST00000246515.1 SLURP1CGUCACCAGCGUGGUCAUGC  887 chr8 ENST00000246515.1 SLURP1CUUGCAGGUGUAGCACUUGA  888 chr8 ENST00000246515.1 SOSTDC1AUCAAGCCAGAAAUGGAGGC  889 chr7 ENST00000307068.4 SOSTDC1AGAAAUCCUUUAUUCACAUG  890 chr7 ENST00000307068.4 SOSTDC1UUAGGAUGCAUGCAAGGGGA  891 chr7 ENST00000307068.4 SP100UCUGAGAGUCCAUUUUCAGG  892 chr2 ENST00000340126.8 SP100AGUGACAAAGAUGAUUCGCU  893 chr2 ENST00000340126.8 SP100ACCCAGUCAGUCUUACCUGU  894 chr2 ENST00000340126.8 SPI1GUCCCCCACAGACCAUUACU  895 chr11 ENST00000378538.7 SPI1GGGGGUGGAAGUCCCAGUAA  896 chr11 ENST00000378538.7 SPI1CGCUGUGCACGUGGUGGGGG  897 chr11 ENST00000378538.7 SPI1ACUCGCUGUGCACGUGGUGG  898 chr11 ENST00000378538.7 SPP1AAUGGUGAGACUCAUCAGAC  899 chr4 ENST00000237623.11 SPP1UCGGUUGCUGGCAGGUCCGU  900 chr4 ENST00000237623.11 SPP1UGAUGGCCGAGGUGAUAGUG  901 chr4 ENST00000237623.11 TBX21CCCGCCCCGGAUGGGCAUCG  902 ch17 ENST00000177694.1 TBX21GGCAUCGUGGAGCCGGGUUG  903 ch17 ENST00000177694.1 TBX21GGGUUGCGGAGACAUGCUGA  904 ch17 ENST00000177694.1 TBX21GUCGCUCCCCGGCAUCGGCU  905 ch17 ENST00000177694.1 TCAPGCACUGCCCCUGCUGGUGGU  906 chr17 ENST00000309889.2 TCAPAGUACCAGCUGCCCUACCAG  907 chr17 ENST00000309889.2 TCAPCUCCUUGGUGGCGCCCAUCU  908 chr17 ENST00000309889.2 TGFB1*GCCGCAGCUUGGACAGGAUC  909 chr19 ENST00000221930.5 TGFB1*CUCCAUGUCGAUAGUCUUGC  910 chr19 ENST00000221930.5 TGFB1*AGCAGCCGCAGCCCGGAGGG  911 chr19 ENST00000221930.5 TGFB2*UACCUGCAGCACACUCGAUA  912 chr1 ENST00000366930.8 TGFB2*UCGGGCUCAGGAUAGUCUUC  913 chr1 ENST00000366930.8 TGFB2*CUUCUCCUGGAGCAAGUCCC  914 chr1 ENST00000366930.8 TGFB3*GACAGAUCUUGAGCAAGCUC  915 chr14 ENST00000238682.7 TGFB3*UGGUGCAAGUGGACAGAGAG  916 chr14 ENST00000238682.7 TGFB3*GCACUUGCAAAGGGCUCUGG  917 chr14 ENST00000238682.7 TGFBR1**UUUUCAGUAAAGUCAUCACC  918 chr9 ENST00000374994.8 TGFBR1**CUGCAUCUCACUCAUGUUGA  919 chr9 ENST00000374994.8 TGFBR1**CCUCUUCAUUUGGCACUCGA  920 chr9 ENST00000374994.8 TGFBR2**UCUACUGCUACCGCGUUAAC  921 chr3 ENST00000295754.9 TGFBR2**CGAGCACUGUGCCAUCAUCC  922 chr3 ENST00000295754.9 TGFBR2**GUUGAUGUUGUUGGCACACG  923 chr3 ENST00000295754.9 TGFBR3**CAGCCCAGUUGUGCCUCUGC  924 chr1 ENST00000212355.8 TGFBR3**CAUCAAGGCCUGGACAGGAU  925 chr1 ENST00000212355.8 TGFBR3**CCCUUGGCAGGUCCAGAGCC  926 chr1 ENST00000212355.8 THBS1UCCUGUCUAACAGAGUCUGG  927 chr15 ENST00000260356.5 THBS1GUCGGCGCCCAGACCCCUUG  928 chr15 ENST00000260356.5 THBS1UCAGGUUGGCAUCCUCGAUG  929 chr15 ENST00000260356.5 THNSL2GAGAAGUGGUCCAUCUGUCC  930 chr2 ENST00000324166.6 THNSL2UGGCGUCACAUAUGCAUUUA  931 chr2 ENST00000324166.6 THNSL2UCUUCUCCAGGAAGUACUGC  932 chr2 ENST00000324166.6 THPOCCUGUCCAGAAAGCUGCCCC  933 chr3 ENST00000204615.11 THPOCCAUCACUCCCUCCAGCAGA  934 chr3 ENST00000204615.11 THPOUCUUUCUCAGGAGGAGACCA  935 chr3 ENST00000204615.11 TIMP1CAGGGGCUCAAAGGGGGCCA  936 chrX ENST00000218388.8 TIMP1GACACAGGUGCAGGCCCUGC  937 chrX ENST00000218388.8 TIMP1GGGUGAGGACUCACCGAGGU  938 chrX ENST00000218388.8 TNF*GAUCAUGCUUUCAGUGCUCA  939 chr6 ENST00000449264.2 TNF*CAAGAAGACAGGGGGGCCCC  940 chr6 ENST00000449264.2 TNF*GGCGCCUGCCACGAUCAGGA  941 chr6 ENST00000449264.2 TNFRSF4**CCGGCCCCUGCUCAGGAAGU  942 chr1 ENST00000379236.3 TNFRSF4**UGAGCGGAAGCAGCUGUGCA  943 chr1 ENST00000379236.3 TNFRSF4**GCAGCUGUGCACGGCCACAC  944 chr1 ENST00000379236.3 TNFRSF4**GCGGCAGACUGUGUCCUGUG  945 chr1 ENST00000379236.3 TNFRSF11**GUCUCCCGCAGGCAAGGCCC  946 chr18 ENST00000586569.2 TNFRSF11**CCCCCGGCGCUGCGCGUGCA  947 chr18 ENST00000586569.2 TNFRSF11**CCGCAACACCGAGUGCGCGC  948 chr18 ENST00000586569.2 TNFRSF11**GCCAGCUGUCUGUGUAGUAG  949 chr8 ENST00000297350.8 TNFRSF11**AACAACACUGUACAGCAAAG  950 chr8 ENST00000297350.8 TNFRSF11**ACUUUGGAGGAAACGUUUCC  951 chr8 ENST00000297350.8 TNFRSF1AAGCAAAUCGAAUUAUUUUGA  952 chr12 ENST00000162749.6 TNFRSF1AUUCUCCCUGUCCCCUAGGUG  953 chr12 ENST00000162749.6 TNFRSF1ACCAGGUGCUCCUGGAGCUGU  954 chr12 ENST00000162749.6 TNFRSF9**UGUGAACAGGAUUGUAAACA  955 chr1 ENST00000377507.7 TNFRSF9**CAGAGUGUGACUGCACUCCA  956 chr1 ENST00000377507.7 TNFRSF9**GGGACUUUGUAGGUGUUUUC  957 chr1 ENST00000377507.7 TNFSF9***GGGGUCCAGUGAAGCGUCAG  958 chr19 ENST00000245817.4 TNFSF9***AUACGCCUCUGACGCUUCAC  959 chr19 ENST00000245817.4 TNFSF9***CGGGAGGCCACGGGGCUUCG  960 chr19 ENST00000245817.4 TNFSF9***CACUGGACCCCGAAGCCCCG  961 chr19 ENST00000245817.4 TNFSF10CUACCUUUCUAACGAGCUGA  962 chr3 ENST00000241261.6 TNFSF10GUUCAUACUCUCUUCGUCAU  963 chr3 ENST00000241261.6 TNFSF10GAAACAAGCAAUGCCACUUU  964 chr3 ENST00000241261.6 TNFSF11CCAUCUUCUGAUAUUCUAUU  965 chr13 ENST00000398795.6 TNFSF11AGAUUUUCAAGACACAACUC  966 chr13 ENST00000398795.6 TNFSF11UUCAUGUAGGAGAAUUAAAC  967 chr13 ENST00000398795.6 TNFSF12CCGCCCCCAUGGCCGCCCGU  968 chr17 ENST00000293825.10 TNFSF12CCUGCUGGUCCCGCUCGCGC  969 chr17 ENST00000293825.10 TNFSF12CCGGGCAUCGCUGUCCGCCC  970 chr17 ENST00000293825.10 TNFSF12-CCGCCCCCAUGGCCGCCCGU  971 chr17 ENST00000293826.4 TNFSF12-CCUGCUGGUCCCGCUCGCGC  972 chr17 ENST00000293826.4 TNFSF12-CCGGGCAUCGCUGUCCGCCC  973 chr17 ENST00000293826.4 TNFSF13GGGGGGCCCAGUCAGAGAGC  974 chr17 ENST00000338784.8 TNFSF13CAGAGCCAUGGCACAAGCCA  975 chr17 ENST00000338784.8 TNFSF13AGAGAGGUGAGCCGGCUGCA  976 chr17 ENST00000338784.8 TNFSF13BUCAUUUCUUCUCUUUUCUUA  977 chr13 ENST00000375887.8 TNFSF13BCUCCAAAGACGGAAAGCUGC  978 chr13 ENST00000375887.8 TNFSF13BCACGGUGGUGUCUUUCUACC  979 chr13 ENST00000375887.8 TNFSF14CACACCGCCCAGCUGCACCU  980 chr19 ENST00000599359.1 TNFSF14GGGCCCCAUCGUGGUAGCUG  981 chr19 ENST00000599359.1 TNFSF14GCUGCCGGUCAAGCUGGAGU  982 chr19 ENST00000599359.1 TNFSF15UCAUCCCACGGAAUGUGACC  983 chr9 ENST00000374045.4 TNFSF15AUUUGUUGGUAUAGUUCAUU  984 chr9 ENST00000374045.4 TNFSF15UGAUUUUUAAAGUGCUGUGU  985 chr9 ENST00000374045.4 TNFSF18AAUAAAGAUUAGCCAACUGA  986 chr1 ENST00000404377.3 TNFSF18GCAAAAGAGCCACAGCUUCC  987 chr1 ENST00000404377.3 TNFSF18AAGUGGCUCAAACACAUUUU  988 chr1 ENST00000404377.3 TNFSF4CCUCAUCCUUCUGGUAAUGA  989 chr1 ENST00000281834.3 TNFSF4GUUUUAUCUCAUCUCCCUGA  990 chr1 ENST00000281834.3 TNFSF4CUAGAAUAUAAGAAGGAGAA  991 chr1 ENST00000281834.3 TNFSF8UCUGUGCCUUGUCUUCACGG  992 chr9 ENST00000223795.2 TNFSF8GCUCGUGGUCCCCAGGUGGC  993 chr9 ENST00000223795.2 TNFSF8UGAGUGCUUGCUGCAGCCCU  994 chr9 ENST00000223795.2 TNFSF9AUACGCCUCUGACGCUUCAC  995 chr19 ENST00000245817.4 TNFSF9ACGCGGCAGGCGCGAGCGCG  996 chr19 ENST00000245817.4 TNFSF9CGUCUUCCUCGCCUGCCCCU  997 chr19 ENST00000245817.4 TRIM16CUCCUCGGAGAAGCUUGGCA  998 chr17 ENST00000336708.11 TRIM16GGUCACCCAGCCCAGAUUCU  999 chr17 ENST00000336708.11 TRIM16AGCCUCCCAGAUGGCUGAGU 1000 chr17 ENST00000336708.11 TSLPUGGAUUUCAGUAAGGCAAUG 1001 chr5 ENST00000344895.3 TSLPAAUGUUCGCCAUGAAAACUA 1002 chr5 ENST00000344895.3 TSLPCAAGGUACAGCAAACGUCUG 1003 chr5 ENST00000344895.3 TWSG1GUGAGUGCCCGGAAGAGAGA 1004 chr18 ENST00000262120.9 TWSG1UGUGAAAGUUCUUCUGCAAC 1005 chr18 ENST00000262120.9 TWSG1ACAGACACAUUCUGGUGGUG 1006 chr18 ENST00000262120.9 TXLNAUAACCAGGGGGGCCCCGGCG 1007 chr1 ENST00000373609.1 TXLNAAGAGAAGUCCCGGACCUAUG 1008 chr1 ENST00000373609.1 TXLNAUGUGUUUGGAUCCCCCUUGG 1009 chr1 ENST00000373609.1 VASNGGCAGCUUUGCCGGCCUGCC 1010 chr16 ENST00000304735.3 VASNACUCGCCAACCUCAGCAACC 1011 chr16 ENST00000304735.3 VASNAUGAGACCUUCCGUGGCCUG 1012 chr16 ENST00000304735.3 VEGFACAGGGGCCGGAGCCCGCGCC 1013 chr6 ENST00000425836.6 VEGFAUUCUCGCUUCGGAGGAGCCG 1014 chr6 ENST00000425836.6 VEGFAAAGUGCUAGCUCGGGCCGGG 1015 chr6 ENST00000425836.6 VSTM1CGAAGCUGAAUUCCCCUUCA 1016 chr19 ENST00000338372.6 VSTM1UGCGCAAGGUGAACGACUCU 1017 chr19 ENST00000338372.6 VSTM1UUCAACCACCGAGCUGGGCC 1018 chr19 ENST00000338372.6 WFIKKN1GCUCCUUCUCACAGCGGUCG 1019 chr16 ENST00000319070.2 WFIKKN1CCGCUGCUAUAUGGACGCCG 1020 chr16 ENST00000319070.2 WFIKKN1CCUGCAAGCACGUGCUCAGC 1021 chr16 ENST00000319070.2 WFIKKN2GUGCAAAGACCGCUGUGAGA 1022 chr17 ENST00000311378.4 WFIKKN2CCGCUGCUACAUGGAUGCCG 1023 chr17 ENST00000311378.4 WFIKKN2CCUGCCGCUAUCACUUCACC 1024 chr17 ENST00000311378.4 WNT1AGACUCCAAGAGUCUGCAAC 1025 chr12 ENST00000293549.3 WNT1GCGUCUGAUACGCCAAAAUC 1026 chr12 ENST00000293549.3 WNT1GGCAGUUCCGGAAUCGCCGC 1027 chr12 ENST00000293549.3 WNT2UGUUGCAAUUCCAGCGGUGC 1028 chr7 ENST00000265441.7 WNT2CUAAUGGCACGCAUCACAUC 1029 chr7 ENST00000265441.7 WNT2GAGCUACAGGUGGCUCCUCC 1030 chr7 ENST00000265441.7 WNT5AUGCAGUUCCACCUUCGAUGU 1031 chr3 ENST00000264634.8 WNT5ACUUCUCCGAUGUACUGCAUG 1032 chr3 ENST00000264634.8 WNT5ACCUGCCAGUUGGCUGCAGAG 1033 chr3 ENST00000264634.8 WNT7AAGAGCGCACCGUCUUCGGGA 1034 chr3 ENST00000285018.4 WNT7AACUGAAACUGACACUCGUCC 1035 chr3 ENST00000285018.4 WNT7AUGGCAGAUCGCCCGCUGUCU 1036 chr3 ENST00000285018.4 XCL1*GGAGUGAAGUCUCAGAUAAG 1037 chr1 ENST00000367818.3 XCL1*GGAGUGAAGUCUCAGAUAAG 1038 chr1 ENST00000367818.3 XCL1*GGAGUGAAGUCUCAGAUAAG 1039 chr1 ENST00000367818.3 XCL2*GAGUGUAUUUCUAUACCUCU 1040 chr1 ENST00000367819.2 XCL2*UAGGGAGUGAAGUCUCACAU 1041 chr1 ENST00000367819.2 XCL2*UAGGGAGUGAAGUCUCACAU 1042 chr1 ENST00000367819.2 ZFP36CCUCCAUGGUCGGAUGGCAC 1043 chr19 ENST00000597629.1 ZFP36UCGGAGGGGCUCAGGCUCCA 1044 chr19 ENST00000597629.1 ZFP36GGAGGGCCGCAGCUGUGGCU 1045 chr19 ENST00000597629.1 *indicatescytokines/chemokines produced by T cells that activate or localizemyeloid cells **indicates T cell surface receptor genes that activatemyeloid or CAR-T cells ***indicates T cell surface receptors that areintegrated into CAR-T cell signaling thus endogenous receptors areredundant {circumflex over ( )}indicates cytokines that drive Tcell/CAR-T cell differentiation Bold rows indicate transcription factorsthat drive T cell/CAR-T cell differentiation

Example 6 Protocol—Nucleofection Using Nucleofector 4D

4×10⁶ cells per reaction are used. EO-115—100 μl transfection volume isprogrammed, and the entire supplement added to the Nucleofector™Solution P3. Cell culture plates are prepared by filling appropriatenumber of wells with desired volume of recommended culture media (2 mlin 6 well plate) and pre-incubating/equilibrating plates in a humidified37° C./5% CO₂ incubator. Beads are magnetically removed (twice to ensurecomplete removal), then cells counted and cell density determined. Therequired number of cells are centrifuged at 90×g for 10 minutes at roomtemperature, the supernatant removed completely. Cells are thenresuspended in PBS (1 ml) and transferred to a microcentrifuge tube, andthe required number of cells centrifuged at 90×g for 10 minutes at roomtemperature. The supernatant is removed completely, and the cell pelletresuspended carefully in complete room temperature 4D Nucleofector™Solution P3, 4×10⁶ per 100 μl). Twenty μg of gRNA (gGM-CSF) is added toeach tube of 15 μg Cas9 mRNA. Then 100 μl of cells is added to each tubeof Cas9/gRNA, gently mixed and everything transferred into theNucleocuvette™. The cuvette is gently tapped to remove bubbles.Electroporation is carried out using program (Human T cell stim EO-115).After run completion, the Nucleocuvette™ is carefully removed from thevessel from the retainer using a specialized tool. Cells are resuspendedwith pre-warmed medium. The media is then taken up from destinationwell, added to cuvette, and gently pipetted up and down two to threetimes. This is then transferred to well. This procedure is repeated withmedia from same well and incubated at 37° C.

CAR Transduction (Day 2).

Genome-edited CAR-T cells may then be transduced with one or more CARstargeted to (i.e., that recognizes) one or more targets, for examplewith a lentivirus containing a CAR construct. Any other suitable methodof transduction may be used.

Protocol—To transduce T cells with lentivirus: One μl of polybrene isadded for each ml media (8 mg/ml stock). The required amount of virus isthen added to give required M.O.I. Cells and virus are mixed and placedback in incubator at 37° C.

Assessment of Transduction Efficiency (Day 10).

Samples of cells may then be assessed for transduction efficiency bytaking a 5×10⁵ cells from each sample and analyzing by flow cytometry.Samples are washed with RB, and 3 μl of anti-CD34 PE antibody added (todetect the CAR as the construct contains human truncated CD34).Thereafter, 5 ul of CD3 APC is added, the cells washed, and flowcytometry performed. CAR-T cells should be CD3ε positive, CD34 positive.

Assessment of Genetic Deletion.

To assess genetic deletion, 5×10⁵ cells are harvested from each sampleand their DNA extracted. Gene editing efficiency is assessed usingtarget sequencing of the target loci using TIDE-analysis or deepsequencing.

Assessment of Tumor Burden and Cytokine Level.

T cells are harvested (Day 11). Tumor burden may be imaged in mouseusing bioluminescent imaging. 3×10⁷ CAR-T are injected per mouse I.P.

Serum cytokine levels (Day 12) are measured, e.g., using the Luminexmultiplex cytokine profiling assay to check for elevations inCRS-related cytokines. A 4-hr chromium release assay against targetscells (Raji) may be performed to assess in vitro activity (Day 11).

Example 7 Additional Examples of CAR-Bearing Immune Effector Cells

Several types of chimeric antigen receptor (CAR)-bearing immune effectorcells that are deficient in a cytokine may be made using the methodsabove. Tables 11-13 below give Examples.

TABLE 11 Mono, Gene Dual, or CAR Antigen TCR Deleted/ Example CellTandem Target(s) Deletion(s) Modifications Suppressed 1 T-Cell Mono CD19— — GM-CSF 2 T-Cell Mono CD19 — — CCL2 3 T-Cell Mono CD19 — — MCP-2 4T-Cell Mono CD19 — — G-CSF 5 T-Cell Mono CD19 — — M-CSF 6 T-Cell MonoCD19 — — Il-4 7 T-Cell Mono CD19 — — IFNγ 8 T-Cell Mono CD19 — TRACGM-CSF 9 T-Cell Mono CD19 — TRAC CCL2 10 T-Cell Mono CD19 — TRAC MCP-211 T-Cell Mono CD19 — TRAC G-CSF 12 T-Cell Mono CD19 — TRAC M-CSF 13T-Cell Mono CD19 — TRAC Il-4 14 T-Cell Mono CD19 — TRAC IFNγ 15 T-CellMono CD20 — — GM-CSF 16 T-Cell Mono CD20 — — CCL2 17 T-Cell Mono CD20 —— MCP-2 18 T-Cell Mono CD20 — — G-CSF 19 T-Cell Mono CD20 — — M-CSF 20T-Cell Mono CD20 — — Il-4 21 T-Cell Mono CD20 — — IFNγ 22 T-Cell MonoCD20 — TRAC GM-CSF 23 T-Cell Mono CD20 — TRAC CCL2 24 T-Cell Mono CD20 —TRAC MCP-2 25 T-Cell Mono CD20 — TRAC G-CSF 26 T-Cell Mono CD20 — TRACM-CSF 27 T-Cell Mono CD20 — TRAC Il-4 28 T-Cell Mono CD20 — TRAC IFNγ 29T-Cell Mono BCMA — — GM-CSF 30 T-Cell Mono BCMA — — CCL2 31 T-Cell MonoBCMA — — MCP-2 32 T-Cell Mono BCMA — — G-CSF 33 T-Cell Mono BCMA — —M-CSF 34 T-Cell Mono BCMA — — Il-4 35 T-Cell Mono BCMA — — IFNγ 36T-Cell Mono BCMA — TRAC GM-CSF 37 T-Cell Mono BCMA — TRAC CCL2 38 T-CellMono BCMA — TRAC MCP-2 39 T-Cell Mono BCMA — TRAC G-CSF 40 T-Cell MonoBCMA — TRAC M-CSF 41 T-Cell Mono BCMA — TRAC Il-4 42 T-Cell Mono BCMA —TRAC IFNγ 43 T-Cell Mono Mesothelin — — GM-CSF 44 T-Cell Mono Mesothelin— — CCL2 45 T-Cell Mono Mesothelin — — MCP-2 46 T-Cell Mono Mesothelin —— G-CSF 47 T-Cell Mono Mesothelin — — M-CSF 48 T-Cell Mono Mesothelin —— Il-4 49 T-Cell Mono Mesothelin — — IFNγ 50 T-Cell Mono Mesothelin —TRAC GM-CSF 51 T-Cell Mono Mesothelin — TRAC CCL2 52 T-Cell MonoMesothelin — TRAC MCP-2 53 T-Cell Mono Mesothelin — TRAC G-CSF 54 T-CellMono Mesothelin — TRAC M-CSF 55 T-Cell Mono Mesothelin — TRAC Il-4 56T-Cell Mono Mesothelin — TRAC IFNγ 57 T-Cell Mono CD7 CD7 TRAC GM-CSF 58T-Cell Mono CD7 CD7 TRAC CCL2 59 T-Cell Mono CD7 CD7 TRAC MCP-2 60T-Cell Mono CD7 CD7 TRAC G-CSF 61 T-Cell Mono CD7 CD7 TRAC M-CSF 62T-Cell Mono CD7 CD7 TRAC Il-4 63 T-Cell Mono CD7 CD7 TRAC IFNγ 64 T-CellMono CD3ε CD3ε — GM-CSF 65 T-Cell Mono CD3ε CD3ε — CCL2 66 T-Cell MonoCD3ε CD3ε — MCP-2 67 T-Cell Mono CD3ε CD3ε — G-CSF 68 T-Cell Mono CD3εCD3ε — M-CSF 69 T-Cell Mono CD3ε CD3ε — Il-4 70 T-Cell Mono CD3ε CD3ε —IFNγ 71 T-Cell Mono CD2 CD2 TRAC GM-CSF 72 T-Cell Mono CD2 CD2 TRAC CCL273 T-Cell Mono CD2 CD2 TRAC MCP-2 74 T-Cell Mono CD2 CD2 TRAC G-CSF 75T-Cell Mono CD2 CD2 TRAC M-CSF 76 T-Cell Mono CD2 CD2 TRAC Il-4 77T-Cell Mono CD2 CD2 TRAC IFNγ 78 T-Cell Mono CD5 — TRAC GM-CSF 79 T-CellMono CD5 — TRAC CCL2 80 T-Cell Mono CD5 — TRAC MCP-2 81 T-Cell Mono CD5— TRAC G-CSF 82 T-Cell Mono CD5 — TRAC M-CSF 83 T-Cell Mono CD5 — TRACIl-4 84 T-Cell Mono CD5 — TRAC IFNγ 85 T-Cell Mono CD5 CD5 TRAC GM-CSF86 T-Cell Mono CD5 CD5 TRAC CCL2 87 T-Cell Mono CD5 CD5 TRAC MCP-2 88T-Cell Mono CD5 CD5 TRAC G-CSF 89 T-Cell Mono CD5 CD5 TRAC M-CSF 90T-Cell Mono CD5 CD5 TRAC Il-4 91 T-Cell Mono CD5 CD5 TRAC IFNγ 92 T-CellTandem CD7xCD2 CD7 & CD2 TRAC GM-CSF 93 T-Cell Tandem CD7xCD2 CD7 & CD2TRAC CCL2 94 T-Cell Tandem CD7xCD2 CD7 & CD2 TRAC MCP-2 95 T-Cell TandemCD7xCD2 CD7 & CD2 TRAC G-CSF 96 T-Cell Tandem CD7xCD2 CD7 & CD2 TRACM-CSF 97 T-Cell Tandem CD7xCD2 CD7 & CD2 TRAC Il-4 98 T-Cell TandemCD7xCD2 CD7 & CD2 TRAC IFNγ 99 T-Cell Tandem CD3εxCD2 CD3 & CD2 — GM-CSF100 T-Cell Tandem CD3εxCD2 CD3 & CD2 — CCL2 101 T-Cell Tandem CD3εxCD2CD3 & CD2 — MCP-2 102 T-Cell Tandem CD3εxCD2 CD3 & CD2 — G-CSF 103T-Cell Tandem CD3εxCD2 CD3 & CD2 — M-CSF 104 T-Cell Tandem CD3εxCD2 CD3& CD2 — Il-4 105 T-Cell Tandem CD3εxCD2 CD3 & CD2 — IFNγ 106 T-CellTandem CD19xCD20 — TRAC GM-CSF 107 T-Cell Tandem CD19xCD20 — TRAC CCL2108 T-Cell Tandem CD19xCD20 — TRAC MCP-2 109 T-Cell Tandem CD19xCD20 —TRAC G-CSF 110 T-Cell Tandem CD19xCD20 — TRAC M-CSF 111 T-Cell TandemCD19xCD20 — TRAC Il-4 112 T-Cell Tandem CD19xCD20 — TRAC IFNγ 113 T-CellDual CD7xCD2 CD7 & CD2 TRAC GM-CSF 114 T-Cell Dual CD7xCD2 CD7 & CD2TRAC CCL2 115 T-Cell Dual CD7xCD2 CD7 & CD2 TRAC MCP-2 116 T-Cell DualCD7xCD2 CD7 & CD2 TRAC G-CSF 117 T-Cell Dual CD7xCD2 CD7 & CD2 TRACM-CSF 118 T-Cell Dual CD7xCD2 CD7 & CD2 TRAC Il-4 119 T-Cell DualCD7xCD2 CD7 & CD2 TRAC IFNγ 120 T-Cell Dual CD3εxCD2 CD3 & CD2 — GM-CSF121 T-Cell Dual CD3εxCD2 CD3 & CD2 — CCL2 122 T-Cell Dual CD3εxCD2 CD3 &CD2 — MCP-2 123 T-Cell Dual CD3εxCD2 CD3 & CD2 — G-CSF 124 T-Cell DualCD3εxCD2 CD3 & CD2 — M-CSF 125 T-Cell Dual CD3εxCD2 CD3 & CD2 — Il-4 126T-Cell Dual CD3εxCD2 CD3 & CD2 — IFNγ 127 T-Cell Dual CD19xCD20 — TRACGM-CSF 128 T-Cell Dual CD19xCD20 — TRAC CCL2 129 T-Cell Dual CD19xCD20 —TRAC MCP-2 130 T-Cell Dual CD19xCD20 — TRAC G-CSF 131 T-Cell DualCD19xCD20 — TRAC M-CSF 132 T-Cell Dual CD19xCD20 — TRAC Il-4 133 T-CellDual CD19xCD20 — TRAC IFNγ

TABLE 12 Mono, Gene Dual, or CAR Antigen Deleted/ Example Cell TandemTarget(s) Deletion(s) Suppressed 134 NK Cell Mono CD19 — GM-CSF 135 NKCell Mono CD19 — CCL2 136 NK Cell Mono CD19 — MCP-2 137 NK Cell MonoCD19 — G-CSF 138 NK Cell Mono CD19 — M-CSF 139 NK Cell Mono CD19 — Il-4140 NK Cell Mono CD19 — IFNγ 141 NK Cell Mono CD19 — GM-CSF 142 NK CellMono CD19 — CCL2 143 NK Cell Mono CD19 — MCP-2 144 NK Cell Mono CD19 —G-CSF 145 NK Cell Mono CD19 — M-CSF 146 NK Cell Mono CD19 — Il-4 147 NKCell Mono CD19 — IFNγ 148 NK Cell Mono CD20 — GM-CSF 149 NK Cell MonoCD20 — CCL2 150 NK Cell Mono CD20 — MCP-2 151 NK Cell Mono CD20 — G-CSF152 NK Cell Mono CD20 — M-CSF 153 NK Cell Mono CD20 — Il-4 154 NK CellMono CD20 — IFNγ 155 NK Cell Mono CD20 — GM-CSF 156 NK Cell Mono CD20 —CCL2 157 NK Cell Mono CD20 — MCP-2 158 NK Cell Mono CD20 — G-CSF 159 NKCell Mono CD20 — M-CSF 160 NK Cell Mono CD20 — Il-4 161 NK Cell MonoCD20 — IFNγ 162 NK Cell Mono BCMA — GM-CSF 163 NK Cell Mono BCMA — CCL2164 NK Cell Mono BCMA — MCP-2 165 NK Cell Mono BCMA — G-CSF 166 NK CellMono BCMA — M-CSF 167 NK Cell Mono BCMA — Il-4 168 NK Cell Mono BCMA —IFNγ 169 NK Cell Mono BCMA — GM-CSF 170 NK Cell Mono BCMA — CCL2 171 NKCell Mono BCMA — MCP-2 172 NK Cell Mono BCMA — G-CSF 173 NK Cell MonoBCMA — M-CSF 174 NK Cell Mono BCMA — Il-4 175 NK Cell Mono BCMA — IFNγ176 NK Cell Mono Mesothelin — GM-CSF 177 NK Cell Mono Mesothelin — CCL2178 NK Cell Mono Mesothelin — MCP-2 179 NK Cell Mono Mesothelin — G-CSF180 NK Cell Mono Mesothelin — M-CSF 181 NK Cell Mono Mesothelin — Il-4182 NK Cell Mono Mesothelin — IFNγ 183 NK Cell Mono Mesothelin — GM-CSF184 NK Cell Mono Mesothelin — CCL2 185 NK Cell Mono Mesothelin — MCP-2186 NK Cell Mono Mesothelin — G-CSF 187 NK Cell Mono Mesothelin — M-CSF188 NK Cell Mono Mesothelin — Il-4 189 NK Cell Mono Mesothelin — IFNγ190 NK Cell Mono CD7 CD7 GM-CSF 191 NK Cell Mono CD7 CD7 CCL2 192 NKCell Mono CD7 CD7 MCP-2 193 NK Cell Mono CD7 CD7 G-CSF 194 NK Cell MonoCD7 CD7 M-CSF 195 NK Cell Mono CD7 CD7 Il-4 196 NK Cell Mono CD7 CD7IFNγ 197 NK Cell Mono CD3ε CD3ε GM-CSF 198 NK Cell Mono CD3ε CD3ε CCL2199 NK Cell Mono CD3ε CD3ε MCP-2 200 NK Cell Mono CD3ε CD3ε G-CSF 201 NKCell Mono CD3ε CD3ε M-CSF 202 NK Cell Mono CD3ε CD3ε Il-4 203 NK CellMono CD3ε CD3ε IFNγ 204 NK Cell Mono CD2 CD2 GM-CSF 205 NK Cell Mono CD2CD2 CCL2 206 NK Cell Mono CD2 CD2 MCP-2 207 NK Cell Mono CD2 CD2 G-CSF208 NK Cell Mono CD2 CD2 M-CSF 209 NK Cell Mono CD2 CD2 Il-4 210 NK CellMono CD2 CD2 IFNγ 211 NK Cell Mono CD5 — GM-CSF 212 NK Cell Mono CD5 —CCL2 213 NK Cell Mono CD5 — MCP-2 214 NK Cell Mono CD5 — G-CSF 215 NKCell Mono CD5 — M-CSF 216 NK Cell Mono CD5 — Il-4 217 NK Cell Mono CD5 —IFNγ 218 NK Cell Tandem CD7xCD2 CD7 & CD2 GM-CSF 219 NK Cell TandemCD7xCD2 CD7 & CD2 CCL2 220 NK Cell Tandem CD7xCD2 CD7 & CD2 MCP-2 221 NKCell Tandem CD7xCD2 CD7 & CD2 G-CSF 222 NK Cell Tandem CD7xCD2 CD7 & CD2M-CSF 223 NK Cell Tandem CD7xCD2 CD7 & CD2 Il-4 224 NK Cell TandemCD7xCD2 CD7 & CD2 IFNγ 225 NK Cell Tandem CD3εxCD2 CD3 & CD2 GM-C SF 226NK Cell Tandem CD3εxCD2 CD3 & CD2 CCL2 227 NK Cell Tandem CD3εxCD2 CD3 &CD2 MCP-2 228 NK Cell Tandem CD3εxCD2 CD3 & CD2 G-CSF 229 NK Cell TandemCD3εxCD2 CD3 & CD2 M-CSF 230 NK Cell Tandem CD3εxCD2 CD3 & CD2 Il-4 231NK Cell Tandem CD3εxCD2 CD3 & CD2 IFNγ 232 NK Cell Tandem CD19xCD20 —GM-CSF 233 NK Cell Tandem CD19xCD20 — CCL2 234 NK Cell Tandem CD19xCD20— MCP-2 235 NK Cell Tandem CD19xCD20 — G-CSF 236 NK Cell TandemCD19xCD20 — M-CSF 237 NK Cell Tandem CD19xCD20 — Il-4 238 NK Cell TandemCD19xCD20 — IFNγ 239 NK Cell Dual CD7xCD2 CD7 & CD2 GM-C SF 240 NK CellDual CD7xCD2 CD7 & CD2 CCL2 241 NK Cell Dual CD7xCD2 CD7 & CD2 MCP-2 242NK Cell Dual CD7xCD2 CD7 & CD2 G-CSF 243 NK Cell Dual CD7xCD2 CD7 & CD2M-CSF 244 NK Cell Dual CD7xCD2 CD7 & CD2 Il-4 245 NK Cell Dual CD7xCD2CD7 & CD2 IFNγ 246 NK Cell Dual CD3εxCD2 CD3 & CD2 GM-CSF 247 NK CellDual CD3εxCD2 CD3 & CD2 CCL2 248 NK Cell Dual CD3εxCD2 CD3 & CD2 MCP-2249 NK Cell Dual CD3εxCD2 CD3 & CD2 G-CSF 250 NK Cell Dual CD3εxCD2 CD3& CD2 M-CSF 251 NK Cell Dual CD3εxCD2 CD3 & CD2 Il-4 252 NK Cell DualCD3εxCD2 CD3 & CD2 IFNγ 253 NK Cell Dual CD19xCD20 — GM-CSF 254 NK CellDual CD19xCD20 — CCL2 255 NK Cell Dual CD19xCD20 — MCP-2 256 NK CellDual CD19xCD20 — G-CSF 257 NK Cell Dual CD19xCD20 — M-CSF 258 NK CellDual CD19xCD20 — Il-4 259 NK Cell Dual CD19xCD20 — IFNγ

TABLE 13 Mono, Gene Dual, or CAR Antigen Deleted/ Example Cell TandemTarget(s) Deletion(s) Suppressed 260 iNKT Mono CD19 — GM-CSF 261 iNKTMono CD19 — CCL2 262 iNKT Mono CD19 — MCP-2 263 iNKT Mono CD19 — G-CSF264 iNKT Mono CD19 — M-CSF 265 iNKT Mono CD19 — Il-4 266 iNKT Mono CD19— IFNγ 267 iNKT Mono CD19 — GM-CSF 268 iNKT Mono CD19 — CCL2 269 iNKTMono CD19 — MCP-2 270 iNKT Mono CD19 — G-CSF 271 iNKT Mono CD19 — M-CSF272 iNKT Mono CD19 — Il-4 273 iNKT Mono CD19 — IFNγ 274 iNKT Mono CD20 —GM-CSF 275 iNKT Mono CD20 — CCL2 276 iNKT Mono CD20 — MCP-2 277 iNKTMono CD20 — G-CSF 278 iNKT Mono CD20 — M-CSF 279 iNKT Mono CD20 — Il-4280 iNKT Mono CD20 — IFNγ 281 iNKT Mono CD20 — GM-CSF 282 iNKT Mono CD20— CCL2 283 iNKT Mono CD20 — MCP-2 284 iNKT Mono CD20 — G-CSF 285 iNKTMono CD20 — M-CSF 286 iNKT Mono CD20 — Il-4 287 iNKT Mono CD20 — IFNγ288 iNKT Mono BCMA — GM-CSF 289 iNKT Mono BCMA — CCL2 290 iNKT Mono BCMA— MCP-2 291 iNKT Mono BCMA — G-CSF 292 iNKT Mono BCMA — M-CSF 293 iNKTMono BCMA — Il-4 294 iNKT Mono BCMA — IFNγ 295 iNKT Mono BCMA — GM-CSF296 iNKT Mono BCMA — CCL2 297 iNKT Mono BCMA — MCP-2 298 iNKT Mono BCMA— G-CSF 299 iNKT Mono BCMA — M-CSF 300 iNKT Mono BCMA — Il-4 301 iNKTMono BCMA — IFNγ 302 iNKT Mono Mesothelin — GM-CSF 303 iNKT MonoMesothelin — CCL2 304 iNKT Mono Mesothelin — MCP-2 305 iNKT MonoMesothelin — G-CSF 306 iNKT Mono Mesothelin — M-CSF 307 iNKT MonoMesothelin — Il-4 308 iNKT Mono Mesothelin — IFNγ 309 iNKT MonoMesothelin — GM-CSF 310 iNKT Mono Mesothelin — CCL2 311 iNKT MonoMesothelin — MCP-2 312 iNKT Mono Mesothelin — G-CSF 313 iNKT MonoMesothelin — M-CSF 314 iNKT Mono Mesothelin — Il-4 315 iNKT MonoMesothelin — IFNγ 316 iNKT Mono CD7 CD7 GM-CSF 317 iNKT Mono CD7 CD7CCL2 318 iNKT Mono CD7 CD7 MCP-2 319 iNKT Mono CD7 CD7 G-CSF 320 iNKTMono CD7 CD7 M-CSF 321 iNKT Mono CD7 CD7 Il-4 322 iNKT Mono CD7 CD7 IFNγ323 iNKT Mono CD3ε CD3ε GM-CSF 324 iNKT Mono CD3ε CD3ε CCL2 325 iNKTMono CD3ε CD3ε MCP-2 326 iNKT Mono CD3ε CD3ε G-CSF 327 iNKT Mono CD3εCD3ε M-CSF 328 iNKT Mono CD3ε CD3ε Il-4 329 iNKT Mono CD3ε CD3ε IFNγ 330iNKT Mono CD2 CD2 GM-CSF 331 iNKT Mono CD2 CD2 CCL2 332 iNKT Mono CD2CD2 MCP-2 333 iNKT Mono CD2 CD2 G-CSF 334 iNKT Mono CD2 CD2 M-CSF 335iNKT Mono CD2 CD2 Il-4 336 iNKT Mono CD2 CD2 IFNγ 337 iNKT Mono CD5 —GM-CSF 338 iNKT Mono CD5 — CCL2 339 iNKT Mono CD5 — MCP-2 340 iNKT MonoCD5 — G-CSF 341 iNKT Mono CD5 — M-CSF 342 iNKT Mono CD5 — Il-4 343 iNKTMono CD5 — IFNγ 344 iNKT Mono CD5 CD5 GM-C SF 345 iNKT Mono CD5 CD5 CCL2346 iNKT Mono CD5 CD5 MCP-2 347 iNKT Mono CD5 CD5 G-CSF 348 iNKT MonoCD5 CD5 M-CSF 349 iNKT Mono CD5 CD5 Il-4 350 iNKT Mono CD5 CD5 IFNγ 351iNKT Tandem CD7xCD2 CD7 & CD2 GM-C SF 352 iNKT Tandem CD7xCD2 CD7 & CD2CCL2 353 iNKT Tandem CD7xCD2 CD7 & CD2 MCP-2 354 iNKT Tandem CD7xCD2 CD7& CD2 G-CSF 355 iNKT Tandem CD7xCD2 CD7 & CD2 M-CSF 356 iNKT TandemCD7xCD2 CD7 & CD2 Il-4 357 iNKT Tandem CD7xCD2 CD7 & CD2 IFNγ 358 iNKTTandem CD3εxCD2 CD3 & CD2 GM-C SF 359 iNKT Tandem CD3εxCD2 CD3 & CD2CCL2 360 iNKT Tandem CD3εxCD2 CD3 & CD2 MCP-2 361 iNKT Tandem CD3εxCD2CD3 & CD2 G-CSF 362 iNKT Tandem CD3εxCD2 CD3 & CD2 M-CSF 363 iNKT TandemCD3εxCD2 CD3 & CD2 Il-4 364 iNKT Tandem CD3εxCD2 CD3 & CD2 IFNγ 365 iNKTTandem CD19xCD20 — GM-C SF 366 iNKT Tandem CD19xCD20 — CCL2 367 iNKTTandem CD19xCD20 — MCP-2 368 iNKT Tandem CD19xCD20 — G-CSF 369 iNKTTandem CD19xCD20 — M-CSF 370 iNKT Tandem CD19xCD20 — Il-4 371 iNKTTandem CD19xCD20 — IFNγ 372 iNKT Dual CD7xCD2 CD7 & CD2 GM-C SF 373 iNKTDual CD7xCD2 CD7 & CD2 CCL2 374 iNKT Dual CD7xCD2 CD7 & CD2 MCP-2 375iNKT Dual CD7xCD2 CD7 & CD2 G-CSF 376 iNKT Dual CD7xCD2 CD7 & CD2 M-CSF377 iNKT Dual CD7xCD2 CD7 & CD2 Il-4 378 iNKT Dual CD7xCD2 CD7 & CD2IFNγ 379 iNKT Dual CD3εxCD2 CD3 & CD2 GM-C SF 380 iNKT Dual CD3εxCD2 CD3& CD2 CCL2 381 iNKT Dual CD3εxCD2 CD3 & CD2 MCP-2 382 iNKT Dual CD3εxCD2CD3 & CD2 G-CSF 383 iNKT Dual CD3εxCD2 CD3 & CD2 M-CSF 384 iNKT DualCD3εxCD2 CD3 & CD2 Il-4 385 iNKT Dual CD3εxCD2 CD3 & CD2 IFNγ 386 iNKTDual CD19xCD20 — GM-CSF 387 iNKT Dual CD19xCD20 — CCL2 388 iNKT DualCD19xCD20 — MCP-2 389 iNKT Dual CD19xCD20 — G-CSF 390 iNKT DualCD19xCD20 — M-CSF 391 iNKT Dual CD19xCD20 — Il-4 392 iNKT Dual CD19xCD20— IFNγ

Example 8 Biological Assays

The following assays, or variations thereon, may be used to assessefficacy of the cytokine-deficient chimeric antigen receptor(CAR)-bearing immune effector cells disclosed herein.

T-ALL. Testing efficacy of cells in a xenogeneic model of T-ALL: 1×10⁵Click Beetle Red luciferase (CBR) labeled CCRF-CEM T-ALL (99% CD7+ byFACS) cells will be injected I.V. into NSG recipients prior to infusionof 2×10⁶ to 1×10⁷ CART-bearing immune effector cells or non-targetingCAR19-bearing immune effector cells control cells i.v. on day +4. Incontrast to mice receiving CART19-bearing immune effector cells or miceinjected with tumor only, mice receiving CART-bearing immune effectorcells will demonstrate significantly prolonged survival and reducedtumor burden as determined by bioluminescent imaging.

Multiple Myeloma. Testing efficacy of iNKT-CAR-CS1 in a xenogeneic modelof multiple myeloma: 5×10⁵ Click Beetle Red luciferase (CBR) labeledMM.1S (99% CS1+ by FACS) cells will be injected I.V. into NSG recipientsprior to infusion of 2×10⁶ to 1×10⁷ iNKT-CAR-CS1 or non-targetingiNKT-CAR19 control cells i.v. on day +4, or +14 or +28. In contrast tomice receiving iNKT-CAR19 or mice injected with tumor only, micereceiving iNKT-CAR-CS1 will demonstrate significantly prolonged survivaland reduced tumor burden as determined by bioluminescent imaging.

In Vivo Models of Cytokine Release Syndrome and Neurotoxicity

An in vivo mouse model of CRS is disclosed in Giavridis et al., “CARTcell-induced cytokine release syndrome is mediated by macrophages andabated by IL-1 blockade,” Nat Med 2018 May 28. For example, in order toinitiate CRS as a model system, tumor cells are injectedintraperitoneally into immune deficient mice and allowed to develop intoa tumor. The mice are then given CAR-T cells targeting the cancerouscells and monitored for several days to induce the onset of CRS, afterwhich mice are sacrificed and cells and tissue obtained for analysis.Mice may also be treated for CRS and monitored for success or failure oftreatment (i.e., administering antibodies against cytokines produces asa result of administration of CAR-T cells).

Analyses appropriate for monitoring CRS in such a model may includemonitoring of weight change in the mice after administration of CAR-Tcells, percent survival of mice, serum levels of inflammatory factors,i.e., murine SAA3 (equivalent to human C-reactive protein), cytokinelevels before and after administration of CAR-T cells, species of originof pro-inflammatory cytokines (i.e., human versus murine cytokines;and/or percent survival of mice treated with CAR-T cells that receivedantibodies against specific cytokines.

Mice that eventually die from CRS symptoms or complications may beclassified as having severe CRS, while mice that survive but suffergreater than 10% weight loss may be classified as having non-severe CRS.Using this model, it was discovered that monocytes and macrophages arethe main source for IL-6 in CRS.

Another model useful for assessing both CRS and CAR-T associatedneuropathy is disclosed in Norelli, “Monocyte-derived IL-1 and IL-6 aredifferentially required for cytokine-release syndrome and neurotoxicitydue to CART cells,” Nat Med 2018 May 28. In this model, human stemcells, such as hematopoietic stem and progenitor cells (HSPCs), areinjected into humanized NSG mice, which are immunocompromised transgenicmice expressing human stem cell factor, GM-CSF, and IL-3 to support andenhance hematopoiesis from the injected human stem cells. The mice aregiven tumor cells to serve as targets for subsequently administeredCAR-T cells, and then monitored for CRS symptoms. Following injection ofCAR-T cells, these mice exhibit typical symptoms of CRS, including highfever and elevated levels of certain cytokines implicated in CRS, suchas IL-1 and/or IL-6. Control of CRS in these mice may be accomplished byblocking the receptor for the cytokine using, for example, antibodies,depletion of cell types expressing the cytokine, or administration of anantagonist of the cytokine. As above, it was determined that monocytesare the main source of the pro-CRS cytokine IL-6, and depletion ofmonocytes eliminated CRS and protected the mice from death from CRS.

Other CRS animal models are known in the art and may also be used asdeemed appropriate.

Methods for Inducing and Testing Cytokine Release Syndrome for ControlPurposes

In one model, IL-7 may be directly injected into a mouse or other animalmodel to induce or initiate CRS for control purposes, as describedherein. In yet another example, recombinant or transgenic IL-7 may beexpressed in a cell to result in increased IL-7 signaling.

In a still further example, a constitutively signaling cytokinereceptor, such as an IL-7 receptor, may be engineered into an immuneeffector cell such that the immune effector cell itself triggers IL-7signaling, but is unresponsive to extracellular IL-7, and initiation ofIL-7 signaling of surrounding lymphocytes is avoided. Additionally,co-expressing a constitutively signaling IL-7 receptor with a CARrecognizing a specific disease or tumor antigen results in increasedT-cell proliferation, survival, and antitumor activity. A constitutivelyexpressing IL-7 receptor is able to transmit IL-7 signaling without theneed for IL-7 ligand or the common gamma γ_(c) chain, a component of thenative IL-7 receptor, along with IL-7Rα. This can be accomplished byengineering cysteine and/or proline into the transmembrane domain of theIL-7Rα chain, which results in homodimerization of IL-7Rα and subsequentphosphorylation of JAK1/JAK1, which then activates downstream signalingof IL-7.

An example of a method for making and testing a genome-edited CAR-T celldeficient at inducing CRS by insertion of selectable marker into geneedited locus is provided below.

Example 9 Insertion of CAR into T Cell Receptor Gene

A CAR or any protein of interest may be inserted into the gene for the Tcell receptor. MacLeod et al. (“Integration of a CD19 CAR into the TCRAlpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR TCells,”Molec Therapy 25(4):P949-961, 2017) reports the generation ofallogeneic CART cells by targeting the insertion of a CAR transgenedirectly into the native TCR locus using an engineered homingendonuclease and an AAV donor template. Anti-CD19 CAR T cells producedin this manner do not express the endogenous cell-surface TCR, exhibitpotent effector functions in vitro, and mediate clearance of CD19+tumors in an in vivo mouse model. The resulting gene-edited CAR T cellsexhibit potent anti-tumor activity in vitro and in vivo in preclinicalmodels, suggesting that these cells have potential for safe andefficacious use as adoptive cellular therapy in unrelated patients withCD19+ hematological malignancies.

Example 10 Anti-Cytokine/Chemokine Antibodies to Reduce CRS

Introduction of immune effector cells to a patient or subject fortreatment of cancer often results in CRS due to the production andsecretion of cytokines and/or chemokines by the immune effector cells.One way to prevent CRS is to administer antibodies recognizing aspecific CRS-inducing cytokine or chemokine to the patient or subjectsuch that the amount of circulating cytokine/chemokine is reduced. Forexample, as reported by Sachdeva et al., (J Biol Chem 294(14):5430-5437,2019), administration of anti-GMCSF antibodies reduced the GMCSFsecretion thereby effectively reducing CRS. Therefore, administeringantibodies recognizing a specific cytokine and/or chemokine can preventor reduce the occurrence of CRS in a patient or subject.

Example 11 Insertion of CAR into GMCSF Gene

One exemplary way to prevent CRS is to insert a CAR into a gene for acytokine or chemokine that is involved in initiation or prolonging ofCRS. Disruption or ablation of a cytokine or chemokine gene in a CAR-Tor other immune effector cell prevents the initiation of CRS by thatparticular cytokine or chemokine. One example of such a gene is GMCSF,although other genes involved in initiating or prolonging CRS may alsobe disrupted in this or a similar manner as described herein. Disruptionof the GMCSF gene is described at least in Sachdeva et al. (J Biol Chem294(14):5430-5437, 2019) and a description of making and testing a CAR-Tcell inserted into the GM-CSF gene is provided below. Briefly, a TALENor other gene-editing enzyme may be designed or engineered to target acytokine or chemokine gene of choice in a CAR-T cell, and the expressionof the gene monitored by methods known in the art. Significant reductionin the expression and secretion of the cytokine or chemokine gene by theCAR-T cell was reported, which implies that the occurrence of CRS wouldbe reduced. Additionally, this approach was found to simultaneouslymaintain both the proliferation capability and the anti-tumor activityof the CAR-T cell, as assessed by transwell assays and serial killingassays.

In addition to the use of gene editing to delete a gene such as GM-CSF,antibodies to a cytokine or chemokine causing or contributing to CRS mayalso be used. For example, an antibody recognizing the GM-CSF proteinmay be administered to a patient or subject receiving CAR-T therapy.This practice is known in the art, particularly for reduction of CRS asa result of IL-6 signaling using the IL-6R antagonist tocilizumab,however other antibodies or antagonists recognizing cytokines orchemokines, or antagonists of their receptors, may be used as deemedappropriate by a clinician. Appropriate antibodies will bind to thecirculating cytokine or chemokine, and antagonists will bind to thenative receptors for the cytokine or chemokine, thus preventingdownstream CRS-promoting activities in the subject. In some instances,both of these approaches may be employed in a subject, i.e., insertionof a CAR into the gene for a cytokine or chemokine to inactivate thegene, and also administering antibodies against the same cytokine orchemokine to the subject. This approach has been shown to be effectivewhile conferring no negative effects on the activity of the CAR-T cellsin vivo or in vitro (Sterner et al., “GM-CSF inhibition reduces cytokinerelease syndrome and neuroinflammation but enhances CAR-T cell functionin xenografts,” Blood 133:697-709, 2019).

Example 12 Method of Making and Testing Genome-Edited CAR-T CellsDeficient at Inducing CRS by Insertion of Selectable Marker into GeneEdited Loci

Inject tumor in SCID-Beige mice (3e6 Raji containing Luciferase) ifperforming in vivo CRS experiment. This should be completed 3 weeksprior to infusion of CAR-T into mice.

The following steps may be taken to provide a genome-edited,CRS-resistant, CAR-T cell in which the CAR is expressed from the geneedited loci with a selectable marker disclosed herein. It is notpossible to select and purify edited cells based on the deletion ofgenes that encode internal or secreted proteins, thus a selectablemarker is required to enrich for this gene modification. This exampledescribes the making of a CD19CARTΔGMCSFΔCD3ε cell, in which thedeletion of GM-CSF mitigates risk of CRS and deletion of CD3ε preventsTCR signaling and graft vs host disease (GvHD). As those of skill in theart will recognize, certain of the steps may be conducted sequentiallyor out of the order listed below, though perhaps leading to differentefficiency.

Step 1: T Cell Activation (Day 0)

Purify T cells from leukapheresis chamber using a Miltenyi human PanTisolation kit. Resuspend in media. Count cells. Determine number ofhuman T cell activation CD3/CD28 beads required to obtain 3:1 bead:cellratio. Wash beads 2× with T cell media. Dilute cells at 1.256 cells/mLin hXcyte media. Add human T cell activation CD3/CD28 beads. Aliquot 4mL/well of 1.256 cell/mL solution into 6 well plate. Incubate cells at37° C.

Step 2: CRISPR (Day 2)

The target gene is genetically deleted and the CAR inserted into thegene edited loci. The DNA double-stranded break can be repaired usinghomology directed repair using a donor template to repair the break andinsert the desired sequence into the edited loci. Target deletion may beaccomplished by electroporating with Cas9 mRNA and gRNA against thetarget(s). The donor template may be a DNA plasmid, or a double-strandedlinear DNA, or a single stranded-stranded linear DNA containing homologyto the DNA surrounding the double-stranded breaks electroplated with theCas9/gRNA. In this example the homology arms align to either side of thedouble-stranded break induced by gRNA GM-CSF. Additionally, a viralvector such as AAV may be used as the source of the donor template.Other techniques, however, could be used to induce DNA double strandbreaks. These include other genome editing techniques such as TALENs andmega-nucleases.

The sequences of the gRNAs for GM-CSF and CD3ε are as follows:

hGMCSF gRNA: (SEQ ID NO: 50)5′_2′OMe(U(ps)A(ps)C(ps))UCAGGUUCAGGAGACGCGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC2′OMe(U(ps)U(ps)U(ps)U_3′ CD38 gRNA: (SEQ ID NO: 47)5′_2′OMe(A(ps)G(ps)G(ps))GCAUGUCAAUAUUACUGGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC2′OMe(U(ps)U(ps)U(ps)U 3′

Nucleofection Sample ID gRNA#1 gRNA#2 Cas9 Buffer P3 UCART19 20 μg 20 μg15 μg Cas9 100 μl gGM-CSF gCD3ε mRNA

Nucleofection Using Nucleofector 4D:

Perform nucleofection protocol as described above (Example 6), using 20μg of each gRNA (gGM-CSF and gCD3ε) to each tube of 15 μg cas9 mRNA.

Step 3: Transduction of T Cells with AAV Vector Containing HDR RepairConstruct to Introduce CAR and a Selectable Marker into GM-CSF Loci

Sequences for components of vectors described herein are provided in thesequence listing, such as including, but not limited to, SEQ IDNOs:3048-3064. For example, recombinant AAV6 donor vector (FIG. 3,containing ITR-Right homology arm (SEQ ID NO:51), EF1a promotor (SEQ IDNO:52), CAR19 p2a trCD34 (SEQ ID NO:53), Left homology arm (SEQ IDNO:54), ITR (SEQ ID NO:55), is added to the cell culture 2-4 hrs afterelectroporation with a MOI between 1×10⁴ and 1×10⁶.

Step 4: Assessment of CRISPR Activity and Td Efficiency (Day 10)

Take 5×10⁵ cells from each sample and analyze by flow cytometry. Washsamples with RB. Add 3 μl of anti-CD34 PE antibody (This detects theinsertion TrCD34 tag into GM-CSF loci). Add 5 μl of CD3 APC and 2 μl ofanti-FAB BV421 (detects CAR transduction). Wash. Perform Flow cytometry.Cells should be CD3ε-negative, CD34-positive and FAB+. Harvest T cells(Day 11).

Purification of CAR-T cells. TCR-negative cells can be purified usingTCRa/b negative selection to remove TCR positive cells. GM-CSF deletedcells can be enriched using a CD34-positive selection on the MiltenyiAutomacs. This enriches the GM-SCF− cells and removes TCR+ cells.

Step 5: Assessment of CAR-T Activity In Vivo

Inject 3×10⁷ CAR-T per mouse I.P. Assess serum cytokine levels. (Day 12,Day 13, Day 14) Measure serum cytokine levels using Luminex multiplexcytokine profiling assay to check for elevations in CRS relatedcytokines. Perform a 4 hr chromium release assay against targets cells(Raji) to assess in vitro activity (Day 11).

Example 13 Confirmation of GFP Expression with EGFP Integration intoCD3e Locus of Jurkats Under Control of CD3e Promotor

Direct insertion of GFP into the CD3e locus of a Jurkat cell line may beperformed using the method details below.

Days prior: Digest plasmid with PST1 (FIG. 4). Two fragments (3.5 kb and2.6 kb) are generated upon digestion. Purify using gel extraction kitand ethanol precipitate. Resuspend at 500 ng/μl. This generates donortemplate ‘DNA’ in table below

Make and titre AAV. The sequence of the AAV is shown in FIG. 5 andprovided in SEQ ID NOs:______. This generates donor template ‘AAV’ inthe table below.

Donor template ‘plasmid’ is shown in the table below.

Day 0:

Harvest jurkats and count. Spin cells down @100 g for 10 mins. Transfercells to 1.5 m microcentrifuge tube and wash in PBS. Spin cells down@100×g for 10 mins. Resuspend in pre-warmed buffer SE. Add 100 μl totube containing gRNA/Cas9. Transfer to nucleocuvette and zap using theJurkat program on 4D. Transfer to pre-warmed media in 2 ml respectivemedia in a 6-well plate. Return to incubator and expand for 4 days.

TABLE 14 Nucleofector Cell Cas9 Donor Name Solution Cell line numbermRNA gRNA template 1 WT — Jurkat 4 × 10⁶ — 20 μg CD3e — 2 3Δ SE Jurkat 4× 10⁶ 15 μg 20 μg CD3e — 3 P-1ug SE Jurkat 4 × 10⁶ 15 μg 20 μg CD3ePlasmid 1 ug 4 P-2ug SE Jurkat 4 × 10⁶ 15 μg 20 μg CD3e Plasmid 2 ug 5P-2ug SE Jurkat 4 × 10⁶ 15 μg 20 μg CD3e Plasmid 3 ug 6 D-1ug SE Jurkat4 × 10⁶ 15 μg 20 μg CD3e DNA 1ug 7 D-2ug SE Jurkat 4 × 10⁶ 15 μg 20 μgCD3e DNA 2ug 8 D-4ug SE Jurkat 4 × 10⁶ 15 μg 20 μg CD3e DNA 3ug 9 AAV TdSE Jurkat 4 × 10⁶ 15 μg 20 μg CD3e AAV 1e4 10 AAV Td SE Jurkat 4 × 10⁶15 μg 20 μg CD3e AAV 1e5 11 AAV Td SE Jurkat 4 × 10⁶ 15 μg 20 μg CD3eAAV 1e6

Day 4: FACS cells for GFP and CD3 APC. Assess editing efficiency by lossof CD3 and integration of the AAV-GFP donor by GFP fluorescence.

Example 14 Method of Making and Testing a Genome-Edited CAR-T Cells byInsertion of CAR into CD3e Loci

The following steps may be taken to provide a genome-edited CAR-T cellin which the car is expressed from the gene edited loci (CAR-T)disclosed herein. This example describes the making of a CD7CART ACD7ACD3c cell. As those of skill in the art will recognize, certain of thesteps may be conducted sequentially or out of the order listed below,though perhaps leading to different efficiency.

Step 1: T Cell Activation (Day 0)

Purify T cells from leukapheresis chamber using Miltenyi human PanTisolation kit. Resuspend in media. Count cells. Determine number ofhuman T cell activation CD3/CD28 beads required to obtain 3:1 bead:cellratio. Wash beads 2× with T cell media. Dilute cells at 1.256 cells/mLin hXcyte media. Add human T cell activation CD3/CD28 beads. Aliquot 4mL/well of 1.256 cell/mL solution into 6 well plate. Incubate cells at37° C.

Step 2: CRISPR (Day 2)

The target gene is genetically deleted and the CAR inserted into thegene edited loci. The DNA double-stranded break can be repaired usinghomology-directed repair using a donor template to repair the break andinsert the desired sequence into the edited loci. Target deletion may beaccomplished by electroporating with Cas9 mRNA and gRNA against thetarget(s). The donor template may be a DNA plasmid, or double-strandedlinear DNA, or single-stranded linear DNA containing homology to the DNAsurrounding the double-stranded breaks electroporated with theCas9/gRNA. Additionally, a viral vector such as AAV may be used as thesource of the donor template. Other techniques, however, could be usedto induce DNA double-stranded breaks. These include other genome editingtechniques, such as TALENs and mega-nucleases.

Nucleofection Sample ID gRNA#1 gRNA#2 Cas9 Buffer P3 UCART7 20 μg 20 μg15 μg Cas9 100 μl gCD7 gCD3ε mRNA

Nucleofection Using Nucleofector 4D:

Perform nucleofection protocol as described above (Example 6), using 20μg of each gRNA (gCD7 and gCD3ε) to each tube of 15 μg Cas9.

Step 3: Transduction of T cells with AAV vector containing HDR repairconstruct

Recombinant AAV6 (or other serotypes of AAV) donor vector is added tothe cell culture 2-4 hrs after electroporation with an MOI between 1×10⁴and 1×10⁶.

Step 4: Assessment of CRISPR Activity and Td Efficiency (Day 10)

Take 5×10⁵ cells from each sample and analyze by flow cytometry. Washsamples with RB. Add 3 μl of anti-CD34 PE antibody (This detects theCAR, as the construct contains human truncated CD34). Add 5 μl of CD3APC and 2 μl of CD7 BV421. Wash. Perform Flow cytometry. Cells should beCD3ε-negative, CD7-negative and CD34-positive. Harvest T cells (Day 11).

Purification of CAR-T cells. CD34+ (CAR+) and TCR-negative cells can bepurified in a single step using a positive selection of CD34+ cells on aMiltenyi Automacs. This enriches the CAR+ cells and removes and TCR+cells (as CAR insertion disrupts TCR signaling).

Step 5: Assessment of CAR-T Activity In Vivo

Inject tumor in NSG mice (5×10⁵ MOLT3 or HH: containing Luciferase) ifperforming in vivo imaging experiment (Day 7).

Image tumor burden in mouse using bioluminescent imaging. Inject 2×10⁶CD34+ CAR-T per mouse I.V. via tail vein or perform a 4hr chromiumrelease assay against targets cell (MOLT3 or HH) (Day 11). Those ofskill in the art will appreciate that some flexibility is possible inthe specified time frames.

Example 15 Cytokine/Chemokine Gene Silencing Using shRNA

Similar to siRNAs, short hairpin RNA can be used to knock down oreliminate expression of a cytokine/chemokine/transcription factor genein an immune effector cell.

Cherkassky et al. (“Human CAR T cells with cell-intrinsic PD-1checkpoint blockade resist tumor-mediated inhibition,” J Clin Investig2016; 126:3130-3144) reported use of shRNA to knock down expression ofimmune checkpoint PD-1 in CD28 mesothelin-specific CAR-T cells, whichshowed enhanced proliferative function upon antigen stimulation,augmented cytotoxicity, and enhanced cytokine secretion. In addition, aCD19-specific CAR with a PD-1 shRNA lentiviral cassette has been testedfor use in CD19-positive B-cell lymphoma. A list of useful shRNAs andtheir sequences is provided in Tables 15 and 16.

TABLE 15 5′ to 3′(Forward) shRNA sequences for Silencing of Cytokine/Chemokine Genesto Reduce the Incidence of CRS Target SEQ Gene ID Lo- SymbolshRNA Forward Oligo Sequence NO: cation Gene ID No. A2MCCGGAGGCGTCCCTATACCAAATAACTCGAGTTATTTGGTATAGGGACGCCTTTTTTG 1046 chr12ENST00000318602.11 A2MCCGGAGACTGCATCAATCGTCATAACTCGAGTTATGACGATTGATGCAGTCTTTTTTG 1047 chr12ENST00000318602.11 A2MCCGGCCTCCAGACATCCTTGAAATACTCGAGTATTTCAAGGATGTCTGGAGGTTTTTG 1048 chr12ENST00000318602.11 ACKR1CCGGATCCTGTGGGCCTGGTTTATTCTCGAGAATAAACCAGGCCCACAGGATTTTTTG 1049 chr1ENST00000368122.2 ACKR1CCGGTGGCAGAAGCCCTGGCAATTTCTCGAGAAATTGCCAGGGCTTCTGCCATTTTTG 1050 chr1ENST00000368122.2 ACKR1CCGGGGCGGATGGTTGAGATCTATCCTCGAGGATAGATCTCAACCATCCGCCTTTTTG 1051 chr1ENST00000368122.2 ACKR2CCGGGAGCACTCTTTATACTATTAACTCGAGTTAATAGTATAAAGAGTGCTCTTTTTG 1052 chr3ENST00000422265.5 ACKR2CCGGGTGGAACTGCCACGCAGATTTCTCGAGAAATCTGCGTGGCAGTTCCACTTTTTG 1053 chr3ENST00000422265.5 ACKR2CCGGCATTGGGTCTTCGGGAGTTTCCTCGAGGAAACTCCCGAAGACCCAATGTTTTTG 1054 chr3ENST00000422265.5 ACKR3CCGGCACTATTGGTGTACCTTATAACTCGAGTTATAAGGTACACCAATAGTGTTTTTG 1055 chr2ENST00000272928.3 ACKR3CCGGGGCATAGTGCTGACATATATTCTCGAGAATATATGTCAGCACTATGCCTTTTTG 1056 chr2ENST00000272928.3 ACKR3CCGGGCCGTTCCCTTCTCCATTATCCTCGAGGATAATGGAGAAGGGAACGGCTTTTTG 1057 chr2ENST00000272928.3 ACVR1CCGGTGATAATTCCCTCGACAAATTCTCGAGAATTTGTCGAGGGAATTATCATTTTTG 1058 chr2ENST00000263640.7 ACVR1CCGGGCAGAACGTATTTAGCCATTACTCGAGTAATGGCTAAATACGTTCTGCTTTTTG 1059 chr2ENST00000263640.7 ACVR1CCGGCTGGTCTGTCTTTGGATAATACTCGAGTATTATCCAAAGACAGACCAGTTTTTG 1060 chr2ENST00000263640.7 ACVR2BCCGGATGTCACGAGGCCTCTCATACCTCGAGGTATGAGAGGCCTCGTGACATTTTTTG 1061 chr3ENST00000352511.4 ACVR2BCCGGCCCAGCTCATGAATGACTTTGCTCGAGCAAAGTCATTCATGAGCTGGGTTTTTG 1062 chr3ENST00000352511.4 ACVR2BCCGGCTTTGGCTTGGCTGTTCGATTCTCGAGAATCGAACAGCCAAGCCAAAGTTTTTG 1063 chr3ENST00000352511.4 ACVRL1CCGGCCGGGAGACTGAGATCTATAACTCGAGTTATAGATCTCAGTCTCCCGGTTTTTG 1064 chr12ENST00000388922.8 ACVRL1CCGGCAGGAGCACCTGATTCCTTTCCTCGAGGAAAGGAATCAGGTGCTCCTGTTTTTG 1065 chr12ENST00000388922.8 ACVRL1CCGGCGTGGAGATCTTCGGTACACACTCGAGTGTGTACCGAAGATCTCCACGTTTTTG 1066 chr12ENST00000388922.8 ADIPOQCCGGGTTGGAGGCCTTTAGATATTACTCGAGTAATATCTAAAGGCCTCCAACTTTTTG 1067 chr3ENST00000320741.6 ADIPOQCCGGATGCTCATATCAATCCTATAACTCGAGTTATAGGATTGATATGAGCATTTTTTG 1068 chr3ENST00000320741.6 ADIPOQCCGGACGGTTAGGAAGTTGATTATTCTCGAGAATAATCAACTTCCTAACCGTTTTTTG 1069 chr3ENST00000320741.6 AGERCCGGCACACTGCAGTCGGAGCTAATCTCGAGATTAGCTCCGACTGCAGTGTGTTTTTG 1070 chr6ENST00000375076.8 AGERCCGGGAAGCCAGAAATTGTAGATTCCTCGAGGAATCTACAATTTCTGGCTTCTTTTTG 1071 chr6ENST00000375076.8 AGERCCGGTGCTGATCCTCCCTGAGATAGCTCGAGCTATCTCAGGGAGGATCAGCATTTTTG 1072 chr6ENST00000375076.8 AGRNCCGGGAGTTCTGTGTGGAAGATAAACTCGAGTTTATCTTCCACACAGAACTCTTTTTG 1073 chr1ENST00000379370.6 AGRNCCGGGCGCACGTATGACAGTGATTGCTCGAGCAATCACTGTCATACGTGCGCTTTTTG 1074 chr1ENST00000379370.6 AGRNCCGGACGACGGAGTCACCTACGAAACTCGAGTTTCGTAGGTGACTCCGTCGTTTTTTG 1075 chr1ENST00000379370.6 AHRCCGGCGGCATAGAGACCGACTTAATCTCGAGATTAAGTCGGTCTCTATGCCGTTTTTG 1076 chr7ENST00000242057.8 AHRCCGGGCGGCATAGAGACCGACTTAACTCGAGTTAAGTCGGTCTCTATGCCGCTTTTTG 1077 chr7ENST00000242057.8 AHRCCGGATCCACAGTCAGCCATAATAACTCGAGTTATTATGGCTGACTGTGGATTTTTTG 1078 chr7ENST00000242057.8 AHRCCGGACTGCTTAAAGTTGGTATTAACTCGAGTTAATACCAACTTTAAGCAGTTTTTTG 1079 chr7ENST00000242057.8 AIMP1CCGGCAGCCTGATCTTCACACTAATCTCGAGATTAGTGTGAAGATCAGGCTGTTTTTG 1080 chr4ENST00000358008.7 AIMP1CCGGAGAAGTAGATGTCGGAGAAATCTCGAGATTTCTCCGACATCTACTTCTTTTTTG 1081 chr4ENST00000358008.7 AIMP1CCGGGCCAGAGTAACCCTGACTAATCTCGAGATTAGTCAGGGTTACTCTGGCTTTTTG 1082 chr4ENST00000358008.7 AREGCCGGCCTCTTTCCAGTGGATCATAACTCGAGTTATGATCCACTGGAAAGAGGTTTTTG 1083 chr4ENST00000395748.7 AREGCCGGTACTCGGCTCAGGCCATTATGCTCGAGCATAATGGCCTGAGCCGAGTATTTTTG 1084 chr4ENST00000395748.7 AREGCCGGATTCACGGAGAATGCAAATATCTCGAGATATTTGCATTCTCCGTGAATTTTTTG 1085 chr4ENST00000395748.7 BCL6CCGGTGTGCCACAGCAATATCTATTCTCGAGAATAGATATTGCTGTGGCACATTTTTG 1086 chr3ENST00000406870.6 BCL6CCGGACTGCGTTAAAGGCTCGATTTCTCGAGAAATCGAGCCTTTAACGCAGTTTTTTG 1087 chr3ENST00000406870.6 BCL6CCGGCCGGCTCAATAACATCGTTAACTCGAGTTAACGATGTTATTGAGCCGGTTTTTG 1088 chr3ENST00000406870.6 BCL6CCGGACAAGCCAGCCGGCTCAATAACTCGAGTTATTGAGCCGGCTGGCTTGTTTTTTG 1089 chr3ENST00000406870.6 BMP1CCGGACTGACGAGGACAGCTATATTCTCGAGAATATAGCTGTCCTCGTCAGTTTTTTG 1090 chr8ENST00000306385.9 BMP1CCGGGCTCGTAAGTCCTCCATCAAACTCGAGTTTGATGGAGGACTTACGAGCTTTTTG 1091 chr8ENST00000306385.9 BMP1CCGGACAGCTGTGCCTACGACTATCCTCGAGGATAGTCGTAGGCACAGCTGTTTTTTG 1092 chr8ENST00000306385.9 BMP10CCGGAGCAAGACGGTGTCGACTTTACTCGAGTAAAGTCGACACCGTCTTGCTTTTTTG 1093 chr2ENST00000295379.1 BMP10CCGGGCGTCGTCACCTACAAGTTTACTCGAGTAAACTTGTAGGTGACGACGCTTTTTG 1094 chr2ENST00000295379.1 BMP10CCGGCATGGCTGAACTTAGGCTATACTCGAGTATAGCCTAAGTTCAGCCATGTTTTTG 1095 chr2ENST00000295379.1 BMP15CCGGTACTACGCGATGGTCTCAATTCTCGAGAATTGAGACCATCGCGTAGTATTTTTG 1096 chrXENST00000252677.3 BMP15CCGGGCCTTCTTGTTACTCTATTTCCTCGAGGAAATAGAGTAACAAGAAGGCTTTTTG 1097 chrXENST00000252677.3 BMP15CCGGATGGAACACAGGGCCCAAATGCTCGAGCATTTGGGCCCTGTGTTCCATTTTTTG 1098 chrXENST00000252677.3 BMP2CCGGGATCATCTGAACTCCACTAATCTCGAGATTAGTGGAGTTCAGATGATCTTTTTG 1099 chr20ENST00000378827.4 BMP2CCGGCCGGAGATTCTTCTTTAATTTCTCGAGAAATTAAAGAAGAATCTCCGGTTTTTG 1100 chr20ENST00000378827.4 BMP2CCGGCAAGATGCTTTAGGAAACAATCTCGAGATTGTTTCCTAAAGCATCTTGTTTTTG 1101 chr20ENST00000378827.4 BMP3CCGGCTTACAGGGACACCGGAATTTCTCGAGAAATTCCGGTGTCCCTGTAAGTTTTTG 1102 chr4ENST00000282701.2 BMP3CCGGGGCCAAATCTCATCGAGATATCTCGAGATATCTCGATGAGATTTGGCCTTTTTG 1103 chr4ENST00000282701.2 BMP3CCGGGTGGATTGAACCTCGGAATTGCTCGAGCAATTCCGAGGTTCAATCCACTTTTTG 1104 chr4ENST00000282701.2 BMP4CCGGCCCTGGTCAATTCTGTCAATTCTCGAGAATTGACAGAATTGACCAGGGTTTTTG 1105 chr14ENST00000245451.8 BMP4CCGGTCCTTGAGGATAGACAGATATCTCGAGATATCTGTCTATCCTCAAGGATTTTTG 1106 chr14ENST00000245451.8 BMP4CCGGAGGGCCAGCATGTCAGGATTACTCGAGTAATCCTGACATGCTGGCCCTTTTTTG 1107 chr14ENST00000245451.8 BMP5CCGGTGGACGCAGTATCAACGTAAACTCGAGTTTACGTTGATACTGCGTCCATTTTTG 1108 chr6ENST00000370830.3 BMP5CCGGCCAGAAGGATACGCTGCATTTCTCGAGAAATGCAGCGTATCCTTCTGGTTTTTG 1109 chr6ENST00000370830.3 BMP5CCGGATGCCACCAACCACGCTATAGCTCGAGCTATAGCGTGGTTGGTGGCATTTTTTG 1110 chr6ENST00000370830.3 BMP6CCGGATACAGGAATATGGTTGTAAGCTCGAGCTTACAACCATATTCCTGTATTTTTTG 1111 chr6ENST00000283147.6 BMP6CCGGCGCCGACAACAGAGTCGTAATCTCGAGATTACGACTCTGTTGTCGGCGTTTTTG 1112 chr6ENST00000283147.6 BMP6CCGGCTGTCTATCAAAGGTAGATTTCTCGAGAAATCTACCTTTGATAGACAGTTTTTG 1113 chr6ENST00000283147.6 BMP7CCGGACGTTCCGGATCAGCGTTTATCTCGAGATAAACGCTGATCCGGAACGTTTTTTG 1114 chr20ENST00000395863.7 BMP7CCGGACTCGTTTCCAGAGGTAATTACTCGAGTAATTACCTCTGGAAACGAGTTTTTTG 1115 chr20ENST00000395863.7 BMP7CCGGACCATCGAGAGTTCCGGTTTGCTCGAGCAAACCGGAACTCTCGATGGTTTTTTG 1116 chr20ENST00000395863.7 BMP8ACCGGAGGGTGCAGTTAGCATATTAGCTCGAGCTAATATGCTAACTGCACCCTTTTTTG 1117 chr1ENST00000331593.5 BMP8ACCGGAGCACAGAAGTCCTATCTTAGCTCGAGCTAAGATAGGACTTCTGTGCTTTTTTG 1118 chr1ENST00000331593.5 BMP8ACCGGAGGTACAACACTGGCCATTTCCTCGAGGAAATGGCCAGTGTTGTACCTTTTTTG 1119 chr1ENST00000331593.5 BMP8BCCGGCCAAGGCTACTCGGCCTATTACTCGAGTAATAGGCCGAGTAGCCTTGGTTTTTG 1120 chr1ENST00000372827.7 BMP8BCCGGGACCCTCACAACCACGTACATCTCGAGATGTACGTGGTTGTGAGGGTCTTTTTG 1121 chr1ENST00000372827.7 BMP8BCCGGCGTTAACATGGTGGAGCGAGACTCGAGTCTCGCTCCACCATGTTAACGTTTTTG 1122 chr1ENST00000372827.7 BMPR2CCGGGAACGGCTATGTGCGTTTAAACTCGAGTTTAAACGCACATAGCCGTTCTTTTTG 1123 chr2ENST00000374580.8 BMPR2CCGGGCCTATGGAGTGAAATTATTTCTCGAGAAATAATTTCACTCCATAGGCTTTTTG 1124 chr2ENST00000374580.8 BMPR2CCGGATTACCACGAGGAGATCATTACTCGAGTAATGATCTCCTCGTGGTAATTTTTTG 1125 chr2ENST00000374580.8 C10orf99CCGGCATCATGTGAGGCTCTGTAAACTCGAGTTTACAGAGCCTCACATGATGTTTTTG 1126 chr10ENST00000372126.3 C10orf99CCGGCCCAACTCAACAAACCTGAAACTCGAGTTTCAGGTTTGTTGAGTTGGGTTTTTG 1127 chr10ENST00000372126.3 C10orf99CCGGGCCATCAACTTTCAGAGCTATCTCGAGATAGCTCTGAAAGTTGATGGCTTTTTG 1128 chr10ENST00000372126.3 C1QTNF4CCGGACACCGAGTTCGTCAACATTGCTCGAGCAATGTTGACGAACTCGGTGTTTTTTG 1129 chrllENST00000302514.3 C1QTNF4CCGGGCGTAAGACGCTGTCGGTTAACTCGAGTTAACCGACAGCGTCTTACGCTTTTTG 1130 chrllENST00000302514.3 C1QTNF4CCGGCGAGGTGCAGGCCATGATTTACTCGAGTAAATCATGGCCTGCACCTCGTTTTTG 1131 chrllENST00000302514.3 C5CCGGACGATGGAGCCTGCGTTAATACTCGAGTATTAACGCAGGCTCCATCGTTTTTTG 1132 chr9ENST00000223642.2 C5CCGGTCCCGACTTCTGGTCTATTACCTCGAGGTAATAGACCAGAAGTCGGGATTTTTG 1133 chr9ENST00000223642.2 C5CCGGGCCCGAGAGAACAGCTTATATCTCGAGATATAAGCTGTTCTCTCGGGCTTTTTG 1134 chr9ENST00000223642.2 CCL1CCGGGCAATCCTGTGTTACAGAAATCTCGAGATTTCTGTAACACAGGATTGCTTTTTG 1135 chr17ENST00000225842.3 CCL1CCGGCTGCTCCAATGAGGGCTTAATCTCGAGATTAAGCCCTCATTGGAGCAGTTTTTG 1136 chr17ENST00000225842.3 CCL1CCGGCCTGAGGGCAATCCTGTGTTACTCGAGTAACACAGGATTGCCCTCAGGTTTTTG 1137 chr17ENST00000225842.3 CCL11CCGGCCAACTCCAAAGCCATAAATACTCGAGTATTTATGGCTTTGGAGTTGGTTTTTG 1138 chr17ENST00000305869.3 CCL11CCGGCATTCTGAGGTAACCTCATTACTCGAGTAATGAGGTTACCTCAGAATGTTTTTG 1139 chr17ENST00000305869.3 CCL11CCGGTCCTCCATGAATATCAGTTATCTCGAGATAACTGATATTCATGGAGGATTTTTG 1140 chr17ENST00000305869.3 CCL13CCGGTGGAATACTTCTACCATAATTCTCGAGAATTATGGTAGAAGTATTCCATTTTTG 1141 chr17ENST00000225844.6 CCL13CCGGTCAAGCTGGAGTACGTGAAATCTCGAGATTTCACGTACTCCAGCTTGATTTTTG 1142 chr17ENST00000225844.6 CCL13CCGGACTCAACGTCCCATCTACTTGCTCGAGCAAGTAGATGGGACGTTGAGTTTTTTG 1143 chr17ENST00000225844.6 CCL14CCGGCCTAGGGACCAAGACTGAATCCTCGAGGATTCAGTCTTGGTCCCTAGGTTTTTG 1144 chr17ENST00000618404.4 CCL14CCGGCAGCGGATTATGGATTACTATCTCGAGATAGTAATCCATAATCCGCTGTTTTTG 1145 chr17ENST00000618404.4 CCL14CCGGCAAGCCCGGAATTGTCTTCATCTCGAGATGAAGACAATTCCGGGCTTGTTTTTG 1146 chr17ENST00000618404.4 CCL15CCGGGCTGAAGCCCTACTCAATATACTCGAGTATATTGAGTAGGGCTTCAGCTTTTTG 1147 chr17ENST00000617897.1 CCL15CCGGACAGAGTTAATGATGTCAAAGCTCGAGCTTTGACATCATTAACTCTGTTTTTTG 1148 chr17ENST00000617897.1 CCL15CCGGATCCCGTGTTCACTCATGAAACTCGAGTTTCATGAGTGAACACGGGATTTTTTG 1149 chr17ENST00000617897.1 CCL16CCGGAGGAGAAGTATTTCGAATATTCTCGAGAATATTCGAAATACTTCTCCTTTTTTG 1150 chr17ENST00000611905.1 CCL16CCGGAGGAACTTGTCCACGGTTAAACTCGAGTTTAACCGTGGACAAGTTCCTTTTTTG 1151 chr17ENST00000611905.1 CCL16CCGGCTGCCTGAAGTATTATGAGAACTCGAGTTCTCATAATACTTCAGGCAGTTTTTG 1152 chr17ENST00000611905.1 CCL17CCGGGAGAGTGAAGAATGCAGTTAACTCGAGTTAACTGCATTCTTCACTCTCTTTTTG 1153 chr16ENST00000219244.8 CCL17CCGGGAGTACTTCAAGGGAGCCATTCTCGAGAATGGCTCCCTTGAAGTACTCTTTTTG 1154 chr16ENST00000219244.8 CCL17CCGGGCAAAGCCTTGAGAGGTCTTGCTCGAGCAAGACCTCTCAAGGCTTTGCTTTTTG 1155 chr16ENST00000219244.8 CCL18CCGGTCTATTGTTGAGCTGCATTATCTCGAGATAATGCAGCTCAACAATAGATTTTTG 1156 chr17ENST00000616054.1 CCL18CCGGCCTTCAACTCTTCGTACATTCCTCGAGGAATGTACGAAGAGTTGAAGGTTTTTG 1157 chr17ENST00000616054.1 CCL18CCGGGTCTATACCTCCTGGCAGATTCTCGAGAATCTGCCAGGAGGTATAGACTTTTTG 1158 chr17ENST00000616054.1 CCL19CCGGGAGTCAAGCATTGTGAATTATCTCGAGATAATTCACAATGCTTGACTCTTTTTG 1159 chr9ENST00000311925.6 CCL19CCGGGCCGCAGCAGTTAACCTATGACTCGAGTCATAGGTTAACTGCTGCGGCTTTTTG 1160 chr9ENST00000311925.6 CCL19CCGGCCAACTCTGAGTGGCACCAATCTCGAGATTGGTGCCACTCAGAGTTGGTTTTTG 1161 chr9ENST00000311925.6 CCL2CCGGCCCAGTCACCTGCTGTTATAACTCGAGTTATAACAGCAGGTGACTGGGTTTTTG 1162 chr17ENST00000225831.4 CCL2CCGGCCCAGTCACCTGCTGTTATAACTCGAGTTATAACAGCAGGTGACTGGGTTTTTG 1163 chr17ENST00000225831.4 CCL2CCGGGCTCGCGAGCTATAGAAGAATCTCGAGATTCTTCTATAGCTCGCGAGCTTTTTG 1164 chr17ENST00000225831.4 CCL20CCGGAGTTGTCTGTGTGCGCAAATCCTCGAGGATTTGCGCACACAGACAACTTTTTTG 1165 chr2ENST00000358813.4 CCL20CCGGGACCGTATTCTTCATCCTAAACTCGAGTTTAGGATGAAGAATACGGTCTTTTTG 1166 chr2ENST00000358813.4 CCL20CCGGAGGGTTTAGTGCTTATCTAATCTCGAGATTAGATAAGCACTAAACCCTTTTTTG 1167 chr2ENST00000358813.4 CCL21CCGGCACTCTTTCTCCTGCTTTAACCTCGAGGTTAAAGCAGGAGAAAGAGTGTTTTTG 1168 chr9ENST00000259607.6 CCL21CCGGGAGCTATGTGCAGACCCAAAGCTCGAGCTTTGGGTCTGCACATAGCTCTTTTTG 1169 chr9ENST00000259607.6 CCL21CCGGCCATCCCAGCTATCCTGTTCTCTCGAGAGAACAGGATAGCTGGGATGGTTTTTG 1170 chr9ENST00000259607.6 CCL22CCGGCCCTACCTCCCTGCCATTATACTCGAGTATAATGGCAGGGAGGTAGGGTTTTTG 1171 chr16ENST00000219235.4 CCL22CCGGGCGTGGTGAAACACTTCTACTCTCGAGAGTAGAAGTGTTTCACCACGCTTTTTG 1172 chr16ENST00000219235.4 CCL22CCGGATGTTGCTGACACCCAGAAAGCTCGAGCTTTCTGGGTGTCAGCAACATTTTTTG 1173 chr16ENST00000219235.4 CCL23CCGGCACTCCTGGAGAGTTACTTTGCTCGAGCAAAGTAACTCTCCAGGAGTGTTTTTG 1174 chr17ENST00000615050.1 CCL23CCGGCCTTTCTCATGCTGCAGGATTCTCGAGAATCCTGCAGCATGAGAAAGGTTTTTG 1175 chr17ENST00000615050.1 CCL23CCGGGAAGCTGGACACACGGATCAACTCGAGTTGATCCGTGTGTCCAGCTTCTTTTTG 1176 chr17ENST00000615050.1 CCL24CCGGAGTGATCTTCACCACCAAGAACTCGAGTTCTTGGTGGTGAAGATCACTTTTTTG 1177 chr7ENST00000222902.6 CCL24CCGGGTTCTTTGTTTCCAAGAGAATCTCGAGATTCTCTTGGAAACAAAGAACTTTTTG 1178 chr7ENST00000222902.6 CCL24CCGGCCTGCTGCATGTTCTTTGTTTCTCGAGAAACAAAGAACATGCAGCAGGTTTTTG 1179 chr7ENST00000222902.6 CCL25CCGGGCCGGATCTTTCTCCGATAAACTCGAGTTTATCGGAGAAAGATCCGGCTTTTTG 1180 chr19ENST00000390669.7 CCL25CCGGGCTCCTGGATGCTCGAAATAACTCGAGTTATTTCGAGCATCCAGGAGCTTTTTG 1181 chr19ENST00000390669.7 CCL25CCGGCCCTCCTGATATCAGCTAATTCTCGAGAATTAGCTGATATCAGGAGGGTTTTTG 1182 chr19ENST00000390669.7 CCL26CCGGCACACGTGGGAGTGACATATCCTCGAGGATATGTCACTCCCACGTGTGTTTTTG 1183 chr7ENST00000005180.8 CCL26CCGGTCCGAAACAATTGTGACTCAGCTCGAGCTGAGTCACAATTGTTTCGGATTTTTG 1184 chr7ENST00000005180.8 CCL26CCGGGCTGTGATATTCACTACCAAACTCGAGTTTGGTAGTGAATATCACAGCTTTTTG 1185 chr7ENST00000005180.8 CCL27CCGGTTCGTGCTTCACCTGGCTCAACTCGAGTTGAGCCAGGTGAAGCACGAATTTTTG 1186 chr9ENST00000259631.4 CCL27CCGGCCGAAAGCCACTCTCAGACAACTCGAGTTGTCTGAGAGTGGCTTTCGGTTTTTG 1187 chr9ENST00000259631.4 CCL27CCGGCAAGCTACTGAGGAAGGTCATCTCGAGATGACCTTCCTCAGTAGCTTGTTTTTG 1188 chr9ENST00000259631.4 CCL28CCGGCGGAGGTTTCACATCATATTTCTCGAGAAATATGATGTGAAACCTCCGTTTTTG 1189 chr5ENST00000361115.4 CCL28CCGGCACGAAACATACGGCCATAAACTCGAGTTTATGGCCGTATGTTTCGTGTTTTTG 1190 chr5ENST00000361115.4 CCL28CCGGTTAGAGAGTCTACAGATAAATCTCGAGATTTATCTGTAGACTCTCTAATTTTTG 1191 chr5ENST00000361115.4 CCL3CCGGCCGGCAGATTCCACAGAATTTCTCGAGAAATTCTGTGGAATCTGCCGGTTTTTG 1192 chr17ENST00000613922.1 CCL3CCGGTTCGATTTCACAGTGTGTTTGCTCGAGCAAACACACTGTGAAATCGAATTTTTG 1193 chr17ENST00000613922.1 CCL3CCGGCAACCAGTTCTCTGCATCACTCTCGAGAGTGATGCAGAGAACTGGTTGTTTTTG 1194 chr17ENST00000613922.1 CCL4CCGGATGTGCCGTGTTATTGTATTACTCGAGTAATACAATAACACGGCACATTTTTTG 1195 chr17ENST00000615863.1 CCL4CCGGTCCTGTCCCTTCTCTTAATTTCTCGAGAAATTAAGAGAAGGGACAGGATTTTTG 1196 chr17ENST00000615863.1 CCL4CCGGCTGTGCTGATCCCAGTGAATCCTCGAGGATTCACTGGGATCAGCACAGTTTTTG 1197 chr17ENST00000615863.1 CCL5CCGGTGAACCTGAACTTACACAAATCTCGAGATTTGTGTAAGTTCAGGTTCATTTTTG 1198 chr17ENST00000603197.5 CCL5CCGGCCTGCTGCTTTGCCTACATTGCTCGAGCAATGTAGGCAAAGCAGCAGGTTTTTG 1199 chr17ENST00000603197.5 CCL5CCGGCTACCACACAGCAGCAGTTACCTCGAGGTAACTGCTGCTGTGTGGTAGTTTTTG 1200 chr17ENST00000603197.5 CCL7CCGGCATAAAGCCTTGGATGTATATCTCGAGATATACATCCAAGGCTTTATGTTTTTG 1201 chr17ENST00000378569.2 CCL7CCGGGCTGCTACAGATTTATCAATACTCGAGTATTGATAAATCTGTAGCAGCTTTTTG 1202 chr17ENST00000378569.2 CCL7CCGGTCTAAGGAATATGAGCTTTATCTCGAGATAAAGCTCATATTCCTTAGATTTTTG 1203 chr17ENST00000378569.2 CCL8CCGGGCTGCTTTAACGTGATCAATACTCGAGTATTGATCACGTTAAAGCAGCTTTTTG 1204 chr17ENST00000394620.1 CCL8CCGGCAGGTGCAGTGTGACATTATTCTCGAGAATAATGTCACACTGCACCTGTTTTTG 1205 chr17ENST00000394620.1 CCL8CCGGTTGTACTGCTGTTGTTGAAATCTCGAGATTTCAACAACAGCAGTACAATTTTTG 1206 chr17ENST00000394620.1 CCR1CCGGATTCTGCTAAGACGACCAAATCTCGAGATTTGGTCGTCTTAGCAGAATTTTTTG 1207 chr3ENST00000296140.3 CCR1CCGGATCTGCTACACAGGGATTATACTCGAGTATAATCCCTGTGTAGCAGATTTTTTG 1208 chr3ENST00000296140.3 CCR1CCGGCCTCTGTACTCCTTGGTATTTCTCGAGAAATACCAAGGAGTACAGAGGTTTTTG 1209 chr3ENST00000296140.3 CCR2CCGGACGGTGCTCCCTGTCATAAATCTCGAGATTTATGACAGGGAGCACCGTTTTTTG 1210 chr3ENST00000445132.2 CCR2CCGGCTTCTGGACTCCCTATAATATCTCGAGATATTATAGGGAGTCCAGAAGTTTTTG 1211 chr3ENST00000445132.2 CCR2CCGGGCTGTATCACATCGGTTATTTCTCGAGAAATAACCGATGTGATACAGCTTTTTG 1212 chr3ENST00000445132.2 CCR3CCGGATACAGGAGGCTCCGAATTATCTCGAGATAATTCGGAGCCTCCTGTATTTTTTG 1213 chr3ENST00000357422.2 CCR3CCGGCCCAGAGGATACAGTATATAGCTCGAGCTATATACTGTATCCTCTGGGTTTTTG 1214 chr3ENST00000357422.2 CCR3CCGGTAGCAGCTCTTCCTGAATTTACTCGAGTAAATTCAGGAAGAGCTGCTATTTTTG 1215 chr3ENST00000357422.2 CCR5CCGGACTCTTGACAGGGCTCTATTTCTCGAGAAATAGAGCCCTGTCAAGAGTTTTTTG 1216 chr3ENST00000292303.4 CCR5CCGGCGAGCGAGCAAGCTCAGTTTACTCGAGTAAACTGAGCTTGCTCGCTCGTTTTTG 1217 chr3ENST00000292303.4 CCR5CCGGTCCATACAGTCAGTATCAATTCTCGAGAATTGATACTGACTGTATGGATTTTTG 1218 chr3ENST00000292303.4 CCR6CCGGGGTCTATGACAGACGTCTATCCTCGAGGATAGACGTCTGTCATAGACCTTTTTG 1219 chr6ENST00000341935.9 CCR6CCGGCGACTCCAGTGAAGATTATTTCTCGAGAAATAATCTTCACTGGAGTCGTTTTTG 1220 chr6ENST00000341935.9 CCR6CCGGTCGACTCCAGTGAAGATTATTCTCGAGAATAATCTTCACTGGAGTCGATTTTTG 1221 chr6ENST00000341935.9 CCR7CCGGGATGAGGTCACGGACGATTACCTCGAGGTAATCGTCCGTGACCTCATCTTTTTG 1222 chr17ENST00000246657.2 CCR7CCGGGCTGGTCGTGTTGACCTATATCTCGAGATATAGGTCAACACGACCAGCTTTTTG 1223 chr17ENST00000246657.2 CCR7CCGGCGTGTTGACCTATATCTATTTCTCGAGAAATAGATATAGGTCAACACGTTTTTG 1224 chr17ENST00000246657.2 CD109CCGGGCCGATCCTTACATAGATATTCTCGAGAATATCTATGTAAGGATCGGCTTTTTG 1225 chr6ENST00000287097.5 CD109CCGGCCCGGAGGAAATGTGACTATTCTCGAGAATAGTCACATTTCCTCCGGGTTTTTG 1226 chr6ENST00000287097.5 CD109CCGGCCGCTTATCATTTGAGACCAACTCGAGTTGGTCTCAAATGATAAGCGGTTTTTG 1227 chr6ENST00000287097.5 CD27CCGGCTTACCTTATGTCAGTGAGATCTCGAGATCTCACTGACATAAGGTAAGTTTTTG 1228 chr12ENST00000266557.3 CD27CCGGGCACTGTAACTCTGGTCTTCTCTCGAGAGAAGACCAGAGTTACAGTGCTTTTTG 1229 chr12ENST00000266557.3 CD27CCGGCCACCCACTTACCTTATGTCACTCGAGTGACATAAGGTAAGTGGGTGGTTTTTG 1230 chr12ENST00000266557.3 CD27CCGGGCCAGATGTGTGAGCCAGGAACTCGAGTTCCTGGCTCACACATCTGGCTTTTTG 1231 chr12ENST00000266557.3 CD28CCGGCCTCCAGAATTTGTATGTTAACTCGAGTTAACATACAAATTCTGGAGGTTTTTG 1232 ch2ENST00000458610.6 CD28CCGGCAACCTTAGCTGCAAGTATTCCTCGAGGAATACTTGCAGCTAAGGTTGTTTTTG 1233 ch2ENST00000458610.6 CD28CCGGTGGAGTCCTGGCTTGCTATAGCTCGAGCTATAGCAAGCCAGGACTCCATTTTTG 1234 ch2ENST00000458610.6 CD28CCGGCCTCCTCCTTACCTAGACAATCTCGAGATTGTCTAGGTAAGGAGGAGGTTTTTG 1235 ch2ENST00000458610.6 CD36CCGGAGAACCTATTGATGGATTAAACTCGAGTTTAATCCATCAATAGGTTCTTTTTTG 1236 chr7ENST00000309881.11 CD36CCGGGCCATAATCGACACATATAAACTCGAGTTTATATGTGTCGATTATGGCTTTTTG 1237 chr7ENST00000309881.11 CD36CCGGACGGCTGCAGGTCAACCTATTCTCGAGAATAGGTTGACCTGCAGCCGTTTTTTG 1238 chr7ENST00000309881.11 CD4CCGGCCTGATCATCAAGAATCTTAACTCGAGTTAAGATTCTTGATGATCAGGTTTTTG 1239 chr12ENST00000011653.8 CD4CCGGAGAGCGGATGTCTCAGATCAACTCGAGTTGATCTGAGACATCCGCTCTTTTTTG 1240 chr12ENST00000011653.8 CD4CCGGCCACTCGCCTTTACAGTTGAACTCGAGTTCAACTGTAAAGGCGAGTGGTTTTTG 1241 chr12ENST00000011653.8 CD40LGCCGGGGGAAACAGCTGACCGTTAAACTCGAGTTTAACGGTCAGCTGTTTCCCTTTTTG 1242 chrXENST00000370629.6 CD40LGCCGGTTCGAGTCAAGCTCCATTTATCTCGAGATAAATGGAGCTTGACTCGAATTTTTG 1243 chrXENST00000370629.6 CD40LGCCGGTGACGCTGGGAGTCTTCATAACTCGAGTTATGAAGACTCCCAGCGTCATTTTTG 1244 chrXENST00000370629.6 CD70CCGGCCATCGTGATGGCATCTACATCTCGAGATGTAGATGCCATCACGATGGTTTTTG 1245 chr19ENST00000245903.3 CD70CCGGCAGCTACGTATCCATCGTGATCTCGAGATCACGATGGATACGTAGCTGTTTTTG 1246 chr19ENST00000245903.3 CD70CCGGCCAACCTCACTGGGACACTTTCTCGAGAAAGTGTCCCAGTGAGGTTGGTTTTTG 1247 chr19ENST00000245903.3 CD74CCGGCAAGTCGGAACAGCAGATAACCTCGAGGTTATCTGCTGTTCCGACTTGTTTTTG 1248 chr5ENST00000009530.11 CD74CCGGGAGAACCTGAGACACCTTAAGCTCGAGCTTAAGGTGTCTCAGGTTCTCTTTTTG 1249 chr5ENST00000009530.11 CD74CCGGCCACACAGCTACAGCTTTCTTCTCGAGAAGAAAGCTGTAGCTGTGTGGTTTTTG 1250 chr5ENST00000009530.11 CD8ACCGGGCTGGACTTCGCCTGTGATATCTCGAGATATCACAGGCGAAGTCCAGCTTTTTG 1251 ch2ENST00000409511.6 CD8ACCGGGTGTATTCATTCTCATGATTACTCGAGTAATCATGAGAATGAATACACTTTTTG 1252 ch2ENST00000409511.6 CD8ACCGGCCAGAGACAGCTTGATCAAAGCTCGAGCTTTGATCAAGCTGTCTCTGGTTTTTG 1253 ch2ENST00000409511.6 CD8ACCGGCCTTCTCCTGTCACTGGTTATCTCGAGATAACCAGTGACAGGAGAAGGTTTTTG 1254 ch2ENST00000409511.6 CER1CCGGGAGAAGATGCTGTCCAGATTTCTCGAGAAATCTGGACAGCATCTTCTCTTTTTG 1255 chr9ENST00000380911.3 CER1CCGGCCAGCCGATAGATGGAATGAACTCGAGTTCATTCCATCTATCGGCTGGTTTTTG 1256 chr9ENST00000380911.3 CER1CCGGCAAGAAATTCTGGCACCACTTCTCGAGAAGTGGTGCCAGAATTTCTTGTTTTTG 1257 chr9ENST00000380911.3 CHRDCCGGACGTCCTGCAAAGTGTCCTTTCTCGAGAAAGGACACTTTGCAGGACGTTTTTTG 1258 chr3ENST00000204604.5 CHRDCCGGACTGATCCAGAGCTGGAGAAACTCGAGTTTCTCCAGCTCTGGATCAGTTTTTTG 1259 chr3ENST00000204604.5 CHRDCCGGCGGCTGCTGAAGGGATTCTATCTCGAGATAGAATCCCTTCAGCAGCCGTTTTTG 1260 chr3ENST00000204604.5 CKLFCCGGCCTTTGCTTGTGTTTGCACTTCTCGAGAAGTGCAAACACAAGCAAAGGTTTTTG 1261 chr16ENST00000264001.8 CKLFCCGGCCCTGAACCATATATTGTTATCTCGAGATAACAATATATGGTTCAGGGTTTTTG 1262 chr16ENST00000264001.8 CKLFCCGGTGGATTTGAAGTCACCGTTATCTCGAGATAACGGTGACTTCAAATCCATTTTTG 1263 chr16ENST00000264001.8 CLCF1CCGGGAAACAAACATGGTGGCAATTCTCGAGAATTGCCACCATGTTTGTTTCTTTTTG 1264 chr11ENST00000312438.7 CLCF1CCGGCCACAGGATTTCCTGAAAGTTCTCGAGAACTTTCAGGAAATCCTGTGGTTTTTG 1265 chr11ENST00000312438.7 CLCF1CCGGCATGGTGGCAATTCTACACAACTCGAGTTGTGTAGAATTGCCACCATGTTTTTG 1266 chr11ENST00000312438.7 CMTM1CCGGCACCACTTGCTGACCTATTTACTCGAGTAAATAGGTCAGCAAGTGGTGTTTTTG 1267 chr16ENST00000379500.6 CMTM1CCGGGACCTATTTACATTGGCCCTTCTCGAGAAGGGCCAATGTAAATAGGTCTTTTTG 1268 chr16ENST00000379500.6 CMTM1CCGGGCTGTGTTCCTTTCAGTAGTTCTCGAGAACTACTGAAAGGAACACAGCTTTTTG 1269 chr16ENST00000379500.6 CMTM2CCGGGTAAGGAGCCATCGGACAAACCTCGAGGTTTGTCCGATGGCTCCTTACTTTTTG 1270 chr16ENST00000268595.2 CMTM2CCGGCTTACTTGCTGTGATCCTTATCTCGAGATAAGGATCACAGCAAGTAAGTTTTTG 1271 chr16ENST00000268595.2 CMTM2CCGGCATAAGGAGCCATCGGACAAACTCGAGTTTGTCCGATGGCTCCTTATGTTTTTG 1272 chr16ENST00000268595.2 CMTM3CCGGCATCGTGTTTGCAACTGATTTCTCGAGAAATCAGTTGCAAACACGATGTTTTTG 1273 chr16ENST00000361909.8 CMTM3CCGGGCTTCTTAACAGATGGCATTTCTCGAGAAATGCCATCTGTTAAGAAGCTTTTTG 1274 chr16ENST00000361909.8 CMTM3CCGGGCTTCTTAACAGATGGCATTTCTCGAGAAATGCCATCTGTTAAGAAGCTTTTTG 1275 chr16ENST00000361909.8 CMTM4CCGGCAACTGGAATCTGACAGATTTCTCGAGAAATCTGTCAGATTCCAGTTGTTTTTG 1276 chr16ENST00000394106.6 CMTM4CCGGGACTGGCGTCTTGCTGATTATCTCGAGATAATCAGCAAGACGCCAGTCTTTTTG 1277 chr16ENST00000394106.6 CMTM4CCGGGCAGAAATTGCTGCCGTGATACTCGAGTATCACGGCAGCAATTTCTGCTTTTTG 1278 chr16ENST00000394106.6 CMTM5CCGGCAAGATCTACCGGACTGAGATCTCGAGATCTCAGTCCGGTAGATCTTGTTTTTG 1279 chr14ENST00000359320.7 CMTM5CCGGCCTGACCCTCATCATCTTCATCTCGAGATGAAGATGATGAGGGTCAGGTTTTTG 1280 chr14ENST00000359320.7 CMTM5CCGGCTTCCTCTATGCCACCCAGTACTCGAGTACTGGGTGGCATAGAGGAAGTTTTTG 1281 chr14ENST00000359320.7 CMTM6CCGGGCCCTCACTGAGCCACTTAATCTCGAGATTAAGTGGCTCAGTGAGGGCTTTTTG 1282 chr3ENST00000205636.3 CMTM6CCGGCCCAAGACAGTGAAAGTAATTCTCGAGAATTACTTTCACTGTCTTGGGTTTTTG 1283 chr3ENST00000205636.3 CMTM6CCGGCCCAAGACAGTGAAAGTAATTCTCGAGAATTACTTTCACTGTCTTGGGTTTTTG 1284 chr3ENST00000205636.3 CMTM7CCGGCTGCTGAAAGTGGCGCAAATGCTCGAGCATTTGCGCCACTTTCAGCAGTTTTTG 1285 chr3ENST00000334983.9 CMTM7CCGGCAAAGCCCTGTCCTAATTTATCTCGAGATAAATTAGGACAGGGCTTTGTTTTTG 1286 chr3ENST00000334983.9 CMTM7CCGGCCTGTCGATCTTTGGTTTCATCTCGAGATGAAACCAAAGATCGACAGGTTTTTG 1287 chr3ENST00000334983.9 CMTM8CCGGTGCTGGTATGGACGCTTATTGCTCGAGCAATAAGCGTCCATACCAGCATTTTTG 1288 chr3ENST00000307526.3 CMTM8CCGGGCAAAGTGTTGTAGCTTATAACTCGAGTTATAAGCTACAACACTTTGCTTTTTG 1289 chr3ENST00000307526.3 CMTM8CCGGATATTCCCAGAGAATTGTATTCTCGAGAATACAATTCTCTGGGAATATTTTTTG 1290 chr3ENST00000307526.3 CNTFCCGGGTAACCTCTACAGGCATTTAACTCGAGTTAAATGCCTGTAGAGGTTACTTTTTG 1291 chr11ENST00000361987.5 CNTFCCGGGTTGAAGGACTACAGGTATTTCTCGAGAAATACCTGTAGTCCTTCAACTTTTTG 1292 chr11ENST00000361987.5 CNTFCCGGGGTGACTTCCATCAAGCTATACTCGAGTATAGCTTGATGGAAGTCACCTTTTTG 1293 chr11ENST00000361987.5 CNTFRCCGGCATTCTCTTCAGACACAATTTCTCGAGAAATTGTGTCTGAAGAGAATGTTTTTG 1294 chr9ENST00000351266.8 CNTFRCCGGGCATTCTCTTCAGACACAATTCTCGAGAATTGTGTCTGAAGAGAATGCTTTTTG 1295 chr9ENST00000351266.8 CNTFRCCGGGCCGGGAAGGAGTACATTATCCTCGAGGATAATGTACTCCTTCCCGGCTTTTTG 1296 chr9ENST00000351266.8 COPS5CCGGCTAAGGATCACCATTACTTTACTCGAGTAAAGTAATGGTGATCCTTAGTTTTTG 1297 chr8ENST00000357849.8 COPS5CCGGCCAGACTATTCCACTTAATAACTCGAGTTATTAAGTGGAATAGTCTGGTTTTTG 1298 chr8ENST00000357849.8 COPS5CCGGCAGTCTCTGAGAAGTACTTTACTCGAGTAAAGTACTTCTCAGAGACTGTTTTTG 1299 chr8ENST00000357849.8 CRLF1CCGGCGATGTACTCACGCTGGATATCTCGAGATATCCAGCGTGAGTACATCGTTTTTG 1300 chr19ENST00000392386.7 CRLF1CCGGCGATGTACTCACGCTGGATATCTCGAGATATCCAGCGTGAGTACATCGTTTTTG 1301 chr19ENST00000392386.7 CRLF1CCGGCCCAGAGAAACCCGTCAACATCTCGAGATGTTGACGGGTTTCTCTGGGTTTTTG 1302 chr19ENST00000392386.7 CSF1CCGGTCTCCTGGTACAAGACATAATCTCGAGATTATGTCTTGTACCAGGAGATTTTTG 1303 chr1ENST00000329608.10 CSF1CCGGGTCGGCCTGATTTCCCGTAAACTCGAGTTTACGGGAAATCAGGCCGACTTTTTG 1304 chr1ENST00000329608.10 CSF1CCGGTTGACAAGGACTGGAATATTTCTCGAGAAATATTCCAGTCCTTGTCAATTTTTG 1305 chr1ENST00000329608.10 CSF1RCCGGGTGAACAGCAAGTTCTATAAACTCGAGTTTATAGAACTTGCTGTTCACTTTTTG 1306 chr5ENST00000286301.7 CSF1RCCGGACAGGAGAGAGCGGGACTATACTCGAGTATAGTCCCGCTCTCTCCTGTTTTTTG 1307 chr5ENST00000286301.7 CSF1RCCGGGCTGCTATTGTACAAGTATAACTCGAGTTATACTTGTACAATAGCAGCTTTTTG 1308 chr5ENST00000286301.7 CSF2CCGGGGAGCTGCTCTCTCATGAAACCTCGAGGTTTCATGAGAGAGCAGCTCCTTTTTG 1309 chr5ENST00000296871.3 CSF2CCGGCCCAGATTATCACCTTTGAAACTCGAGTTTCAAAGGTGATAATCTGGGTTTTTG 1310 chr5ENST00000296871.3 CSF2CCGGGAAGTCATCTCAGAAATGTTTCTCGAGAAACATTTCTGAGATGACTTCTTTTTG 1311 chr5ENST00000296871.3 CSF3CCGGGTCTATTTAAGCCTCATATTTCTCGAGAAATATGAGGCTTAAATAGACTTTTTG 1312 chr17ENST00000225474.6 CSF3CCGGGATAGGTAAATACCAAGTATTCTCGAGAATACTTGGTATTTACCTATCTTTTTG 1313 chr17ENST00000225474.6 CSF3CCGGGCTTAGAGCAAGTGAGGAAGACTCGAGTCTTCCTCACTTGCTCTAAGCTTTTTG 1314 chr17ENST00000225474.6 CSF3RCCGGCAGCCAGGCCTGCACATAAATCTCGAGATTTATGTGCAGGCCTGGCTGTTTTTG 1315 chr1ENST00000361632.8 CSF3RCCGGCTATGCCTACTCTCAAGAAATCTCGAGATTTCTTGAGAGTAGGCATAGTTTTTG 1316 chr1ENST00000361632.8 CSF3RCCGGCCAGCTTCACTCTGAAGAGTTCTCGAGAACTCTTCAGAGTGAAGCTGGTTTTTG 1317 chr1ENST00000361632.8 CTF1CCGGGAGCAGCTGCTCCAGGAATATCTCGAGATATTCCTGGAGCAGCTGCTCTTTTTG 1318 chr16ENST00000279804.2 CTF1CCGGGTCTCTCCTTCCGCTTCTTTGCTCGAGCAAAGAAGCGGAAGGAGAGACTTTTTG 1319 chr16ENST00000279804.2 CTF1CCGGTGTCTGTCTGTCTGCTCTTAGCTCGAGCTAAGAGCAGACAGACAGACATTTTTG 1320 chr16ENST00000279804.2 CX3CL1CCGGCCCGGAGCTGTGGTAGTAATTCTCGAGAATTACTACCACAGCTCCGGGTTTTTG 1321 chr16ENST00000006053.6 CX3CL1CCGGGCTGCTGCCCTAACTCGAAATCTCGAGATTTCGAGTTAGGGCAGCAGCTTTTTG 1322 chr16ENST00000006053.6 CX3CL1CCGGCGGTGTGACGAAATGCAACATCTCGAGATGTTGCATTTCGTCACACCGTTTTTG 1323 chr16ENST00000006053.6 CX3CR1CCGGTGGCCTGTGTCTAGTTGTTTGCTCGAGCAAACAACTAGACACAGGCCATTTTTG 1324 chr3ENST00000399220.2 CX3CR1CCGGTGGGATCCCTCATCCTCATACCTCGAGGTATGAGGATGAGGGATCCCATTTTTG 1325 chr3ENST00000399220.2 CX3CR1CCGGGCTTTGCTCATCCACTATCAACTCGAGTTGATAGTGGATGAGCAAAGCTTTTTG 1326 chr3ENST00000399220.2 CXCL1CCGGACCTGCACACTGTCCTATTATCTCGAGATAATAGGACAGTGTGCAGGTTTTTTG 1327 chr4ENST00000395761.3 CXCL1CCGGAGATGCTGAACAGTGACAAATCTCGAGATTTGTCACTGTTCAGCATCTTTTTTG 1328 chr4ENST00000395761.3 CXCL1CCGGGTTCTCCAGTCATTATGTTAACTCGAGTTAACATAATGACTGGAGAACTTTTTG 1329 chr4ENST00000395761.3 CXCL10CCGGGTATATGTCAAGCCATAATTGCTCGAGCAATTATGGCTTGACATATACTTTTTG 1330 chr4ENST00000306602.2 CXCL10CCGGACTCTACCCTGGCACTATAATCTCGAGATTATAGTGCCAGGGTAGAGTTTTTTG 1331 chr4ENST00000306602.2 CXCL10CCGGCCTGTTAATCCAAGGTCTTTACTCGAGTAAAGACCTTGGATTAACAGGTTTTTG 1332 chr4ENST00000306602.2 CXCL11CCGGGCTGGTTACCATCGGAGTTTACTCGAGTAAACTCCGATGGTAACCAGCTTTTTG 1333 chr4ENST00000306621.7 CXCL11CCGGGCAGTGAAAGTGGCAGATATTCTCGAGAATATCTGCCACTTTCACTGCTTTTTG 1334 chr4ENST00000306621.7 CXCL11CCGGGAAGCAAGCAAGGCTTATAATCTCGAGATTATAAGCCTTGCTTGCTTCTTTTTG 1335 chr4ENST00000306621.7 CXCL12CCGGGCTTAGACTAAGGCCATTATTCTCGAGAATAATGGCCTTAGTCTAAGCTTTTTG 1336 chr10ENST00000343575.10 CXCL12CCGGCTCTCACTATACCAGTATAATCTCGAGATTATACTGGTATAGTGAGAGTTTTTG 1337 chr10ENST00000343575.10 CXCL12CCGGCAAACTGTGCCCTTCAGATTGCTCGAGCAATCTGAAGGGCACAGTTTGTTTTTG 1338 chr10ENST00000343575.10 CXCL13CCGGGATTCCCTGATGCTGATATTTCTCGAGAAATATCAGCATCAGGGAATCTTTTTG 1339 chr4ENST00000286758.4 CXCL13CCGGAGGAATCCATGTAGTAGATATCTCGAGATATCTACTACATGGATTCCTTTTTTG 1340 chr4ENST00000286758.4 CXCL13CCGGAGGTGTTCTGGAGGTCTATTACTCGAGTAATAGACCTCCAGAACACCTTTTTTG 1341 chr4ENST00000286758.4 CXCL14CCGGATTTGTCCATACGTCACTATACTCGAGTATAGTGACGTATGGACAAATTTTTTG 1342 chr5ENST00000337225.5 CXCL14CCGGCAAAGGACTTTGCAGATTAAACTCGAGTTTAATCTGCAAAGTCCTTTGTTTTTG 1343 chr5ENST00000337225.5 CXCL14CCGGGCGCAGGGTCTACGAAGAATACTCGAGTATTCTTCGTAGACCCTGCGCTTTTTG 1344 chr5ENST00000337225.5 CXCL16CCGGACATCCAGCCTACACGTATTTCTCGAGAAATACGTGTAGGCTGGATGTTTTTTG 1345 chr17ENST00000293778.10 CXCL16CCGGTCTGAAGGTGCGAGGATTATACTCGAGTATAATCCTCGCACCTTCAGATTTTTG 1346 chr17ENST00000293778.10 CXCL16CCGGTCCAGATCTGCCGGTTCATTACTCGAGTAATGAACCGGCAGATCTGGATTTTTG 1347 chr17ENST00000293778.10 CXCL17CCGGGCGCCCACTCTTCCAATTAAACTCGAGTTTAATTGGAAGAGTGGGCGCTTTTTG 1348 chr19ENST00000601181.5 CXCL17CCGGTCCAGAGCCTGCCAGCAATTTCTCGAGAAATTGCTGGCAGGCTCTGGATTTTTG 1349 chr19ENST00000601181.5 CXCL17CCGGAGAATGTGAGTGCAAAGATTGCTCGAGCAATCTTTGCACTCACATTCTTTTTTG 1350 chr19ENST00000601181.5 CXCL2CCGGCTTGCACACTCTCCCATTATACTCGAGTATAATGGGAGAGTGTGCAAGTTTTTG 1351 chr4ENST00000508487.2 CXCL2CCGGGCAGATATTCTCTAGTCATTTCTCGAGAAATGACTAGAGAATATCTGCTTTTTG 1352 chr4ENST00000508487.2 CXCL2CCGGATTTCTTCGTGATGACATATCCTCGAGGATATGTCATCACGAAGAAATTTTTTG 1353 chr4ENST00000508487.2 CXCL3CCGGTTACGAGGGTTCTACTTATTTCTCGAGAAATAAGTAGAACCCTCGTAATTTTTG 1354 chr4ENST00000296026.4 CXCL3CCGGATTTAGTGGGAGACCATAATGCTCGAGCATTATGGTCTCCCACTAAATTTTTTG 1355 chr4ENST00000296026.4 CXCL3CCGGACTGACAGGAGAGAAGTAAGACTCGAGTCTTACTTCTCTCCTGTCAGTTTTTTG 1356 chr4ENST00000296026.4 CXCL5CCGGTGAATTGTAGGTGACTATTATCTCGAGATAATAGTCACCTACAATTCATTTTTG 1357 chr4ENST00000296027.4 CXCL5CCGGCAGACCACGCAAGGAGTTCATCTCGAGATGAACTCCTTGCGTGGTCTGTTTTTG 1358 chr4ENST00000296027.4 CXCL5CCGGCGGGAAGGAAATTTGTCTTGACTCGAGTCAAGACAAATTTCCTTCCCGTTTTTG 1359 chr4ENST00000296027.4 CXCL6CCGGTTTACCCTAGGATGCTATTTACTCGAGTAAATAGCATCCTAGGGTAAATTTTTG 1360 chr4ENST00000226317.9 CXCL6CCGGGTTGCACTTGTTTACGCGTTACTCGAGTAACGCGTAAACAAGTGCAACTTTTTG 1361 chr4ENST00000226317.9 CXCL6CCGGGCTGTGGATTTCGTATGGAAACTCGAGTTTCCATACGAAATCCACAGCTTTTTG 1362 chr4ENST00000226317.9 CXCL8CCGGTGCGCCAACACAGAAATTATTCTCGAGAATAATTTCTGTGTTGGCGCATTTTTG 1363 chr4ENST00000307407.7 CXCL8CCGGCAAGAGAATATCCGAACTTTACTCGAGTAAAGTTCGGATATTCTCTTGTTTTTG 1364 chr4ENST00000307407.7 CXCL8CCGGTGCACGGGAGAATATACAAATCTCGAGATTTGTATATTCTCCCGTGCATTTTTG 1365 chr4ENST00000307407.7 CXCL9CCGGCCAAAGGAGGATGGCATATAACTCGAGTTATATGCCATCCTCCTTTGGTTTTTG 1366 chr4ENST00000264888.5 CXCL9CCGGCCAAACGTTAAGAATTGTTAACTCGAGTTAACAATTCTTAACGTTTGGTTTTTG 1367 chr4ENST00000264888.5 CXCL9CCGGGATGTGAAGGAACTGATTAAACTCGAGTTTAATCAGTTCCTTCACATCTTTTTG 1368 chr4ENST00000264888.5 CXCR1CCGGCTTGGCACGTCATCGTGTTACCTCGAGGTAACACGATGACGTGCCAAGTTTTTG 1369 chr2ENST00000295683.2 CXCR1CCGGACCCACTAACTGGCTAATTAGCTCGAGCTAATTAGCCAGTTAGTGGGTTTTTTG 1370 chr2ENST00000295683.2 CXCR1CCGGGAGACACTCAACAAGTATGTTCTCGAGAACATACTTGTTGAGTGTCTCTTTTTG 1371 chr2ENST00000295683.2 CXCR2CCGGGAAGCGCTACTTGGTCAAATTCTCGAGAATTTGACCAAGTAGCGCTTCTTTTTG 1372 chr2ENST00000318507.6 CXCR2CCGGGCCACTAAATTGACACTTAAACTCGAGTTTAAGTGTCAATTTAGTGGCTTTTTG 1373 chr2ENST00000318507.6 CXCR2CCGGCCCTGGAAATCAACAAGTATTCTCGAGAATACTTGTTGATTTCCAGGGTTTTTG 1374 chr2ENST00000318507.6 CXCR3CCGGCCTTCTCATTTGGAAACTAAACTCGAGTTTAGTTTCCAAATGAGAAGGTTTTTG 1375 chrXENST00000373693.3 CXCR3CCGGCGCTACCTGAACATAGTTCATCTCGAGATGAACTATGTTCAGGTAGCGTTTTTG 1376 chrXENST00000373693.3 CXCR3CCGGGAGTACAAGGCATGGCGTAGACTCGAGTCTACGCCATGCCTTGTACTCTTTTTG 1377 chrXENST00000373693.3 CXCR4CCGGCTATTCCCGACTTCATCTTTGCTCGAGCAAAGATGAAGTCGGGAATAGTTTTTG 1378 chr2ENST00000409817.1 CXCR4CCGGGCGTGTAGTGAATCACGTAAACTCGAGTTTACGTGATTCACTACACGCTTTTTG 1379 chr2ENST00000409817.1 CXCR4CCGGCCTGTTCTTAAGACGTGATTTCTCGAGAAATCACGTCTTAAGAACAGGTTTTTG 1380 chr2ENST00000409817.1 CXCR6CCGGGCTTGCTCATCTGGGTGATATCTCGAGATATCACCCAGATGAGCAAGCTTTTTG 1381 chr3ENST00000304552.4 CXCR6CCGGTACTGGGCATCTACACTATTACTCGAGTAATAGTGTAGATGCCCAGTATTTTTG 1382 chr3ENST00000304552.4 CXCR6CCGGTTATCTATGGCAATGTCTTTACTCGAGTAAAGACATTGCCATAGATAATTTTTG 1383 chr3ENST00000304552.4 EBI3CCGGTGAACTGTCACTGTGAGATATCTCGAGATATCTCACAGTGACAGTTCATTTTTG 1384 chr19ENST00000221847.5 EBI3CCGGATGTACTACTCTCTCCTTTACCTCGAGGTAAAGGAGAGAGTAGTACATTTTTTG 1385 chr19ENST00000221847.5 EBI3CCGGGCCTTTCATAACAGAGCACATCTCGAGATGTGCTCTGTTATGAAAGGCTTTTTG 1386 chr19ENST00000221847.5 EDN1CCGGCCATGAGAAACAGCGTCAAATCTCGAGATTTGACGCTGTTTCTCATGGTTTTTG 1387 chr6ENST00000379375.5 EDN1CCGGGCTCGTCCCTGATGGATAAAGCTCGAGCTTTATCCATCAGGGACGAGCTTTTTG 1388 chr6ENST00000379375.5 EDN1CCGGAGACAAGAAGTGCTGGAATTTCTCGAGAAATTCCAGCACTTCTTGTCTTTTTTG 1389 chr6ENST00000379375.5 ELANECCGGGCACTGCGTGGCGAATGTAAACTCGAGTTTACATTCGCCACGCAGTGCTTTTTG 1390 chr19ENST00000263621.1 ELANECCGGTGCTCAACGACATCGTGATTCCTCGAGGAATCACGATGTCGTTGAGCATTTTTG 1391 chr19ENST00000263621.1 ELANECCGGCAACGGGCTAATCCACGGAATCTCGAGATTCCGTGGATTAGCCCGTTGTTTTTG 1392 chr19ENST00000263621.1 ENGCCGGGCAGGTGTCAGCAAGTATGATCTCGAGATCATACTTGCTGACACCTGCTTTTTG 1393 chr9ENST00000344849.4 ENGCCGGGCAGGTGTCAGCAAGTATGATCTCGAGATCATACTTGCTGACACCTGCTTTTTG 1394 chr9ENST00000344849.4 ENGCCGGGTCTTGCAGAAACAGTCCATTCTCGAGAATGGACTGTTTCTGCAAGACTTTTTG 1395 chr9ENST00000344849.4 EPOCCGGCCCAGACACCAAAGTTAATTTCTCGAGAAATTAACTTTGGTGTCTGGGTTTTTG 1396 chr7ENST00000252723.2 EPOCCGGTGCAGCTGCATGTGGATAAAGCTCGAGCTTTATCCACATGCAGCTGCATTTTTG 1397 chr7ENST00000252723.2 EPOCCGGAGAGCAACTCTGAGATCTAAGCTCGAGCTTAGATCTCAGAGTTGCTCTTTTTTG 1398 chr7ENST00000252723.2 FAM3BCCGGTTGGAACTCCCTTCCGAAATTCTCGAGAATTTCGGAAGGGAGTTCCAATTTTTG 1399 chr21ENST00000357985.6 FAM3BCCGGTAAATCCAACAGCCCATATTTCTCGAGAAATATGGGCTGTTGGATTTATTTTTG 1400 chr21ENST00000357985.6 FAM3BCCGGTCAGGTCTAGCTGGGTATTTACTCGAGTAAATACCCAGCTAGACCTGATTTTTG 1401 chr21ENST00000357985.6 FAM3CCCGGCTTGGTGTGTGCATGAGTATTCTCGAGAATACTCATGCACACACCAAGTTTTTG 1402 chr7ENST00000359943.7 FAM3CCCGGGAGGAGATGTGGCACCATTTACTCGAGTAAATGGTGCCACATCTCCTCTTTTTG 1403 chr7ENST00000359943.7 FAM3CCCGGGCCATACAAGATGGAACAATACTCGAGTATTGTTCCATCTTGTATGGCTTTTTG 1404 chr7ENST00000359943.7 FAM3DCCGGCACCTAGTGAAATTCCTTAAACTCGAGTTTAAGGAATTTCACTAGGTGTTTTTG 1405 chr3ENST00000358781.6 FAM3DCCGGCATGTACTCTGGAGATGTTATCTCGAGATAACATCTCCAGAGTACATGTTTTTG 1406 chr3ENST00000358781.6 FAM3DCCGGCAATGTGGGCAGAGGCCTAAACTCGAGTTTAGGCCTCTGCCCACATTGTTTTTG 1407 chr3ENST00000358781.6 FASCCGGGCGTATGACACATTGATTAAACTCGAGTTTAATCAATGTGTCATACGCTTTTTG 1408 chr10ENST00000355740.6 FASCCGGCCTGAAACAGTGGCAATAAATCTCGAGATTTATTGCCACTGTTTCAGGTTTTTG 1409 chr10ENST00000355740.6 FASCCGGCTATCATCCTCAAGGACATTACTCGAGTAATGTCCTTGAGGATGATAGTTTTTG 1410 chr10ENST00000355740.6 FASLGCCGGGACTAGAGGCTTGCATAATAACTCGAGTTATTATGCAAGCCTCTAGTCTTTTTG 1411 chr1ENST00000367721.2 FASLGCCGGACTGGGCTGTACTTTGTATATCTCGAGATATACAAAGTACAGCCCAGTTTTTTG 1412 chr1ENST00000367721.2 FASLGCCGGTGAGCTCTCTCTGGTCAATTTCTCGAGAAATTGACCAGAGAGAGCTCATTTTTG 1413 chr1ENST00000367721.2 FGF2CCGGGAAACGAACTGGGCAGTATAACTCGAGTTATACTGCCCAGTTCGTTTCTTTTTG 1414 chr4ENST00000608478.1 FGF2CCGGTATAGCTCAGTTTGGATAATTCTCGAGAATTATCCAAACTGAGCTATATTTTTG 1415 chr4ENST00000608478.1 FGF2CCGGTGAACGATTGGAATCTAATAACTCGAGTTATTAGATTCCAATCGTTCATTTTTG 1416 chr4ENST00000608478.1 FLT3LGCCGGCTGTCTGACTACCTGCTTCAACTCGAGTTGAAGCAGGTAGTCAGACAGTTTTTG 1417 chr19ENST00000594009.5 FLT3LGCCGGTCCTCCGACTTCGCTGTCAAACTCGAGTTTGACAGCGAAGTCGGAGGATTTTTG 1418 chr19ENST00000594009.5 FLT3LGCCGGGCTTCGTCCAGACCAACATCTCTCGAGAGATGTTGGTCTGGACGAAGCTTTTTG 1419 chr19ENST00000594009.5 FOXP3CCGGAGCTGGAGTTCCGCAAGAAACCTCGAGGTTTCTTGCGGAACTCCAGCTTTTTTG 1420 chrXENST00000376207.8 FOXP3CCGGTCCTACCCACTGCTGGCAAATCTCGAGATTTGCCAGCAGTGGGTAGGATTTTTG 1421 chrXENST00000376207.8 FOXP3CCGGTGTCCCTCACTCAACACAAACCTCGAGGTTTGTGTTGAGTGAGGGACATTTTTG 1422 chrXENST00000376207.8 FOXP3CCGGCACACGCATGTTTGCCTTCTTCTCGAGAAGAAGGCAAACATGCGTGTGTTTTTG 1423 chrXENST00000376207.8 FZD4CCGGCGTGTGTGATTGCCTGTTATTCTCGAGAATAACAGGCAATCACACACGTTTTTG 1424 chr11ENST00000531380.1 FZD4CCGGTCTCAGTATGTGCTATAATATCTCGAGATATTATAGCACATACTGAGATTTTTG 1425 chr11ENST00000531380.1 FZD4CCGGTTCTCAGTATGTGCTATAATACTCGAGTATTATAGCACATACTGAGAATTTTTG 1426 chr11ENST00000531380.1 GATA3CCGGAGCCTAAACGCGATGGATATACTCGAGTATATCCATCGCGTTTAGGCTTTTTTG 1427 chr10ENST00000346208.4 GATA3CCGGCCCAAGAACAGCTCGTTTAACCTCGAGGTTAAACGAGCTGTTCTTGGGTTTTTG 1428 chr10ENST00000346208.4 GATA3CCGGGCCAAGAAGTTTAAGGAATATCTCGAGATATTCCTTAAACTTCTTGGCTTTTTG 1429 chr10ENST00000346208.4 GATA3CCGGCCCTGTAATTGTTGTTTGTATCTCGAGATACAAACAACAATTACAGGGTTTTTG 1430 chr10ENST00000346208.4 GBP1CCGGCCAGATGAGTACCTGACATACCTCGAGGTATGTCAGGTACTCATCTGGTTTTTG 1431 chr1ENST00000370473.4 GBP1CCGGCGACGAAAGGCATGTACCATACTCGAGTATGGTACATGCCTTTCGTCGTTTTTG 1432 chr1ENST00000370473.4 GBP1CCGGCGACGAAAGGCATGTACCATACTCGAGTATGGTACATGCCTTTCGTCGTTTTTG 1433 chr1ENST00000370473.4 GDF1CCGGGTTCACCAAGCTCAACATTTACTCGAGTAAATGTTGAGCTTGGTGAACTTTTTG 1434 chr19ENST00000247005.7 GDF1CCGGGAGTTCACCAAGCTCAACATTCTCGAGAATGTTGAGCTTGGTGAACTCTTTTTG 1435 chr19ENST00000247005.7 GDF1CCGGCCCTTATGAACCTCTACTGGTCTCGAGACCAGTAGAGGTTCATAAGGGTTTTTG 1436 chr19ENST00000247005.7 GDF10CCGGCAGGATAATCGTGGTGTAAATCTCGAGATTTACACCACGATTATCCTGTTTTTG 1437 chr10ENST00000580279.1 GDF10CCGGCGACCAGAAGGCCGTGTATTTCTCGAGAAATACACGGCCTTCTGGTCGTTTTTG 1438 chr10ENST00000580279.1 GDF10CCGGCTGTCCGCCAGTGCATCATTACTCGAGTAATGATGCACTGGCGGACAGTTTTTG 1439 chr10ENST00000580279.1 GDF11CCGGCCTGCAGATCTTGCGACTAAACTCGAGTTTAGTCGCAAGATCTGCAGGTTTTTG 1440 chr12ENST00000257868.9 GDF11CCGGGATCGCTGTGGCTGCTCTTAACTCGAGTTAAGAGCAGCCACAGCGATCTTTTTG 1441 chr12ENST00000257868.9 GDF11CCGGGAGATGTAGAGACAGTGATAGCTCGAGCTATCACTGTCTCTACATCTCTTTTTG 1442 chr12ENST00000257868.9 GDF15CCGGAGACTCCAGATTCCGAGAGTTCTCGAGAACTCTCGGAATCTGGAGTCTTTTTTG 1443 chr19ENST00000252809.3 GDF15CCGGGCTCCAGACCTATGATGACTTCTCGAGAAGTCATCATAGGTCTGGAGCTTTTTG 1444 chr19ENST00000252809.3 GDF15CCGGAGAGCTGGGAAGATTCGAACACTCGAGTGTTCGAATCTTCCCAGCTCTTTTTTG 1445 chr19ENST00000252809.3 GDF2CCGGCAACAGGTACACGTCCGATAACTCGAGTTATCGGACGTGTACCTGTTGTTTTTG 1446 chr10ENST00000581492.2 GDF2CCGGTGAAAGGAAGCGTGGTCATTTCTCGAGAAATGACCACGCTTCCTTTCATTTTTG 1447 chr10ENST00000581492.2 GDF2CCGGTATGAAGCCTACGAGTGTAAGCTCGAGCTTACACTCGTAGGCTTCATATTTTTG 1448 chr10ENST00000581492.2 GDF3CCGGACCGTCACCAGCTATTCATTACTCGAGTAATGAATAGCTGGTGACGGTTTTTTG 1449 chr12ENST00000329913.3 GDF3CCGGCTCTCAACAGCTCCAATTATGCTCGAGCATAATTGGAGCTGTTGAGAGTTTTTG 1450 chr12ENST00000329913.3 GDF3CCGGTTGGGCCAGGCAGTCCAATTTCTCGAGAAATTGGACTGCCTGGCCCAATTTTTG 1451 chr12ENST00000329913.3 GDF5CCGGCAACACCATCACCAGCTTTATCTCGAGATAAAGCTGGTGATGGTGTTGTTTTTG 1452 chr20ENST00000374369.7 GDF5CCGGATGAGACTCAGCCCACCATTTCTCGAGAAATGGTGGGCTGAGTCTCATTTTTTG 1453 chr20ENST00000374369.7 GDF5CCGGTGAGTGTGACTTGGGCTAAAGCTCGAGCTTTAGCCCAAGTCACACTCATTTTTG 1454 chr20ENST00000374369.7 GDF6CCGGGACTCCCATCAGCATTCTATACTCGAGTATAGAATGCTGATGGGAGTCTTTTTG 1455 chr8ENST00000287020.6 GDF6CCGGCGAGTACATGCTGTCAATCTACTCGAGTAGATTGACAGCATGTACTCGTTTTTG 1456 chr8ENST00000287020.6 GDF6CCGGCAGTCTTCCAAGTCGGCTAATCTCGAGATTAGCCGACTTGGAAGACTGTTTTTG 1457 chr8ENST00000287020.6 GDF7CCGGGCAGAGGAAAGAGAGCTTATTCTCGAGAATAAGCTCTCTTTCCTCTGCTTTTTG 1458 chr2ENST00000272224.4 GDF7CCGGGTTCGACGTGTCCAGCCTTAACTCGAGTTAAGGCTGGACACGTCGAACTTTTTG 1459 chr2ENST00000272224.4 GDF7CCGGCCACTTCATGATGTCGCTTTACTCGAGTAAAGCGACATCATGAAGTGGTTTTTG 1460 chr2ENST00000272224.4 GDF9CCGGGATGGCTCAATTGCCTATAAACTCGAGTTTATAGGCAATTGAGCCATCTTTTTG 1461 chr5ENST00000378673.2 GDF9CCGGCCATCAGTGGAACTGCTATTTCTCGAGAAATAGCAGTTCCACTGATGGTTTTTG 1462 chr5ENST00000378673.2 GDF9CCGGGAGTGAATACTTCAGACAATTCTCGAGAATTGTCTGAAGTATTCACTCTTTTTG 1463 chr5ENST00000378673.2 GPICCGGCGTCTGGTATGTCTCCAACATCTCGAGATGTTGGAGACATACCAGACGTTTTTG 1464 chr19ENST00000356487.9 GPICCGGCGTCTGGTATGTCTCCAACATCTCGAGATGTTGGAGACATACCAGACGTTTTTG 1465 chr19ENST00000356487.9 GPICCGGGCGGATGTTCAATGGTGAGAACTCGAGTTCTCACCATTGAACATCCGCTTTTTG 1466 chr19ENST00000356487.9 GREM1CCGGGCAGTGTCGTTGCATATCCATCTCGAGATGGATATGCAACGACACTGCTTTTTG 1467 chr15ENST00000622074.1 GREM1CCGGACAGCCACCTACCAAGAAGAACTCGAGTTCTTCTTGGTAGGTGGCTGTTTTTTG 1468 chr15ENST00000622074.1 GREM1CCGGCAACAGTCGCACCATCATCAACTCGAGTTGATGATGGTGCGACTGTTGTTTTTG 1469 chr15ENST00000622074.1 GREM2CCGGGCTGTGAAGGAAGGAAATTTACTCGAGTAAATTTCCTTCCTTCACAGCTTTTTG 1470 chr1ENST00000318160.4 GREM2CCGGCAAGGTGCATTTCTGTCATTTCTCGAGAAATGACAGAAATGCACCTTGTTTTTG 1471 chr1ENST00000318160.4 GREM2CCGGCGGAAGTAGACGTAACTTATTCTCGAGAATAAGTTACGTCTACTTCCGTTTTTG 1472 chr1ENST00000318160.4 GRNCCGGGCCCTGATAGTCAGTTCGAATCTCGAGATTCGAACTGACTATCAGGGCTTTTTG 1473 chr17ENST00000053867.7 GRNCCGGGCCCTGATAGTCAGTTCGAATCTCGAGATTCGAACTGACTATCAGGGCTTTTTG 1474 chr17ENST00000053867.7 GRNCCGGCTTCCAAAGATCAGGTAACAACTCGAGTTGTTACCTGATCTTTGGAAGTTTTTG 1475 chr17ENST00000053867.7 HAX1CCGGACAGACACTTCGGGACTCAATCTCGAGATTGAGTCCCGAAGTGTCTGTTTTTTG 1476 chr1ENST00000328703.11 HAX1CCGGCCAGCCCAAATCCTATTTCAACTCGAGTTGAAATAGGATTTGGGCTGGTTTTTG 1477 chr1ENST00000328703.11 HAX1CCGGCCAGAGGCCATTTCATAGGTTCTCGAGAACCTATGAAATGGCCTCTGGTTTTTG 1478 chr1ENST00000328703.11 HFE2CCGGGACATGATCATTAGCCATAAGCTCGAGCTTATGGCTAATGATCATGTCTTTTTG 1479 chr1ENST00000336751.10 HFE2CCGGGCCTACATTGGCACAACTATACTCGAGTATAGTTGTGCCAATGTAGGCTTTTTG 1480 chr1ENST00000336751.10 HFE2CCGGGAAGCTCACCATCATATTTAACTCGAGTTAAATATGATGGTGAGCTTCTTTTTG 1481 chr1ENST00000336751.10 HMGB1CCGGGATGCAGCTTATACGAAATAACTCGAGTTATTTCGTATAAGCTGCATCTTTTTG 1482 chr13ENST00000339872.8 HMGB1CCGGGTTGGTGCACAGCACAAATTACTCGAGTAATTTGTGCTGTGCACCAACTTTTTG 1483 chr13ENST00000339872.8 HMGB1CCGGAGAAGATGATGATGATGAATACTCGAGTATTCATCATCATCATCTTCTTTTTTG 1484 chr13ENST00000339872.8 HYAL2CCGGCCTGCCAGTACCTCAAAGATTCTCGAGAATCTTTGAGGTACTGGCAGGTTTTTG 1485 chr3ENST00000357750.8 HYAL2CCGGCCTGCCAGTACCTCAAAGATTCTCGAGAATCTTTGAGGTACTGGCAGGTTTTTG 1486 chr3ENST00000357750.8 HYAL2CCGGCTGGACCTGAATGCCTTTGATCTCGAGATCAAAGGCATTCAGGTCCAGTTTTTG 1487 chr3ENST00000357750.8 ICAM3CCGGGTCCAGCTCACGAGGCAAATACTCGAGTATTTGCCTCGTGAGCTGGACTTTTTG 1488 chr19ENST00000160262.9 ICAM3CCGGCCAGCTCAACTTCAGCTAAATCTCGAGATTTAGCTGAAGTTGAGCTGGTTTTTG 1489 chr19ENST00000160262.9 ICAM3CCGGGCACTTGAAATGGAAAGATAACTCGAGTTATCTTTCCATTTCAAGTGCTTTTTG 1490 chr19ENST00000160262.9 ICAM3CCGGGAGCGGCAGTTACCATGTTAGCTCGAGCTAACATGGTAACTGCCGCTCTTTTTG 1491 chr19ENST00000160262.9 ICOSCCGGGCACGACCCTAACGGTGAATACTCGAGTATTCACCGTTAGGGTCGTGCTTTTTG 1492 ch2ENST00000316386.10 ICOSCCGGGTCCGCATTTCACTATCATACCTCGAGGTATGATAGTGAAATGCGGACTTTTTG 1493 ch2ENST00000316386.10 ICOSCCGGCCATTCTCATGCCAACTATTACTCGAGTAATAGTTGGCATGAGAATGGTTTTTG 1494 ch2ENST00000316386.10 ICOSCCGGCACAGATGTGACCCTATAATACTCGAGTATTATAGGGTCACATCTGTGTTTTTG 1495 ch2ENST00000316386.10 IFNA10CCGGTGTAAAGAAGTGTCGTGTATACTCGAGTATACACGACACTTCTTTACATTTTTG 1496 chr9ENST00000357374.2 IFNA10CCGGATAACCACGACGCGTTGAATCCTCGAGGATTCAACGCGTCGTGGTTATTTTTTG 1497 chr9ENST00000357374.2 IFNA10CCGGCCTGGGACAAATGGGAAGAATCTCGAGATTCTTCCCATTTGTCCCAGGTTTTTG 1498 chr9ENST00000357374.2 IFNA14CCGGCTGGGCTGTAATCTGTCTCAACTCGAGTTGAGACAGATTACAGCCCAGTTTTTG 1499 chr9ENST00000380222.3 IFNA14CCGGCCTGAATAACAGGAGGACTTTCTCGAGAAAGTCCTCCTGTTATTCAGGTTTTTG 1500 chr9ENST00000380222.3 IFNA14CCGGGCAGCAGACCTTCAATCTCTTCTCGAGAAGAGATTGAAGGTCTGCTGCTTTTTG 1501 chr9ENST00000380222.3 IFNA16CCGGTGTAAAGAAGCATCGTGTTTACTCGAGTAAACACGATGCTTCTTTACATTTTTG 1502 chr9ENST00000380216.1 IFNA16CCGGATGATCCTCATTGATTAATACCTCGAGGTATTAATCAATGAGGATCATTTTTTG 1503 chr9ENST00000380216.1 IFNA16CCGGCCTGAAGGACAGATATGATTTCTCGAGAAATCATATCTGTCCTTCAGGTTTTTG 1504 chr9ENST00000380216.1 IFNA2CCGGGCACAGTGGTTAATGTAATAACTCGAGTTATTACATTAACCACTGTGCTTTTTG 1505 chr9ENST00000380206.3 IFNA2CCGGTATGACCATGACACGATTTAACTCGAGTTAAATCGTGTCATGGTCATATTTTTG 1506 chr9ENST00000380206.3 IFNA2CCGGCCATGCTGACTGATCCATTATCTCGAGATAATGGATCAGTCAGCATGGTTTTTG 1507 chr9ENST00000380206.3 IFNA5CCGGACTTGGGATGAGACACTTCTACTCGAGTAGAAGTGTCTCATCCCAAGTTTTTTG 1508 chr9ENST00000610521.1 IFNA5CCGGAGTGGAAGACACTCCTCTGATCTCGAGATCAGAGGAGTGTCTTCCACTTTTTTG 1509 chr9ENST00000610521.1 IFNA5CCGGTCAACTGCAAGTCAATCTGTTCTCGAGAACAGATTGACTTGCAGTTGATTTTTG 1510 chr9ENST00000610521.1 IFNA6CCGGGACAGACATGACTTCAGATTTCTCGAGAAATCTGAAGTCATGTCTGTCTTTTTG 1511 chr9ENST00000380210.1 IFNA6CCGGCTGTCCTCCATGAGGTGATTCCTCGAGGAATCACCTCATGGAGGACAGTTTTTG 1512 chr9ENST00000380210.1 IFNA6CCGGAGGCTTCTAGACAAACTCTATCTCGAGATAGAGTTTGTCTAGAAGCCTTTTTTG 1513 chr9ENST00000380210.1 IFNA8CCGGTAACTATCTATAGGGCTTAAACTCGAGTTTAAGCCCTATAGATAGTTATTTTTG 1514 chr9ENST00000380205.1 IFNA8CCGGCCAGGAGGAGTTTGATGATAACTCGAGTTATCATCAAACTCCTCCTGGTTTTTG 1515 chr9ENST00000380205.1 IFNA8CCGGGACCTGGTACAACACGGAAATCTCGAGATTTCCGTGTTGTACCAGGTCTTTTTG 1516 chr9ENST00000380205.1 IFNAR1CCGGGCCAAGATTCAGGAAATTATTCTCGAGAATAATTTCCTGAATCTTGGCTTTTTG 1517 chr21ENST00000270139.7 IFNAR1CCGGGCTCTCCCGTTTGTCATTTATCTCGAGATAAATGACAAACGGGAGAGCTTTTTG 1518 chr21ENST00000270139.7 IFNAR1CCGGATGAACTGTGTCAAGTATAAGCTCGAGCTTATACTTGACACAGTTCATTTTTTG 1519 chr21ENST00000270139.7 IFNAR2CCGGGAGTGGAAATTTCACCTATATCTCGAGATATAGGTGAAATTTCCACTCTTTTTG 1520 chr21ENST00000342136.8 IFNAR2CCGGTGTATATCAGCCTCGTGTTTGCTCGAGCAAACACGAGGCTGATATACATTTTTG 1521 chr21ENST00000342136.8 IFNAR2CCGGGCAAATACCACAAGATCATTTCTCGAGAAATGATCTTGTGGTATTTGCTTTTTG 1522 chr21ENST00000342136.8 IFNB1CCGGATTGAATGGGAGGCTTGAATACTCGAGTATTCAAGCCTCCCATTCAATTTTTTG 1523 chr9ENST00000380232.3 IFNB1CCGGCCTACAAAGAAGCAGCAATTTCTCGAGAAATTGCTGCTTCTTTGTAGGTTTTTG 1524 chr9ENST00000380232.3 IFNB1CCGGCTAATGTCTATCATCAGATAACTCGAGTTATCTGATGATAGACATTAGTTTTTG 1525 chr9ENST00000380232.3 IFNECCGGGGTAGTGATAACCTTAGATTACTCGAGTAATCTAAGGTTATCACTACCTTTTTG 1526 chr9ENST00000448696.4 IFNECCGGAGCCTCTTCAGGGCAAATATTCTCGAGAATATTTGCCCTGAAGAGGCTTTTTTG 1527 chr9ENST00000448696.4 IFNECCGGCATAGAGTGGTAATACAATTTCTCGAGAAATTGTATTACCACTCTATGTTTTTG 1528 chr9ENST00000448696.4 IFNGCCGGGGTTGTCCTGCCTGCAATATTCTCGAGAATATTGCAGGCAGGACAACCTTTTTG 1529 chr12ENST00000229135.3 IFNGCCGGCATTCAGATGTAGCGGATAATCTCGAGATTATCCGCTACATCTGAATGTTTTTG 1530 chr12ENST00000229135.3 IFNGCCGGTGTTACTGCCAGGACCCATATCTCGAGATATGGGTCCTGGCAGTAACATTTTTG 1531 chr12ENST00000229135.3 IFNGR1CCGGACGAGCAGGAAGTCGATTATGCTCGAGCATAATCGACTTCCTGCTCGTTTTTTG 1532 chr6ENST00000367739.8 IFNGR1CCGGCATGAACCCTATCGTATATTGCTCGAGCAATATACGATAGGGTTCATGTTTTTG 1533 chr6ENST00000367739.8 IFNGR1CCGGCGGAAGTGAGATCCAGTATAACTCGAGTTATACTGGATCTCACTTCCGTTTTTG 1534 chr6ENST00000367739.8 IFNKCCGGGAGATTGTGGCTACGCAAATGCTCGAGCATTTGCGTAGCCACAATCTCTTTTTG 1535 chr9ENST00000276943.2 IFNKCCGGCTGTTCAGATTCAAGATTATTCTCGAGAATAATCTTGAATCTGAACAGTTTTTG 1536 chr9ENST00000276943.2 IFNKCCGGTCAGCCAACACACCTTCAAATCTCGAGATTTGAAGGTGTGTTGGCTGATTTTTG 1537 chr9ENST00000276943.2 IFNL1CCGGCTCACGCGAGACCTCAAATATCTCGAGATATTTGAGGTCTCGCGTGAGTTTTTG 1538 chr19ENST00000333625.2 IFNL1CCGGGCCACATTGGCAGGTTCAAATCTCGAGATTTGAACCTGCCAATGTGGCTTTTTG 1539 chr19ENST00000333625.2 IFNL1CCGGGAGTTGCAGCTCTCCTGTCTTCTCGAGAAGACAGGAGAGCTGCAACTCTTTTTG 1540 chr19ENST00000333625.2 IFNL3CCGGAGGGCCAAAGATGCCTTAGAACTCGAGTTCTAAGGCATCTTTGGCCCTTTTTTG 1541 chr19ENST00000413851.2 IFNL3CCGGGCCTTTAAGAGGGCCAAAGATCTCGAGATCTTTGGCCCTCTTAAAGGCTTTTTG 1542 chr19ENST00000413851.2 IFNL3CCGGTGCCACATAGCCCAGTTCAAGCTCGAGCTTGAACTGGGCTATGTGGCATTTTTG 1543 chr19ENST00000413851.2 IFNW1CCGGAGACTCTTATTTCGGCTTTAACTCGAGTTAAAGCCGAAATAAGAGTCTTTTTTG 1544 chr9ENST00000380229.3 IFNW1CCGGTCAGTCCCTAAGATGTTATTTCTCGAGAAATAACATCTTAGGGACTGATTTTTG 1545 chr9ENST00000380229.3 IFNW1CCGGCGGTATATTAAGCCAGTATATCTCGAGATATACTGGCTTAATATACCGTTTTTG 1546 chr9ENST00000380229.3 IL10CCGGAGCTTCTCTGTGAACGATTTACTCGAGTAAATCGTTCACAGAGAAGCTTTTTTG 1547 chr1ENST00000423557.1 IL10CCGGGCAGGTGAAGAATGCCTTTAACTCGAGTTAAAGGCATTCTTCACCTGCTTTTTG 1548 chr1ENST00000423557.1 IL10CCGGGCTGGACAACTTGTTGTTAAACTCGAGTTTAACAACAAGTTGTCCAGCTTTTTG 1549 chr1ENST00000423557.1 IL10RACCGGTCTGTCGCTTCCCGAAGTAACCTCGAGGTTACTTCGGGAAGCGACAGATTTTTG 1550 chr11ENST00000227752.7 IL10RACCGGGAAACAGGATCCTCTAGAAATCTCGAGATTTCTAGAGGATCCTGTTTCTTTTTG 1551 chr11ENST00000227752.7 IL10RACCGGGAACTCTTTCCTGTATCATAACTCGAGTTATGATACAGGAAAGAGTTCTTTTTG 1552 chr11ENST00000227752.7 IL11CCGGATATCCACTTGAGGGCGATTTCTCGAGAAATCGCCCTCAAGTGGATATTTTTTG 1553 chr19ENST00000264563.6 IL11CCGGCCTTCCAAAGCCAGATCTTATCTCGAGATAAGATCTGGCTTTGGAAGGTTTTTG 1554 chr19ENST00000264563.6 IL11CCGGTGCACAGCTGAGGGACAAATTCTCGAGAATTTGTCCCTCAGCTGTGCATTTTTG 1555 chr19ENST00000264563.6 IL11RACCGGCGGCAGATTCCACCTATAATTCTCGAGAATTATAGGTGGAATCTGCCGTTTTTG 1556 chr9ENST00000318041.13 IL11RACCGGTCGGCAGATTCCACCTATAATCTCGAGATTATAGGTGGAATCTGCCGATTTTTG 1557 chr9ENST00000318041.13 IL11RACCGGTGGAGCCAGTACCGGATTAATCTCGAGATTAATCCGGTACTGGCTCCATTTTTG 1558 chr9ENST00000318041.13 IL12ACCGGTGATACCTCTGATCAAGTATTCTCGAGAATACTTGATCAGAGGTATCATTTTTG 1559 chr3ENST00000305579.6 IL12ACCGGCCTGTGCCTTAGTAGTATTTACTCGAGTAAATACTACTAAGGCACAGGTTTTTG 1560 chr3ENST00000305579.6 IL12ACCGGCCTGTTTACCATTGGAATTAACTCGAGTTAATTCCAATGGTAAACAGGTTTTTG 1561 chr3ENST00000305579.6 IL12BCCGGGAATTTGGTCCACTGATATTTCTCGAGAAATATCAGTGGACCAAATTCTTTTTG 1562 chr5ENST00000231228.2 IL12BCCGGCCATGGGCCTTCATGCTATTTCTCGAGAAATAGCATGAAGGCCCATGGTTTTTG 1563 chr5ENST00000231228.2 IL12BCCGGTTAGATGCTAAATGCTCATTGCTCGAGCAATGAGCATTTAGCATCTAATTTTTG 1564 chr5ENST00000231228.2 IL12RB1CCGGCAGCTCTACAACTCAGTTAAACTCGAGTTTAACTGAGTTGTAGAGCTGTTTTTG 1565 chr19ENST00000593993.6 IL12RB1CCGGGTCATCTCCTCGAACCAATTTCTCGAGAAATTGGTTCGAGGAGATGACTTTTTG 1566 chr19ENST00000593993.6 IL12RB1CCGGCCAACGGGACCACCATGTATTCTCGAGAATACATGGTGGTCCCGTTGGTTTTTG 1567 chr19ENST00000593993.6 IL13CCGGACTTCGAAAGCATCATTATTTCTCGAGAAATAATGATGCTTTCGAAGTTTTTTG 1568 chr5ENST00000304506.7 IL13CCGGATTGAAGTTGCAGATTCATTTCTCGAGAAATGAATCTGCAACTTCAATTTTTTG 1569 chr5ENST00000304506.7 IL13CCGGCCTGCTCTTACATTTAAAGAACTCGAGTTCTTTAAATGTAAGAGCAGGTTTTTG 1570 chr5ENST00000304506.7 IL15CCGGGAAGATCTTATTCAATCTATGCTCGAGCATAGATTGAATAAGATCTTCTTTTTG 1571 chr4ENST00000296545.11 IL15CCGGTAAGGGTGATAGTCAAATTATCTCGAGATAATTTGACTATCACCCTTATTTTTG 1572 chr4ENST00000296545.11 IL15CCGGCACTCTGCTGCTTAGACATAACTCGAGTTATGTCTAAGCAGCAGAGTGTTTTTG 1573 chr4ENST00000296545.11 IL16CCGGTGGGACCACGTGAGATCATTCCTCGAGGAATGATCTCACGTGGTCCCATTTTTG 1574 chr15ENST00000302987.8 IL16CCGGGTTCTGGATGAAGCAACATTACTCGAGTAATGTTGCTTCATCCAGAACTTTTTG 1575 chr15ENST00000302987.8 IL16CCGGCCCAAACAGTGACATTTATTTCTCGAGAAATAAATGTCACTGTTTGGGTTTTTG 1576 chr15ENST00000302987.8 IL17ACCGGATCAGTTCTGCCTAGGTAAATCTCGAGATTTACCTAGGCAGAACTGATTTTTTG 1577 chr6ENST00000340057.1 IL17ACCGGGAGCTATTTAAGGATCTATTTCTCGAGAAATAGATCCTTAAATAGCTCTTTTTG 1578 chr6ENST00000340057.1 IL17ACCGGGGTCAACCTGAACATCCATAACTCGAGTTATGGATGTTCAGGTTGACCTTTTTG 1579 chr6ENST00000340057.1 IL17BCCGGTATGCCCGCATGGAGGAGTATCTCGAGATACTCCTCCATGCGGGCATATTTTTG 1580 chr5ENST00000261796.3 IL17BCCGGGTGTCACGGATGAAACCGTATCTCGAGATACGGTTTCATCCGTGACACTTTTTG 1581 chr5ENST00000261796.3 IL17BCCGGGCAGCTGTGGATGTCCAACAACTCGAGTTGTTGGACATCCACAGCTGCTTTTTG 1582 chr5ENST00000261796.3 IL17CCCGGGCACCTCTTCCAGCCCTTAAACTCGAGTTTAAGGGCTGGAAGAGGTGCTTTTTG 1583 chr16ENST00000244241.4 IL17CCCGGCTTTGCCTTCCACACCGAGTTCTCGAGAACTCGGTGTGGAAGGCAAAGTTTTTG 1584 chr16ENST00000244241.4 IL17CCCGGATCTCCAGCCTCAGTAGTTGGCTCGAGCCAACTACTGAGGCTGGAGATTTTTTG 1585 chr16ENST00000244241.4 IL17DCCGGAGAGCTACTCTGTTACATTTCCTCGAGGAAATGTAACAGAGTAGCTCTTTTTTG 1586 chr13ENST00000304920.3 IL17DCCGGCAAAGAGATAGGGACGCATATCTCGAGATATGCGTCCCTATCTCTTTGTTTTTG 1587 chr13ENST00000304920.3 IL17DCCGGAGACAGCATCAACTCCAGCATCTCGAGATGCTGGAGTTGATGCTGTCTTTTTTG 1588 chr13ENST00000304920.3 IL17FCCGGTCATCCACCATGTGCAGTAAGCTCGAGCTTACTGCACATGGTGGATGATTTTTG 1589 chr6ENST00000336123.4 IL17FCCGGGTACTTGCTGCTGTCGATATTCTCGAGAATATCGACAGCAGCAAGTACTTTTTG 1590 chr6ENST00000336123.4 IL17FCCGGCGTTTCCATGTCACGTAACATCTCGAGATGTTACGTGACATGGAAACGTTTTTG 1591 chr6ENST00000336123.4 IL18CCGGCCCGGACCATATTTATTATAACTCGAGTTATAATAAATATGGTCCGGGTTTTTG 1592 chr11ENST00000280357.11 IL18CCGGTGATTCTGACTGTAGAGATAACTCGAGTTATCTCTACAGTCAGAATCATTTTTG 1593 chr11ENST00000280357.11 IL18CCGGTGGCAAGCTTGAATCTAAATTCTCGAGAATTTAGATTCAAGCTTGCCATTTTTG 1594 chr11ENST00000280357.11 IL18BPCCGGGGTCCCTTCTCTCACCAAATTCTCGAGAATTTGGTGAGAGAAGGGACCTTTTTG 1595 chr11ENST00000260049.9 IL18BPCCGGTCCCATGTCTCTGCTCATTTACTCGAGTAAATGAGCAGAGACATGGGATTTTTG 1596 chr11ENST00000260049.9 IL18BPCCGGCTGGGCAATGGTTCCTTCATTCTCGAGAATGAAGGAACCATTGCCCAGTTTTTG 1597 chr11ENST00000260049.9 IL19CCGGGTCCACGCTGCTGCCATTAAACTCGAGTTTAATGGCAGCAGCGTGGACTTTTTG 1598 chrlENST00000270218.10 IL19CCGGTCCACAGACATGCACCATATACTCGAGTATATGGTGCATGTCTGTGGATTTTTG 1599 chrlENST00000270218.10 IL19CCGGTGATGACAAGGAACCTGTATACTCGAGTATACAGGTTCCTTGTCATCATTTTTG 1600 chrlENST00000270218.10 IL1ACCGGGTGGAACCAACACTAACATATCTCGAGATATGTTAGTGTTGGTTCCACTTTTTG 1601 chr2ENST00000263339.3 IL1ACCGGGCCCTCAATCAAAGTATAATTCTCGAGAATTATACTTTGATTGAGGGCTTTTTG 1602 chr2ENST00000263339.3 IL1ACCGGTATTACAGATGGGCAAATTAACTCGAGTTAATTTGCCCATCTGTAATATTTTTG 1603 chr2ENST00000263339.3 IL1BCCGGATCAATAACAAGCTGGAATTTCTCGAGAAATTCCAGCTTGTTATTGATTTTTTG 1604 chr2ENST00000263341.6 IL1BCCGGAGCAACCGCTTCCCTATTTATCTCGAGATAAATAGGGAAGCGGTTGCTTTTTTG 1605 chr2ENST00000263341.6 IL1BCCGGCTGACTTCACCATGCAATTTGCTCGAGCAAATTGCATGGTGAAGTCAGTTTTTG 1606 chr2ENST00000263341.6 IL1F10CCGGTCCTTGTGGGCTCAGTTTAATCTCGAGATTAAACTGAGCCCACAAGGATTTTTG 1607 chr2ENST00000341010.6 IL1F10CCGGGGTCTATGGTAGGCAGAATAACTCGAGTTATTCTGCCTACCATAGACCTTTTTG 1608 chr2ENST00000341010.6 IL1F10CCGGTGCAGACCAGAAGGCTCTATACTCGAGTATAGAGCCTTCTGGTCTGCATTTTTG 1609 chr2ENST00000341010.6 IL1R1CCGGGCCAAGAATACACATGGTATACTCGAGTATACCATGTGTATTCTTGGCTTTTTG 1610 chr2ENST00000410023.5 IL1R1CCGGATAATGCACAAGCCATATTTACTCGAGTAAATATGGCTTGTGCATTATTTTTTG 1611 chr2ENST00000410023.5 IL1R1CCGGTGGTATAGATGCAGCATATATCTCGAGATATATGCTGCATCTATACCATTTTTG 1612 chr2ENST00000410023.5 IL1R2CCGGCAATCCCGTGTAAGGTGTTTCCTCGAGGAAACACCTTACACGGGATTGTTTTTG 1613 chr2ENST00000332549.7 IL1R2CCGGGACCATTCCTGTGATCATTTCCTCGAGGAAATGATCACAGGAATGGTCTTTTTG 1614 chr2ENST00000332549.7 IL1R2CCGGCGTTCATCTCATACCCGCAAACTCGAGTTTGCGGGTATGAGATGAACGTTTTTG 1615 chr2ENST00000332549.7 IL1RAPL1CCGGCAAAGCAAGCGGCTGATTATTCTCGAGAATAATCAGCCGCTTGCTTTGTTTTTG 1616 chrXENST00000378993.5 IL1RAPL1CCGGGCCAGCGTTCTCCTTCATAAACTCGAGTTTATGAAGGAGAACGCTGGCTTTTTG 1617 chrXENST00000378993.5 IL1RAPL1CCGGTCAAGCTCCTGACGGTCATTACTCGAGTAATGACCGTCAGGAGCTTGATTTTTG 1618 chrXENST00000378993.5 IL1RL1CCGGTTACACCGTGGATTGGTATTACTCGAGTAATACCAATCCACGGTGTAATTTTTG 1619 chr2ENST00000233954.5 IL1RL1CCGGAGTTGCTGATTCTGGTATTTACTCGAGTAAATACCAGAATCAGCAACTTTTTTG 1620 chr2ENST00000233954.5 IL1RL1CCGGCGTGAAGGAAGAGGATTTATTCTCGAGAATAAATCCTCTTCCTTCACGTTTTTG 1621 chr2ENST00000233954.5 IL1RNCCGGGCAAGGACCAAATGTCAATTTCTCGAGAAATTGACATTTGGTCCTTGCTTTTTG 1622 chr2ENST00000409930.3 IL1RNCCGGCGTCATGGTCACCAAATTCTACTCGAGTAGAATTTGGTGACCATGACGTTTTTG 1623 chr2ENST00000409930.3 IL1RNCCGGCTGCCTCCAGAATGGTCTTTCCTCGAGGAAAGACCATTCTGGAGGCAGTTTTTG 1624 chr2ENST00000409930.3 IL2CCGGGCTACCTATTGTAACTATTATCTCGAGATAATAGTTACAATAGGTAGCTTTTTG 1625 chr4ENST00000226730.4 IL2CCGGCAGCTACAACTGGAGCATTTACTCGAGTAAATGCTCCAGTTGTAGCTGTTTTTG 1626 chr4ENST00000226730.4 IL2CCGGTGCTGGATTTACAGATGATTTCTCGAGAAATCATCTGTAAATCCAGCATTTTTG 1627 chr4ENST00000226730.4 IL20CCGGCTGATGCTCTGTGAGATATTTCTCGAGAAATATCTCACAGAGCATCAGTTTTTG 1628 chr1ENST00000367096.7 IL20CCGGTGGTCACAGTGTATCTTATTTCTCGAGAAATAAGATACACTGTGACCATTTTTG 1629 chr1ENST00000367096.7 IL20CCGGGGACTGAAGACACTCAATTTGCTCGAGCAAATTGAGTGTCTTCAGTCCTTTTTG 1630 chr1ENST00000367096.7 IL20RACCGGCCAGTATTATGCCAAAGTTAACTCGAGTTAACTTTGGCATAATACTGGTTTTTG 1631 chr6ENST00000316649.9 IL20RACCGGGAGGGTCTTCAAGGAGTTAAACTCGAGTTTAACTCCTTGAAGACCCTCTTTTTG 1632 chr6ENST00000316649.9 IL20RACCGGGCTTCGCATTTGATGGAAATTCTCGAGAATTTCCATCAAATGCGAAGCTTTTTG 1633 chr6ENST00000316649.9 IL20RBCCGGCAGTGTACTATTCTGTCGAATCTCGAGATTCGACAGAATAGTACACTGTTTTTG 1634 chr3ENST00000329582.8 IL20RBCCGGCCAGAATAATCCTTGAGAGAACTCGAGTTCTCTCAAGGATTATTCTGGTTTTTG 1635 chr3ENST00000329582.8 IL20RBCCGGCTCTGTACTCTCAACCAACATCTCGAGATGTTGGTTGAGAGTACAGAGTTTTTG 1636 chr3ENST00000329582.8 IL21CCGGAGGAAACCACCTTCCACAAATCTCGAGATTTGTGGAAGGTGGTTTCCTTTTTTG 1637 chr4ENST00000264497.7 IL21CCGGATGACTTGGTCCCTGAATTTCCTCGAGGAAATTCAGGGACCAAGTCATTTTTTG 1638 chr4ENST00000264497.7 IL21CCGGCTTTCAGAAGGCCCAACTAAACTCGAGTTTAGTTGGGCCTTCTGAAAGTTTTTG 1639 chr4ENST00000264497.7 IL22CCGGAGGCTAAGCACATGTCATATTCTCGAGAATATGACATGTGCTTAGCCTTTTTTG 1640 chr12ENST00000328087.5 IL22CCGGGTTTCCATAATCAGTACTTTACTCGAGTAAAGTACTGATTATGGAAACTTTTTG 1641 chr12ENST00000328087.5 IL22CCGGAGACTTTCTAAGCATAGATATCTCGAGATATCTATGCTTAGAAAGTCTTTTTTG 1642 chr12ENST00000328087.5 IL22RA1CCGGGGACACTTTCTAGTCCTAAACCTCGAGGTTTAGGACTAGAAAGTGTCCTTTTTG 1643 chr1ENST00000270800.1 IL22RA1CCGGAGGGACACCACAGTACCTAAACTCGAGTTTAGGTACTGTGGTGTCCCTTTTTTG 1644 chr1ENST00000270800.1 IL22RA1CCGGCTGTCCGAGATCACCTACTTACTCGAGTAAGTAGGTGATCTCGGACAGTTTTTG 1645 chr1ENST00000270800.1 IL22RA2CCGGAGACATACAGGAACCTTATTACTCGAGTAATAAGGTTCCTGTATGTCTTTTTTG 1646 chr6ENST00000349184.8 IL22RA2CCGGCTCGTGTTTGAAGGATCTTATCTCGAGATAAGATCCTTCAAACACGAGTTTTTG 1647 chr6ENST00000349184.8 IL22RA2CCGGTGCTCCAAATTTACCATATAGCTCGAGCTATATGGTAAATTTGGAGCATTTTTG 1648 chr6ENST00000349184.8 IL23ACCGGAGCTGCTAGGATCGGATATTTCTCGAGAAATATCCGATCCTAGCAGCTTTTTTG 1649 chr12ENST00000228534.5 IL23ACCGGCTGTGAGCCAACAGGTTAATTCTCGAGAATTAACCTGTTGGCTCACAGTTTTTG 1650 chr12ENST00000228534.5 IL23ACCGGGGATCCACCAGGGTCTGATTTCTCGAGAAATCAGACCCTGGTGGATCCTTTTTG 1651 chr12ENST00000228534.5 IL23RCCGGCTTTCTTTGATTGGGATATTTCTCGAGAAATATCCCAATCAAAGAAAGTTTTTG 1652 chr1ENST00000347310.9 IL23RCCGGTATCTCACCTCAAGCTATATTCTCGAGAATATAGCTTGAGGTGAGATATTTTTG 1653 chr1ENST00000347310.9 IL23RCCGGCGACAATACTACAGTTGTATACTCGAGTATACAACTGTAGTATTGTCGTTTTTG 1654 chr1ENST00000347310.9 IL24CCGGCACAGGCGGTTTCTGCTATTCCTCGAGGAATAGCAGAAACCGCCTGTGTTTTTG 1655 chr1ENST00000294984.6 IL24CCGGGTCAGGACTCTGAAGTCATTCCTCGAGGAATGACTTCAGAGTCCTGACTTTTTG 1656 chr1ENST00000294984.6 IL24CCGGTCGGATGCTGAGAGCTGTTACCTCGAGGTAACAGCTCTCAGCATCCGATTTTTG 1657 chr1ENST00000294984.6 IL25CCGGACAGGCACTTTCTAGATATTTCTCGAGAAATATCTAGAAAGTGCCTGTTTTTTG 1658 chr14ENST00000329715.2 IL25CCGGCCACAACCAGACTGTCTTCTACTCGAGTAGAAGACAGTCTGGTTGTGGTTTTTG 1659 chr14ENST00000329715.2 IL25CCGGTCCTGTAGGGCCAGTGAAGATCTCGAGATCTTCACTGGCCCTACAGGATTTTTG 1660 chr14ENST00000329715.2 IL26CCGGAGCTGTTGACGCTCTCTATATCTCGAGATATAGAGAGCGTCAACAGCTTTTTTG 1661 chr12ENST00000229134.4 IL26CCGGAGTACATTGTGTCAACTTAATCTCGAGATTAAGTTGACACAATGTACTTTTTTG 1662 chr12ENST00000229134.4 IL26CCGGCGATTCCAGAAGACCGCATAACTCGAGTTATGCGGTCTTCTGGAATCGTTTTTG 1663 chr12ENST00000229134.4 IL27CCGGACTCCTTGGAGCTCGTCTTATCTCGAGATAAGACGAGCTCCAAGGAGTTTTTTG 1664 chr16ENST00000356897.1 IL27CCGGACTTTAGGACTGGAGTCTTGGCTCGAGCCAAGACTCCAGTCCTAAAGTTTTTTG 1665 chr16ENST00000356897.1 IL27CCGGCATCATCAGCCTTGGACAAGGCTCGAGCCTTGTCCAAGGCTGATGATGTTTTTG 1666 chr16ENST00000356897.1 IL2RACCGGCCTCGTCACAACAACAGATTTCTCGAGAAATCTGTTGTTGTGACGAGGTTTTTG 1667 chr10ENST00000379959.7 IL2RACCGGACCCTATACAACTGGACATTGCTCGAGCAATGTCCAGTTGTATAGGGTTTTTTG 1668 chr10ENST00000379959.7 IL2RACCGGACTCGGAACACAACGAAACAACTCGAGTTGTTTCGTTGTGTTCCGAGTTTTTTG 1669 chr10ENST00000379959.7 IL2RBCCGGAGTCCCAGACCTGGTGGATTTCTCGAGAAATCCACCAGGTCTGGGACTTTTTTG 1670 chr22ENST00000216223.9 IL2RBCCGGGACCCACAGATGCAACATAAGCTCGAGCTTATGTTGCATCTGTGGGTCTTTTTG 1671 chr22ENST00000216223.9 IL2RBCCGGCCAGACACCCAGTATGAGTTTCTCGAGAAACTCATACTGGGTGTCTGGTTTTTG 1672 chr22ENST00000216223.9 IL2RGCCGGTCGTGTTCGGAGCCGCTTTAACTCGAGTTAAAGCGGCTCCGAACACGATTTTTG 1673 chrXENST00000374202.6 IL2RGCCGGCCAACCTCACTCTGCATTATTCTCGAGAATAATGCAGAGTGAGGTTGGTTTTTG 1674 chrXENST00000374202.6 IL2RGCCGGTTGGCTCCATGGGATTGATTACTCGAGTAATCAATCCCATGGAGCCAATTTTTG 1675 chrXENST00000374202.6 IL3CCGGTTATCCCATTGAGACTATTTACTCGAGTAAATAGTCTCAATGGGATAATTTTTG 1676 chr5ENST00000296870.2 IL3CCGGCGGCATCAGATGAATTGTTAACTCGAGTTAACAATTCATCTGATGCCGTTTTTG 1677 chr5ENST00000296870.2 IL3CCGGGCAATTGAGAGCATTCTTAAACTCGAGTTTAAGAATGCTCTCAATTGCTTTTTG 1678 chr5ENST00000296870.2 IL31CCGGGCATATCTCAAGACAATCAGACTCGAGTCTGATTGTCTTGAGATATGCTTTTTG 1679 chr12ENST00000377035.1 IL31CCGGCCAAGTGATGATGTACAGAAACTCGAGTTTCTGTACATCATCACTTGGTTTTTG 1680 chr12ENST00000377035.1 IL31CCGGCCTGACTATTTCTCAACAGTTCTCGAGAACTGTTGAGAAATAGTCAGGTTTTTG 1681 chr12ENST00000377035.1 IL31RACCGGCATCAAACGAATGATTCAAATCTCGAGATTTGAATCATTCGTTTGATGTTTTTG 1682 chr5ENST00000447346.6 IL31RACCGGCGCCTGTTTCATCTGATTTAACTCGAGTTAAATCAGATGAAACAGGCGTTTTTG 1683 chr5ENST00000447346.6 IL31RACCGGTTTCCTGTGTCTACTACTATACTCGAGTATAGTAGTAGACACAGGAAATTTTTG 1684 chr5ENST00000447346.6 IL32CCGGTGTCGCCCTGGCATCTTAATACTCGAGTATTAAGATGCCAGGGCGACATTTTTG 1685 chr16ENST00000325568.9 IL32CCGGAGAGCTCACTCCTCTACTTGACTCGAGTCAAGTAGAGGAGTGAGCTCTTTTTTG 1686 chr16ENST00000325568.9 IL32CCGGAGAGCTGGAGGACGACTTCAACTCGAGTTGAAGTCGTCCTCCAGCTCTTTTTTG 1687 chr16ENST00000325568.9 IL33CCGGGAGTGCTTTGCCTTTGGTATACTCGAGTATACCAAAGGCAAAGCACTCTTTTTG 1688 chr9ENST00000381434.7 IL33CCGGGCACTCCAACTGTGTTTCATTCTCGAGAATGAAACACAGTTGGAGTGCTTTTTG 1689 chr9ENST00000381434.7 IL33CCGGCCTGTTACTTTAGGAGAGAAACTCGAGTTTCTCTCCTAAAGTAACAGGTTTTTG 1690 chr9ENST00000381434.7 IL34CCGGGCCGACTTCAGTACATGAAACCTCGAGGTTTCATGTACTGAAGTCGGCTTTTTG 1691 chr16ENST00000288098.6 IL34CCGGCAGAGCCCTCATTGCAGTATGCTCGAGCATACTGCAATGAGGGCTCTGTTTTTG 1692 chr16ENST00000288098.6 IL34CCGGCCGTGTTGTCCCTCTTGAATGCTCGAGCATTCAAGAGGGACAACACGGTTTTTG 1693 chr16ENST00000288098.6 IL36ACCGGCTCCAGTCACTATTGCCTTAACTCGAGTTAAGGCAATAGTGACTGGAGTTTTTG 1694 chr2ENST00000259211.6 IL36ACCGGTTCAGGACCAGACGCTCATAGCTCGAGCTATGAGCGTCTGGTCCTGAATTTTTG 1695 chr2ENST00000259211.6 IL36ACCGGCTCTGCCTGATGTGTGCTAAACTCGAGTTTAGCACACATCAGGCAGAGTTTTTG 1696 chr2ENST00000259211.6 IL36BCCGGATCCTATGCTATTCGTGATTCCTCGAGGAATCACGAATAGCATAGGATTTTTTG 1697 chr2ENST00000327407.2 IL36BCCGGCCTGAGTGGAAATTCTTTAATCTCGAGATTAAAGAATTTCCACTCAGGTTTTTG 1698 chr2ENST00000327407.2 IL36BCCGGTTGGACTACATAACCTGTAAACTCGAGTTTACAGGTTATGTAGTCCAATTTTTG 1699 chr2ENST00000327407.2 IL36GCCGGTGATATCATCCAGTCTTTATACTCGAGTATAAAGACTGGATGATATCATTTTTG 1700 chr2ENST00000259205.4 IL36GCCGGCAGGAGAGCTGGGTGGTATAACTCGAGTTATACCACCCAGCTCTCCTGTTTTTG 1701 chr2ENST00000259205.4 IL36GCCGGGGGAATCCAGAATCCAGAAATCTCGAGATTTCTGGATTCTGGATTCCCTTTTTG 1702 chr2ENST00000259205.4 IL36RNCCGGCTCGGCATTGAAGGTGCTTTACTCGAGTAAAGCACCTTCAATGCCGAGTTTTTG 1703 chr2ENST00000346807.7 IL36RNCCGGTGGTTCCCAGTTTGGATAAATCTCGAGATTTATCCAAACTGGGAACCATTTTTG 1704 chr2ENST00000346807.7 IL36RNCCGGGGGAATCATTCCTGCTTAATGCTCGAGCATTAAGCAGGAATGATTCCCTTTTTG 1705 chr2ENST00000346807.7 IL37CCGGCTCTACTGTGACAAGGATAAACTCGAGTTTATCCTTGTCACAGTAGAGTTTTTG 1706 chr2ENST00000263326.7 IL37CCGGTGCACCTCCTGCAATTGTAATCTCGAGATTACAATTGCAGGAGGTGCATTTTTG 1707 chr2ENST00000263326.7 IL37CCGGGTTCACACAAAGATCTTCTTTCTCGAGAAAGAAGATCTTTGTGTGAACTTTTTG 1708 chr2ENST00000263326.7 IL4CCGGAGCTGATCCGATTCCTGAAACCTCGAGGTTTCAGGAATCGGATCAGCTTTTTTG 1709 chr5ENST00000231449.6 IL4CCGGCCACGGACACAAGTGCGATATCTCGAGATATCGCACTTGTGTCCGTGGTTTTTG 1710 chr5ENST00000231449.6 IL4CCGGTAGCATGTGCCGGCAACTTTGCTCGAGCAAAGTTGCCGGCACATGCTATTTTTG 1711 chr5ENST00000231449.6 IL5CCGGGCAAGAGTTTCTTGGTGTAATCTCGAGATTACACCAAGAAACTCTTGCTTTTTG 1712 chr5ENST00000231454.5 IL5CCGGGGGTACTGTGGAAAGACTATTCTCGAGAATAGTCTTTCCACAGTACCCTTTTTG 1713 chr5ENST00000231454.5 IL5CCGGGAAAGAGTCAGGCCTTAATTTCTCGAGAAATTAAGGCCTGACTCTTTCTTTTTG 1714 chr5ENST00000231454.5 IL6CCGGATGAGCGTTAGGACACTATTTCTCGAGAAATAGTGTCCTAACGCTCATTTTTTG 1715 chr7ENST00000258743.9 IL6CCGGGAGTACCTCCAGAACAGATTTCTCGAGAAATCTGTTCTGGAGGTACTCTTTTTG 1716 chr7ENST00000258743.9 IL6CCGGATGTGAAGCTGAGTTAATTTACTCGAGTAAATTAACTCAGCTTCACATTTTTTG 1717 chr7ENST00000258743.9 IL6RCCGGGCAGGCACTTACTACTAATAACTCGAGTTATTAGTAGTAAGTGCCTGCTTTTTG 1718 chr1ENST00000368485.7 IL6RCCGGTATCGGGCTGAACGGTCAAAGCTCGAGCTTTGACCGTTCAGCCCGATATTTTTG 1719 chr1ENST00000368485.7 IL6RCCGGCTGGACCCTGTGGATGATAAACTCGAGTTTATCATCCACAGGGTCCAGTTTTTG 1720 chr1ENST00000368485.7 IL6STCCGGACCGTGCATCGCACCTATTTACTCGAGTAAATAGGTGCGATGCACGGTTTTTTG 1721 chr5ENST00000336909.9 IL6STCCGGACTTCAGCAGTACCTATAAAGCTCGAGCTTTATAGGTACTGCTGAAGTTTTTTG 1722 chr5ENST00000336909.9 IL6STCCGGCGGCCAGAAGATCTACAATTACTCGAGTAATTGTAGATCTTCTGGCCGTTTTTG 1723 chr5ENST00000336909.9 IL7CCGGGCTCGCAAGTTGAGGCAATTTCTCGAGAAATTGCCTCAACTTGCGAGCTTTTTG 1724 chr8ENST00000263851.8 IL7CCGGGCTCACTATGAATCTATTATACTCGAGTATAATAGATTCATAGTGAGCTTTTTG 1725 chr8ENST00000263851.8 IL7CCGGGTGTTTCCTAAAGAGACTATTCTCGAGAATAGTCTCTTTAGGAAACACTTTTTG 1726 chr8ENST00000263851.8 IL9CCGGACCACCATGCAAACAAGATACCTCGAGGTATCTTGTTTGCATGGTGGTTTTTTG 1727 chr5ENST00000274520.1 IL9CCGGGAACAACAAGTGTCCATATTTCTCGAGAAATATGGACACTTGTTGTTCTTTTTG 1728 chr5ENST00000274520.1 IL9CCGGCTGAAGAGTCTTCTGGAAATTCTCGAGAATTTCCAGAAGACTCTTCAGTTTTTG 1729 chr5ENST00000274520.1 INHACCGGCCTCGGATGGAGGTTACTCTTCTCGAGAAGAGTAACCTCCATCCGAGGTTTTTG 1730 chr2ENST00000243786.2 INHACCGGGCAGCACTGTGCTTGTATCTACTCGAGTAGATACAAGCACAGTGCTGCTTTTTG 1731 chr2ENST00000243786.2 INHACCGGTGGAGGTTACTCTTTCAAGTACTCGAGTACTTGAAAGAGTAACCTCCATTTTTG 1732 chr2ENST00000243786.2 INHBACCGGAGGCACTTTCCTACCCAATTACTCGAGTAATTGGGTAGGAAAGTGCCTTTTTTG 1733 chr7ENST00000242208.4 INHBACCGGGAGAATGGTGTACCCTTTATTCTCGAGAATAAAGGGTACACCATTCTCTTTTTG 1734 chr7ENST00000242208.4 INHBACCGGAGACGCTGCACTTCGAGATTTCTCGAGAAATCTCGAAGTGCAGCGTCTTTTTTG 1735 chr7ENST00000242208.4 INHBBCCGGCAAATGGATGCGGTGACAAATCTCGAGATTTGTCACCGCATCCATTTGTTTTTG 1736 chr2ENST00000295228.3 INHBBCCGGGCTGGAACGACTGGATCATAGCTCGAGCTATGATCCAGTCGTTCCAGCTTTTTG 1737 chr2ENST00000295228.3 INHBBCCGGTGATGAGTACAACATCGTCAACTCGAGTTGACGATGTTGTACTCATCATTTTTG 1738 chr2ENST00000295228.3 INHBCCCGGTCAACCAGACTCGTCTTGATTCTCGAGAATCAAGACGAGTCTGGTTGATTTTTG 1739 chr12ENST00000309668.2 INHBCCCGGCAAGACTGACATACCTGACATCTCGAGATGTCAGGTATGTCAGTCTTGTTTTTG 1740 chr12ENST00000309668.2 INHBCCCGGCAGGCCAGTCTCATGTTCTTTCTCGAGAAAGAACATGAGACTGGCCTGTTTTTG 1741 chr12ENST00000309668.2 INHBECCGGCTCCTCTACCTGGATCATAATCTCGAGATTATGATCCAGGTAGAGGAGTTTTTG 1742 chr12ENST00000266646.2 INHBECCGGACCTGGGCTGGCATACCTTAACTCGAGTTAAGGTATGCCAGCCCAGGTTTTTTG 1743 chr12ENST00000266646.2 INHBECCGGGCAGCCCTTCCTAGAGCTTAACTCGAGTTAAGCTCTAGGAAGGGCTGCTTTTTG 1744 chr12ENST00000266646.2 ITGA4CCGGCCAACGCTTCAGTGATCAATCCTCGAGGATTGATCACTGAAGCGTTGGTTTTTG 1745 chr2ENST00000397033.6 ITGA4CCGGTGTAGAACACATCAAGCATTTCTCGAGAAATGCTTGATGTGTTCTACATTTTTG 1746 chr2ENST00000397033.6 ITGA4CCGGCATGATCTTGTGACATATTATCTCGAGATAATATGTCACAAGATCATGTTTTTG 1747 chr2ENST00000397033.6 ITGAVCCGGTTGAAGTGTACCCTAGCATTTCTCGAGAAATGCTAGGGTACACTTCAATTTTTG 1748 chr2ENST00000261023.7 ITGAVCCGGCACTCCAAGAACATGACTATTCTCGAGAATAGTCATGTTCTTGGAGTGTTTTTG 1749 chr2ENST00000261023.7 ITGAVCCGGGTGAGGTCGAAACAGGATAAACTCGAGTTTATCCTGTTTCGACCTCACTTTTTG 1750 chr2ENST00000261023.7 ITGB1CCGGTTTGTAGGAAGAGGGATAATACTCGAGTATTATCCCTCTTCCTACAAATTTTTG 1751 chr10ENST00000302278.7 ITGB1CCGGGCCTTGCATTACTGCTGATATCTCGAGATATCAGCAGTAATGCAAGGCTTTTTG 1752 chr10ENST00000302278.7 ITGB1CCGGGCCTTGCATTACTGCTGATATCTCGAGATATCAGCAGTAATGCAAGGCTTTTTG 1753 chr10ENST00000302278.7 ITGB3CCGGGTCGTCAGATTCCAGTACTATCTCGAGATAGTACTGGAATCTGACGACTTTTTG 1754 chr17ENST00000559488.5 ITGB3CCGGGTCGTCAGATTCCAGTACTATCTCGAGATAGTACTGGAATCTGACGACTTTTTG 1755 chr17ENST00000559488.5 ITGB3CCGGCCACGTCTACCTTCACCAATACTCGAGTATTGGTGAAGGTAGACGTGGTTTTTG 1756 chr17ENST00000559488.5 KITCCGGACTTCATCTAACGAGATTAAACTCGAGTTTAATCTCGTTAGATGAAGTTTTTTG 1757 chr4ENST00000288135.5 KITCCGGGCGACGAGATTAGGCTGTTATCTCGAGATAACAGCCTAATCTCGTCGCTTTTTG 1758 chr4ENST00000288135.5 KITCCGGACGAGTTGGCCCTAGACTTAGCTCGAGCTAAGTCTAGGGCCAACTCGTTTTTTG 1759 chr4ENST00000288135.5 KITLGCCGGGCAGGAATCGTGTGACTAATACTCGAGTATTAGTCACACGATTCCTGCTTTTTG 1760 chr12ENST00000228280.9 KITLGCCGGGCAGGAATCGTGTGACTAATACTCGAGTATTAGTCACACGATTCCTGCTTTTTG 1761 chr12ENST00000228280.9 KITLGCCGGCCTATTTAATCCTCTCGTCAACTCGAGTTGACGAGAGGATTAAATAGGTTTTTG 1762 chr12ENST00000228280.9 KLHL20CCGGGCCAATACATGGAGGTTATATCTCGAGATATAACCTCCATGTATTGGCTTTTTG 1763 chr1ENST00000209884.4 KLHL20CCGGGCCGCAAGAACGACCACTAATCTCGAGATTAGTGGTCGTTCTTGCGGCTTTTTG 1764 chr1ENST00000209884.4 KLHL20CCGGCACATTGTGAATCCCATATTTCTCGAGAAATATGGGATTCACAATGTGTTTTTG 1765 chr1ENST00000209884.4 LEFTY1CCGGACAAGTTACCTCACCTAATTTCTCGAGAAATTAGGTGAGGTAACTTGTTTTTTG 1766 chr1ENST00000272134.5 LEFTY1CCGGAGCCCAATGTGTCATTGTTTACTCGAGTAAACAATGACACATTGGGCTTTTTTG 1767 chr1ENST00000272134.5 LEFTY1CCGGTCTCTAGTGAGCCCTGAATTTCTCGAGAAATTCAGGGCTCACTAGAGATTTTTG 1768 chr1ENST00000272134.5 LEFTY2CCGGAGTTACTCCATCCCAATTTAGCTCGAGCTAAATTGGGATGGAGTAACTTTTTTG 1769 chr1ENST00000366820.9 LEFTY2CCGGCTAAGCACTTACGTGAGTAAACTCGAGTTTACTCACGTAAGTGCTTAGTTTTTG 1770 chr1ENST00000366820.9 LEFTY2CCGGTAGGCGCCTGGTGTATCCATTCTCGAGAATGGATACACCAGGCGCCTATTTTTG 1771 chr1ENST00000366820.9 LIFCCGGGCAGTGCCAATGCCCTCTTTACTCGAGTAAAGAGGGCATTGGCACTGCTTTTTG 1772 chr22ENST00000249075.3 LIFCCGGACCGCATAGTCGTGTACCTTGCTCGAGCAAGGTACACGACTATGCGGTTTTTTG 1773 chr22ENST00000249075.3 LIFCCGGCAACAACCTGGACAAGCTATGCTCGAGCATAGCTTGTCCAGGTTGTTGTTTTTG 1774 chr22ENST00000249075.3 LIFRCCGGTGACTTGCGACTACGTCATTACTCGAGTAATGACGTAGTCGCAAGTCATTTTTG 1775 chr5ENST00000263409.8 LIFRCCGGACTTCTGCAGATTCGATATTACTCGAGTAATATCGAATCTGCAGAAGTTTTTTG 1776 chr5ENST00000263409.8 LIFRCCGGGTAGGCTCAGACATAACATTTCTCGAGAAATGTTATGTCTGAGCCTACTTTTTG 1777 chr5ENST00000263409.8 LTACCGGGCCCTAGTACTGTCTTCTTTGCTCGAGCAAAGAAGACAGTACTAGGGCTTTTTG 1778 chr6ENST00000418386.2 LTACCGGGATCAAGTCACCGGAGCTTTCCTCGAGGAAAGCTCCGGTGACTTGATCTTTTTG 1779 chr6ENST00000418386.2 LTACCGGGCTCCCAGAAGATGGTGTATCCTCGAGGATACACCATCTTCTGGGAGCTTTTTG 1780 chr6ENST00000418386.2 LTBCCGGGCGAGAGGGAAGACCTTCTTTCTCGAGAAAGAAGGTCTTCCCTCTCGCTTTTTG 1781 chr6ENST00000429299.2 LTBCCGGCGAGAGGGTGTACGTCAACATCTCGAGATGTTGACGTACACCCTCTCGTTTTTG 1782 chr6ENST00000429299.2 LTBCCGGGACGAAGGAACAGGCGTTTCTCTCGAGAGAAACGCCTGTTCCTTCGTCTTTTTG 1783 chr6ENST00000429299.2 LTBP1CCGGGATGACCTGTGTCGATGTAAACTCGAGTTTACATCGACACAGGTCATCTTTTTG 1784 chr2ENST00000407925.5 LTBP1CCGGGGTGGAACAGTGCTGTTATTTCTCGAGAAATAACAGCACTGTTCCACCTTTTTG 1785 chr2ENST00000407925.5 LTBP1CCGGCCGTTGAATACCGCCTTGAATCTCGAGATTCAAGGCGGTATTCAACGGTTTTTG 1786 chr2ENST00000407925.5 LTBP3CCGGGCATCCTCAATGGATGTGAAACTCGAGTTTCACATCCATTGAGGATGCTTTTTG 1787 chr11ENST00000322147.8 LTBP3CCGGTGTTGTTCGGGTCGGAGATTTCTCGAGAAATCTCCGACCCGAACAACATTTTTG 1788 chr11ENST00000322147.8 LTBP3CCGGAGCGCTTCAAGGTGGTCTTTGCTCGAGCAAAGACCACCTTGAAGCGCTTTTTTG 1789 chr11ENST00000322147.8 LTBP4CCGGGCTTCGACATGCCAGACTTTGCTCGAGCAAAGTCTGGCATGTCGAAGCTTTTTG 1790 chr19ENST00000308370.11 LTBP4CCGGTGAAACACTACAGGGTGTATGCTCGAGCATACACCCTGTAGTGTTTCATTTTTG 1791 chr19ENST00000308370.11 LTBP4CCGGCAACCGGCTTTGAAAGAGTTACTCGAGTAACTCTTTCAAAGCCGGTTGTTTTTG 1792 chr19ENST00000308370.11 MAFCCGGTCAGTGGGATACGCCACATTTCTCGAGAAATGTGGCGTATCCCACTGATTTTTG 1793 chr16ENST00000326043.4 MAFCCGGTTTATGGTGTGTGCAAGTAAACTCGAGTTTACTTGCACACACCATAAATTTTTG 1794 chr16ENST00000326043.4 MAFCCGGGTTAGAGAAGAAGGCTATTAACTCGAGTTAATAGCCTTCTTCTCTAACTTTTTG 1795 chr16ENST00000326043.4 MAFCCGGTGTTAATGACTTCGATCTGATCTCGAGATCAGATCGAAGTCATTAACATTTTTG 1796 chr16ENST00000326043.4 MIFCCGGCTACATCAACTATTACGACATCTCGAGATGTCGTAATAGTTGATGTAGTTTTTG 1797 chr22ENST00000215754.7 MIFCCGGCTACATCAACTATTACGACATCTCGAGATGTCGTAATAGTTGATGTAGTTTTTG 1798 chr22ENST00000215754.7 MIFCCGGGACAGGGTCTACATCAACTATCTCGAGATAGTTGATGTAGACCCTGTCTTTTTG 1799 chr22ENST00000215754.7 MINOS1-CCGGGCCAAGCTGCACAATTTAATACTCGAGTATTAAATTGTGCAGCTTGGCTTTTTG 1800 chr1ENST00000602662.1 MINOS1-CCGGGCTGGCACTGTTCCCAGATAACTCGAGTTATCTGGGAACAGTGCCAGCTTTTTG 1801 chr1ENST00000602662.1 MINOS1-CCGGAGAAAGACCACTGGCAGAAACCTCGAGGTTTCTGCCAGTGGTCTTTCTTTTTTG 1802 chr1ENST00000602662.1 MSTNCCGGAGGCCCAACTATGGATATATTCTCGAGAATATATCCATAGTTGGGCCTTTTTTG 1803 chr2ENST00000260950.4 MSTNCCGGGAGCTAGAAGGAGATCAAATTCTCGAGAATTTGATCTCCTTCTAGCTCTTTTTG 1804 chr2ENST00000260950.4 MSTNCCGGGTATGCTTTAAAGTCTATTTCCTCGAGGAAATAGACTTTAAAGCATACTTTTTG 1805 chr2ENST00000260950.4 NAMPTCCGGAGCGATAGCTATGACATTTATCTCGAGATAAATGTCATAGCTATCGCTTTTTTG 1806 chr7ENST00000222553.7 NAMPTCCGGGTGAAGATCTAAGACATTTAACTCGAGTTAAATGTCTTAGATCTTCACTTTTTG 1807 chr7ENST00000222553.7 NAMPTCCGGTACAAGGTTACTCACTATAAACTCGAGTTTATAGTGAGTAACCTTGTATTTTTG 1808 chr7ENST00000222553.7 NBL1CCGGGCCAAGCTGCACAATTTAATACTCGAGTATTAAATTGTGCAGCTTGGCTTTTTG 1809 chr1ENST00000375136.7 NBL1CCGGGCTGGCACTGTTCCCAGATAACTCGAGTTATCTGGGAACAGTGCCAGCTTTTTG 1810 chr1ENST00000375136.7 NBL1CCGGAGAAAGACCACTGGCAGAAACCTCGAGGTTTCTGCCAGTGGTCTTTCTTTTTTG 1811 chr1ENST00000375136.7 NDPCCGGCTGCTAAAGGTTACCGATTTCCTCGAGGAAATCGGTAACCTTTAGCAGTTTTTG 1812 chrXENST00000378062.5 NDPCCGGCTCTGCATATTCTAGTAATAACTCGAGTTATTACTAGAATATGCAGAGTTTTTG 1813 chrXENST00000378062.5 NDPCCGGACGGACAGCTCATTCATAATGCTCGAGCATTATGAATGAGCTGTCCGTTTTTTG 1814 chrXENST00000378062.5 NLRP7CCGGCCGTTCAAGGAAATTTCTATTCTCGAGAATAGAAATTTCCTTGAACGGTTTTTG 1815 chr19ENST00000328092.9 NLRP7CCGGCGGGTCTCTAAGATGTCTTATCTCGAGATAAGACATCTTAGAGACCCGTTTTTG 1816 chr19ENST00000328092.9 NLRP7CCGGACCTGCTCAGAAATCATAAATCTCGAGATTTATGATTTCTGAGCAGGTTTTTTG 1817 chr19ENST00000328092.9 NODALCCGGGTGCTCCTAGATCACCATAAACTCGAGTTTATGGTGATCTAGGAGCACTTTTTG 1818 chr10ENST00000287139.7 NODALCCGGCACCTATAGCTTTCATGTATTCTCGAGAATACATGAAAGCTATAGGTGTTTTTG 1819 chr10ENST00000287139.7 NODALCCGGGCATGCTGTATGTGGATAATGCTCGAGCATTATCCACATACAGCATGCTTTTTG 1820 chr10ENST00000287139.7 NOGCCGGAGGTCAGTATTATACGTTAAACTCGAGTTTAACGTATAATACTGACCTTTTTTG 1821 chr17ENST00000332822.4 NOGCCGGATTCTGGTTGTTGCTAATAATCTCGAGATTATTAGCAACAACCAGAATTTTTTG 1822 chr17ENST00000332822.4 NOGCCGGTGCGGAGGAAGTTACAGATGTCTCGAGACATCTGTAACTTCCTCCGCATTTTTG 1823 chr17ENST00000332822.4 NRG1CCGGGATATCACAGAGGCCTATAACCTCGAGGTTATAGGCCTCTGTGATATCTTTTTG 1824 chr8ENST00000287842.7 NRG1CCGGGGCTGATTCTGGAGAGTATATCTCGAGATATACTCTCCAGAATCAGCCTTTTTG 1825 chr8ENST00000287842.7 NRG1CCGGGACAGTGCCTCTGCCAATATCCTCGAGGATATTGGCAGAGGCACTGTCTTTTTG 1826 chr8ENST00000287842.7 NRP1CCGGTATACTAGAATCACCGCATTTCTCGAGAAATGCGGTGATTCTAGTATATTTTTG 1827 chr10ENST00000265371.8 NRP1CCGGCAGCCTTGAATGCACTTATATCTCGAGATATAAGTGCATTCAAGGCTGTTTTTG 1828 chr10ENST00000265371.8 NRP1CCGGCAGCCTTGAATGCACTTATATCTCGAGATATAAGTGCATTCAAGGCTGTTTTTG 1829 chr10ENST00000265371.8 NRP2CCGGCGACTGCAAGTATGACTTTATCTCGAGATAAAGTCATACTTGCAGTCGTTTTTG 1830 chr2ENST00000357785.9 NRP2CCGGCCGGATTGCTAATGAACAGATCTCGAGATCTGTTCATTAGCAATCCGGTTTTTG 1831 chr2ENST00000357785.9 NRP2CCGGCCTCAACTTCAACCCTCACTTCTCGAGAAGTGAGGGTTGAAGTTGAGGTTTTTG 1832 chr2ENST00000357785.9 OSMCCGGACTTCCTCCTTTCCGTGTTTCCTCGAGGAAACACGGAAAGGAGGAAGTTTTTTG 1833 chr22ENST00000215781.2 OSMCCGGGGACCGACTTTCCATTGATTCCTCGAGGAATCAATGGAAAGTCGGTCCTTTTTG 1834 chr22ENST00000215781.2 OSMCCGGTGGTCCTTGCACTCCTGTTTCCTCGAGGAAACAGGAGTGCAAGGACCATTTTTG 1835 chr22ENST00000215781.2 OSMRCCGGTAACCTGACTCATCGAGTTTACTCGAGTAAACTCGATGAGTCAGGTTATTTTTG 1836 chr5ENST00000274276.7 OSMRCCGGAGGAGAACCCTCACCTAATAACTCGAGTTATTAGGTGAGGGTTCTCCTTTTTTG 1837 chr5ENST00000274276.7 OSMRCCGGGCACTCCATAAGGAATAATTTCTCGAGAAATTATTCCTTATGGAGTGCTTTTTG 1838 chr5ENST00000274276.7 PARK7CCGGGTAGCCGTGATGTGGTCATTTCTCGAGAAATGACCACATCACGGCTACTTTTTG 1839 chr1ENST00000338639.9 PARK7CCGGGCAATTGTTGAAGCCCTGAATCTCGAGATTCAGGGCTTCAACAATTGCTTTTTG 1840 chr1ENST00000338639.9 PARK7CCGGACTCTGAGAATCGTGTGGAAACTCGAGTTTCCACACGATTCTCAGAGTTTTTTG 1841 chr1ENST00000338639.9 PDPNCCGGGCCTCTGGTATGAGAAATAAACTCGAGTTTATTTCTCATACCAGAGGCTTTTTG 1842 chr1ENST00000294489.10 PDPNCCGGAGTCCACGCGCAAGAACAAAGCTCGAGCTTTGTTCTTGCGCGTGGACTTTTTTG 1843 chr1ENST00000294489.10 PDPNCCGGTGACCCTGGTTGGAATCATAGCTCGAGCTATGATTCCAACCAGGGTCATTTTTG 1844 chr1ENST00000294489.10 PF4CCGGACGCTGAAGAATGGAAGGAAACTCGAGTTTCCTTCCATTCTTCAGCGTTTTTTG 1845 chr4ENST00000296029.3 PF4CCGGCCAACTGATAGCCACGCTGAACTCGAGTTCAGCGTGGCTATCAGTTGGTTTTTG 1846 chr4ENST00000296029.3 PF4CCGGCACGCTGAAGAATGGAAGGAACTCGAGTTCCTTCCATTCTTCAGCGTGTTTTTG 1847 chr4ENST00000296029.3 PF4V1CCGGGTTGTGGTATAGTCAATCTATCTCGAGATAGATTGACTATACCACAACTTTTTG 1848 chr4ENST00000226524.3 PF4V1CCGGAGCTGCCTAAGTGTGCACTTTCTCGAGAAAGTGCACACTTAGGCAGCTTTTTTG 1849 chr4ENST00000226524.3 PF4V1CCGGCTGACACATCACAATTTCATACTCGAGTATGAAATTGTGATGTGTCAGTTTTTG 1850 chr4ENST00000226524.3 PGLYRP1CCGGGTGCCCACTCAGGTCACTTATCTCGAGATAAGTGACCTGAGTGGGCACTTTTTG 1851 chr19ENST00000008938.4 PGLYRP1CCGGCTTACGCTATGTGGTGGTATCCTCGAGGATACCACCACATAGCGTAAGTTTTTG 1852 chr19ENST00000008938.4 PGLYRP1CCGGCATCAGCTTCATGGGCAACTACTCGAGTAGTTGCCCATGAAGCTGATGTTTTTG 1853 chr19ENST00000008938.4 PLP2CCGGCCTGTCGGTGATTGAGATGATCTCGAGATCATCTCAATCACCGACAGGTTTTTG 1854 chrXENST00000376327.5 PLP2CCGGCCTGTCGGTGATTGAGATGATCTCGAGATCATCTCAATCACCGACAGGTTTTTG 1855 chrXENST00000376327.5 PLP2CCGGCGAAAGGGAATCCTCCTGTTTCTCGAGAAACAGGAGGATTCCCTTTCGTTTTTG 1856 chrXENST00000376327.5 PPBPCCGGAGGTGATGAATCTGCTGATTACTCGAGTAATCAGCAGATTCATCACCTTTTTTG 1857 chr4ENST00000296028.3 PPBPCCGGTGTTTCTGCCAAACTTCTTTACTCGAGTAAAGAAGTTTGGCAGAAACATTTTTG 1858 chr4ENST00000296028.3 PPBPCCGGCTCCCAGGAAGGGTAGAATTTCTCGAGAAATTCTACCCTTCCTGGGAGTTTTTG 1859 chr4ENST00000296028.3 PXDNCCGGAGATTGCGACTGGACTCAAACCTCGAGGTTTGAGTCCAGTCGCAATCTTTTTTG 1860 chr2ENST00000252804.8 PXDNCCGGGTTCCTGACGTCAGTCGAAATCTCGAGATTTCGACTGACGTCAGGAACTTTTTG 1861 chr2ENST00000252804.8 PXDNCCGGGAAGGATTCTTGACCATCAATCTCGAGATTGATGGTCAAGAATCCTTCTTTTTG 1862 chr2ENST00000252804.8 RORCCCGGCACCTCACAAATTGAAGTGATCTCGAGATCACTTCAATTTGTGAGGTGTTTTTG 1863 chr1ENST00000318247.6 RORCCCGGGCCCTCATATTCCAACAACTTCTCGAGAAGTTGTTGGAATATGAGGGCTTTTTG 1864 chr1ENST00000318247.6 RORCCCGGGCTTCTCAAAGCAGGAGCAATCTCGAGATTGCTCCTGCTTTGAGAAGCTTTTTG 1865 chr1ENST00000318247.6 RORCCCGGCGAGGATGAGATTGCCCTCTACTCGAGTAGAGGGCAATCTCATCCTCGTTTTTG 1866 chr1ENST00000318247.6 SCG2CCGGACGACAAGGATCAAGAATTAGCTCGAGCTAATTCTTGATCCTTGTCGTTTTTTG 1867 chr2ENST00000305409.2 SCG2CCGGCCTGTCTCTTATCCCTTTAATCTCGAGATTAAAGGGATAAGAGACAGGTTTTTG 1868 chr2ENST00000305409.2 SCG2CCGGGAAAGCAGCCCAGATTATAATCTCGAGATTATAATCTGGGCTGCTTTCTTTTTG 1869 chr2ENST00000305409.2 SCGB3A1CCGGTCATAGAGGGCTCCCAGAAGTCTCGAGACTTCTGGGAGCCCTCTATGATTTTTG 1870 chr5ENST00000292641.3 SCGB3A1CCGGCCCGTGAACCACCTCATAGAGCTCGAGCTCTATGAGGTGGTTCACGGGTTTTTG 1871 chr5ENST00000292641.3 SCGB3A1CCGGGACTGGAGCATCTACACCTGACTCGAGTCAGGTGTAGATGCTCCAGTCTTTTTG 1872 chr5ENST00000292641.3 SECTM1CCGGCACCAGAGAAATAACAGACAACTCGAGTTGTCTGTTATTTCTCTGGTGTTTTTG 1873 chr17ENST00000269389.7 SECTM1CCGGCCATGACTCGAATATCTGAAACTCGAGTTTCAGATATTCGAGTCATGGTTTTTG 1874 chr17ENST00000269389.7 SECTM1CCGGCCATGACTCGAATATCTGAAACTCGAGTTTCAGATATTCGAGTCATGGTTTTTG 1875 chr17ENST00000269389.7 SLURP1CCGGGTGCTTCCTGCAGGACCATTACTCGAGTAATGGTCCTGCAGGAAGCACTTTTTG 1876 chr8ENST00000246515.1 SLURP1CCGGAGACCTCTGCAACTCGGAACTCTCGAGAGTTCCGAGTTGCAGAGGTCTTTTTTG 1877 chr8ENST00000246515.1 SLURP1CCGGCTCAAGTGCTACACCTGCAAGCTCGAGCTTGCAGGTGTAGCACTTGAGTTTTTG 1878 chr8ENST00000246515.1 SOSTDC1CCGGGATGCCACAGAAATCCTTTATCTCGAGATAAAGGATTTCTGTGGCATCTTTTTG 1879 chr7ENST00000307068.4 SOSTDC1CCGGGGAACTGCGTTCCACCAAATACTCGAGTATTTGGTGGAACGCAGTTCCTTTTTG 1880 chr7ENST00000307068.4 SOSTDC1CCGGTGAATCTTCACAGTAACATTTCTCGAGAAATGTTACTGTGAAGATTCATTTTTG 1881 chr7ENST00000307068.4 SP100CCGGGAAGTGAGCCTGTGATCAATACTCGAGTATTGATCACAGGCTCACTTCTTTTTG 1882 chr2ENST00000340126.8 SP100CCGGTATACGCTGCGGTGGATATACCTCGAGGTATATCCACCGCAGCGTATATTTTTG 1883 chr2ENST00000340126.8 SP100CCGGTCGTGATCTCATCACAAATAACTCGAGTTATTTGTGATGAGATCACGATTTTTG 1884 chr2ENST00000340126.8 SPI1CCGGGCCCTATGACACGGATCTATACTCGAGTATAGATCCGTGTCATAGGGCTTTTTG 1885 chr11ENST00000378538.7 SPI1CCGGAGAGCTTCGCCGAGAACAACTCTCGAGAGTTGTTCTCGGCGAAGCTCTTTTTTG 1886 chr11ENST00000378538.7 SPI1CCGGCGGATCTATACCAACGCCAAACTCGAGTTTGGCGTTGGTATAGATCCGTTTTTG 1887 chr11ENST00000378538.7 SPI1CCGGCCGTATGTAAATCAGATCTCCCTCGAGGGAGATCTGATTTACATACGGTTTTTG 1888 chr11ENST00000378538.7 SPP1CCGGCCACAAGCAGTCCAGATTATACTCGAGTATAATCTGGACTGCTTGTGGTTTTTG 1889 chr4ENST00000237623.11 SPP1CCGGCCGAGGTGATAGTGTGGTTTACTCGAGTAAACCACACTATCACCTCGGTTTTTG 1890 chr4ENST00000237623.11 SPP1CCGGCTTCAGGGTTATGTCTATGTTCTCGAGAACATAGACATAACCCTGAAGTTTTTG 1891 chr4ENST00000237623.11 TBX21CCGGGCCCTAACTACAGTCGTTTACCTCGAGGTAAACGACTGTAGTTAGGGCTTTTTG 1892 ch17ENSTO0000177694.1 TBX21CCGGCCTGTTGTGGTCCAAGTTTAACTCGAGTTAAACTTGGACCACAACAGGTTTTTG 1893 ch17ENSTO0000177694.1 TBX21CCGGCGCTTCCAACACGCATATCTTCTCGAGAAGATATGCGTGTTGGAAGCGTTTTTG 1894 ch17ENSTO0000177694.1 TBX21CCGGACAATGTGACCCAGATGATTGCTCGAGCAATCATCTGGGTCACATTGTTTTTTG 1895 ch17ENSTO0000177694.1 TCAPCCGGCTTTGTAGTTTGCCCAGAGTTCTCGAGAACTCTGGGCAAACTACAAAGTTTTTG 1896 chr17ENST00000309889.2 TCAPCCGGGGCCATGGCTGCTTTGTAGTTCTCGAGAACTACAAAGCAGCCATGGCCTTTTTG 1897 chr17ENST00000309889.2 TCAPCCGGGGTGGCTGAGATCACAAAGCACTCGAGTGCTTTGTGATCTCAGCCACCTTTTTG 1898 chr17ENST00000309889.2 TGFB1CCGGACTGCGGATCTCTGTGTCATTCTCGAGAATGACACAGAGATCCGCAGTTTTTTG 1899 chr19ENST00000221930.5 TGFB1CCGGCCACAACGAAATCTATGACAACTCGAGTTGTCATAGATTTCGTTGTGGTTTTTG 1900 chr19ENST00000221930.5 TGFB1CCGGCCACAACGAAATCTATGACAACTCGAGTTGTCATAGATTTCGTTGTGGTTTTTG 1901 chr19ENST00000221930.5 TGFB2CCGGGCGGCCTATTGCTTTAGAAATCTCGAGATTTCTAAAGCAATAGGCCGCTTTTTG 1902 chr1ENST00000366930.8 TGFB2CCGGGCTGGAGCATGCCCGTATTTACTCGAGTAAATACGGGCATGCTCCAGCTTTTTG 1903 chr1ENST00000366930.8 TGFB2CCGGTTGCTGCCTACGTCCACTTTACTCGAGTAAAGTGGACGTAGGCAGCAATTTTTG 1904 chr1ENST00000366930.8 TGFB3CCGGCATTGCCAAACAGCGCTATATCTCGAGATATAGCGCTGTTTGGCAATGTTTTTG 1905 chr14ENST00000238682.7 TGFB3CCGGGCTCTAGGGAATCTGGATTATCTCGAGATAATCCAGATTCCCTAGAGCTTTTTG 1906 chr14ENST00000238682.7 TGFB3CCGGCGGAATACTATGCCAAAGAAACTCGAGTTTCTTTGGCATAGTATTCCGTTTTTG 1907 chr14ENST00000238682.7 TGFBR1CCGGGCCTTGAGAGTAATGGCTAAACTCGAGTTTAGCCATTACTCTCAAGGCTTTTTG 1908 chr9ENST00000374994.8 TGFBR1CCGGCTCATGTTGATGGTCTATATCCTCGAGGATATAGACCATCAACATGAGTTTTTG 1909 chr9ENST00000374994.8 TGFBR1CCGGGAAGTTGCTGTTAAGATATTCCTCGAGGAATATCTTAACAGCAACTTCTTTTTG 1910 chr9ENST00000374994.8 TGFBR2CCGGCGTTCAGAAGTCGGTTAATAACTCGAGTTATTAACCGACTTCTGAACGTTTTTG 1911 chr3ENST00000295754.9 TGFBR2CCGGCTCTAGGCTTTATCGTGTTTACTCGAGTAAACACGATAAAGCCTAGAGTTTTTG 1912 chr3ENST00000295754.9 TGFBR2CCGGCTCAGGAAATGAGATTGATTTCTCGAGAAATCAATCTCATTTCCTGAGTTTTTG 1913 chr3ENST00000295754.9 TGFBR3CCGGGGAGTTGGTAAAGGGTTAATACTCGAGTATTAACCCTTTACCAACTCCTTTTTG 1914 chr1ENST00000212355.8 TGFBR3CCGGTAATGGATTTCCGGGAGATATCTCGAGATATCTCCCGGAAATCCATTATTTTTG 1915 chr1ENST00000212355.8 TGFBR3CCGGCACACCCAGGGCTAGTATAAACTCGAGTTTATACTAGCCCTGGGTGTGTTTTTG 1916 chr1ENST00000212355.8 THBS1CCGGGTAGGTTATGATGAGTTTAATCTCGAGATTAAACTCATCATAACCTACTTTTTG 1917 chr15ENST00000260356.5 THBS1CCGGCGTGACTGTAAGATTGTAAATCTCGAGATTTACAATCTTACAGTCACGTTTTTG 1918 chr15ENST00000260356.5 THBS1CCGGGAGATCCCTAATCATCAAATTCTCGAGAATTTGATGATTAGGGATCTCTTTTTG 1919 chr15ENST00000260356.5 THNSL2CCGGGAGCCGATCAAGACTGTGTTTCTCGAGAAACACAGTCTTGATCGGCTCTTTTTG 1920 chr2ENST00000324166.6 THNSL2CCGGGCTGCCATTGAGAGTGTTCAACTCGAGTTGAACACTCTCAATGGCAGCTTTTTG 1921 chr2ENST00000324166.6 THNSL2CCGGGCTGCCATTGAGAGTGTTCAACTCGAGTTGAACACTCTCAATGGCAGCTTTTTG 1922 chr2ENST00000324166.6 THPOCCGGGACCTCCGAGTCCTCAGTAAACTCGAGTTTACTGAGGACTCGGAGGTCTTTTTG 1923 chr3ENST00000204615.11 THPOCCGGAGCTAGCTCTTTGGTCTATTTCTCGAGAAATAGACCAAAGAGCTAGCTTTTTTG 1924 chr3ENST00000204615.11 THPOCCGGCAACCTCCAGCCTGGATATTCCTCGAGGAATATCCAGGCTGGAGGTTGTTTTTG 1925 chr3ENST00000204615.11 TIMP1CCGGGCACAGTGTTTCCCTGTTTATCTCGAGATAAACAGGGAAACACTGTGCTTTTTG 1926 chrXENST00000218388.8 TIMP1CCGGGCACAGTGTTTCCCTGTTTATCTCGAGATAAACAGGGAAACACTGTGCTTTTTG 1927 chrXENST00000218388.8 TIMP1CCGGACAGACGGCCTTCTGCAATTCCTCGAGGAATTGCAGAAGGCCGTCTGTTTTTTG 1928 chrXENST00000218388.8 TNFCCGGGAACCCAAGCTTAGAACTTTACTCGAGTAAAGTTCTAAGCTTGGGTTCTTTTTG 1929 chr6ENST00000449264.2 TNFCCGGGGAGCCAGCTCCCTCTATTTACTCGAGTAAATAGAGGGAGCTGGCTCCTTTTTG 1930 chr6ENST00000449264.2 TNFCCGGTGGCGTGGAGCTGAGAGATAACTCGAGTTATCTCTCAGCTCCACGCCATTTTTG 1931 chr6ENST00000449264.2 TNFRSF4CCGGGCACGTGGTGTAACCTCAGAACTCGAGTTCTGAGGTTACACCACGTGCTTTTTG 1932 chrlENST00000379236.3 TNFRSF4CCGGCAGCAATAGCTCGGACGCAATCTCGAGATTGCGTCCGAGCTATTGCTGTTTTTG 1933 chr1ENST00000379236.3 TNFRSF4CCGGGACAGCTACAAGCCTGGAGTTCTCGAGAACTCCAGGCTTGTAGCTGTCTTTTTG 1934 chr1ENST00000379236.3 TNFRSF4CCGGGCTTCTACAACGACGTGGTCACTCGAGTGACCACGTCGTTGTAGAAGCTTTTTG 1935 chr1ENST00000379236.3 TNFRSF11CCGGTGTTTACTTGCCCGGTTTAATCTCGAGATTAAACCGGGCAAGTAAACATTTTTG 1936 chr18ENST00000586569.2 TNFRSF11CCGGTGTACCAGTGAGAAGCATTATCTCGAGATAATGCTTCTCACTGGTACATTTTTG 1937 chr18ENST00000586569.2 TNFRSF11CCGGTGGGACGGTGCTGTAACAAATCTCGAGATTTGTTACAGCACCGTCCCATTTTTG 1938 chr18ENST00000586569.2 TNFRSF11CCGGGAAAGCACTCACAGCTAATTTCTCGAGAAATTAGCTGTGAGTGCTTTCTTTTTG 1939 chr8ENST00000297350.8 TNFRSF11CCGGGATAAATGCTTGCTGCATAAACTCGAGTTTATGCAGCAAGCATTTATCTTTTTG 1940 chr8ENST00000297350.8 TNFRSF11CCGGCCAGTGTGTGTTCATTGTAAACTCGAGTTTACAATGAACACACACTGGTTTTTG 1941 chr8ENST00000297350.8 TNFRSF1ACCGGAGAACCAGTACCGGCATTATTCTCGAGAATAATGCCGGTACTGGTTCTTTTTTG 1942 chr12ENST00000162749.6 TNFRSF1ACCGGGGAGCTGTTGGTGGGAATATACTCGAGTATATTCCCACCAACAGCTCCTTTTTG 1943 chr12ENST00000162749.6 TNFRSF1ACCGGCTTGAAGGAACTACTACTAAGCTCGAGCTTAGTAGTAGTTCCTTCAAGTTTTTG 1944 chr12ENST00000162749.6 TNFRSF9CCGGGCTCCGTTTCTCTGTTGTTAACTCGAGTTAACAACAGAGAAACGGAGCTTTTTG 1945 chrlENST00000377507.7 TNFRSF9CCGGCAAGAACACCATCCTACATAACTCGAGTTATGTAGGATGGTGTTCTTGTTTTTG 1946 chrlENST00000377507.7 TNFRSF9CCGGCAGTCCCTGTCCTCCAAATAGCTCGAGCTATTTGGAGGACAGGGACTGTTTTTG 1947 chrlENST00000377507.7 TNFSF9CCGGCAAGTTGGACCTTGATATTTACTCGAGTAAATATCAAGGTCCAACTTGTTTTTG 1948 chr19ENST00000245817.4 TNFSF9CCGGCTACTATGTCTTCTTTCAACTCTCGAGAGTTGAAAGAAGACATAGTAGTTTTTG 1949 chr19ENST00000245817.4 TNFSF9CCGGCCCTTCACCGAGGTCGGAATACTCGAGTATTCCGACCTCGGTGAAGGGTTTTTG 1950 chr19ENST00000245817.4 TNFSF9CCGGTGAGCTACAAAGAGGACACGACTCGAGTCGTGTCCTCTTTGTAGCTCATTTTTG 1951 chr19ENST00000245817.4 TNFSF10CCGGAGAAATAGTTGTTGGTCTAAACTCGAGTTTAGACCAACAACTATTTCTTTTTTG 1952 chr3ENST00000241261.6 TNFSF10CCGGAGTTATCCTGACCCTATATTGCTCGAGCAATATAGGGTCAGGATAACTTTTTTG 1953 chr3ENST00000241261.6 TNFSF10CCGGGACAAACAAATGGTCCAATATCTCGAGATATTGGACCATTTGTTTGTCTTTTTG 1954 chr3ENST00000241261.6 TNFSF11CCGGCTAATGGTGTACGTCACTAAACTCGAGTTTAGTGACGTACACCATTAGTTTTTG 1955 chr13ENST00000398795.6 TNFSF11CCGGCCGGATCAGGATGCAACATACCTCGAGGTATGTTGCATCCTGATCCGGTTTTTG 1956 chr13ENST00000398795.6 TNFSF11CCGGGCAGTATATTTCTTCGTTCTTCTCGAGAAGAACGAAGAAATATACTGCTTTTTG 1957 chr13ENST00000398795.6 TNFSF12CCGGGTATTCCCACTCTTATCTTACCTCGAGGTAAGATAAGAGTGGGAATACTTTTTG 1958 chr17ENST00000293825.10 TNFSF12CCGGGGGCATTGTGTTCACTGTACTCTCGAGAGTACAGTGAACACAATGCCCTTTTTG 1959 chr17ENST00000293825.10 TNFSF12CCGGCAGATGGAGGTTACACAACTTCTCGAGAAGTTGTGTAACCTCCATCTGTTTTTG 1960 chr17ENST00000293825.10 TNFSF12-CCGGCCTCACCTACTTCGGACTCTTCTCGAGAAGAGTCCGAAGTAGGTGAGGTTTTTG 1961 chr17ENST00000293826.4 TNFSF12-CCGGCTGTACTGTCAGGTGCACTTTCTCGAGAAAGTGCACCTGACAGTACAGTTTTTG 1962 chr17ENST00000293826.4 TNFSF12-CCGGGCGCAGGCAGATGGAGGTTACCTCGAGGTAACCTCCATCTGCCTGCGCTTTTTG 1963 chr17ENST00000293826.4 TNFSF13CCGGCAGTTGCCCTCTGGTTGAGTTCTCGAGAACTCAACCAGAGGGCAACTGTTTTTG 1964 chr17ENST00000338784.8 TNFSF13CCGGATGGCTCTGCTGACCCAACAACTCGAGTTGTTGGGTCAGCAGAGCCATTTTTTG 1965 chr17ENST00000338784.8 TNFSF13CCGGCCCAACAAACAGAGCTGCAGACTCGAGTCTGCAGCTCTGTTTGTTGGGTTTTTG 1966 chr17ENST00000338784.8 TNFSF13BCCGGCCTGAAACACTACCCAATAATCTCGAGATTATTGGGTAGTGTTTCAGGTTTTTG 1967 chr13ENST00000375887.8 TNFSF13BCCGGCTACGCCATGGGACATCTAATCTCGAGATTAGATGTCCCATGGCGTAGTTTTTG 1968 chr13ENST00000375887.8 TNFSF13BCCGGGTGACTTTGTTTCGATGTATTCTCGAGAATACATCGAAACAAAGTCACTTTTTG 1969 chr13ENST00000375887.8 TNFSF14CCGGTCCTGGGAGCAGCTGATACAACTCGAGTTGTATCAGCTGCTCCCAGGATTTTTG 1970 chr19ENST00000599359.1 TNFSF14CCGGGACAGACCGACATCCCATTCACTCGAGTGAATGGGATGTCGGTCTGTCTTTTTG 1971 chr19ENST00000599359.1 TNFSF14CCGGATGGGTCTGACACGTGGAGAACTCGAGTTCTCCACGTGTCAGACCCATTTTTTG 1972 chr19ENST00000599359.1 TNFSF15CCGGATTAAGACACTGATCACTAAACTCGAGTTTAGTGATCAGTGTCTTAATTTTTTG 1973 chr9ENST00000374045.4 TNFSF15CCGGGTCGGGAGACTACTTCATTTACTCGAGTAAATGAAGTAGTCTCCCGACTTTTTG 1974 chr9ENST00000374045.4 TNFSF15CCGGACTATAGGAGGAGAGCAAATACTCGAGTATTTGCTCTCCTCCTATAGTTTTTTG 1975 chr9ENST00000374045.4 TNFSF18CCGGCCTTCAGTTGGCTAATCTTTACTCGAGTAAAGATTAGCCAACTGAAGGTTTTTG 1976 chr1ENST00000404377.3 TNFSF18CCGGCTGAACCTCCTTGCGTGAATACTCGAGTATTCACGCAAGGAGGTTCAGTTTTTG 1977 chr1ENST00000404377.3 TNFSF18CCGGATGATACAAACTCTAACAAACCTCGAGGTTTGTTAGAGTTTGTATCATTTTTTG 1978 chr1ENST00000404377.3 TNFSF4CCGGGTGGCCTCTCTGACTTACAAACTCGAGTTTGTAAGTCAGAGAGGCCACTTTTTG 1979 chr1ENST00000281834.3 TNFSF4CCGGGCAGAACAACTCAGTCATCATCTCGAGATGATGACTGAGTTGTTCTGCTTTTTG 1980 chr1ENST00000281834.3 TNFSF4CCGGGCCAAGATTCGAGAGGAACAACTCGAGTTGTTCCTCTCGAATCTTGGCTTTTTG 1981 chr1ENST00000281834.3 TNFSF8CCGGACTGTATGGTCTTGATCTATTCTCGAGAATAGATCAAGACCATACAGTTTTTTG 1982 chr9ENST00000223795.2 TNFSF8CCGGCAAACTACACAGGGTATTAAACTCGAGTTTAATACCCTGTGTAGTTTGTTTTTG 1983 chr9ENST00000223795.2 TNFSF8CCGGGTGGATACATTCCAGTACATACTCGAGTATGTACTGGAATGTATCCACTTTTTG 1984 chr9ENST00000223795.2 TNFSF9CCGGCAAGTTGGACCTTGATATTTACTCGAGTAAATATCAAGGTCCAACTTGTTTTTG 1985 chr19ENST00000245817.4 TNFSF9CCGGCTACTATGTCTTCTTTCAACTCTCGAGAGTTGAAAGAAGACATAGTAGTTTTTG 1986 chr19ENST00000245817.4 TNFSF9CCGGCCCTTCACCGAGGTCGGAATACTCGAGTATTCCGACCTCGGTGAAGGGTTTTTG 1987 chr19ENST00000245817.4 TRIM16CCGGGCCGTTGTTCAGCGCAAATATCTCGAGATATTTGCGCTGAACAACGGCTTTTTG 1988 chr17ENST00000336708.11 TRIM16CCGGGCCGTTGTTCAGCGCAAATATCTCGAGATATTTGCGCTGAACAACGGCTTTTTG 1989 chr17ENST00000336708.11 TRIM16CCGGCCGCATCAGGTGAACATCAAACTCGAGTTTGATGTTCACCTGATGCGGTTTTTG 1990 chr17ENST00000336708.11 TSLPCCGGACTCAATGATAGCACCTAAACCTCGAGGTTTAGGTGCTATCATTGAGTTTTTTG 1991 chr5ENST00000344895.3 TSLPCCGGCGTCGCTTCAATCGACCTTTACTCGAGTAAAGGTCGATTGAAGCGACGTTTTTG 1992 chr5ENST00000344895.3 TSLPCCGGCCATCTTTATTATGGTCATATCTCGAGATATGACCATAATAAAGATGGTTTTTG 1993 chr5ENST00000344895.3 TWSG1CCGGGACTGTGTTGGTATGTGTAATCTCGAGATTACACATACCAACACAGTCITTTTG 1994 chr18ENST00000262120.9 TWSG1CCGGGCGCCTTATTCCAGTGACAAACTCGAGTTTGTCACTGGAATAAGGCGCTTTTTG 1995 chr18ENST00000262120.9 TWSG1CCGGGAATCACTGAGCTGTAACAAACTCGAGTTTGTTACAGCTCAGTGATTCTTTTTG 1996 chr18ENST00000262120.9 TXLNACCGGGCACATACTGTGTGGACAATACTCGAGTATTGTCCACACAGTATGTGCTTTTTG 1997 chr1ENST00000373609.1 TXLNACCGGTGCTGATGCAGACATTGAATACTCGAGTATTCAATGTCTGCATCAGCATTTTTG 1998 chr1ENST00000373609.1 TXLNACCGGAGCGAGGTATTCACCACATTCCTCGAGGAATGTGGTGAATACCTCGCTTTTTTG 1999 chr1ENST00000373609.1 VASNCCGGAGCTTGACTACGCCGACTTTGCTCGAGCAAAGTCGGCGTAGTCAAGCTTTTTTG 2000 chr16ENST00000304735.3 VASNCCGGAGCCAACAGGCTGCATGAAATCTCGAGATTTCATGCAGCCTGTTGGCTTTTTTG 2001 chr16ENST00000304735.3 VASNCCGGGAGATCCTTTCCCATTTATTCCTCGAGGAATAAATGGGAAAGGATCTCTTTTTG 2002 chr16ENST00000304735.3 VEGFACCGGCAAGATCCGCAGACGTGTAAACTCGAGTTTACACGTCTGCGGATCTTGTTTTTG 2003 chr6ENST00000425836.6 VEGFACCGGCAAGATCCGCAGACGTGTAAACTCGAGTTTACACGTCTGCGGATCTTGTTTTTG 2004 chr6ENST00000425836.6 VEGFACCGGGCGCAAGAAATCCCGGTATAACTCGAGTTATACCGGGATTTCTTGCGCTTTTTG 2005 chr6ENST00000425836.6 VSTM1CCGGATGAATATGCGGCACTGAAAGCTCGAGCTITCAGTGCCGCATATTCATTTTTTG 2006 chr19ENST00000338372.6 VSTM1CCGGCATTCCCAGAATGTGACATTTCTCGAGAAATGTCACATTCTGGGAATGTTTTTG 2007 chr19ENST00000338372.6 VSTM1CCGGGAGTGACCTATGCTGAGCTAACTCGAGTTAGCTCAGCATAGGTCACTCTTTTTG 2008 chr19ENST00000338372.6 WFIKKN1CCGGTGCGCCCTGATCAGATGTATGCTCGAGCATACATCTGATCAGGGCGCATTTTTG 2009 chr16ENST00000319070.2 WFIKKN1CCGGGGACGTGCTCAAGGATGACAACTCGAGTTGTCATCCTTGAGCACGTCCTTTTTG 2010 chr16ENST00000319070.2 WFIKKN1CCGGAGTGCTGCATCAACGTGTGTGCTCGAGCACACACGTTGATGCAGCACTTTTTTG 2011 chr16ENST00000319070.2 WFIKKN2CCGGTCAAGTTCTTGGGCACCAAGTCTCGAGACTTGGTGCCCAAGAACTTGATTTTTG 2012 chr17ENST00000311378.4 WFIKKN2CCGGTACAACCGCTGCTATATGGACCTCGAGGTCCATATAGCAGCGGTTGTATTTTTG 2013 chr17ENST00000311378.4 WFIKKN2CCGGCACCAGCTTGCTCAGATATTCCTCGAGGAATATCTGAGCAAGCTGGTGTTTTTG 2014 chr17ENST00000311378.4 WNT1CCGGCTGTCGAGAAACGGCGTTTATCTCGAGATAAACGCCGTTTCTCGACAGTTTTTG 2015 chr12ENST00000293549.3 WNT1CCGGGACCTCGTCTACTTCGAGAAACTCGAGTTTCTCGAAGTAGACGAGGTCTTTTTG 2016 chr12ENST00000293549.3 WNT1CCGGGCCACGAGTTTGGATGTTGTACTCGAGTACAACATCCAAACTCGTGGCTTTTTG 2017 chr12ENST00000293549.3 WNT2CCGGCCACAAATGGTCCCAATTAAGCTCGAGCTTAATTGGGACCATTTGTGGTTTTTG 2018 chr7ENST00000265441.7 WNT2CCGGTCGGGAATCTGCCTTTGTTTACTCGAGTAAACAAAGGCAGATTCCCGATTTTTG 2019 chr7ENST00000265441.7 WNT2CCGGTTGACTATGGGATCAAATTTGCTCGAGCAAATTTGATCCCATAGTCAATTTTTG 2020 chr7ENST00000265441.7 WNT5ACCGGCTCCCAGGACCCGCTTATTTACTCGAGTAAATAAGCGGGTCCTGGGAGTTTTTG 2021 chr3ENST00000264634.8 WNT5ACCGGCAAAGAATGCCAGTATCAATTCTCGAGAATTGATACTGGCATTCTTTGTTTTTG 2022 chr3ENST00000264634.8 WNT5ACCGGCCTGTTCAGATGTCAGAAGTACTCGAGTACTTCTGACATCTGAACAGGTTTTTG 2023 chr3ENST00000264634.8 WNT7ACCGGCATAGGAGAAGGCTCACAAATCTCGAGATTTGTGAGCCTTCTCCTATGTTTTTG 2024 chr3ENST00000285018.4 WNT7ACCGGGGCGCAAGCATCATCTGTAACCTCGAGGTTACAGATGATGCTTGCGCCTTTTTG 2025 chr3ENST00000285018.4 WNT7ACCGGTCTTCGGGAAGGAGCTCAAAGCTCGAGCTTTGAGCTCCTTCCCGAAGATTTTTG 2026 chr3ENST00000285018.4 XCL1CCGGGCTGTGACAATGGCAACAATTCTCGAGAATTGTTGCCATTGTCACAGCTTTTTG 2027 chr1ENST00000367818.3 XCL1CCGGTTCAACTTGTCTCTATAATAGCTCGAGCTATTATAGAGACAAGTTGAATTTTTG 2028 chr1ENST00000367818.3 XCL1CCGGAGATTCTGGCTAGTGTCTATCCTCGAGGATAGACACTAGCCAGAATCTTTTTTG 2029 chr1ENST00000367818.3 XCL2CCGGACTGCCAGTTAGCAGAATCAACTCGAGTTGATTCTGCTAACTGGCAGTTTTTTG 2030 chr1ENST00000367819.2 XCL2CCGGGTAGGGAGTGAAGTCTCACATCTCGAGATGTGAGACTTCACTCCCTACTTTTTG 2031 chr1ENST00000367819.2 XCL2CCGGGAAATCCAACACCAGAAATAACTCGAGTTATTTCTGGTGTTGGATTTCTTTTTG 2032 chr1ENST00000367819.2 ZFP36CCGGGATCCGACCCTGATGAATATGCTCGAGCATATTCATCAGGGTCGGATCTTTTTG 2033 chr19ENST00000597629.1 ZFP36CCGGATCTGTCTCCTAGAATCTTATCTCGAGATAAGATTCTAGGAGACAGATTTTTTG 2034 chr19ENST00000597629.1 ZFP36CCGGCCCTTTATTTATGACGACTTTCTCGAGAAAGTCGTCATAAATAAAGGGTTTTTG 2035 chr19ENST00000597629.1

TABLE 16 3′ to 5′(Reverse) shRNA sequences for Silencing of Cytokine/ChemokineGenes to Reduce the Incidence of CRS Target SEQ Gene ID SymbolshRNA Reverse Oligo Sequence NO: Location Gene ID No. A2MAATTCAAAAAAGGCGTCCCTATACCAAATAACTCGA 2036 chr12 ENST000003GTTATTTGGTATAGGGACGCCT 18602.11 A2M AATTCAAAAAAGACTGCATCAATCGTCATAACTCGA2037 chr12 ENST000003 GTTATGACGATTGATGCAGTCT 18602.11 A2MAATTCAAAAACCTCCAGACATCCTTGAAATACTCGA 2038 chr12 ENST000003GTATTTCAAGGATGTCTGGAGG 18602.11 ACKR1AATTCAAAAAATCCTGTGGGCCTGGTTTATTCTCGA 2039 chr1 ENST000003GAATAAACCAGGCCCACAGGAT 68122.2 ACKR1AATTCAAAAATGGCAGAAGCCCTGGCAATTTCTCGA 2040 chr1 ENST000003GAAATTGCCAGGGCTTCTGCCA 68122.2 ACKR1AATTCAAAAAGGCGGATGGTTGAGATCTATCCTCGA 2041 chr1 ENST000003GGATAGATCTCAACCATCCGCC 68122.2 ACKR2AATTCAAAAAGAGCACTCTTTATACTATTAACTCGA 2042 chr3 ENST000004GTTAATAGTATAAAGAGTGCTC 22265.5 ACKR2AATTCAAAAAGTGGAACTGCCACGCAGATTTCTCGA 2043 chr3 ENST000004GAAATCTGCGTGGCAGTTCCAC 22265.5 ACKR2AATTCAAAAACATTGGGTCTTCGGGAGTTTCCTCGA 2044 chr3 ENST000004GGAAACTCCCGAAGACCCAATG 22265.5 ACKR3AATTCAAAAACACTATTGGTGTACCTTATAACTCGA 2045 chr2 ENST000002GTTATAAGGTACACCAATAGTG 72928.3 ACKR3AATTCAAAAAGGCATAGTGCTGACATATATTCTCGA 2046 chr2 ENST000002GAATATATGTCAGCACTATGCC 72928.3 ACKR3AATTCAAAAAGCCGTTCCCTTCTCCATTATCCTCGA 2047 chr2 ENST000002GGATAATGGAGAAGGGAACGGC 72928.3 ACVR1AATTCAAAAATGATAATTCCCTCGACAAATTCTCGA 2048 chr2 ENST000002GAATTTGTCGAGGGAATTATCA 63640.7 ACVR1AATTCAAAAAGCAGAACGTATTTAGCCATTACTCGA 2049 chr2 ENST000002GTAATGGCTAAATACGTTCTGC 63640.7 ACVR1AATTCAAAAACTGGTCTGTCTTTGGATAATACTCGA 2050 chr2 ENST000002GTATTATCCAAAGACAGACCAG 63640.7 ACVR2BAATTCAAAAAATGTCACGAGGCCTCTCATACCTCGA 2051 chr3 ENST000003GGTATGAGAGGCCTCGTGACAT 52511.4 ACVR2BAATTCAAAAACCCAGCTCATGAATGACTTTGCTCGA 2052 chr3 ENST000003GCAAAGTCATTCATGAGCTGGG 52511.4 ACVR2BAATTCAAAAACTTTGGCTTGGCTGTTCGATTCTCGA 2053 chr3 ENST000003GAATCGAACAGCCAAGCCAAAG 52511.4 ACVRL1AATTCAAAAACCGGGAGACTGAGATCTATAACTCG 2054 chr12 ENST000003AGTTATAGATCTCAGTCTCCCGG 88922.8 ACVRL1AATTCAAAAACAGGAGCACCTGATTCCTTTCCTCGA 2055 chr12 ENST000003GGAAAGGAATCAGGTGCTCCTG 88922.8 ACVRL1AATTCAAAAACGTGGAGATCTTCGGTACACACTCGA 2056 chr12 ENST000003GTGTGTACCGAAGATCTCCACG 88922.8 ADIPOQAATTCAAAAAGTTGGAGGCCTTTAGATATTACTCGA 2057 chr3 ENST000003GTAATATCTAAAGGCCTCCAAC 20741.6 ADIPOQAATTCAAAAAATGCTCATATCAATCCTATAACTCGA 2058 chr3 ENST000003GTTATAGGATTGATATGAGCAT 20741.6 ADIPOQAATTCAAAAAACGGTTAGGAAGTTGATTATTCTCGA 2059 chr3 ENST000003GAATAATCAACTTCCTAACCGT 20741.6 AGER AATTCAAAAACACACTGCAGTCGGAGCTAATCTCGA2060 chr6 ENST000003 GATTAGCTCCGACTGCAGTGTG 75076.8 AGERAATTCAAAAAGAAGCCAGAAATTGTAGATTCCTCG 2061 chr6 ENST000003AGGAATCTACAATTTCTGGCTTC 75076.8 AGERAATTCAAAAATGCTGATCCTCCCTGAGATAGCTCGA 2062 chr6 ENST000003GCTATCTCAGGGAGGATCAGCA 75076.8 AGRN AATTCAAAAAGAGTTCTGTGTGGAAGATAAACTCG2063 chr1 ENST000003 AGTTTATCTTCCACACAGAACTC 79370.6 AGRNAATTCAAAAAGCGCACGTATGACAGTGATTGCTCGA 2064 chr1 ENST000003GCAATCACTGTCATACGTGCGC 79370.6 AGRN AATTCAAAAAACGACGGAGTCACCTACGAAACTCG2065 chr1 ENST000003 AGTTTCGTAGGTGACTCCGTCGT 79370.6 AHRAATTCAAAAACGGCATAGAGACCGACTTAATCTCG 2066 chr7 ENST000002AGATTAAGTCGGTCTCTATGCCG 42057.8 AHR AATTCAAAAAGCGGCATAGAGACCGACTTAACTCG2067 chr7 ENST000002 AGTTAAGTCGGTCTCTATGCCGC 42057.8 AHRAATTCAAAAAATCCACAGTCAGCCATAATAACTCGA 2068 chr7 ENST000002GTTATTATGGCTGACTGTGGAT 42057.8 AHR AATTCAAAAAACTGCTTAAAGTTGGTATTAACTCGA2069 chr7 ENST000002 GTTAATACCAACTTTAAGCAGT 42057.8 AIMP1AATTCAAAAACAGCCTGATCTTCACACTAATCTCGA 2070 chr4 ENST000003GATTAGTGTGAAGATCAGGCTG 58008.7 AIMP1 AATTCAAAAAAGAAGTAGATGTCGGAGAAATCTCG2071 chr4 ENST000003 AGATTTCTCCGACATCTACTTCT 58008.7 AIMP1AATTCAAAAAGCCAGAGTAACCCTGACTAATCTCGA 2072 chr4 ENST000003GATTAGTCAGGGTTACTCTGGC 58008.7 AREG AATTCAAAAACCTCTTTCCAGTGGATCATAACTCGA2073 chr4 ENST000003 GTTATGATCCACTGGAAAGAGG 95748.7 AREGAATTCAAAAATACTCGGCTCAGGCCATTATGCTCGA 2074 chr4 ENST000003GCATAATGGCCTGAGCCGAGTA 95748.7 AREG AATTCAAAAAATTCACGGAGAATGCAAATATCTCG2075 chr4 ENST000003 AGATATTTGCATTCTCCGTGAAT 95748.7 BCL6AATTCAAAAATGTGCCACAGCAATATCTATTCTCGA 2076 chr3 ENST000004GAATAGATATTGCTGTGGCACA 06870.6 BCL6 AATTCAAAAAACTGCGTTAAAGGCTCGATTTCTCGA2077 chr3 ENST000004 GAAATCGAGCCTTTAACGCAGT 06870.6 BCL6AATTCAAAAACCGGCTCAATAACATCGTTAACTCGA 2078 chr3 ENST000004GTTAACGATGTTATTGAGCCGG 06870.6 BCL6 AATTCAAAAAACAAGCCAGCCGGCTCAATAACTCG2079 chr3 ENST000004 AGTTATTGAGCCGGCTGGCTTGT 06870.6 BMP1AATTCAAAAAACTGACGAGGACAGCTATATTCTCGA 2080 chr8 ENST000003GAATATAGCTGTCCTCGTCAGT 06385.9 BMP1 AATTCAAAAAGCTCGTAAGTCCTCCATCAAACTCGA2081 chr8 ENST000003 GTTTGATGGAGGACTTACGAGC 06385.9 BMP1AATTCAAAAAACAGCTGTGCCTACGACTATCCTCGA 2082 chr8 ENST000003GGATAGTCGTAGGCACAGCTGT 06385.9 BMP10AATTCAAAAAAGCAAGACGGTGTCGACTTTACTCGA 2083 chr2 ENST000002GTAAAGTCGACACCGTCTTGCT 95379.1 BMP10AATTCAAAAAGCGTCGTCACCTACAAGTTTACTCGA 2084 chr2 ENST000002GTAAACTTGTAGGTGACGACGC 95379.1 BMP10AATTCAAAAACATGGCTGAACTTAGGCTATACTCGA 2085 chr2 ENST000002GTATAGCCTAAGTTCAGCCATG 95379.1 BMP15AATTCAAAAATACTACGCGATGGTCTCAATTCTCGA 2086 chrX ENST000002GAATTGAGACCATCGCGTAGTA 52677.3 BMP15AATTCAAAAAGCCTTCTTGTTACTCTATTTCCTCGAG 2087 chrX ENST000002GAAATAGAGTAACAAGAAGGC 52677.3 BMP15 AATTCAAAAAATGGAACACAGGGCCCAAATGCTCG2088 chrX ENST000002 AGCATTTGGGCCCTGTGTTCCAT 52677.3 BMP2AATTCAAAAAGATCATCTGAACTCCACTAATCTCGA 2089 chr20 ENST000003GATTAGTGGAGTTCAGATGATC 78827.4 BMP2 AATTCAAAAACCGGAGATTCTTCTTTAATTTCTCGA2090 chr20 ENST000003 GAAATTAAAGAAGAATCTCCGG 78827.4 BMP2AATTCAAAAACAAGATGCTTTAGGAAACAATCTCG 2091 chr20 ENST000003AGATTGTTTCCTAAAGCATCTTG 78827.4 BMP3AATTCAAAAACTTACAGGGACACCGGAATTTCTCGA 2092 chr4 ENST000002GAAATTCCGGTGTCCCTGTAAG 82701.2 BMP3 AATTCAAAAAGGCCAAATCTCATCGAGATATCTCGA2093 chr4 ENST000002 GATATCTCGATGAGATTTGGCC 82701.2 BMP3AATTCAAAAAGTGGATTGAACCTCGGAATTGCTCGA 2094 chr4 ENST000002GCAATTCCGAGGTTCAATCCAC 82701.2 BMP4 AATTCAAAAACCCTGGTCAATTCTGTCAATTCTCGA2095 chr14 ENST000002 GAATTGACAGAATTGACCAGGG 45451.8 BMP4AATTCAAAAATCCTTGAGGATAGACAGATATCTCGA 2096 chr14 ENST000002GATATCTGTCTATCCTCAAGGA 45451.8 BMP4 AATTCAAAAAAGGGCCAGCATGTCAGGATTACTCG2097 chr14 ENST000002 AGTAATCCTGACATGCTGGCCCT 45451.8 BMP5AATTCAAAAATGGACGCAGTATCAACGTAAACTCG 2098 chr6 ENST000003AGTTTACGTTGATACTGCGTCCA 70830.3 BMP5AATTCAAAAACCAGAAGGATACGCTGCATTTCTCGA 2099 chr6 ENST000003GAAATGCAGCGTATCCTTCTGG 70830.3 BMP5 AATTCAAAAAATGCCACCAACCACGCTATAGCTCGA2100 chr6 ENST000003 GCTATAGCGTGGTTGGTGGCAT 70830.3 BMP6AATTCAAAAAATACAGGAATATGGTTGTAAGCTCG 2101 chr6 ENST000002AGCTTACAACCATATTCCTGTAT 83147.6 BMP6 AATTCAAAAACGCCGACAACAGAGTCGTAATCTCG2102 chr6 ENST000002 AGATTACGACTCTGTTGTCGGCG 83147.6 BMP6AATTCAAAAACTGTCTATCAAAGGTAGATTTCTCGA 2103 chr6 ENST000002GAAATCTACCTTTGATAGACAG 83147.6 BMP7 AATTCAAAAAACGTTCCGGATCAGCGTTTATCTCGA2104 chr20 ENST000003 GATAAACGCTGATCCGGAACGT 95863.7 BMP7AATTCAAAAAACTCGTTTCCAGAGGTAATTACTCGA 2105 chr20 ENST000003GTAATTACCTCTGGAAACGAGT 95863.7 BMP7 AATTCAAAAAACCATCGAGAGTTCCGGTTTGCTCGA2106 chr20 ENST000003 GCAAACCGGAACTCTCGATGGT 95863.7 BMP8AAATTCAAAAAAGGGTGCAGTTAGCATATTAGCTCGA 2107 chr1 ENST000003GCTAATATGCTAACTGCACCCT 31593.5 BMP8AAATTCAAAAAAGCACAGAAGTCCTATCTTAGCTCGA 2108 chr1 ENST000003GCTAAGATAGGACTTCTGTGCT 31593.5 BMP8AAATTCAAAAAAGGTACAACACTGGCCATTTCCTCGA 2109 chr1 ENST000003GGAAATGGCCAGTGTTGTACCT 31593.5 BMP8BAATTCAAAAACCAAGGCTACTCGGCCTATTACTCGA 2110 chr1 ENST000003GTAATAGGCCGAGTAGCCTTGG 72827.7 BMP8BAATTCAAAAAGACCCTCACAACCACGTACATCTCGA 2111 chr1 ENST000003GATGTACGTGGTTGTGAGGGTC 72827.7 BMP8B AATTCAAAAACGTTAACATGGTGGAGCGAGACTCG2112 chr1 ENST000003 AGTCTCGCTCCACCATGTTAACG 72827.7 BMPR2AATTCAAAAAGAACGGCTATGTGCGTTTAAACTCGA 2113 chr2 ENST000003GTTTAAACGCACATAGCCGTTC 74580.8 BMPR2AATTCAAAAAGCCTATGGAGTGAAATTATTTCTCGA 2114 chr2 ENST000003GAAATAATTTCACTCCATAGGC 74580.8 BMPR2AATTCAAAAAATTACCACGAGGAGATCATTACTCGA 2115 chr2 ENST000003GTAATGATCTCCTCGTGGTAAT 74580.8 C10orf99AATTCAAAAACATCATGTGAGGCTCTGTAAACTCGA 2116 chr10 ENST000003GTTTACAGAGCCTCACATGATG 72126.3 C10orf99AATTCAAAAACCCAACTCAACAAACCTGAAACTCG 2117 chr10 ENST000003AGTTTCAGGTTTGTTGAGTTGGG 72126.3 C10orf99AATTCAAAAAGCCATCAACTTTCAGAGCTATCTCGA 2118 chr10 ENST000003GATAGCTCTGAAAGTTGATGGC 72126.3 C1QTNF4AATTCAAAAAACACCGAGTTCGTCAACATTGCTCGA 2119 chr11 ENST000003GCAATGTTGACGAACTCGGTGT 02514.3 C1QTNF4AATTCAAAAAGCGTAAGACGCTGTCGGTTAACTCGA 2120 chr11 ENST000003GTTAACCGACAGCGTCTTACGC 02514.3 C1QTNF4AATTCAAAAACGAGGTGCAGGCCATGATTTACTCGA 2121 chr11 ENST000003GTAAATCATGGCCTGCACCTCG 02514.3 C5 AATTCAAAAAACGATGGAGCCTGCGTTAATACTCGA2122 chr9 ENST000002 GTATTAACGCAGGCTCCATCGT 23642.2 C5AATTCAAAAATCCCGACTTCTGGTCTATTACCTCGA 2123 chr9 ENST000002GGTAATAGACCAGAAGTCGGGA 23642.2 C5 AATTCAAAAAGCCCGAGAGAACAGCTTATATCTCG2124 chr9 ENST000002 AGATATAAGCTGTTCTCTCGGGC 23642.2 CCL1AATTCAAAAAGCAATCCTGTGTTACAGAAATCTCGA 2125 chr17 ENST000002GATTTCTGTAACACAGGATTGC 25842.3 CCL1 AATTCAAAAACTGCTCCAATGAGGGCTTAATCTCGA2126 chr17 ENST000002 GATTAAGCCCTCATTGGAGCAG 25842.3 CCL1AATTCAAAAACCTGAGGGCAATCCTGTGTTACTCGA 2127 chr17 ENST000002GTAACACAGGATTGCCCTCAGG 25842.3 CCL11 AATTCAAAAACCAACTCCAAAGCCATAAATACTCG2128 chr17 ENST000003 AGTATTTATGGCTTTGGAGTTGG 05869.3 CCL11AATTCAAAAACATTCTGAGGTAACCTCATTACTCGA 2129 chr17 ENST000003GTAATGAGGTTACCTCAGAATG 05869.3 CCL11AATTCAAAAATCCTCCATGAATATCAGTTATCTCGA 2130 chr17 ENST000003GATAACTGATATTCATGGAGGA 05869.3 CCL13AATTCAAAAATGGAATACTTCTACCATAATTCTCGA 2131 chr17 ENST000002GAATTATGGTAGAAGTATTCCA 25844.6 CCL13 AATTCAAAAATCAAGCTGGAGTACGTGAAATCTCG2132 chr17 ENST000002 AGATTTCACGTACTCCAGCTTGA 25844.6 CCL13AATTCAAAAAACTCAACGTCCCATCTACTTGCTCGA 2133 chr17 ENST000002GCAAGTAGATGGGACGTTGAGT 25844.6 CCL14 AATTCAAAAACCTAGGGACCAAGACTGAATCCTCG2134 chr17 ENST000006 AGGATTCAGTCTTGGTCCCTAGG 18404.4 CCL14AATTCAAAAACAGCGGATTATGGATTACTATCTCGA 2135 chr17 ENST000006GATAGTAATCCATAATCCGCTG 18404.4 CCL14AATTCAAAAACAAGCCCGGAATTGTCTTCATCTCGA 2136 chr17 ENST000006GATGAAGACAATTCCGGGCTTG 18404.4 CCL15AATTCAAAAAGCTGAAGCCCTACTCAATATACTCGA 2137 chr17 ENST000006GTATATTGAGTAGGGCTTCAGC 17897.1 CCL15 AATTCAAAAAACAGAGTTAATGATGTCAAAGCTCG2138 chr17 ENST000006 AGCTTTGACATCATTAACTCTGT 17897.1 CCL15AATTCAAAAAATCCCGTGTTCACTCATGAAACTCGA 2139 chr17 ENST000006GTTTCATGAGTGAACACGGGAT 17897.1 CCL16AATTCAAAAAAGGAGAAGTATTTCGAATATTCTCGA 2140 chr17 ENST000006GAATATTCGAAATACTTCTCCT 11905.1 CCL16AATTCAAAAAAGGAACTTGTCCACGGTTAAACTCGA 2141 chr17 ENST000006GTTTAACCGTGGACAAGTTCCT 11905.1 CCL16AATTCAAAAACTGCCTGAAGTATTATGAGAACTCGA 2142 chr17 ENST000006GTTCTCATAATACTTCAGGCAG 11905.1 CCL17 AATTCAAAAAGAGAGTGAAGAATGCAGTTAACTCG2143 chr16 ENST000002 AGTTAACTGCATTCTTCACTCTC 19244.8 CCL17AATTCAAAAAGAGTACTTCAAGGGAGCCATTCTCGA 2144 chr16 ENST000002GAATGGCTCCCTTGAAGTACTC 19244.8 CCL17AATTCAAAAAGCAAAGCCTTGAGAGGTCTTGCTCGA 2145 chr16 ENST000002GCAAGACCTCTCAAGGCTTTGC 19244.8 CCL18AATTCAAAAATCTATTGTTGAGCTGCATTATCTCGA 2146 chr17 ENST000006GATAATGCAGCTCAACAATAGA 16054.1 CCL18AATTCAAAAACCTTCAACTCTTCGTACATTCCTCGA 2147 chr17 ENST000006GGAATGTACGAAGAGTTGAAGG 16054.1 CCL18AATTCAAAAAGTCTATACCTCCTGGCAGATTCTCGA 2148 chr17 ENST000006GAATCTGCCAGGAGGTATAGAC 16054.1 CCL19AATTCAAAAAGAGTCAAGCATTGTGAATTATCTCGA 2149 chr9 ENST000003GATAATTCACAATGCTTGACTC 11925.6 CCL19AATTCAAAAAGCCGCAGCAGTTAACCTATGACTCGA 2150 chr9 ENST000003GTCATAGGTTAACTGCTGCGGC 11925.6 CCL19AATTCAAAAACCAACTCTGAGTGGCACCAATCTCGA 2151 chr9 ENST000003GATTGGTGCCACTCAGAGTTGG 11925.6 CCL2 AATTCAAAAACCCAGTCACCTGCTGTTATAACTCGA2152 chr17 ENST000002 GTTATAACAGCAGGTGACTGGG 25831.4 CCL2AATTCAAAAACCCAGTCACCTGCTGTTATAACTCGA 2153 chr17 ENST000002GTTATAACAGCAGGTGACTGGG 25831.4 CCL2 AATTCAAAAAGCTCGCGAGCTATAGAAGAATCTCG2154 chr17 ENST000002 AGATTCTTCTATAGCTCGCGAGC 25831.4 CCL20AATTCAAAAAAGTTGTCTGTGTGCGCAAATCCTCGA 2155 chr2 ENST000003GGATTTGCGCACACAGACAACT 58813.4 CCL20AATTCAAAAAGACCGTATTCTTCATCCTAAACTCGA 2156 chr2 ENST000003GTTTAGGATGAAGAATACGGTC 58813.4 CCL20AATTCAAAAAAGGGTTTAGTGCTTATCTAATCTCGA 2157 chr2 ENST000003GATTAGATAAGCACTAAACCCT 58813.4 CCL21AATTCAAAAACACTCTTTCTCCTGCTTTAACCTCGA 2158 chr9 ENST000002GGTTAAAGCAGGAGAAAGAGTG 59607.6 CCL21 AATTCAAAAAGAGCTATGTGCAGACCCAAAGCTCG2159 chr9 ENST000002 AGCTTTGGGTCTGCACATAGCTC 59607.6 CCL21AATTCAAAAACCATCCCAGCTATCCTGTTCTCTCGA 2160 chr9 ENST000002GAGAACAGGATAGCTGGGATGG 59607.6 CCL22AATTCAAAAACCCTACCTCCCTGCCATTATACTCGA 2161 chr16 ENST000002GTATAATGGCAGGGAGGTAGGG 19235.4 CCL22AATTCAAAAAGCGTGGTGAAACACTTCTACTCTCGA 2162 chr16 ENST000002GAGTAGAAGTGTTTCACCACGC 19235.4 CCL22 AATTCAAAAAATGTTGCTGACACCCAGAAAGCTCG2163 chr16 ENST000002 AGCTTTCTGGGTGTCAGCAACAT 19235.4 CCL23AATTCAAAAACACTCCTGGAGAGTTACTTTGCTCGA 2164 chr17 ENST000006GCAAAGTAACTCTCCAGGAGTG 15050.1 CCL23AATTCAAAAACCTTTCTCATGCTGCAGGATTCTCGA 2165 chr17 ENST000006GAATCCTGCAGCATGAGAAAGG 15050.1 CCL23 AATTCAAAAAGAAGCTGGACACACGGATCAACTCG2166 chr17 ENST000006 AGTTGATCCGTGTGTCCAGCTTC 15050.1 CCL24AATTCAAAAAAGTGATCTTCACCACCAAGAACTCGA 2167 chr7 ENST000002GTTCTTGGTGGTGAAGATCACT 22902.6 CCL24AATTCAAAAAGTTCTTTGTTTCCAAGAGAATCTCGA 2168 chr7 ENST000002GATTCTCTTGGAAACAAAGAAC 22902.6 CCL24AATTCAAAAACCTGCTGCATGTTCTTTGTTTCTCGAG 2169 chr7 ENST000002AAACAAAGAACATGCAGCAGG 22902.6 CCL25 AATTCAAAAAGCCGGATCTTTCTCCGATAAACTCGA2170 chr19 ENST000003 GTTTATCGGAGAAAGATCCGGC 90669.7 CCL25AATTCAAAAAGCTCCTGGATGCTCGAAATAACTCGA 2171 chr19 ENST000003GTTATTTCGAGCATCCAGGAGC 90669.7 CCL25AATTCAAAAACCCTCCTGATATCAGCTAATTCTCGA 2172 chr19 ENST000003GAATTAGCTGATATCAGGAGGG 90669.7 CCL26 AATTCAAAAACACACGTGGGAGTGACATATCCTCG2173 chr7 ENST000000 AGGATATGTCACTCCCACGTGTG 05180.8 CCL26AATTCAAAAATCCGAAACAATTGTGACTCAGCTCGA 2174 chr7 ENST000000GCTGAGTCACAATTGTTTCGGA 05180.8 CCL26AATTCAAAAAGCTGTGATATTCACTACCAAACTCGA 2175 chr7 ENST000000GTTTGGTAGTGAATATCACAGC 05180.8 CCL27AATTCAAAAATTCGTGCTTCACCTGGCTCAACTCGA 2176 chr9 ENST000002GTTGAGCCAGGTGAAGCACGAA 59631.4 CCL27 AATTCAAAAACCGAAAGCCACTCTCAGACAACTCG2177 chr9 ENST000002 AGTTGTCTGAGAGTGGCTTTCGG 59631.4 CCL27AATTCAAAAACAAGCTACTGAGGAAGGTCATCTCG 2178 chr9 ENST000002AGATGACCTTCCTCAGTAGCTTG 59631.4 CCL28AATTCAAAAACGGAGGTTTCACATCATATTTCTCGA 2179 chr5 ENST000003GAAATATGATGTGAAACCTCCG 61115.4 CCL28 AATTCAAAAACACGAAACATACGGCCATAAACTCG2180 chr5 ENST000003 AGTTTATGGCCGTATGTTTCGTG 61115.4 CCL28AATTCAAAAATTAGAGAGTCTACAGATAAATCTCGA 2181 chr5 ENST000003GATTTATCTGTAGACTCTCTAA 61115.4 CCL3 AATTCAAAAACCGGCAGATTCCACAGAATTTCTCGA2182 chr17 ENST000006 GAAATTCTGTGGAATCTGCCGG 13922.1 CCL3AATTCAAAAATTCGATTTCACAGTGTGTTTGCTCGA 2183 chr17 ENST000006GCAAACACACTGTGAAATCGAA 13922.1 CCL3 AATTCAAAAACAACCAGTTCTCTGCATCACTCTCGA2184 chr17 ENST000006 GAGTGATGCAGAGAACTGGTTG 13922.1 CCL4AATTCAAAAAATGTGCCGTGTTATTGTATTACTCGA 2185 chr17 ENST000006GTAATACAATAACACGGCACAT 15863.1 CCL4AATTCAAAAATCCTGTCCCTTCTCTTAATTTCTCGAG 2186 chr17 ENST000006AAATTAAGAGAAGGGACAGGA 15863.1 CCL4 AATTCAAAAACTGTGCTGATCCCAGTGAATCCTCGA2187 chr17 ENST000006 GGATTCACTGGGATCAGCACAG 15863.1 CCL5AATTCAAAAATGAACCTGAACTTACACAAATCTCGA 2188 chr17 ENST000006GATTTGTGTAAGTTCAGGTTCA 03197.5 CCL5 AATTCAAAAACCTGCTGCTTTGCCTACATTGCTCGA2189 chr17 ENST000006 GCAATGTAGGCAAAGCAGCAGG 03197.5 CCL5AATTCAAAAACTACCACACAGCAGCAGTTACCTCGA 2190 chr17 ENST000006GGTAACTGCTGCTGTGTGGTAG 03197.5 CCL7 AATTCAAAAACATAAAGCCTTGGATGTATATCTCGA2191 chr17 ENST000003 GATATACATCCAAGGCTTTATG 78569.2 CCL7AATTCAAAAAGCTGCTACAGATTTATCAATACTCGA 2192 chr17 ENST000003GTATTGATAAATCTGTAGCAGC 78569.2 CCL7 AATTCAAAAATCTAAGGAATATGAGCTTTATCTCGA2193 chr17 ENST000003 GATAAAGCTCATATTCCTTAGA 78569.2 CCL8AATTCAAAAAGCTGCTTTAACGTGATCAATACTCGA 2194 chr17 ENST000003GTATTGATCACGTTAAAGCAGC 94620.1 CCL8 AATTCAAAAACAGGTGCAGTGTGACATTATTCTCGA2195 chr17 ENST000003 GAATAATGTCACACTGCACCTG 94620.1 CCL8AATTCAAAAATTGTACTGCTGTTGTTGAAATCTCGA 2196 chr17 ENST000003GATTTCAACAACAGCAGTACAA 94620.1 CCR1 AATTCAAAAAATTCTGCTAAGACGACCAAATCTCGA2197 chr3 ENST000002 GATTTGGTCGTCTTAGCAGAAT 96140.3 CCR1AATTCAAAAAATCTGCTACACAGGGATTATACTCGA 2198 chr3 ENST000002GTATAATCCCTGTGTAGCAGAT 96140.3 CCR1 AATTCAAAAACCTCTGTACTCCTTGGTATTTCTCGA2199 chr3 ENST000002 GAAATACCAAGGAGTACAGAGG 96140.3 CCR2AATTCAAAAAACGGTGCTCCCTGTCATAAATCTCGA 2200 chr3 ENST000004GATTTATGACAGGGAGCACCGT 45132.2 CCR2 AATTCAAAAACTTCTGGACTCCCTATAATATCTCGA2201 chr3 ENST000004 GATATTATAGGGAGTCCAGAAG 45132.2 CCR2AATTCAAAAAGCTGTATCACATCGGTTATTTCTCGA 2202 chr3 ENST000004GAAATAACCGATGTGATACAGC 45132.2 CCR3 AATTCAAAAAATACAGGAGGCTCCGAATTATCTCGA2203 chr3 ENST000003 GATAATTCGGAGCCTCCTGTAT 57422.2 CCR3AATTCAAAAACCCAGAGGATACAGTATATAGCTCG 2204 chr3 ENST000003AGCTATATACTGTATCCTCTGGG 57422.2 CCR3AATTCAAAAATAGCAGCTCTTCCTGAATTTACTCGA 2205 chr3 ENST000003GTAAATTCAGGAAGAGCTGCTA 57422.2 CCR5 AATTCAAAAAACTCTTGACAGGGCTCTATTTCTCGA2206 chr3 ENST000002 GAAATAGAGCCCTGTCAAGAGT 92303.4 CCR5AATTCAAAAACGAGCGAGCAAGCTCAGTTTACTCG 2207 chr3 ENST000002AGTAAACTGAGCTTGCTCGCTCG 92303.4 CCR5AATTCAAAAATCCATACAGTCAGTATCAATTCTCGA 2208 chr3 ENST000002GAATTGATACTGACTGTATGGA 92303.4 CCR6 AATTCAAAAAGGTCTATGACAGACGTCTATCCTCGA2209 chr6 ENST000003 GGATAGACGTCTGTCATAGACC 41935.9 CCR6AATTCAAAAACGACTCCAGTGAAGATTATTTCTCGA 2210 chr6 ENST000003GAAATAATCTTCACTGGAGTCG 41935.9 CCR6 AATTCAAAAATCGACTCCAGTGAAGATTATTCTCGA2211 chr6 ENST000003 GAATAATCTTCACTGGAGTCGA 41935.9 CCR7AATTCAAAAAGATGAGGTCACGGACGATTACCTCG 2212 chr17 ENST000002AGGTAATCGTCCGTGACCTCATC 46657.2 CCR7AATTCAAAAAGCTGGTCGTGTTGACCTATATCTCGA 2213 chr17 ENST000002GATATAGGTCAACACGACCAGC 46657.2 CCR7 AATTCAAAAACGTGTTGACCTATATCTATTTCTCGA2214 Chr17 ENST000002 GAAATAGATATAGGTCAACACG 46657.2 CD109AATTCAAAAAGCCGATCCTTACATAGATATTCTCGA 2215 Chr6 ENST000002GAATATCTATGTAAGGATCGGC 87097.5 CD109AATTCAAAAACCCGGAGGAAATGTGACTATTCTCGA 2216 Chr6 ENST000002GAATAGTCACATTTCCTCCGGG 87097.5 CD109AATTCAAAAACCGCTTATCATTTGAGACCAACTCGA 2217 Chr6 ENST000002GTTGGTCTCAAATGATAAGCGG 87097.5 CD27 AATTCAAAAACTTACCTTATGTCAGTGAGATCTCGA2218 chr12 ENST000002 GATCTCACTGACATAAGGTAAG 66557.3 CD27AATTCAAAAAGCACTGTAACTCTGGTCTTCTCTCGA 2219 chr12 ENST000002GAGAAGACCAGAGTTACAGTGC 66557.3 CD27 AATTCAAAAACCACCCACTTACCTTATGTCACTCGA2220 chr12 ENST000002 GTGACATAAGGTAAGTGGGTGG 66557.3 CD27AATTCAAAAAGCCAGATGTGTGAGCCAGGAACTCG 2221 chr12 ENST000002AGTTCCTGGCTCACACATCTGGC 66557.3 CD28AATTCAAAAACCTCCAGAATTTGTATGTTAACTCGA 2222 ch2 ENST000004GTTAACATACAAATTCTGGAGG 58610.6 CD28 AATTCAAAAACAACCTTAGCTGCAAGTATTCCTCGA2223 ch2 ENST000004 GGAATACTTGCAGCTAAGGTTG 58610.6 CD28AATTCAAAAATGGAGTCCTGGCTTGCTATAGCTCGA 2224 ch2 ENST000004GCTATAGCAAGCCAGGACTCCA 58610.6 CD28 AATTCAAAAACCTCCTCCTTACCTAGACAATCTCGA2225 ch2 ENST000004 GATTGTCTAGGTAAGGAGGAGG 58610.6 CD36AATTCAAAAAAGAACCTATTGATGGATTAAACTCGA 2226 chr7 ENST000003GTTTAATCCATCAATAGGTTCT 09881.11 CD36 AATTCAAAAAGCCATAATCGACACATATAAACTCG2227 chr7 ENST000003 AGTTTATATGTGTCGATTATGGC 09881.11 CD36AATTCAAAAAACGGCTGCAGGTCAACCTATTCTCGA 2228 chr7 ENST000003GAATAGGTTGACCTGCAGCCGT 09881.11 CD4 AATTCAAAAACCTGATCATCAAGAATCTTAACTCGA2229 chr12 ENST000000 GTTAAGATTCTTGATGATCAGG 11653.8 CD4AATTCAAAAAAGAGCGGATGTCTCAGATCAACTCG 2230 chr12 ENST000000AGTTGATCTGAGACATCCGCTCT 11653.8 CD4 AATTCAAAAACCACTCGCCTTTACAGTTGAACTCGA2231 chr12 ENST000000 GTTCAACTGTAAAGGCGAGTGG 11653.8 CD40LGAATTCAAAAAGGGAAACAGCTGACCGTTAAACTCG 2232 chrX ENST000003AGTTTAACGGTCAGCTGTTTCCC 70629.6 CD40LGAATTCAAAAATTCGAGTCAAGCTCCATTTATCTCGA 2233 chrX ENST000003GATAAATGGAGCTTGACTCGAA 70629.6 CD40LGAATTCAAAAATGACGCTGGGAGTCTTCATAACTCGA 2234 chrX ENST000003GTTATGAAGACTCCCAGCGTCA 70629.6 CD70 AATTCAAAAACCATCGTGATGGCATCTACATCTCGA2235 chr19 ENST000002 GATGTAGATGCCATCACGATGG 45903.3 CD70AATTCAAAAACAGCTACGTATCCATCGTGATCTCGA 2236 chr19 ENST000002GATCACGATGGATACGTAGCTG 45903.3 CD70 AATTCAAAAACCAACCTCACTGGGACACTTTCTCGA2237 chr19 ENST000002 GAAAGTGTCCCAGTGAGGTTGG 45903.3 CD74AATTCAAAAACAAGTCGGAACAGCAGATAACCTCG 2238 chr5 ENST000000AGGTTATCTGCTGTTCCGACTTG 09530.11 CD74AATTCAAAAAGAGAACCTGAGACACCTTAAGCTCG 2239 chr5 ENST000000AGCTTAAGGTGTCTCAGGTTCTC 09530.11 CD74AATTCAAAAACCACACAGCTACAGCTTTCTTCTCGA 2240 chr5 ENST000000GAAGAAAGCTGTAGCTGTGTGG 09530.11 CD8AAATTCAAAAAGCTGGACTTCGCCTGTGATATCTCGA 2241 ch2 ENST000004GATATCACAGGCGAAGTCCAGC 09511.6 CD8A AATTCAAAAAGTGTATTCATTCTCATGATTACTCGA2242 ch2 ENST000004 GTAATCATGAGAATGAATACAC 09511.6 CD8AAATTCAAAAACCAGAGACAGCTTGATCAAAGCTCG 2243 ch2 ENST000004AGCTTTGATCAAGCTGTCTCTGG 09511.6 CD8AAATTCAAAAACCTTCTCCTGTCACTGGTTATCTCGA 2244 ch2 ENST000004GATAACCAGTGACAGGAGAAGG 09511.6 CER1 AATTCAAAAAGAGAAGATGCTGTCCAGATTTCTCGA2245 chr9 ENST000003 GAAATCTGGACAGCATCTTCTC 80911.3 CER1AATTCAAAAACCAGCCGATAGATGGAATGAACTCG 2246 chr9 ENST000003AGTTCATTCCATCTATCGGCTGG 80911.3 CER1AATTCAAAAACAAGAAATTCTGGCACCACTTCTCGA 2247 chr9 ENST000003GAAGTGGTGCCAGAATTTCTTG 80911.3 CHRD AATTCAAAAAACGTCCTGCAAAGTGTCCTTTCTCGA2248 chr3 ENST000002 GAAAGGACACTTTGCAGGACGT 04604.5 CHRDAATTCAAAAAACTGATCCAGAGCTGGAGAAACTCG 2249 chr3 ENST000002AGTTTCTCCAGCTCTGGATCAGT 04604.5 CHRDAATTCAAAAACGGCTGCTGAAGGGATTCTATCTCGA 2250 chr3 ENST000002GATAGAATCCCTTCAGCAGCCG 04604.5 CKLFAATTCAAAAACCTTTGCTTGTGTTTGCACTTCTCGAG 2251 chr16 ENST000002AAGTGCAAACACAAGCAAAGG 64001.8 CKLF AATTCAAAAACCCTGAACCATATATTGTTATCTCGA2252 chr16 ENST000002 GATAACAATATATGGTTCAGGG 64001.8 CKLFAATTCAAAAATGGATTTGAAGTCACCGTTATCTCGA 2253 chr16 ENST000002GATAACGGTGACTTCAAATCCA 64001.8 CLCF1 AATTCAAAAAGAAACAAACATGGTGGCAATTCTCG2254 chr11 ENST000003 AGAATTGCCACCATGTTTGTTTC 12438.7 CLCF1AATTCAAAAACCACAGGATTTCCTGAAAGTTCTCGA 2255 chr11 ENST000003GAACTTTCAGGAAATCCTGTGG 12438.7 CLCF1AATTCAAAAACATGGTGGCAATTCTACACAACTCGA 2256 chr11 ENST000003GTTGTGTAGAATTGCCACCATG 12438.7 CMTM1AATTCAAAAACACCACTTGCTGACCTATTTACTCGA 2257 chr16 ENST000003GTAAATAGGTCAGCAAGTGGTG 79500.6 CMTM1AATTCAAAAAGACCTATTTACATTGGCCCTTCTCGA 2258 chr16 ENST000003GAAGGGCCAATGTAAATAGGTC 79500.6 CMTM1AATTCAAAAAGCTGTGTTCCTTTCAGTAGTTCTCGA 2259 chr16 ENST000003GAACTACTGAAAGGAACACAGC 79500.6 CMTM2 AATTCAAAAAGTAAGGAGCCATCGGACAAACCTCG2260 chr16 ENST000002 AGGTTTGTCCGATGGCTCCTTAC 68595.2 CMTM2AATTCAAAAACTTACTTGCTGTGATCCTTATCTCGA 2261 chr16 ENST000002GATAAGGATCACAGCAAGTAAG 68595.2 CMTM2 AATTCAAAAACATAAGGAGCCATCGGACAAACTCG2262 chr16 ENST000002 AGTTTGTCCGATGGCTCCTTATG 68595.2 CMTM3AATTCAAAAACATCGTGTTTGCAACTGATTTCTCGA 2263 chr16 ENST000003GAAATCAGTTGCAAACACGATG 61909.8 CMTM3AATTCAAAAAGCTTCTTAACAGATGGCATTTCTCGA 2264 chr16 ENST000003GAAATGCCATCTGTTAAGAAGC 61909.8 CMTM3AATTCAAAAAGCTTCTTAACAGATGGCATTTCTCGA 2265 chr16 ENST000003GAAATGCCATCTGTTAAGAAGC 61909.8 CMTM4AATTCAAAAACAACTGGAATCTGACAGATTTCTCGA 2266 chr16 ENST000003GAAATCTGTCAGATTCCAGTTG 94106.6 CMTM4AATTCAAAAAGACTGGCGTCTTGCTGATTATCTCGA 2267 chr16 ENST000003GATAATCAGCAAGACGCCAGTC 94106.6 CMTM4AATTCAAAAAGCAGAAATTGCTGCCGTGATACTCGA 2268 chr16 ENST000003GTATCACGGCAGCAATTTCTGC 94106.6 CMTM5 AATTCAAAAACAAGATCTACCGGACTGAGATCTCG2269 chr14 ENST000003 AGATCTCAGTCCGGTAGATCTTG 59320.7 CMTM5AATTCAAAAACCTGACCCTCATCATCTTCATCTCGA 2270 chr14 ENST000003GATGAAGATGATGAGGGTCAGG 59320.7 CMTM5AATTCAAAAACTTCCTCTATGCCACCCAGTACTCGA 2271 chr14 ENST000003GTACTGGGTGGCATAGAGGAAG 59320.7 CMTM6AATTCAAAAAGCCCTCACTGAGCCACTTAATCTCGA 2272 chr3 ENST000002GATTAAGTGGCTCAGTGAGGGC 05636.3 CMTM6 AATTCAAAAACCCAAGACAGTGAAAGTAATTCTCG2273 chr3 ENST000002 AGAATTACTTTCACTGTCTTGGG 05636.3 CMTM6AATTCAAAAACCCAAGACAGTGAAAGTAATTCTCG 2274 chr3 ENST000002AGAATTACTTTCACTGTCTTGGG 05636.3 CMTM7AATTCAAAAACTGCTGAAAGTGGCGCAAATGCTCG 2275 chr3 ENST000003AGCATTTGCGCCACTTTCAGCAG 34983.9 CMTM7AATTCAAAAACAAAGCCCTGTCCTAATTTATCTCGA 2276 chr3 ENST000003GATAAATTAGGACAGGGCTTTG 34983.9 CMTM7AATTCAAAAACCTGTCGATCTTTGGTTTCATCTCGA 2277 chr3 ENST000003GATGAAACCAAAGATCGACAGG 34983.9 CMTM8AATTCAAAAATGCTGGTATGGACGCTTATTGCTCGA 2278 chr3 ENST000003GCAATAAGCGTCCATACCAGCA 07526.3 CMTM8AATTCAAAAAGCAAAGTGTTGTAGCTTATAACTCGA 2279 chr3 ENST000003GTTATAAGCTACAACACTTTGC 07526.3 CMTM8AATTCAAAAAATATTCCCAGAGAATTGTATTCTCGA 2280 chr3 ENST000003GAATACAATTCTCTGGGAATAT 07526.3 CNTF AATTCAAAAAGTAACCTCTACAGGCATTTAACTCGA2281 chr11 ENST000003 GTTAAATGCCTGTAGAGGTTAC 61987.5 CNTFAATTCAAAAAGTTGAAGGACTACAGGTATTTCTCGA 2282 chr11 ENST000003GAAATACCTGTAGTCCTTCAAC 61987.5 CNTF AATTCAAAAAGGTGACTTCCATCAAGCTATACTCGA2283 chr11 ENST000003 GTATAGCTTGATGGAAGTCACC 61987.5 CNTFRAATTCAAAAACATTCTCTTCAGACACAATTTCTCGA 2284 chr9 ENST000003GAAATTGTGTCTGAAGAGAATG 51266.8 CNTFRAATTCAAAAAGCATTCTCTTCAGACACAATTCTCGA 2285 chr9 ENST000003GAATTGTGTCTGAAGAGAATGC 51266.8 CNTFR AATTCAAAAAGCCGGGAAGGAGTACATTATCCTCG2286 chr9 ENST000003 AGGATAATGTACTCCTTCCCGGC 51266.8 COPS5AATTCAAAAACTAAGGATCACCATTACTTTACTCGA 2287 chr8 ENST000003GTAAAGTAATGGTGATCCTTAG 57849.8 COPS5AATTCAAAAACCAGACTATTCCACTTAATAACTCGA 2288 chr8 ENST000003GTTATTAAGTGGAATAGTCTGG 57849.8 COPS5AATTCAAAAACAGTCTCTGAGAAGTACTTTACTCGA 2289 chr8 ENST000003GTAAAGTACTTCTCAGAGACTG 57849.8 CRLF1AATTCAAAAACGATGTACTCACGCTGGATATCTCGA 2290 chr19 ENST000003GATATCCAGCGTGAGTACATCG 92386.7 CRLF1AATTCAAAAACGATGTACTCACGCTGGATATCTCGA 2291 chr19 ENST000003GATATCCAGCGTGAGTACATCG 92386.7 CRLF1 AATTCAAAAACCCAGAGAAACCCGTCAACATCTCG2292 chr19 ENST000003 AGATGTTGACGGGTTTCTCTGGG 92386.7 CSF1AATTCAAAAATCTCCTGGTACAAGACATAATCTCGA 2293 chr1 ENST000003GATTATGTCTTGTACCAGGAGA 29608.10 CSF1AATTCAAAAAGTCGGCCTGATTTCCCGTAAACTCGA 2294 chr1 ENST000003GTTTACGGGAAATCAGGCCGAC 29608.10 CSF1AATTCAAAAATTGACAAGGACTGGAATATTTCTCGA 2295 chr1 ENST000003GAAATATTCCAGTCCTTGTCAA 29608.10 CSF AATTCAAAAAGTGAACAGCAAGTTCTATAAACTCG2296 chr5 ENST000002 AGTTTATAGAACTTGCTGTTCAC 86301.7 CSF1RAATTCAAAAAACAGGAGAGAGCGGGACTATACTCG 2297 chr5 ENST000002AGTATAGTCCCGCTCTCTCCTGT 86301.7 CSF1RAATTCAAAAAGCTGCTATTGTACAAGTATAACTCGA 2298 Chr5 ENST000002GTTATACTTGTACAATAGCAGC 86301.7 CSF2 AATTCAAAAAGGAGCTGCTCTCTCATGAAACCTCGA2299 chr5 ENST000002 GGTTTCATGAGAGAGCAGCTCC 96871.3 CSF2AATTCAAAAACCCAGATTATCACCTTTGAAACTCGA 2300 chr5 ENST000002GTTTCAAAGGTGATAATCTGGG 96871.3 CSF2 AATTCAAAAAGAAGTCATCTCAGAAATGTTTCTCGA2301 chr5 ENST000002 GAAACATTTCTGAGATGACTTC 96871.3 CSF3AATTCAAAAAGTCTATTTAAGCCTCATATTTCTCGA 2302 chr17 ENST000002GAAATATGAGGCTTAAATAGAC 25474.6 CSF3 AATTCAAAAAGATAGGTAAATACCAAGTATTCTCGA2303 chr17 ENST000002 GAATACTTGGTATTTACCTATC 25474.6 CSF3AATTCAAAAAGCTTAGAGCAAGTGAGGAAGACTCG 2304 chr17 ENST000002AGTCTTCCTCACTTGCTCTAAGC 25474.6 CSF3RAATTCAAAAACAGCCAGGCCTGCACATAAATCTCG 2305 chr1 ENST000003AGATTTATGTGCAGGCCTGGCTG 61632.8 CSF3RAATTCAAAAACTATGCCTACTCTCAAGAAATCTCGA 2306 chr1 ENST000003GATTTCTTGAGAGTAGGCATAG 61632.8 CSF3RAATTCAAAAACCAGCTTCACTCTGAAGAGTTCTCGA 2307 chr1 ENST000003GAACTCTTCAGAGTGAAGCTGG 61632.8 CTF1 AATTCAAAAAGAGCAGCTGCTCCAGGAATATCTCG2308 chr16 ENST000002 AGATATTCCTGGAGCAGCTGCTC 79804.2 CTF1AATTCAAAAAGTCTCTCCTTCCGCTTCTTTGCTCGAG 2309 chr16 ENST000002CAAAGAAGCGGAAGGAGAGAC 79804.2 CTF1 AATTCAAAAATGTCTGTCTGTCTGCTCTTAGCTCGA2310 chr16 ENST000002 GCTAAGAGCAGACAGACAGACA 79804.2 CX3CL1AATTCAAAAACCCGGAGCTGTGGTAGTAATTCTCGA 2311 chr16 ENST000000GAATTACTACCACAGCTCCGGG 06053.6 CX3CL1AATTCAAAAAGCTGCTGCCCTAACTCGAAATCTCGA 2312 chr16 ENST000000GATTTCGAGTTAGGGCAGCAGC 06053.6 CX3CL1AATTCAAAAACGGTGTGACGAAATGCAACATCTCG 2313 chr16 ENST000000AGATGTTGCATTTCGTCACACCG 06053.6 CX3CR1AATTCAAAAATGGCCTGTGTCTAGTTGTTTGCTCGA 2314 chr3 ENST000003GCAAACAACTAGACACAGGCCA 99220.2 CX3CR1AATTCAAAAATGGGATCCCTCATCCTCATACCTCGA 2315 chr3 ENST000003GGTATGAGGATGAGGGATCCCA 99220.2 CX3CR1AATTCAAAAAGCTTTGCTCATCCACTATCAACTCGA 2316 chr3 ENST000003GTTGATAGTGGATGAGCAAAGC 99220.2 CXCL1AATTCAAAAAACCTGCACACTGTCCTATTATCTCGA 2317 chr4 ENST000003GATAATAGGACAGTGTGCAGGT 95761.3 CXCL1 AATTCAAAAAAGATGCTGAACAGTGACAAATCTCG2318 chr4 ENST000003 AGATTTGTCACTGTTCAGCATCT 95761.3 CXCL1AATTCAAAAAGTTCTCCAGTCATTATGTTAACTCGA 2319 chr4 ENST000003GTTAACATAATGACTGGAGAAC 95761.3 CXCL10AATTCAAAAAGTATATGTCAAGCCATAATTGCTCGA 2320 chr4 ENST000003GCAATTATGGCTTGACATATAC 06602.2 CXCL10AATTCAAAAAACTCTACCCTGGCACTATAATCTCGA 2321 chr4 ENST000003GATTATAGTGCCAGGGTAGAGT 06602.2 CXCL10AATTCAAAAACCTGTTAATCCAAGGTCTTTACTCGA 2322 chr4 ENST000003GTAAAGACCTTGGATTAACAGG 06602.2 CXCL11AATTCAAAAAGCTGGTTACCATCGGAGTTTACTCGA 2323 chr4 ENST000003GTAAACTCCGATGGTAACCAGC 06621.7 CXCL11AATTCAAAAAGCAGTGAAAGTGGCAGATATTCTCG 2324 chr4 ENST000003AGAATATCTGCCACTTTCACTGC 06621.7 CXCL11AATTCAAAAAGAAGCAAGCAAGGCTTATAATCTCG 2325 chr4 ENST000003AGATTATAAGCCTTGCTTGCTTC 06621.7 CXCL12AATTCAAAAAGCTTAGACTAAGGCCATTATTCTCGA 2326 chr10 ENST000003GAATAATGGCCTTAGTCTAAGC 43575.10 CXCL12AATTCAAAAACTCTCACTATACCAGTATAATCTCGA 2327 chr10 ENST000003GATTATACTGGTATAGTGAGAG 43575.10 CXCL12AATTCAAAAACAAACTGTGCCCTTCAGATTGCTCGA 2328 chr10 ENST000003GCAATCTGAAGGGCACAGTTTG 43575.10 CXCL13AATTCAAAAAGATTCCCTGATGCTGATATTTCTCGA 2329 chr4 ENST000002GAAATATCAGCATCAGGGAATC 86758.4 CXCL13AATTCAAAAAAGGAATCCATGTAGTAGATATCTCGA 2330 chr4 ENST000002GATATCTACTACATGGATTCCT 86758.4 CXCL13AATTCAAAAAAGGTGTTCTGGAGGTCTATTACTCGA 2331 chr4 ENST000002GTAATAGACCTCCAGAACACCT 86758.4 CXCL14AATTCAAAAAATTTGTCCATACGTCACTATACTCGA 2332 chr5 ENST000003GTATAGTGACGTATGGACAAAT 37225.5 CXCL14AATTCAAAAACAAAGGACTTTGCAGATTAAACTCG 2333 chr5 ENST000003AGTTTAATCTGCAAAGTCCTTTG 37225.5 CXCL14AATTCAAAAAGCGCAGGGTCTACGAAGAATACTCG 2334 chr5 ENST000003AGTATTCTTCGTAGACCCTGCGC 37225.5 CXCL16AATTCAAAAAACATCCAGCCTACACGTATTTCTCGA 2335 chr17 ENST000002GAAATACGTGTAGGCTGGATGT 93778.10 CXCL16AATTCAAAAATCTGAAGGTGCGAGGATTATACTCGA 2336 chr17 ENST000002GTATAATCCTCGCACCTTCAGA 93778.10 CXCL16AATTCAAAAATCCAGATCTGCCGGTTCATTACTCGA 2337 chr17 ENST000002GTAATGAACCGGCAGATCTGGA 93778.10 CXCL17AATTCAAAAAGCGCCCACTCTTCCAATTAAACTCGA 2338 chr19 ENST000006GTTTAATTGGAAGAGTGGGCGC 01181.5 CXCL17AATTCAAAAATCCAGAGCCTGCCAGCAATTTCTCGA 2339 chr19 ENST000006GAAATTGCTGGCAGGCTCTGGA 01181.5 CXCL17AATTCAAAAAAGAATGTGAGTGCAAAGATTGCTCG 2340 chr19 ENST000006AGCAATCTTTGCACTCACATTCT 01181.5 CXCL2AATTCAAAAACTTGCACACTCTCCCATTATACTCGA 2341 chr4 ENST000005GTATAATGGGAGAGTGTGCAAG 08487.2 CXCL2AATTCAAAAAGCAGATATTCTCTAGTCATTTCTCGA 2342 chr4 ENST000005GAAATGACTAGAGAATATCTGC 08487.2 CXCL2AATTCAAAAAATTTCTTCGTGATGACATATCCTCGA 2343 chr4 ENST000005GGATATGTCATCACGAAGAAAT 08487.2 CXCL3AATTCAAAAATTACGAGGGTTCTACTTATTTCTCGA 2344 chr4 ENST000002GAAATAAGTAGAACCCTCGTAA 96026.4 CXCL3AATTCAAAAAATTTAGTGGGAGACCATAATGCTCGA 2345 chr4 ENST000002GCATTATGGTCTCCCACTAAAT 96026.4 CXCL3 AATTCAAAAAACTGACAGGAGAGAAGTAAGACTCG2346 chr4 ENST000002 AGTCTTACTTCTCTCCTGTCAGT 96026.4 CXCL5AATTCAAAAATGAATTGTAGGTGACTATTATCTCGA 2347 chr4 ENST000002GATAATAGTCACCTACAATTCA 96027.4 CXCL5 AATTCAAAAACAGACCACGCAAGGAGTTCATCTCG2348 chr4 ENST000002 AGATGAACTCCTTGCGTGGTCTG 96027.4 CXCL5AATTCAAAAACGGGAAGGAAATTTGTCTTGACTCGA 2349 chr4 ENST000002GTCAAGACAAATTTCCTTCCCG 96027.4 CXCL6AATTCAAAAATTTACCCTAGGATGCTATTTACTCGA 2350 chr4 ENST000002GTAAATAGCATCCTAGGGTAAA 26317.9 CXCL6AATTCAAAAAGTTGCACTTGTTTACGCGTTACTCGA 2351 chr4 ENST000002GTAACGCGTAAACAAGTGCAAC 26317.9 CXCL6AATTCAAAAAGCTGTGGATTTCGTATGGAAACTCGA 2352 chr4 ENST000002GTTTCCATACGAAATCCACAGC 26317.9 CXCL8AATTCAAAAATGCGCCAACACAGAAATTATTCTCGA 2353 chr4 ENST000003GAATAATTTCTGTGTTGGCGCA 07407.7 CXCL8AATTCAAAAACAAGAGAATATCCGAACTTTACTCGA 2354 chr4 ENST000003GTAAAGTTCGGATATTCTCTTG 07407.7 CXCL8 AATTCAAAAATGCACGGGAGAATATACAAATCTCG2355 chr4 ENST000003 AGATTTGTATATTCTCCCGTGCA 07407.7 CXCL9AATTCAAAAACCAAAGGAGGATGGCATATAACTCG 2356 chr4 ENST000002AGTTATATGCCATCCTCCTTTGG 64888.5 CXCL9AATTCAAAAACCAAACGTTAAGAATTGTTAACTCGA 2357 chr4 ENST000002GTTAACAATTCTTAACGTTTGG 64888.5 CXCL9 AATTCAAAAAGATGTGAAGGAACTGATTAAACTCG2358 chr4 ENST000002 AGTTTAATCAGTTCCTTCACATC 64888.5 CXCR1AATTCAAAAACTTGGCACGTCATCGTGTTACCTCGA 2359 chr2 ENST000002GGTAACACGATGACGTGCCAAG 95683.2 CXCR1AATTCAAAAAACCCACTAACTGGCTAATTAGCTCGA 2360 chr2 ENST000002GCTAATTAGCCAGTTAGTGGGT 95683.2 CXCR1AATTCAAAAAGAGACACTCAACAAGTATGTTCTCGA 2361 chr2 ENST000002GAACATACTTGTTGAGTGTCTC 95683.2 CXCR2AATTCAAAAAGAAGCGCTACTTGGTCAAATTCTCGA 2362 chr2 ENST000003GAATTTGACCAAGTAGCGCTTC 18507.6 CXCR2AATTCAAAAAGCCACTAAATTGACACTTAAACTCGA 2363 chr2 ENST000003GTTTAAGTGTCAATTTAGTGGC 18507.6 CXCR2AATTCAAAAACCCTGGAAATCAACAAGTATTCTCGA 2364 chr2 ENST000003GAATACTTGTTGATTTCCAGGG 18507.6 CXCR3AATTCAAAAACCTTCTCATTTGGAAACTAAACTCGA 2365 chrX ENST000003GTTTAGTTTCCAAATGAGAAGG 73693.3 CXCR3AATTCAAAAACGCTACCTGAACATAGTTCATCTCGA 2366 chrX ENST000003GATGAACTATGTTCAGGTAGCG 73693.3 CXCR3 AATTCAAAAAGAGTACAAGGCATGGCGTAGACTCG2367 chrX ENST000003 AGTCTACGCCATGCCTTGTACTC 73693.3 CXCR4AATTCAAAAACTATTCCCGACTTCATCTTTGCTCGA 2368 chr2 ENST000004GCAAAGATGAAGTCGGGAATAG 09817.1 CXCR4 AATTCAAAAAGCGTGTAGTGAATCACGTAAACTCG2369 chr2 ENST000004 AGTTTACGTGATTCACTACACGC 09817.1 CXCR4AATTCAAAAACCTGTTCTTAAGACGTGATTTCTCGA 2370 chr2 ENST000004GAAATCACGTCTTAAGAACAGG 09817.1 CXCR6AATTCAAAAAGCTTGCTCATCTGGGTGATATCTCGA 2371 chr3 ENST000003GATATCACCCAGATGAGCAAGC 04552.4 CXCR6AATTCAAAAATACTGGGCATCTACACTATTACTCGA 2372 chr3 ENST000003GTAATAGTGTAGATGCCCAGTA 04552.4 CXCR6AATTCAAAAATTATCTATGGCAATGTCTTTACTCGA 2373 chr3 ENST000003GTAAAGACATTGCCATAGATAA 04552.4 EBI3 AATTCAAAAATGAACTGTCACTGTGAGATATCTCGA2374 chr19 ENST000002 GATATCTCACAGTGACAGTTCA 21847.5 EBI3AATTCAAAAAATGTACTACTCTCTCCTTTACCTCGA 2375 chr19 ENST000002GGTAAAGGAGAGAGTAGTACAT 21847.5 EBI3 AATTCAAAAAGCCTTTCATAACAGAGCACATCTCGA2376 chr19 ENST000002 GATGTGCTCTGTTATGAAAGGC 21847.5 EDN1AATTCAAAAACCATGAGAAACAGCGTCAAATCTCG 2377 chr6 ENST000003AGATTTGACGCTGTTTCTCATGG 79375.5 EDN1AATTCAAAAAGCTCGTCCCTGATGGATAAAGCTCGA 2378 chr6 ENST000003GCTTTATCCATCAGGGACGAGC 79375.5 EDN1 AATTCAAAAAAGACAAGAAGTGCTGGAATTTCTCG2379 chr6 ENST000003 AGAAATTCCAGCACTTCTTGTCT 79375.5 ELANEAATTCAAAAAGCACTGCGTGGCGAATGTAAACTCG 2380 chr19 ENST000002AGTTTACATTCGCCACGCAGTGC 63621.1 ELANEAATTCAAAAATGCTCAACGACATCGTGATTCCTCGA 2381 chr19 ENST000002GGAATCACGATGTCGTTGAGCA 63621.1 ELANE AATTCAAAAACAACGGGCTAATCCACGGAATCTCG2382 chr19 ENST000002 AGATTCCGTGGATTAGCCCGTTG 63621.1 ENGAATTCAAAAAGCAGGTGTCAGCAAGTATGATCTCG 2383 chr9 ENST000003AGATCATACTTGCTGACACCTGC 44849.4 ENG AATTCAAAAAGCAGGTGTCAGCAAGTATGATCTCG2384 chr9 ENST000003 AGATCATACTTGCTGACACCTGC 44849.4 ENGAATTCAAAAAGTCTTGCAGAAACAGTCCATTCTCGA 2385 chr9 ENST000003GAATGGACTGTTTCTGCAAGAC 44849.4 EPO AATTCAAAAACCCAGACACCAAAGTTAATTTCTCGA2386 chr7 ENST000002 GAAATTAACTTTGGTGTCTGGG 52723.2 EPOAATTCAAAAATGCAGCTGCATGTGGATAAAGCTCG 2387 chr7 ENST000002AGCTTTATCCACATGCAGCTGCA 52723.2 EPO AATTCAAAAAAGAGCAACTCTGAGATCTAAGCTCG2388 chr7 ENST000002 AGCTTAGATCTCAGAGTTGCTCT 52723.2 FAM3BAATTCAAAAATTGGAACTCCCTTCCGAAATTCTCGA 2389 chr21 ENST000003GAATTTCGGAAGGGAGTTCCAA 57985.6 FAM3BAATTCAAAAATAAATCCAACAGCCCATATTTCTCGA 2390 chr21 ENST000003GAAATATGGGCTGTTGGATTTA 57985.6 FAM3BAATTCAAAAATCAGGTCTAGCTGGGTATTTACTCGA 2391 chr21 ENST000003GTAAATACCCAGCTAGACCTGA 57985.6 FAM3CAATTCAAAAACTTGGTGTGTGCATGAGTATTCTCGA 2392 chr7 ENST000003GAATACTCATGCACACACCAAG 59943.7 FAM3C AATTCAAAAAGAGGAGATGTGGCACCATTTACTCG2393 chr7 ENST000003 AGTAAATGGTGCCACATCTCCTC 59943.7 FAM3CAATTCAAAAAGCCATACAAGATGGAACAATACTCG 2394 chr7 ENST000003AGTATTGTTCCATCTTGTATGGC 59943.7 FAM3DAATTCAAAAACACCTAGTGAAATTCCTTAAACTCGA 2395 chr3 ENST000003GTTTAAGGAATTTCACTAGGTG 58781.6 FAM3DAATTCAAAAACATGTACTCTGGAGATGTTATCTCGA 2396 chr3 ENST000003GATAACATCTCCAGAGTACATG 58781.6 FAM3D AATTCAAAAACAATGTGGGCAGAGGCCTAAACTCG2397 chr3 ENST000003 AGTTTAGGCCTCTGCCCACATTG 58781.6 FASAATTCAAAAAGCGTATGACACATTGATTAAACTCGA 2398 chr10 ENST000003GTTTAATCAATGTGTCATACGC 55740.6 FAS AATTCAAAAACCTGAAACAGTGGCAATAAATCTCG2399 chr10 ENST000003 AGATTTATTGCCACTGTTTCAGG 55740.6 FASAATTCAAAAACTATCATCCTCAAGGACATTACTCGA 2400 chr10 ENST000003GTAATGTCCTTGAGGATGATAG 55740.6 FASLG AATTCAAAAAGACTAGAGGCTTGCATAATAACTCG2401 chr1 ENST000003 AGTTATTATGCAAGCCTCTAGTC 67721.2 FASLGAATTCAAAAAACTGGGCTGTACTTTGTATATCTCGA 2402 chr1 ENST000003GATATACAAAGTACAGCCCAGT 67721.2 FASLGAATTCAAAAATGAGCTCTCTCTGGTCAATTTCTCGA 2403 chr1 ENST000003GAAATTGACCAGAGAGAGCTCA 67721.2 FGF2 AATTCAAAAAGAAACGAACTGGGCAGTATAACTCG2404 chr4 ENST000006 AGTTATACTGCCCAGTTCGTTTC 08478.1 FGF2AATTCAAAAATATAGCTCAGTTTGGATAATTCTCGA 2405 chr4 ENST000006GAATTATCCAAACTGAGCTATA 08478.1 FGF2 AATTCAAAAATGAACGATTGGAATCTAATAACTCGA2406 chr4 ENST000006 GTTATTAGATTCCAATCGTTCA 08478.1 FLT3LGAATTCAAAAACTGTCTGACTACCTGCTTCAACTCGA 2407 chr19 ENST000005GTTGAAGCAGGTAGTCAGACAG 94009.5 FLT3LGAATTCAAAAATCCTCCGACTTCGCTGTCAAACTCGA 2408 chr19 ENST000005GTTTGACAGCGAAGTCGGAGGA 94009.5 FLT3LGAATTCAAAAAGCTTCGTCCAGACCAACATCTCTCGA 2409 chr19 ENST000005GAGATGTTGGTCTGGACGAAGC 94009.5 FOXP3 AATTCAAAAAAGCTGGAGTTCCGCAAGAAACCTCG2410 chrX ENST000003 AGGTTTCTTGCGGAACTCCAGCT 76207.8 FOXP3AATTCAAAAATCCTACCCACTGCTGGCAAATCTCGA 2411 chrX ENST000003GATTTGCCAGCAGTGGGTAGGA 76207.8 FOXP3AATTCAAAAATGTCCCTCACTCAACACAAACCTCGA 2412 chrX ENST000003GGTTTGTGTTGAGTGAGGGACA 76207.8 FOXP3AATTCAAAAACACACGCATGTTTGCCTTCTTCTCGA 2413 chrX ENST000003GAAGAAGGCAAACATGCGTGTG 76207.8 FZD4 AATTCAAAAACGTGTGTGATTGCCTGTTATTCTCGA2414 chr11 ENST000005 GAATAACAGGCAATCACACACG 31380.1 FZD4AATTCAAAAATCTCAGTATGTGCTATAATATCTCGA 2415 chr11 ENST000005GATATTATAGCACATACTGAGA 31380.1 FZD4 AATTCAAAAATTCTCAGTATGTGCTATAATACTCGA2416 chr11 ENST000005 GTATTATAGCACATACTGAGAA 31380.1 GATA3AATTCAAAAAAGCCTAAACGCGATGGATATACTCG 2417 chr10 ENST000003AGTATATCCATCGCGTTTAGGCT 46208.4 GATA3AATTCAAAAACCCAAGAACAGCTCGTTTAACCTCGA 2418 chr10 ENST000003GGTTAAACGAGCTGTTCTTGGG 46208.4 GATA3 AATTCAAAAAGCCAAGAAGTTTAAGGAATATCTCG2419 chr10 ENST000003 AGATATTCCTTAAACTTCTTGGC 46208.4 GATA3AATTCAAAAACCCTGTAATTGTTGTTTGTATCTCGA 2420 chr10 ENST000003GATACAAACAACAATTACAGGG 46208.4 GBP1 AATTCAAAAACCAGATGAGTACCTGACATACCTCGA2421 chr1 ENST000003 GGTATGTCAGGTACTCATCTGG 70473.4 GBP1AATTCAAAAACGACGAAAGGCATGTACCATACTCG 2422 chr1 ENST000003AGTATGGTACATGCCTTTCGTCG 70473.4 GBP1 AATTCAAAAACGACGAAAGGCATGTACCATACTCG2423 chr1 ENST000003 AGTATGGTACATGCCTTTCGTCG 70473.4 GDF1AATTCAAAAAGTTCACCAAGCTCAACATTTACTCGA 2424 chr19 ENST000002GTAAATGTTGAGCTTGGTGAAC 47005.7 GDF1 AATTCAAAAAGAGTTCACCAAGCTCAACATTCTCGA2425 chr19 ENST000002 GAATGTTGAGCTTGGTGAACTC 47005.7 GDF1AATTCAAAAACCCTTATGAACCTCTACTGGTCTCGA 2426 chr19 ENST000002GACCAGTAGAGGTTCATAAGGG 47005.7 GDF10AATTCAAAAACAGGATAATCGTGGTGTAAATCTCGA 2427 chr10 ENST000005GATTTACACCACGATTATCCTG 80279.1 GDF10AATTCAAAAACGACCAGAAGGCCGTGTATTTCTCGA 2428 chr10 ENST000005GAAATACACGGCCTTCTGGTCG 80279.1 GDF10AATTCAAAAACTGTCCGCCAGTGCATCATTACTCGA 2429 chr10 ENST000005GTAATGATGCACTGGCGGACAG 80279.1 GDF11AATTCAAAAACCTGCAGATCTTGCGACTAAACTCGA 2430 chr12 ENST000002GTTTAGTCGCAAGATCTGCAGG 57868.9 GDF11AATTCAAAAAGATCGCTGTGGCTGCTCTTAACTCGA 2431 chr12 ENST000002GTTAAGAGCAGCCACAGCGATC 57868.9 GDF11 AATTCAAAAAGAGATGTAGAGACAGTGATAGCTCG2432 chr12 ENST000002 AGCTATCACTGTCTCTACATCTC 57868.9 GDF15AATTCAAAAAAGACTCCAGATTCCGAGAGTTCTCGA 2433 chr19 ENST000002GAACTCTCGGAATCTGGAGTCT 52809.3 GDF15AATTCAAAAAGCTCCAGACCTATGATGACTTCTCGA 2434 chr19 ENST000002GAAGTCATCATAGGTCTGGAGC 52809.3 GDF15 AATTCAAAAAAGAGCTGGGAAGATTCGAACACTCG2435 chr19 ENST000002 AGTGTTCGAATCTTCCCAGCTCT 52809.3 GDF2AATTCAAAAACAACAGGTACACGTCCGATAACTCG 2436 chr10 ENST000005AGTTATCGGACGTGTACCTGTTG 81492.2 GDF2AATTCAAAAATGAAAGGAAGCGTGGTCATTTCTCGA 2437 chr10 ENST000005GAAATGACCACGCTTCCTTTCA 81492.2 GDF2 AATTCAAAAATATGAAGCCTACGAGTGTAAGCTCG2438 chr10 ENST000005 AGCTTACACTCGTAGGCTTCATA 81492.2 GDF3AATTCAAAAAACCGTCACCAGCTATTCATTACTCGA 2439 chr12 ENST000003GTAATGAATAGCTGGTGACGGT 29913.3 GDF3 AATTCAAAAACTCTCAACAGCTCCAATTATGCTCGA2440 chr12 ENST000003 GCATAATTGGAGCTGTTGAGAG 29913.3 GDF3AATTCAAAAATTGGGCCAGGCAGTCCAATTTCTCGA 2441 chr12 ENST000003GAAATTGGACTGCCTGGCCCAA 29913.3 GDF5 AATTCAAAAACAACACCATCACCAGCTTTATCTCGA2442 chr20 ENST000003 GATAAAGCTGGTGATGGTGTTG 74369.7 GDF5AATTCAAAAAATGAGACTCAGCCCACCATTTCTCGA 2443 chr20 ENST000003GAAATGGTGGGCTGAGTCTCAT 74369.7 GDF5 AATTCAAAAATGAGTGTGACTTGGGCTAAAGCTCGA2444 chr20 ENST000003 GCTTTAGCCCAAGTCACACTCA 74369.7 GDF6AATTCAAAAAGACTCCCATCAGCATTCTATACTCGA 2445 chr8 ENST000002GTATAGAATGCTGATGGGAGTC 87020.6 GDF6 AATTCAAAAACGAGTACATGCTGTCAATCTACTCGA2446 chr8 ENST000002 GTAGATTGACAGCATGTACTCG 87020.6 GDF6AATTCAAAAACAGTCTTCCAAGTCGGCTAATCTCGA 2447 chr8 ENST000002GATTAGCCGACTTGGAAGACTG 87020.6 GDF7 AATTCAAAAAGCAGAGGAAAGAGAGCTTATTCTCG2448 chr2 ENST000002 AGAATAAGCTCTCTTTCCTCTGC 72224.4 GDF7AATTCAAAAAGTTCGACGTGTCCAGCCTTAACTCGA 2449 Chr2 ENST000002GTTAAGGCTGGACACGTCGAAC 72224.4 GDF7 AATTCAAAAACCACTTCATGATGTCGCTTTACTCGA2450 Chr2 ENST000002 GTAAAGCGACATCATGAAGTGG 72224.4 GDF9AATTCAAAAAGATGGCTCAATTGCCTATAAACTCGA 2451 Chr5 ENST000003GTTTATAGGCAATTGAGCCATC 78673.2 GDF9 AATTCAAAAACCATCAGTGGAACTGCTATTTCTCGA2452 Chr5 ENST000003 GAAATAGCAGTTCCACTGATGG 78673.2 GDF9AATTCAAAAAGAGTGAATACTTCAGACAATTCTCGA 2453 Chr5 ENST000003GAATTGTCTGAAGTATTCACTC 78673.2 GPI AATTCAAAAACGTCTGGTATGTCTCCAACATCTCGA2454 chr19 ENST000003 GATGTTGGAGACATACCAGACG 56487.9 GPIAATTCAAAAACGTCTGGTATGTCTCCAACATCTCGA 2455 chr19 ENST000003GATGTTGGAGACATACCAGACG 56487.9 GPI AATTCAAAAAGCGGATGTTCAATGGTGAGAACTCG2456 chr19 ENST000003 AGTTCTCACCATTGAACATCCGC 56487.9 GREM1AATTCAAAAAGCAGTGTCGTTGCATATCCATCTCGA 2457 chr15 ENST000006GATGGATATGCAACGACACTGC 22074.1 GREM1 AATTCAAAAAACAGCCACCTACCAAGAAGAACTCG2458 chr15 ENST000006 AGTTCTTCTTGGTAGGTGGCTGT 22074.1 GREM1AATTCAAAAACAACAGTCGCACCATCATCAACTCGA 2459 chr15 ENST000006GTTGATGATGGTGCGACTGTTG 22074.1 GREM2 AATTCAAAAAGCTGTGAAGGAAGGAAATTTACTCG2460 chr1 ENST000003 AGTAAATTTCCTTCCTTCACAGC 18160.4 GREM2AATTCAAAAACAAGGTGCATTTCTGTCATTTCTCGA 2461 chr1 ENST000003GAAATGACAGAAATGCACCTTG 18160.4 GREM2AATTCAAAAACGGAAGTAGACGTAACTTATTCTCGA 2462 chr1 ENST000003GAATAAGTTACGTCTACTTCCG 18160.4 GRN AATTCAAAAAGCCCTGATAGTCAGTTCGAATCTCGA2463 chr17 ENST000000 GATTCGAACTGACTATCAGGGC 53867.7 GRNAATTCAAAAAGCCCTGATAGTCAGTTCGAATCTCGA 2464 chr17 ENST000000GATTCGAACTGACTATCAGGGC 53867.7 GRN AATTCAAAAACTTCCAAAGATCAGGTAACAACTCG2465 chr17 ENST000000 AGTTGTTACCTGATCTTTGGAAG 53867.7 HAX1AATTCAAAAAACAGACACTTCGGGACTCAATCTCGA 2466 chr1 ENST000003GATTGAGTCCCGAAGTGTCTGT 28703.11 HAX1AATTCAAAAACCAGCCCAAATCCTATTTCAACTCGA 2467 chr1 ENST000003GTTGAAATAGGATTTGGGCTGG 28703.11 HAX1AATTCAAAAACCAGAGGCCATTTCATAGGTTCTCGA 2468 chr1 ENST000003GAACCTATGAAATGGCCTCTGG 28703.11 HFE2AATTCAAAAAGACATGATCATTAGCCATAAGCTCGA 2469 chr1 ENST000003GCTTATGGCTAATGATCATGTC 36751.10 HFE2AATTCAAAAAGCCTACATTGGCACAACTATACTCGA 2470 chr1 ENST000003GTATAGTTGTGCCAATGTAGGC 36751.10 HFE2AATTCAAAAAGAAGCTCACCATCATATTTAACTCGA 2471 chr1 ENST000003GTTAAATATGATGGTGAGCTTC 36751.10 HMGB1AATTCAAAAAGATGCAGCTTATACGAAATAACTCG 2472 chr13 ENST000003AGTTATTTCGTATAAGCTGCATC 39872.8 HMGB1AATTCAAAAAGTTGGTGCACAGCACAAATTACTCGA 2473 chr13 ENST000003GTAATTTGTGCTGTGCACCAAC 39872.8 HMGB1 AATTCAAAAAAGAAGATGATGATGATGAATACTCG2474 chr13 ENST000003 AGTATTCATCATCATCATCTTCT 39872.8 HYAL2AATTCAAAAACCTGCCAGTACCTCAAAGATTCTCGA 2475 chr3 ENST000003GAATCTTTGAGGTACTGGCAGG 57750.8 HYAL2AATTCAAAAACCTGCCAGTACCTCAAAGATTCTCGA 2476 chr3 ENST000003GAATCTTTGAGGTACTGGCAGG 57750.8 HYAL2AATTCAAAAACTGGACCTGAATGCCTTTGATCTCGA 2477 chr3 ENST000003GATCAAAGGCATTCAGGTCCAG 57750.8 ICAM3 AATTCAAAAAGTCCAGCTCACGAGGCAAATACTCG2478 chr19 ENST000001 AGTATTTGCCTCGTGAGCTGGAC 60262.9 ICAM3AATTCAAAAACCAGCTCAACTTCAGCTAAATCTCGA 2479 chr19 ENST000001GATTTAGCTGAAGTTGAGCTGG 60262.9 ICAM3 AATTCAAAAAGCACTTGAAATGGAAAGATAACTCG2480 chr19 ENST000001 AGTTATCTTTCCATTTCAAGTGC 60262.9 ICAM3AATTCAAAAAGAGCGGCAGTTACCATGTTAGCTCGA 2481 chr19 ENST000001GCTAACATGGTAACTGCCGCTC 60262.9 ICOS AATTCAAAAAGCACGACCCTAACGGTGAATACTCG2482 ch2 ENST000003 AGTATTCACCGTTAGGGTCGTGC 16386.10 ICOSAATTCAAAAAGTCCGCATTTCACTATCATACCTCGA 2483 ch2 ENST000003GGTATGATAGTGAAATGCGGAC 16386.10 ICOSAATTCAAAAACCATTCTCATGCCAACTATTACTCGA 2484 ch2 ENST000003GTAATAGTTGGCATGAGAATGG 16386.10 ICOSAATTCAAAAACACAGATGTGACCCTATAATACTCGA 2485 ch2 ENST000003GTATTATAGGGTCACATCTGTG 16386.10 IFNA10AATTCAAAAATGTAAAGAAGTGTCGTGTATACTCGA 2486 chr9 ENST000003GTATACACGACACTTCTTTACA 57374.2 IFNA10AATTCAAAAAATAACCACGACGCGTTGAATCCTCGA 2487 chr9 ENST000003GGATTCAACGCGTCGTGGTTAT 57374.2 IFNA10AATTCAAAAACCTGGGACAAATGGGAAGAATCTCG 2488 chr9 ENST000003AGATTCTTCCCATTTGTCCCAGG 57374.2 IFNA14AATTCAAAAACTGGGCTGTAATCTGTCTCAACTCGA 2489 chr9 ENST000003GTTGAGACAGATTACAGCCCAG 80222.3 IFNA14AATTCAAAAACCTGAATAACAGGAGGACTTTCTCGA 2490 chr9 ENST000003GAAAGTCCTCCTGTTATTCAGG 80222.3 IFNA14AATTCAAAAAGCAGCAGACCTTCAATCTCTTCTCGA 2491 chr9 ENST000003GAAGAGATTGAAGGTCTGCTGC 80222.3 IFNA16AATTCAAAAATGTAAAGAAGCATCGTGTTTACTCGA 2492 chr9 ENST000003GTAAACACGATGCTTCTTTACA 80216.1 IFNA16AATTCAAAAAATGATCCTCATTGATTAATACCTCGA 2493 chr9 ENST000003GGTATTAATCAATGAGGATCAT 80216.1 IFNA16AATTCAAAAACCTGAAGGACAGATATGATTTCTCGA 2494 chr9 ENST000003GAAATCATATCTGTCCTTCAGG 80216.1 IFNA2AATTCAAAAAGCACAGTGGTTAATGTAATAACTCGA 2495 chr9 ENST000003GTTATTACATTAACCACTGTGC 80206.3 IFNA2AATTCAAAAATATGACCATGACACGATTTAACTCGA 2496 chr9 ENST000003GTTAAATCGTGTCATGGTCATA 80206.3 IFNA2AATTCAAAAACCATGCTGACTGATCCATTATCTCGA 2497 chr9 ENST000003GATAATGGATCAGTCAGCATGG 80206.3 IFNA5AATTCAAAAAACTTGGGATGAGACACTTCTACTCGA 2498 chr9 ENST000006GTAGAAGTGTCTCATCCCAAGT 10521.1 IFNA5AATTCAAAAAAGTGGAAGACACTCCTCTGATCTCGA 2499 chr9 ENST000006GATCAGAGGAGTGTCTTCCACT 10521.1 IFNA5AATTCAAAAATCAACTGCAAGTCAATCTGTTCTCGA 2500 chr9 ENST000006GAACAGATTGACTTGCAGTTGA 10521.1 IFNA6AATTCAAAAAGACAGACATGACTTCAGATTTCTCGA 2501 chr9 ENST000003GAAATCTGAAGTCATGTCTGTC 80210.1 IFNA6AATTCAAAAACTGTCCTCCATGAGGTGATTCCTCGA 2502 chr9 ENST000003GGAATCACCTCATGGAGGACAG 80210.1 IFNA6AATTCAAAAAAGGCTTCTAGACAAACTCTATCTCGA 2503 chr9 ENST000003GATAGAGTTTGTCTAGAAGCCT 80210.1 IFNA8AATTCAAAAATAACTATCTATAGGGCTTAAACTCGA 2504 chr9 ENST000003GTTTAAGCCCTATAGATAGTTA 80205.1 IFNA8 AATTCAAAAACCAGGAGGAGTTTGATGATAACTCG2505 chr9 ENST000003 AGTTATCATCAAACTCCTCCTGG 80205.1 IFNA8AATTCAAAAAGACCTGGTACAACACGGAAATCTCG 2506 chr9 ENST000003AGATTTCCGTGTTGTACCAGGTC 80205.1 IFNAR1AATTCAAAAAGCCAAGATTCAGGAAATTATTCTCGA 2507 chr21 ENST000002GAATAATTTCCTGAATCTTGGC 70139.7 IFNAR1AATTCAAAAAGCTCTCCCGTTTGTCATTTATCTCGA 2508 chr21 ENST000002GATAAATGACAAACGGGAGAGC 70139.7 IFNAR1AATTCAAAAAATGAACTGTGTCAAGTATAAGCTCGA 2509 chr21 ENST000002GCTTATACTTGACACAGTTCAT 70139.7 IFNAR2AATTCAAAAAGAGTGGAAATTTCACCTATATCTCGA 2510 chr21 ENST000003GATATAGGTGAAATTTCCACTC 42136.8 IFNAR2AATTCAAAAATGTATATCAGCCTCGTGTTTGCTCGA 2511 chr21 ENST000003GCAAACACGAGGCTGATATACA 42136.8 IFNAR2AATTCAAAAAGCAAATACCACAAGATCATTTCTCGA 2512 chr21 ENST000003GAAATGATCTTGTGGTATTTGC 42136.8 IFNB1 AATTCAAAAAATTGAATGGGAGGCTTGAATACTCG2513 chr9 ENST000003 AGTATTCAAGCCTCCCATTCAAT 80232.3 IFNB1AATTCAAAAACCTACAAAGAAGCAGCAATTTCTCG 2514 chr9 ENST000003AGAAATTGCTGCTTCTTTGTAGG 80232.3 IFNB1AATTCAAAAACTAATGTCTATCATCAGATAACTCGA 2515 chr9 ENST000003GTTATCTGATGATAGACATTAG 80232.3 IFNE AATTCAAAAAGGTAGTGATAACCTTAGATTACTCGA2516 chr9 ENST000004 GTAATCTAAGGTTATCACTACC 48696.4 IFNEAATTCAAAAAAGCCTCTTCAGGGCAAATATTCTCGA 2517 chr9 ENST000004GAATATTTGCCCTGAAGAGGCT 48696.4 IFNE AATTCAAAAACATAGAGTGGTAATACAATTTCTCGA2518 chr9 ENST000004 GAAATTGTATTACCACTCTATG 48696.4 IFNGAATTCAAAAAGGTTGTCCTGCCTGCAATATTCTCGA 2519 chr12 ENST000002GAATATTGCAGGCAGGACAACC 29135.3 IFNG AATTCAAAAACATTCAGATGTAGCGGATAATCTCGA2520 chr12 ENST000002 GATTATCCGCTACATCTGAATG 29135.3 IFNGAATTCAAAAATGTTACTGCCAGGACCCATATCTCGA 2521 chr12 ENST000002GATATGGGTCCTGGCAGTAACA 29135.3 IFNGR1AATTCAAAAAACGAGCAGGAAGTCGATTATGCTCG 2522 chr6 ENST000003AGCATAATCGACTTCCTGCTCGT 67739.8 IFNGR1AATTCAAAAACATGAACCCTATCGTATATTGCTCGA 2523 chr6 ENST000003GCAATATACGATAGGGTTCATG 67739.8 IFNGR1AATTCAAAAACGGAAGTGAGATCCAGTATAACTCG 2524 chr6 ENST000003AGTTATACTGGATCTCACTTCCG 67739.8 IFNK AATTCAAAAAGAGATTGTGGCTACGCAAATGCTCG2525 chr9 ENST000002 AGCATTTGCGTAGCCACAATCTC 76943.2 IFNKAATTCAAAAACTGTTCAGATTCAAGATTATTCTCGA 2526 chr9 ENST000002GAATAATCTTGAATCTGAACAG 76943.2 IFNK AATTCAAAAATCAGCCAACACACCTTCAAATCTCGA2527 chr9 ENST000002 GATTTGAAGGTGTGTTGGCTGA 76943.2 IFNL1AATTCAAAAACTCACGCGAGACCTCAAATATCTCGA 2528 chr19 ENST000003GATATTTGAGGTCTCGCGTGAG 33625.2 IFNL1AATTCAAAAAGCCACATTGGCAGGTTCAAATCTCGA 2529 chr19 ENST000003GATTTGAACCTGCCAATGTGGC 33625.2 IFNL1AATTCAAAAAGAGTTGCAGCTCTCCTGTCTTCTCGA 2530 chr19 ENST000003GAAGACAGGAGAGCTGCAACTC 33625.2 IFNL3 AATTCAAAAAAGGGCCAAAGATGCCTTAGAACTCG2531 chr19 ENST000004 AGTTCTAAGGCATCTTTGGCCCT 13851.2 IFNL3AATTCAAAAAGCCTTTAAGAGGGCCAAAGATCTCG 2532 chr19 ENST000004AGATCTTTGGCCCTCTTAAAGGC 13851.2 IFNL3AATTCAAAAATGCCACATAGCCCAGTTCAAGCTCGA 2533 chr19 ENST000004GCTTGAACTGGGCTATGTGGCA 13851.2 IFNW1AATTCAAAAAAGACTCTTATTTCGGCTTTAACTCGA 2534 chr9 ENST000003GTTAAAGCCGAAATAAGAGTCT 80229.3 IFNW1AATTCAAAAATCAGTCCCTAAGATGTTATTTCTCGA 2535 chr9 ENST000003GAAATAACATCTTAGGGACTGA 80229.3 IFNW1AATTCAAAAACGGTATATTAAGCCAGTATATCTCGA 2536 chr9 ENST000003GATATACTGGCTTAATATACCG 80229.3 IL10 AATTCAAAAAAGCTTCTCTGTGAACGATTTACTCGA2537 chr1 ENST000004 GTAAATCGTTCACAGAGAAGCT 23557.1 IL10AATTCAAAAAGCAGGTGAAGAATGCCTTTAACTCG 2538 chr1 ENST000004AGTTAAAGGCATTCTTCACCTGC 23557.1 IL10AATTCAAAAAGCTGGACAACTTGTTGTTAAACTCGA 2539 chr1 ENST000004GTTTAACAACAAGTTGTCCAGC 23557.1 IL10RAAATTCAAAAATCTGTCGCTTCCCGAAGTAACCTCGA 2540 chr11 ENST000002GGTTACTTCGGGAAGCGACAGA 27752.7 IL10RAAATTCAAAAAGAAACAGGATCCTCTAGAAATCTCG 2541 chr11 ENST000002AGATTTCTAGAGGATCCTGTTTC 27752.7 IL10RAAATTCAAAAAGAACTCTTTCCTGTATCATAACTCGA 2542 chr11 ENST000002GTTATGATACAGGAAAGAGTTC 27752.7 IL11 AATTCAAAAAATATCCACTTGAGGGCGATTTCTCGA2543 chr19 ENST000002 GAAATCGCCCTCAAGTGGATAT 64563.6 IL11AATTCAAAAACCTTCCAAAGCCAGATCTTATCTCGA 2544 chr19 ENST000002GATAAGATCTGGCTTTGGAAGG 64563.6 IL11 AATTCAAAAATGCACAGCTGAGGGACAAATTCTCG2545 chr19 ENST000002 AGAATTTGTCCCTCAGCTGTGCA 64563.6 IL11RAAATTCAAAAACGGCAGATTCCACCTATAATTCTCGA 2546 chr9 ENST000003GAATTATAGGTGGAATCTGCCG 18041.13 IL11RAAATTCAAAAATCGGCAGATTCCACCTATAATCTCGA 2547 chr9 ENST000003GATTATAGGTGGAATCTGCCGA 18041.13 IL11RAAATTCAAAAATGGAGCCAGTACCGGATTAATCTCGA 2548 chr9 ENST000003GATTAATCCGGTACTGGCTCCA 18041.13 IL12AAATTCAAAAATGATACCTCTGATCAAGTATTCTCGA 2549 chr3 ENST000003GAATACTTGATCAGAGGTATCA 05579.6 IL12AAATTCAAAAACCTGTGCCTTAGTAGTATTTACTCGA 2550 chr3 ENST000003GTAAATACTACTAAGGCACAGG 05579.6 IL12AAATTCAAAAACCTGTTTACCATTGGAATTAACTCGA 2551 chr3 ENST000003GTTAATTCCAATGGTAAACAGG 05579.6 IL12BAATTCAAAAAGAATTTGGTCCACTGATATTTCTCGA 2552 chr5 ENST000002GAAATATCAGTGGACCAAATTC 31228.2 IL12BAATTCAAAAACCATGGGCCTTCATGCTATTTCTCGA 2553 chr5 ENST000002GAAATAGCATGAAGGCCCATGG 31228.2 IL12BAATTCAAAAATTAGATGCTAAATGCTCATTGCTCGA 2554 chr5 ENST000002GCAATGAGCATTTAGCATCTAA 31228.2 IL12RB1AATTCAAAAACAGCTCTACAACTCAGTTAAACTCGA 2555 chr19 ENST000005GTTTAACTGAGTTGTAGAGCTG 93993.6 IL12RB1AATTCAAAAAGTCATCTCCTCGAACCAATTTCTCGA 2556 chr19 ENST000005GAAATTGGTTCGAGGAGATGAC 93993.6 IL12RB1AATTCAAAAACCAACGGGACCACCATGTATTCTCGA 2557 chr19 ENST000005GAATACATGGTGGTCCCGTTGG 93993.6 IL13 AATTCAAAAAACTTCGAAAGCATCATTATTTCTCGA2558 chr5 ENST000003 GAAATAATGATGCTTTCGAAGT 04506.7 IL13AATTCAAAAAATTGAAGTTGCAGATTCATTTCTCGA 2559 chr5 ENST000003GAAATGAATCTGCAACTTCAAT 04506.7 IL13 AATTCAAAAACCTGCTCTTACATTTAAAGAACTCGA2560 chr5 ENST000003 GTTCTTTAAATGTAAGAGCAGG 04506.7 IL15AATTCAAAAAGAAGATCTTATTCAATCTATGCTCGA 2561 chr4 ENST000002GCATAGATTGAATAAGATCTTC 96545.11 IL15AATTCAAAAATAAGGGTGATAGTCAAATTATCTCGA 2562 chr4 ENST000002GATAATTTGACTATCACCCTTA 96545.11 IL15AATTCAAAAACACTCTGCTGCTTAGACATAACTCGA 2563 chr4 ENST000002GTTATGTCTAAGCAGCAGAGTG 96545.11 IL16AATTCAAAAATGGGACCACGTGAGATCATTCCTCGA 2564 chr15 ENST000003GGAATGATCTCACGTGGTCCCA 02987.8 IL16 AATTCAAAAAGTTCTGGATGAAGCAACATTACTCGA2565 chr15 ENST000003 GTAATGTTGCTTCATCCAGAAC 02987.8 IL16AATTCAAAAACCCAAACAGTGACATTTATTTCTCGA 2566 chr15 ENST000003GAAATAAATGTCACTGTTTGGG 02987.8 IL17AAATTCAAAAAATCAGTTCTGCCTAGGTAAATCTCGA 2567 chr6 ENST000003GATTTACCTAGGCAGAACTGAT 40057.1 IL17AAATTCAAAAAGAGCTATTTAAGGATCTATTTCTCGA 2568 chr6 ENST000003GAAATAGATCCTTAAATAGCTC 40057.1 IL17AAATTCAAAAAGGTCAACCTGAACATCCATAACTCGA 2569 chr6 ENST000003GTTATGGATGTTCAGGTTGACC 40057.1 IL17BAATTCAAAAATATGCCCGCATGGAGGAGTATCTCGA 2570 chr5 ENST000002GATACTCCTCCATGCGGGCATA 61796.3 IL17BAATTCAAAAAGTGTCACGGATGAAACCGTATCTCGA 2571 chr5 ENST000002GATACGGTTTCATCCGTGACAC 61796.3 IL17B AATTCAAAAAGCAGCTGTGGATGTCCAACAACTCG2572 chr5 ENST000002 AGTTGTTGGACATCCACAGCTGC 61796.3 IL17CAATTCAAAAAGCACCTCTTCCAGCCCTTAAACTCGA 2573 chr16 ENST000002GTTTAAGGGCTGGAAGAGGTGC 44241.4 IL17CAATTCAAAAACTTTGCCTTCCACACCGAGTTCTCGA 2574 chr16 ENST000002GAACTCGGTGTGGAAGGCAAAG 44241.4 IL17CAATTCAAAAAATCTCCAGCCTCAGTAGTTGGCTCGA 2575 chr16 ENST000002GCCAACTACTGAGGCTGGAGAT 44241.4 IL17DAATTCAAAAAAGAGCTACTCTGTTACATTTCCTCGA 2576 chr13 ENST000003GGAAATGTAACAGAGTAGCTCT 04920.3 IL17D AATTCAAAAACAAAGAGATAGGGACGCATATCTCG2577 chr13 ENST000003 AGATATGCGTCCCTATCTCTTTG 04920.3 IL17DAATTCAAAAAAGACAGCATCAACTCCAGCATCTCG 2578 chr13 ENST000003AGATGCTGGAGTTGATGCTGTCT 04920.3 IL17FAATTCAAAAATCATCCACCATGTGCAGTAAGCTCGA 2579 chr6 ENST000003GCTTACTGCACATGGTGGATGA 36123.4 IL17FAATTCAAAAAGTACTTGCTGCTGTCGATATTCTCGA 2580 chr6 ENST000003GAATATCGACAGCAGCAAGTAC 36123.4 IL17FAATTCAAAAACGTTTCCATGTCACGTAACATCTCGA 2581 chr6 ENST000003GATGTTACGTGACATGGAAACG 36123.4 IL18 AATTCAAAAACCCGGACCATATTTATTATAACTCGA2582 chr11 ENST000002 GTTATAATAAATATGGTCCGGG 80357.11 IL18AATTCAAAAATGATTCTGACTGTAGAGATAACTCGA 2583 chr11 ENST000002GTTATCTCTACAGTCAGAATCA 80357.11 IL18AATTCAAAAATGGCAAGCTTGAATCTAAATTCTCGA 2584 chr11 ENST000002GAATTTAGATTCAAGCTTGCCA 80357.11 IL18BPAATTCAAAAAGGTCCCTTCTCTCACCAAATTCTCGA 2585 chr11 ENST000002GAATTTGGTGAGAGAAGGGACC 60049.9 IL18BPAATTCAAAAATCCCATGTCTCTGCTCATTTACTCGA 2586 chr11 ENST000002GTAAATGAGCAGAGACATGGGA 60049.9 IL18BPAATTCAAAAACTGGGCAATGGTTCCTTCATTCTCGA 2587 chr11 ENST000002GAATGAAGGAACCATTGCCCAG 60049.9 IL19 AATTCAAAAAGTCCACGCTGCTGCCATTAAACTCGA2588 chr1 ENST000002 GTTTAATGGCAGCAGCGTGGAC 70218.10 IL19AATTCAAAAATCCACAGACATGCACCATATACTCGA 2589 chr1 ENST000002GTATATGGTGCATGTCTGTGGA 70218.10 IL19 AATTCAAAAATGATGACAAGGAACCTGTATACTCG2590 chr1 ENST000002 AGTATACAGGTTCCTTGTCATCA 70218.10 IL1AAATTCAAAAAGTGGAACCAACACTAACATATCTCG 2591 chr2 ENST000002AGATATGTTAGTGTTGGTTCCAC 63339.3 IL1AAATTCAAAAAGCCCTCAATCAAAGTATAATTCTCGA 2592 chr2 ENST000002GAATTATACTTTGATTGAGGGC 63339.3 IL1A AATTCAAAAATATTACAGATGGGCAAATTAACTCGA2593 chr2 ENST000002 GTTAATTTGCCCATCTGTAATA 63339.3 IL1BAATTCAAAAAATCAATAACAAGCTGGAATTTCTCGA 2594 chr2 ENST000002GAAATTCCAGCTTGTTATTGAT 63341.6 IL1B AATTCAAAAAAGCAACCGCTTCCCTATTTATCTCGA2595 chr2 ENST000002 GATAAATAGGGAAGCGGTTGCT 63341.6 IL1BAATTCAAAAACTGACTTCACCATGCAATTTGCTCGA 2596 chr2 ENST000002GCAAATTGCATGGTGAAGTCAG 63341.6 IL1F10AATTCAAAAATCCTTGTGGGCTCAGTTTAATCTCGA 2597 chr2 ENST000003GATTAAACTGAGCCCACAAGGA 41010.6 IL1F10AATTCAAAAAGGTCTATGGTAGGCAGAATAACTCG 2598 chr2 ENST000003AGTTATTCTGCCTACCATAGACC 41010.6 IL1F10AATTCAAAAATGCAGACCAGAAGGCTCTATACTCG 2599 chr2 ENST000003AGTATAGAGCCTTCTGGTCTGCA 41010.6 IL1R1AATTCAAAAAGCCAAGAATACACATGGTATACTCG 2600 chr2 ENST000004AGTATACCATGTGTATTCTTGGC 10023.5 IL1R1AATTCAAAAAATAATGCACAAGCCATATTTACTCGA 2601 chr2 ENST000004GTAAATATGGCTTGTGCATTAT 10023.5 IL1R1AATTCAAAAATGGTATAGATGCAGCATATATCTCGA 2602 chr2 ENST000004GATATATGCTGCATCTATACCA 10023.5 IL1R2AATTCAAAAACAATCCCGTGTAAGGTGTTTCCTCGA 2603 chr2 ENST000003GGAAACACCTTACACGGGATTG 32549.7 IL1R2AATTCAAAAAGACCATTCCTGTGATCATTTCCTCGA 2604 chr2 ENST000003GGAAATGATCACAGGAATGGTC 32549.7 IL1R2AATTCAAAAACGTTCATCTCATACCCGCAAACTCGA 2605 chr2 ENST000003GTTTGCGGGTATGAGATGAACG 32549.7 IL1RAPL1AATTCAAAAACAAAGCAAGCGGCTGATTATTCTCGA 2606 chrX ENST000003GAATAATCAGCCGCTTGCTTTG 78993.5 IL1RAPL1AATTCAAAAAGCCAGCGTTCTCCTTCATAAACTCGA 2607 chrX ENST000003GTTTATGAAGGAGAACGCTGGC 78993.5 IL1RAPL1AATTCAAAAATCAAGCTCCTGACGGTCATTACTCGA 2608 chrX ENST000003GTAATGACCGTCAGGAGCTTGA 78993.5 IL1RL1AATTCAAAAATTACACCGTGGATTGGTATTACTCGA 2609 chr2 ENST000002GTAATACCAATCCACGGTGTAA 33954.5 IL1RL1AATTCAAAAAAGTTGCTGATTCTGGTATTTACTCGA 2610 chr2 ENST000002GTAAATACCAGAATCAGCAACT 33954.5 IL1RL1AATTCAAAAACGTGAAGGAAGAGGATTTATTCTCG 2611 chr2 ENST000002AGAATAAATCCTCTTCCTTCACG 33954.5 IL1RNAATTCAAAAAGCAAGGACCAAATGTCAATTTCTCGA 2612 chr2 ENST000004GAAATTGACATTTGGTCCTTGC 09930.3 IL1RNAATTCAAAAACGTCATGGTCACCAAATTCTACTCGA 2613 chr2 ENST000004GTAGAATTTGGTGACCATGACG 09930.3 IL1RNAATTCAAAAACTGCCTCCAGAATGGTCTTTCCTCGA 2614 chr2 ENST000004GGAAAGACCATTCTGGAGGCAG 09930.3 IL2 AATTCAAAAAGCTACCTATTGTAACTATTATCTCGA2615 chr4 ENST000002 GATAATAGTTACAATAGGTAGC 26730.4 IL2AATTCAAAAACAGCTACAACTGGAGCATTTACTCGA 2616 chr4 ENST000002GTAAATGCTCCAGTTGTAGCTG 26730.4 IL2 AATTCAAAAATGCTGGATTTACAGATGATTTCTCGA2617 chr4 ENST000002 GAAATCATCTGTAAATCCAGCA 26730.4 IL20AATTCAAAAACTGATGCTCTGTGAGATATTTCTCGA 2618 chr1 ENST000003GAAATATCTCACAGAGCATCAG 67096.7 IL20 AATTCAAAAATGGTCACAGTGTATCTTATTTCTCGA2619 chr1 ENST000003 GAAATAAGATACACTGTGACCA 67096.7 IL20AATTCAAAAAGGACTGAAGACACTCAATTTGCTCGA 2620 chr1 ENST000003GCAAATTGAGTGTCTTCAGTCC 67096.7 IL20RAAATTCAAAAACCAGTATTATGCCAAAGTTAACTCGA 2621 chr6 ENST000003GTTAACTTTGGCATAATACTGG 16649.9 IL20RAAATTCAAAAAGAGGGTCTTCAAGGAGTTAAACTCG 2622 chr6 ENST000003AGTTTAACTCCTTGAAGACCCTC 16649.9 IL20RAAATTCAAAAAGCTTCGCATTTGATGGAAATTCTCGA 2623 chr6 ENST000003GAATTTCCATCAAATGCGAAGC 16649.9 IL20RBAATTCAAAAACAGTGTACTATTCTGTCGAATCTCGA 2624 chr3 ENST000003GATTCGACAGAATAGTACACTG 29582.8 IL20RBAATTCAAAAACCAGAATAATCCTTGAGAGAACTCG 2625 chr3 ENST000003AGTTCTCTCAAGGATTATTCTGG 29582.8 IL20RBAATTCAAAAACTCTGTACTCTCAACCAACATCTCGA 2626 chr3 ENST000003GATGTTGGTTGAGAGTACAGAG 29582.8 IL21 AATTCAAAAAAGGAAACCACCTTCCACAAATCTCG2627 chr4 ENST000002 AGATTTGTGGAAGGTGGTTTCCT 64497.7 IL21AATTCAAAAAATGACTTGGTCCCTGAATTTCCTCGA 2628 chr4 ENST000002GGAAATTCAGGGACCAAGTCAT 64497.7 IL21 AATTCAAAAACTTTCAGAAGGCCCAACTAAACTCGA2629 chr4 ENST000002 GTTTAGTTGGGCCTTCTGAAAG 64497.7 IL22AATTCAAAAAAGGCTAAGCACATGTCATATTCTCGA 2630 chr12 ENST000003GAATATGACATGTGCTTAGCCT 28087.5 IL22 AATTCAAAAAGTTTCCATAATCAGTACTTTACTCGA2631 chr12 ENST000003 GTAAAGTACTGATTATGGAAAC 28087.5 IL22AATTCAAAAAAGACTTTCTAAGCATAGATATCTCGA 2632 chr12 ENST000003GATATCTATGCTTAGAAAGTCT 28087.5 IL22RA1AATTCAAAAAGGACACTTTCTAGTCCTAAACCTCGA 2633 chr1 ENST000002GGTTTAGGACTAGAAAGTGTCC 70800.1 IL22RA1AATTCAAAAAAGGGACACCACAGTACCTAAACTCG 2634 chr1 ENST000002AGTTTAGGTACTGTGGTGTCCCT 70800.1 IL22RA1AATTCAAAAACTGTCCGAGATCACCTACTTACTCGA 2635 chr1 ENST000002GTAAGTAGGTGATCTCGGACAG 70800.1 IL22RA2AATTCAAAAAAGACATACAGGAACCTTATTACTCGA 2636 chr6 ENST000003GTAATAAGGTTCCTGTATGTCT 49184.8 IL22RA2AATTCAAAAACTCGTGTTTGAAGGATCTTATCTCGA 2637 chr6 ENST000003GATAAGATCCTTCAAACACGAG 49184.8 IL22RA2AATTCAAAAATGCTCCAAATTTACCATATAGCTCGA 2638 chr6 ENST000003GCTATATGGTAAATTTGGAGCA 49184.8 IL23AAATTCAAAAAAGCTGCTAGGATCGGATATTTCTCGA 2639 chr12 ENST000002GAAATATCCGATCCTAGCAGCT 28534.5 IL23AAATTCAAAAACTGTGAGCCAACAGGTTAATTCTCGA 2640 chr12 ENST000002GAATTAACCTGTTGGCTCACAG 28534.5 IL23AAATTCAAAAAGGATCCACCAGGGTCTGATTTCTCGA 2641 chr12 ENST000002GAAATCAGACCCTGGTGGATCC 28534.5 IL23RAATTCAAAAACTTTCTTTGATTGGGATATTTCTCGA 2642 chr1 ENST000003GAAATATCCCAATCAAAGAAAG 47310.9 IL23RAATTCAAAAATATCTCACCTCAAGCTATATTCTCGA 2643 chr1 ENST000003GAATATAGCTTGAGGTGAGATA 47310.9 IL23RAATTCAAAAACGACAATACTACAGTTGTATACTCGA 2644 chr1 ENST000003GTATACAACTGTAGTATTGTCG 47310.9 IL24 AATTCAAAAACACAGGCGGTTTCTGCTATTCCTCGA2645 chr1 ENST000002 GGAATAGCAGAAACCGCCTGTG 94984.6 IL24AATTCAAAAAGTCAGGACTCTGAAGTCATTCCTCGA 2646 chr1 ENST000002GGAATGACTTCAGAGTCCTGAC 94984.6 IL24 AATTCAAAAATCGGATGCTGAGAGCTGTTACCTCGA2647 chr1 ENST000002 GGTAACAGCTCTCAGCATCCGA 94984.6 IL25AATTCAAAAAACAGGCACTTTCTAGATATTTCTCGA 2648 chr14 ENST000003GAAATATCTAGAAAGTGCCTGT 29715.2 IL25 AATTCAAAAACCACAACCAGACTGTCTTCTACTCGA2649 chr14 ENST000003 GTAGAAGACAGTCTGGTTGTGG 29715.2 IL25AATTCAAAAATCCTGTAGGGCCAGTGAAGATCTCGA 2650 chr14 ENST000003GATCTTCACTGGCCCTACAGGA 29715.2 IL26 AATTCAAAAAAGCTGTTGACGCTCTCTATATCTCGA2651 chr12 ENST000002 GATATAGAGAGCGTCAACAGCT 29134.4 IL26AATTCAAAAAAGTACATTGTGTCAACTTAATCTCGA 2652 chr12 ENST000002GATTAAGTTGACACAATGTACT 29134.4 IL26 AATTCAAAAACGATTCCAGAAGACCGCATAACTCG2653 chr12 ENST000002 AGTTATGCGGTCTTCTGGAATCG 29134.4 IL27AATTCAAAAAACTCCTTGGAGCTCGTCTTATCTCGA 2654 chr16 ENST000003GATAAGACGAGCTCCAAGGAGT 56897.1 IL27 AATTCAAAAAACTTTAGGACTGGAGTCTTGGCTCGA2655 chr16 ENST000003 GCCAAGACTCCAGTCCTAAAGT 56897.1 IL27AATTCAAAAACATCATCAGCCTTGGACAAGGCTCGA 2656 chr16 ENST000003GCCTTGTCCAAGGCTGATGATG 56897.1 IL2RAAATTCAAAAACCTCGTCACAACAACAGATTTCTCGA 2657 chr10 ENST000003GAAATCTGTTGTTGTGACGAGG 79959.7 IL2RAAATTCAAAAAACCCTATACAACTGGACATTGCTCGA 2658 chr10 ENST000003GCAATGTCCAGTTGTATAGGGT 79959.7 IL2RA AATTCAAAAAACTCGGAACACAACGAAACAACTCG2659 chr10 ENST000003 AGTTGTTTCGTTGTGTTCCGAGT 79959.7 IL2RBAATTCAAAAAAGTCCCAGACCTGGTGGATTTCTCGA 2660 chr22 ENST000002GAAATCCACCAGGTCTGGGACT 16223.9 IL2RB AATTCAAAAAGACCCACAGATGCAACATAAGCTCG2661 chr22 ENST000002 AGCTTATGTTGCATCTGTGGGTC 16223.9 IL2RBAATTCAAAAACCAGACACCCAGTATGAGTTTCTCGA 2662 chr22 ENST000002GAAACTCATACTGGGTGTCTGG 16223.9 IL2RGAATTCAAAAATCGTGTTCGGAGCCGCTTTAACTCGA 2663 chrX ENST000003GTTAAAGCGGCTCCGAACACGA 74202.6 IL2RGAATTCAAAAACCAACCTCACTCTGCATTATTCTCGA 2664 chrX ENST000003GAATAATGCAGAGTGAGGTTGG 74202.6 IL2RGAATTCAAAAATTGGCTCCATGGGATTGATTACTCGA 2665 chrX ENST000003GTAATCAATCCCATGGAGCCAA 74202.6 IL3 AATTCAAAAATTATCCCATTGAGACTATTTACTCGA2666 chr5 ENST000002 GTAAATAGTCTCAATGGGATAA 96870.2 IL3AATTCAAAAACGGCATCAGATGAATTGTTAACTCGA 2667 chr5 ENST000002GTTAACAATTCATCTGATGCCG 96870.2 IL3 AATTCAAAAAGCAATTGAGAGCATTCTTAAACTCGA2668 chr5 ENST000002 GTTTAAGAATGCTCTCAATTGC 96870.2 IL31AATTCAAAAAGCATATCTCAAGACAATCAGACTCG 2669 chr12 ENST000003AGTCTGATTGTCTTGAGATATGC 77035.1 IL31 AATTCAAAAACCAAGTGATGATGTACAGAAACTCG2670 chr12 ENST000003 AGTTTCTGTACATCATCACTTGG 77035.1 IL31AATTCAAAAACCTGACTATTTCTCAACAGTTCTCGA 2671 chr12 ENST000003GAACTGTTGAGAAATAGTCAGG 77035.1 IL31RAAATTCAAAAACATCAAACGAATGATTCAAATCTCGA 2672 chr5 ENST000004GATTTGAATCATTCGTTTGATG 47346.6 IL31RAAATTCAAAAACGCCTGTTTCATCTGATTTAACTCGA 2673 chr5 ENST000004GTTAAATCAGATGAAACAGGCG 47346.6 IL31RAAATTCAAAAATTTCCTGTGTCTACTACTATACTCGA 2674 chr5 ENST000004GTATAGTAGTAGACACAGGAAA 47346.6 IL32 AATTCAAAAATGTCGCCCTGGCATCTTAATACTCGA2675 chr16 ENST000003 GTATTAAGATGCCAGGGCGACA 25568.9 IL32AATTCAAAAAAGAGCTCACTCCTCTACTTGACTCGA 2676 chr16 ENST000003GTCAAGTAGAGGAGTGAGCTCT 25568.9 IL32 AATTCAAAAAAGAGCTGGAGGACGACTTCAACTCG2677 chr16 ENST000003 AGTTGAAGTCGTCCTCCAGCTCT 25568.9 IL33AATTCAAAAAGAGTGCTTTGCCTTTGGTATACTCGA 2678 chr9 ENST000003GTATACCAAAGGCAAAGCACTC 81434.7 IL33 AATTCAAAAAGCACTCCAACTGTGTTTCATTCTCGA2679 chr9 ENST000003 GAATGAAACACAGTTGGAGTGC 81434.7 IL33AATTCAAAAACCTGTTACTTTAGGAGAGAAACTCGA 2680 chr9 ENST000003GTTTCTCTCCTAAAGTAACAGG 81434.7 IL34 AATTCAAAAAGCCGACTTCAGTACATGAAACCTCGA2681 chr16 ENST000002 GGTTTCATGTACTGAAGTCGGC 88098.6 IL34AATTCAAAAACAGAGCCCTCATTGCAGTATGCTCGA 2682 chr16 ENST000002GCATACTGCAATGAGGGCTCTG 88098.6 IL34 AATTCAAAAACCGTGTTGTCCCTCTTGAATGCTCGA2683 chr16 ENST000002 GCATTCAAGAGGGACAACACGG 88098.6 IL36AAATTCAAAAACTCCAGTCACTATTGCCTTAACTCGA 2684 chr2 ENST000002GTTAAGGCAATAGTGACTGGAG 59211.6 IL36AAATTCAAAAATTCAGGACCAGACGCTCATAGCTCGA 2685 chr2 ENST000002GCTATGAGCGTCTGGTCCTGAA 59211.6 IL36AAATTCAAAAACTCTGCCTGATGTGTGCTAAACTCGA 2686 chr2 ENST000002GTTTAGCACACATCAGGCAGAG 59211.6 IL36BAATTCAAAAAATCCTATGCTATTCGTGATTCCTCGA 2687 chr2 ENST000003GGAATCACGAATAGCATAGGAT 27407.2 IL36BAATTCAAAAACCTGAGTGGAAATTCTTTAATCTCGA 2688 chr2 ENST000003GATTAAAGAATTTCCACTCAGG 27407.2 IL36BAATTCAAAAATTGGACTACATAACCTGTAAACTCGA 2689 chr2 ENST000003GTTTACAGGTTATGTAGTCCAA 27407.2 IL36GAATTCAAAAATGATATCATCCAGTCTTTATACTCGA 2690 chr2 ENST000002GTATAAAGACTGGATGATATCA 59205.4 IL36G AATTCAAAAACAGGAGAGCTGGGTGGTATAACTCG2691 chr2 ENST000002 AGTTATACCACCCAGCTCTCCTG 59205.4 IL36GAATTCAAAAAGGGAATCCAGAATCCAGAAATCTCG 2692 chr2 ENST000002AGATTTCTGGATTCTGGATTCCC 59205.4 IL36RNAATTCAAAAACTCGGCATTGAAGGTGCTTTACTCGA 2693 chr2 ENST000003GTAAAGCACCTTCAATGCCGAG 46807.7 IL36RNAATTCAAAAATGGTTCCCAGTTTGGATAAATCTCGA 2694 chr2 ENST000003GATTTATCCAAACTGGGAACCA 46807.7 IL36RNAATTCAAAAAGGGAATCATTCCTGCTTAATGCTCGA 2695 chr2 ENST000003GCATTAAGCAGGAATGATTCCC 46807.7 IL37 AATTCAAAAACTCTACTGTGACAAGGATAAACTCGA2696 chr2 ENST000002 GTTTATCCTTGTCACAGTAGAG 63326.7 IL37AATTCAAAAATGCACCTCCTGCAATTGTAATCTCGA 2697 chr2 ENST000002GATTACAATTGCAGGAGGTGCA 63326.7 IL37 AATTCAAAAAGTTCACACAAAGATCTTCTTTCTCGA2698 chr2 ENST000002 GAAAGAAGATCTTTGTGTGAAC 63326.7 IL4AATTCAAAAAAGCTGATCCGATTCCTGAAACCTCGA 2699 chr5 ENST000002GGTTTCAGGAATCGGATCAGCT 31449.6 IL4 AATTCAAAAACCACGGACACAAGTGCGATATCTCG2700 chr5 ENST000002 AGATATCGCACTTGTGTCCGTGG 31449.6 IL4AATTCAAAAATAGCATGTGCCGGCAACTTTGCTCGA 2701 chr5 ENST000002GCAAAGTTGCCGGCACATGCTA 31449.6 IL5 AATTCAAAAAGCAAGAGTTTCTTGGTGTAATCTCGA2702 chr5 ENST000002 GATTACACCAAGAAACTCTTGC 31454.5 IL5AATTCAAAAAGGGTACTGTGGAAAGACTATTCTCGA 2703 chr5 ENST000002GAATAGTCTTTCCACAGTACCC 31454.5 IL5 AATTCAAAAAGAAAGAGTCAGGCCTTAATTTCTCGA2704 chr5 ENST000002 GAAATTAAGGCCTGACTCTTTC 31454.5 IL6AATTCAAAAAATGAGCGTTAGGACACTATTTCTCGA 2705 chr7 ENST000002GAAATAGTGTCCTAACGCTCAT 58743.9 IL6 AATTCAAAAAGAGTACCTCCAGAACAGATTTCTCGA2706 chr7 ENST000002 GAAATCTGTTCTGGAGGTACTC 58743.9 IL6AATTCAAAAAATGTGAAGCTGAGTTAATTTACTCGA 2707 chr7 ENST000002GTAAATTAACTCAGCTTCACAT 58743.9 IL6R AATTCAAAAAGCAGGCACTTACTACTAATAACTCGA2708 chr1 ENST000003 GTTATTAGTAGTAAGTGCCTGC 68485.7 IL6RAATTCAAAAATATCGGGCTGAACGGTCAAAGCTCG 2709 chr1 ENST000003AGCTTTGACCGTTCAGCCCGATA 68485.7 IL6RAATTCAAAAACTGGACCCTGTGGATGATAAACTCGA 2710 chr1 ENST000003GTTTATCATCCACAGGGTCCAG 68485.7 IL6STAATTCAAAAAACCGTGCATCGCACCTATTTACTCGA 2711 chr5 ENST000003GTAAATAGGTGCGATGCACGGT 36909.9 IL6STAATTCAAAAAACTTCAGCAGTACCTATAAAGCTCGA 2712 chr5 ENST000003GCTTTATAGGTACTGCTGAAGT 36909.9 IL6ST AATTCAAAAACGGCCAGAAGATCTACAATTACTCG2713 chr5 ENST000003 AGTAATTGTAGATCTTCTGGCCG 36909.9 IL7AATTCAAAAAGCTCGCAAGTTGAGGCAATTTCTCGA 2714 chr8 ENST000002GAAATTGCCTCAACTTGCGAGC 63851.8 IL7 AATTCAAAAAGCTCACTATGAATCTATTATACTCGA2715 chr8 ENST000002 GTATAATAGATTCATAGTGAGC 63851.8 IL7AATTCAAAAAGTGTTTCCTAAAGAGACTATTCTCGA 2716 chr8 ENST000002GAATAGTCTCTTTAGGAAACAC 63851.8 IL9 AATTCAAAAAACCACCATGCAAACAAGATACCTCG2717 chr5 ENST000002 AGGTATCTTGTTTGCATGGTGGT 74520.1 IL9AATTCAAAAAGAACAACAAGTGTCCATATTTCTCGA 2718 chr5 ENST000002GAAATATGGACACTTGTTGTTC 74520.1 IL9 AATTCAAAAACTGAAGAGTCTTCTGGAAATTCTCGA2719 chr5 ENST000002 GAATTTCCAGAAGACTCTTCAG 74520.1 INHAAATTCAAAAACCTCGGATGGAGGTTACTCTTCTCGA 2720 chr2 ENST000002GAAGAGTAACCTCCATCCGAGG 43786.2 INHA AATTCAAAAAGCAGCACTGTGCTTGTATCTACTCGA2721 chr2 ENST000002 GTAGATACAAGCACAGTGCTGC 43786.2 INHAAATTCAAAAATGGAGGTTACTCTTTCAAGTACTCGA 2722 chr2 ENST000002GTACTTGAAAGAGTAACCTCCA 43786.2 INHBAAATTCAAAAAAGGCACTTTCCTACCCAATTACTCGA 2723 chr7 ENST000002GTAATTGGGTAGGAAAGTGCCT 42208.4 INHBAAATTCAAAAAGAGAATGGTGTACCCTTTATTCTCGA 2724 chr7 ENST000002GAATAAAGGGTACACCATTCTC 42208.4 INHBAAATTCAAAAAAGACGCTGCACTTCGAGATTTCTCGA 2725 chr7 ENST000002GAAATCTCGAAGTGCAGCGTCT 42208.4 INHBB AATTCAAAAACAAATGGATGCGGTGACAAATCTCG2726 chr2 ENST000002 AGATTTGTCACCGCATCCATTTG 95228.3 INHBBAATTCAAAAAGCTGGAACGACTGGATCATAGCTCG 2727 chr2 ENST000002AGCTATGATCCAGTCGTTCCAGC 95228.3 INHBBAATTCAAAAATGATGAGTACAACATCGTCAACTCGA 2728 chr2 ENST000002GTTGACGATGTTGTACTCATCA 95228.3 INHBCAATTCAAAAATCAACCAGACTCGTCTTGATTCTCGA 2729 chr12 ENST000003GAATCAAGACGAGTCTGGTTGA 09668.2 INHBCAATTCAAAAACAAGACTGACATACCTGACATCTCGA 2730 chr12 ENST000003GATGTCAGGTATGTCAGTCTTG 09668.2 INHBCAATTCAAAAACAGGCCAGTCTCATGTTCTTTCTCGA 2731 chr12 ENST000003GAAAGAACATGAGACTGGCCTG 09668.2 INHBEAATTCAAAAACTCCTCTACCTGGATCATAATCTCGA 2732 chr12 ENST000002GATTATGATCCAGGTAGAGGAG 66646.2 INHBEAATTCAAAAAACCTGGGCTGGCATACCTTAACTCGA 2733 chr12 ENST000002GTTAAGGTATGCCAGCCCAGGT 66646.2 INHBEAATTCAAAAAGCAGCCCTTCCTAGAGCTTAACTCGA 2734 chr12 ENST000002GTTAAGCTCTAGGAAGGGCTGC 66646.2 ITGA4AATTCAAAAACCAACGCTTCAGTGATCAATCCTCGA 2735 chr2 ENST000003GGATTGATCACTGAAGCGTTGG 97033.6 ITGA4AATTCAAAAATGTAGAACACATCAAGCATTTCTCGA 2736 chr2 ENST000003GAAATGCTTGATGTGTTCTACA 97033.6 ITGA4AATTCAAAAACATGATCTTGTGACATATTATCTCGA 2737 chr2 ENST000003GATAATATGTCACAAGATCATG 97033.6 ITGAVAATTCAAAAATTGAAGTGTACCCTAGCATTTCTCGA 2738 chr2 ENST000002GAAATGCTAGGGTACACTTCAA 61023.7 ITGAVAATTCAAAAACACTCCAAGAACATGACTATTCTCGA 2739 chr2 ENST000002GAATAGTCATGTTCTTGGAGTG 61023.7 ITGAV AATTCAAAAAGTGAGGTCGAAACAGGATAAACTCG2740 chr2 ENST000002 AGTTTATCCTGTTTCGACCTCAC 61023.7 ITGB1AATTCAAAAATTTGTAGGAAGAGGGATAATACTCG 2741 chr10 ENST000003AGTATTATCCCTCTTCCTACAAA 02278.7 ITGB1AATTCAAAAAGCCTTGCATTACTGCTGATATCTCGA 2742 chr10 ENST000003GATATCAGCAGTAATGCAAGGC 02278.7 ITGB1AATTCAAAAAGCCTTGCATTACTGCTGATATCTCGA 2743 chr10 ENST000003GATATCAGCAGTAATGCAAGGC 02278.7 ITGB3AATTCAAAAAGTCGTCAGATTCCAGTACTATCTCGA 2744 chr17 ENST000005GATAGTACTGGAATCTGACGAC 59488.5 ITGB3AATTCAAAAAGTCGTCAGATTCCAGTACTATCTCGA 2745 chr17 ENST000005GATAGTACTGGAATCTGACGAC 59488.5 ITGB3AATTCAAAAACCACGTCTACCTTCACCAATACTCGA 2746 chr17 ENST000005GTATTGGTGAAGGTAGACGTGG 59488.5 KIT AATTCAAAAAACTTCATCTAACGAGATTAAACTCGA2747 chr4 ENST000002 GTTTAATCTCGTTAGATGAAGT 88135.5 KITAATTCAAAAAGCGACGAGATTAGGCTGTTATCTCGA 2748 chr4 ENST000002GATAACAGCCTAATCTCGTCGC 88135.5 KIT AATTCAAAAAACGAGTTGGCCCTAGACTTAGCTCGA2749 chr4 ENST000002 GCTAAGTCTAGGGCCAACTCGT 88135.5 KITLGAATTCAAAAAGCAGGAATCGTGTGACTAATACTCG 2750 chr12 ENST000002AGTATTAGTCACACGATTCCTGC 28280.9 KITLGAATTCAAAAAGCAGGAATCGTGTGACTAATACTCG 2751 chr12 ENST000002AGTATTAGTCACACGATTCCTGC 28280.9 KITLGAATTCAAAAACCTATTTAATCCTCTCGTCAACTCGA 2752 chr12 ENST000002GTTGACGAGAGGATTAAATAGG 28280.9 KLHL20AATTCAAAAAGCCAATACATGGAGGTTATATCTCGA 2753 chr1 ENST000002GATATAACCTCCATGTATTGGC 09884.4 KLHL20AATTCAAAAAGCCGCAAGAACGACCACTAATCTCG 2754 chr1 ENST000002AGATTAGTGGTCGTTCTTGCGGC 09884.4 KLHL20AATTCAAAAACACATTGTGAATCCCATATTTCTCGA 2755 chr1 ENST000002GAAATATGGGATTCACAATGTG 09884.4 LEFTY1AATTCAAAAAACAAGTTACCTCACCTAATTTCTCGA 2756 chr1 ENST000002GAAATTAGGTGAGGTAACTTGT 72134.5 LEFTY1AATTCAAAAAAGCCCAATGTGTCATTGTTTACTCGA 2757 chr1 ENST000002GTAAACAATGACACATTGGGCT 72134.5 LEFTY1AATTCAAAAATCTCTAGTGAGCCCTGAATTTCTCGA 2758 chr1 ENST000002GAAATTCAGGGCTCACTAGAGA 72134.5 LEFTY2AATTCAAAAAAGTTACTCCATCCCAATTTAGCTCGA 2759 chr1 ENST000003GCTAAATTGGGATGGAGTAACT 66820.9 LEFTY2AATTCAAAAACTAAGCACTTACGTGAGTAAACTCGA 2760 chr1 ENST000003GTTTACTCACGTAAGTGCTTAG 66820.9 LEFTY2AATTCAAAAATAGGCGCCTGGTGTATCCATTCTCGA 2761 chr1 ENST000003GAATGGATACACCAGGCGCCTA 66820.9 LIF AATTCAAAAAGCAGTGCCAATGCCCTCTTTACTCGA2762 chr22 ENST000002 GTAAAGAGGGCATTGGCACTGC 49075.3 LIFAATTCAAAAAACCGCATAGTCGTGTACCTTGCTCGA 2763 chr22 ENST000002GCAAGGTACACGACTATGCGGT 49075.3 LIF AATTCAAAAACAACAACCTGGACAAGCTATGCTCG2764 chr22 ENST000002 AGCATAGCTTGTCCAGGTTGTTG 49075.3 LIFRAATTCAAAAATGACTTGCGACTACGTCATTACTCGA 2765 chr5 ENST000002GTAATGACGTAGTCGCAAGTCA 63409.8 LIFR AATTCAAAAAACTTCTGCAGATTCGATATTACTCGA2766 chr5 ENST000002 GTAATATCGAATCTGCAGAAGT 63409.8 LIFRAATTCAAAAAGTAGGCTCAGACATAACATTTCTCGA 2767 chr5 ENST000002GAAATGTTATGTCTGAGCCTAC 63409.8 LTA AATTCAAAAAGCCCTAGTACTGTCTTCTTTGCTCGA2768 chr6 ENST000004 GCAAAGAAGACAGTACTAGGGC 18386.2 LTAAATTCAAAAAGATCAAGTCACCGGAGCTTTCCTCGA 2769 chr6 ENST000004GGAAAGCTCCGGTGACTTGATC 18386.2 LTA AATTCAAAAAGCTCCCAGAAGATGGTGTATCCTCGA2770 chr6 ENST000004 GGATACACCATCTTCTGGGAGC 18386.2 LTBAATTCAAAAAGCGAGAGGGAAGACCTTCTTTCTCGA 2771 chr6 ENST000004GAAAGAAGGTCTTCCCTCTCGC 29299.2 LTB AATTCAAAAACGAGAGGGTGTACGTCAACATCTCG2772 chr6 ENST000004 AGATGTTGACGTACACCCTCTCG 29299.2 LTBAATTCAAAAAGACGAAGGAACAGGCGTTTCTCTCG 2773 chr6 ENST000004AGAGAAACGCCTGTTCCTTCGTC 29299.2 LTBP1AATTCAAAAAGATGACCTGTGTCGATGTAAACTCGA 2774 chr2 ENST000004GTTTACATCGACACAGGTCATC 07925.5 LTBP1AATTCAAAAAGGTGGAACAGTGCTGTTATTTCTCGA 2775 chr2 ENST000004GAAATAACAGCACTGTTCCACC 07925.5 LTBP1AATTCAAAAACCGTTGAATACCGCCTTGAATCTCGA 2776 chr2 ENST000004GATTCAAGGCGGTATTCAACGG 07925.5 LTBP3AATTCAAAAAGCATCCTCAATGGATGTGAAACTCGA 2777 chr11 ENST000003GTTTCACATCCATTGAGGATGC 22147.8 LTBP3AATTCAAAAATGTTGTTCGGGTCGGAGATTTCTCGA 2778 chr11 ENST000003GAAATCTCCGACCCGAACAACA 22147.8 LTBP3AATTCAAAAAAGCGCTTCAAGGTGGTCTTTGCTCGA 2779 chr11 ENST000003GCAAAGACCACCTTGAAGCGCT 22147.8 LTBP4AATTCAAAAAGCTTCGACATGCCAGACTTTGCTCGA 2780 chr19 ENST000003GCAAAGTCTGGCATGTCGAAGC 08370.11 LTBP4AATTCAAAAATGAAACACTACAGGGTGTATGCTCG 2781 chr19 ENST000003AGCATACACCCTGTAGTGTTTCA 08370.11 LTBP4AATTCAAAAACAACCGGCTTTGAAAGAGTTACTCGA 2782 chr19 ENST000003GTAACTCTTTCAAAGCCGGTTG 08370.11 MAF AATTCAAAAATCAGTGGGATACGCCACATTTCTCGA2783 chr16 ENST000003 GAAATGTGGCGTATCCCACTGA 26043.4 MAFAATTCAAAAATTTATGGTGTGTGCAAGTAAACTCGA 2784 chr16 ENST000003GTTTACTTGCACACACCATAAA 26043.4 MAF AATTCAAAAAGTTAGAGAAGAAGGCTATTAACTCG2785 chr16 ENST000003 AGTTAATAGCCTTCTTCTCTAAC 26043.4 MAFAATTCAAAAATGTTAATGACTTCGATCTGATCTCGA 2786 chr16 ENST000003GATCAGATCGAAGTCATTAACA 26043.4 MIF AATTCAAAAACTACATCAACTATTACGACATCTCGA2787 chr22 ENST000002 GATGTCGTAATAGTTGATGTAG 15754.7 MIFAATTCAAAAACTACATCAACTATTACGACATCTCGA 2788 chr22 ENST000002GATGTCGTAATAGTTGATGTAG 15754.7 MIF AATTCAAAAAGACAGGGTCTACATCAACTATCTCGA2789 chr22 ENST000002 GATAGTTGATGTAGACCCTGTC 15754.7 MINOAATTCAAAAAGCCAAGCTGCACAATTTAATACTCGA 2790 chr1 ENST000006 S1-GTATTAAATTGTGCAGCTTGGC 02662.1 MINO AATTCAAAAAGCTGGCACTGTTCCCAGATAACTCGA2791 chr1 ENST000006 S1- GTTATCTGGGAACAGTGCCAGC 02662.1 MINOAATTCAAAAAAGAAAGACCACTGGCAGAAACCTCG 2792 chr1 ENST000006 S1-AGGTTTCTGCCAGTGGTCTTTCT 02662.1 MSTNAATTCAAAAAAGGCCCAACTATGGATATATTCTCGA 2793 chr2 ENST000002GAATATATCCATAGTTGGGCCT 60950.4 MSTN AATTCAAAAAGAGCTAGAAGGAGATCAAATTCTCG2794 chr2 ENST000002 AGAATTTGATCTCCTTCTAGCTC 60950.4 MSTNAATTCAAAAAGTATGCTTTAAAGTCTATTTCCTCGA 2795 chr2 ENST000002GGAAATAGACTTTAAAGCATAC 60950.4 NAMPTAATTCAAAAAAGCGATAGCTATGACATTTATCTCGA 2796 chr7 ENST000002GATAAATGTCATAGCTATCGCT 22553.7 NAMPTAATTCAAAAAGTGAAGATCTAAGACATTTAACTCGA 2797 chr7 ENST000002GTTAAATGTCTTAGATCTTCAC 22553.7 NAMPTAATTCAAAAATACAAGGTTACTCACTATAAACTCGA 2798 chr7 ENST000002GTTTATAGTGAGTAACCTTGTA 22553.7 NBL1 AATTCAAAAAGCCAAGCTGCACAATTTAATACTCGA2799 chr1 ENST000003 GTATTAAATTGTGCAGCTTGGC 75136.7 NBL1AATTCAAAAAGCTGGCACTGTTCCCAGATAACTCGA 2800 chr1 ENST000003GTTATCTGGGAACAGTGCCAGC 75136.7 NBL1 AATTCAAAAAAGAAAGACCACTGGCAGAAACCTCG2801 chr1 ENST000003 AGGTTTCTGCCAGTGGTCTTTCT 75136.7 NDPAATTCAAAAACTGCTAAAGGTTACCGATTTCCTCGA 2802 chrX ENST000003GGAAATCGGTAACCTTTAGCAG 78062.5 NDP AATTCAAAAACTCTGCATATTCTAGTAATAACTCGA2803 chrX ENST000003 GTTATTACTAGAATATGCAGAG 78062.5 NDPAATTCAAAAAACGGACAGCTCATTCATAATGCTCGA 2804 chrX ENST000003GCATTATGAATGAGCTGTCCGT 78062.5 NLRP7AATTCAAAAACCGTTCAAGGAAATTTCTATTCTCGA 2805 chr19 ENST000003GAATAGAAATTTCCTTGAACGG 28092.9 NLRP7AATTCAAAAACGGGTCTCTAAGATGTCTTATCTCGA 2806 chr19 ENST000003GATAAGACATCTTAGAGACCCG 28092.9 NLRP7AATTCAAAAAACCTGCTCAGAAATCATAAATCTCGA 2807 chr19 ENST000003GATTTATGATTTCTGAGCAGGT 28092.9 NODALAATTCAAAAAGTGCTCCTAGATCACCATAAACTCGA 2808 chr10 ENST000002GTTTATGGTGATCTAGGAGCAC 87139.7 NODALAATTCAAAAACACCTATAGCTTTCATGTATTCTCGA 2809 chr10 ENST000002GAATACATGAAAGCTATAGGTG 87139.7 NODALAATTCAAAAAGCATGCTGTATGTGGATAATGCTCGA 2810 chr10 ENST000002GCATTATCCACATACAGCATGC 87139.7 NOG AATTCAAAAAAGGTCAGTATTATACGTTAAACTCGA2811 chr17 ENST000003 GTTTAACGTATAATACTGACCT 32822.4 NOGAATTCAAAAAATTCTGGTTGTTGCTAATAATCTCGA 2812 chr17 ENST000003GATTATTAGCAACAACCAGAAT 32822.4 NOG AATTCAAAAATGCGGAGGAAGTTACAGATGTCTCG2813 Chr17 ENST000003 AGACATCTGTAACTTCCTCCGCA 32822.4 NRG1AATTCAAAAAGATATCACAGAGGCCTATAACCTCG 2814 Chr8 ENST000002AGGTTATAGGCCTCTGTGATATC 87842.7 NRG1AATTCAAAAAGGCTGATTCTGGAGAGTATATCTCGA 2815 chr8 ENST000002GATATACTCTCCAGAATCAGCC 87842.7 NRG1 AATTCAAAAAGACAGTGCCTCTGCCAATATCCTCGA2816 chr8 ENST000002 GGATATTGGCAGAGGCACTGTC 87842.7 NRP1AATTCAAAAATATACTAGAATCACCGCATTTCTCGA 2817 chr10 ENST000002GAAATGCGGTGATTCTAGTATA 65371.8 NRP1 AATTCAAAAACAGCCTTGAATGCACTTATATCTCGA2818 chr10 ENST000002 GATATAAGTGCATTCAAGGCTG 65371.8 NRP1AATTCAAAAACAGCCTTGAATGCACTTATATCTCGA 2819 chr10 ENST000002GATATAAGTGCATTCAAGGCTG 65371.8 NRP2 AATTCAAAAACGACTGCAAGTATGACTTTATCTCGA2820 chr2 ENST000003 GATAAAGTCATACTTGCAGTCG 57785.9 NRP2AATTCAAAAACCGGATTGCTAATGAACAGATCTCGA 2821 chr2 ENST000003GATCTGTTCATTAGCAATCCGG 57785.9 NRP2 AATTCAAAAACCTCAACTTCAACCCTCACTTCTCGA2822 chr2 ENST000003 GAAGTGAGGGTTGAAGTTGAGG 57785.9 OSMAATTCAAAAAACTTCCTCCTTTCCGTGTTTCCTCGAG 2823 chr22 ENST000002GAAACACGGAAAGGAGGAAGT 15781.2 OSM AATTCAAAAAGGACCGACTTTCCATTGATTCCTCGA2824 chr22 ENST000002 GGAATCAATGGAAAGTCGGTCC 15781.2 OSMAATTCAAAAATGGTCCTTGCACTCCTGTTTCCTCGA 2825 chr22 ENST000002GGAAACAGGAGTGCAAGGACCA 15781.2 OSMR AATTCAAAAATAACCTGACTCATCGAGTTTACTCGA2826 chr5 ENST000002 GTAAACTCGATGAGTCAGGTTA 74276.7 OSMRAATTCAAAAAAGGAGAACCCTCACCTAATAACTCG 2827 chr5 ENST000002AGTTATTAGGTGAGGGTTCTCCT 74276.7 OSMRAATTCAAAAAGCACTCCATAAGGAATAATTTCTCGA 2828 chr5 ENST000002GAAATTATTCCTTATGGAGTGC 74276.7 PARK7AATTCAAAAAGTAGCCGTGATGTGGTCATTTCTCGA 2829 chr1 ENST000003GAAATGACCACATCACGGCTAC 38639.9 PARK7AATTCAAAAAGCAATTGTTGAAGCCCTGAATCTCGA 2830 chr1 ENST000003GATTCAGGGCTTCAACAATTGC 38639.9 PARK7 AATTCAAAAAACTCTGAGAATCGTGTGGAAACTCG2831 chr1 ENST000003 AGTTTCCACACGATTCTCAGAGT 38639.9 PDPNAATTCAAAAAGCCTCTGGTATGAGAAATAAACTCG 2832 chr1 ENST000002AGTTTATTTCTCATACCAGAGGC 94489.10 PDPNAATTCAAAAAAGTCCACGCGCAAGAACAAAGCTCG 2833 chr1 ENST000002AGCTTTGTTCTTGCGCGTGGACT 94489.10 PDPNAATTCAAAAATGACCCTGGTTGGAATCATAGCTCGA 2834 chr1 ENST000002GCTATGATTCCAACCAGGGTCA 94489.10 PF4 AATTCAAAAAACGCTGAAGAATGGAAGGAAACTCG2835 chr4 ENST000002 AGTTTCCTTCCATTCTTCAGCGT 96029.3 PF4AATTCAAAAACCAACTGATAGCCACGCTGAACTCG 2836 chr4 ENST000002AGTTCAGCGTGGCTATCAGTTGG 96029.3 PF4 AATTCAAAAACACGCTGAAGAATGGAAGGAACTCG2837 chr4 ENST000002 AGTTCCTTCCATTCTTCAGCGTG 96029.3 PF4V1AATTCAAAAAGTTGTGGTATAGTCAATCTATCTCGA 2838 chr4 ENST000002GATAGATTGACTATACCACAAC 26524.3 PF4V1AATTCAAAAAAGCTGCCTAAGTGTGCACTTTCTCGA 2839 chr4 ENST000002GAAAGTGCACACTTAGGCAGCT 26524.3 PF4V1AATTCAAAAACTGACACATCACAATTTCATACTCGA 2840 chr4 ENST000002GTATGAAATTGTGATGTGTCAG 26524.3 PGLYRP1AATTCAAAAAGTGCCCACTCAGGTCACTTATCTCGA 2841 chr19 ENST000000GATAAGTGACCTGAGTGGGCAC 08938.4 PGLYRP1AATTCAAAAACTTACGCTATGTGGTGGTATCCTCGA 2842 chr19 ENST000000GGATACCACCACATAGCGTAAG 08938.4 PGLYRP1AATTCAAAAACATCAGCTTCATGGGCAACTACTCGA 2843 chr19 ENST000000GTAGTTGCCCATGAAGCTGATG 08938.4 PLP2 AATTCAAAAACCTGTCGGTGATTGAGATGATCTCGA2844 chrX ENST000003 GATCATCTCAATCACCGACAGG 76327.5 PLP2AATTCAAAAACCTGTCGGTGATTGAGATGATCTCGA 2845 chrX ENST000003GATCATCTCAATCACCGACAGG 76327.5 PLP2 AATTCAAAAACGAAAGGGAATCCTCCTGTTTCTCGA2846 chrX ENST000003 GAAACAGGAGGATTCCCTTTCG 76327.5 PPBPAATTCAAAAAAGGTGATGAATCTGCTGATTACTCGA 2847 chr4 ENST000002GTAATCAGCAGATTCATCACCT 96028.3 PPBP AATTCAAAAATGTTTCTGCCAAACTTCTTTACTCGA2848 chr4 ENST000002 GTAAAGAAGTTTGGCAGAAACA 96028.3 PPBPAATTCAAAAACTCCCAGGAAGGGTAGAATTTCTCGA 2849 chr4 ENST000002GAAATTCTACCCTTCCTGGGAG 96028.3 PXDN AATTCAAAAAAGATTGCGACTGGACTCAAACCTCG2850 chr2 ENST000002 AGGTTTGAGTCCAGTCGCAATCT 52804.8 PXDNAATTCAAAAAGTTCCTGACGTCAGTCGAAATCTCGA 2851 chr2 ENST000002GATTTCGACTGACGTCAGGAAC 52804.8 PXDN AATTCAAAAAGAAGGATTCTTGACCATCAATCTCGA2852 chr2 ENST000002 GATTGATGGTCAAGAATCCTTC 52804.8 RORCAATTCAAAAACACCTCACAAATTGAAGTGATCTCGA 2853 chr1 ENST000003GATCACTTCAATTTGTGAGGTG 18247.6 RORC AATTCAAAAAGCCCTCATATTCCAACAACTTCTCGA2854 chr1 ENST000003 GAAGTTGTTGGAATATGAGGGC 18247.6 RORCAATTCAAAAAGCTTCTCAAAGCAGGAGCAATCTCG 2855 chr1 ENST000003AGATTGCTCCTGCTTTGAGAAGC 18247.6 RORCAATTCAAAAACGAGGATGAGATTGCCCTCTACTCGA 2856 chr1 ENST000003GTAGAGGGCAATCTCATCCTCG 18247.6 SCG2 AATTCAAAAAACGACAAGGATCAAGAATTAGCTCG2857 chr2 ENST000003 AGCTAATTCTTGATCCTTGTCGT 05409.2 SCG2AATTCAAAAACCTGTCTCTTATCCCTTTAATCTCGAG 2858 chr2 ENST000003ATTAAAGGGATAAGAGACAGG 05409.2 SCG2 AATTCAAAAAGAAAGCAGCCCAGATTATAATCTCG2859 chr2 ENST000003 AGATTATAATCTGGGCTGCTTTC 05409.2 SCGB3A1AATTCAAAAATCATAGAGGGCTCCCAGAAGTCTCG 2860 chr5 ENST000002AGACTTCTGGGAGCCCTCTATGA 92641.3 SCGB3A1AATTCAAAAACCCGTGAACCACCTCATAGAGCTCGA 261 chr5 ENST000002GCTCTATGAGGTGGTTCACGGG 92641.3 SCGB3A1AATTCAAAAAGACTGGAGCATCTACACCTGACTCGA 2862 chr5 ENST000002GTCAGGTGTAGATGCTCCAGTC 92641.3 SECTM1AATTCAAAAACACCAGAGAAATAACAGACAACTCG 2863 chr17 ENST000002AGTTGTCTGTTATTTCTCTGGTG 69389.7 SECTM1AATTCAAAAACCATGACTCGAATATCTGAAACTCGA 2864 chr17 ENST000002GTTTCAGATATTCGAGTCATGG 69389.7 SECTM1AATTCAAAAACCATGACTCGAATATCTGAAACTCGA 2865 chr17 ENST000002GTTTCAGATATTCGAGTCATGG 69389.7 SLURP1AATTCAAAAAGTGCTTCCTGCAGGACCATTACTCGA 2866 chr8 ENST000002GTAATGGTCCTGCAGGAAGCAC 46515.1 SLURP1AATTCAAAAAAGACCTCTGCAACTCGGAACTCTCGA 2867 chr8 ENST000002GAGTTCCGAGTTGCAGAGGTCT 46515.1 SLURP1AATTCAAAAACTCAAGTGCTACACCTGCAAGCTCGA 2868 chr8 ENST000002GCTTGCAGGTGTAGCACTTGAG 46515.1 SOSTDC1AATTCAAAAAGATGCCACAGAAATCCTTTATCTCGA 2869 chr7 ENST000003GATAAAGGATTTCTGTGGCATC 07068.4 SOSTDC1AATTCAAAAAGGAACTGCGTTCCACCAAATACTCGA 2870 chr7 ENST000003GTATTTGGTGGAACGCAGTTCC 07068.4 SOSTDC1AATTCAAAAATGAATCTTCACAGTAACATTTCTCGA 2871 chr7 ENST000003GAAATGTTACTGTGAAGATTCA 07068.4 SP100 AATTCAAAAAGAAGTGAGCCTGTGATCAATACTCG2872 chr2 ENST000003 AGTATTGATCACAGGCTCACTTC 40126.8 SP100AATTCAAAAATATACGCTGCGGTGGATATACCTCGA 2873 chr2 ENST000003GGTATATCCACCGCAGCGTATA 40126.8 SP100AATTCAAAAATCGTGATCTCATCACAAATAACTCGA 2874 chr2 ENST000003GTTATTTGTGATGAGATCACGA 40126.8 SPI1 AATTCAAAAAGCCCTATGACACGGATCTATACTCGA2875 chr11 ENST000003 GTATAGATCCGTGTCATAGGGC 78538.7 SPI1AATTCAAAAAAGAGCTTCGCCGAGAACAACTCTCG 2876 chr11 ENST000003AGAGTTGTTCTCGGCGAAGCTCT 78538.7 SPI1 AATTCAAAAACGGATCTATACCAACGCCAAACTCG2877 chr11 ENST000003 AGTTTGGCGTTGGTATAGATCCG 78538.7 SPI1AATTCAAAAACCGTATGTAAATCAGATCTCCCTCGA 2878 chr11 ENST000003GGGAGATCTGATTTACATACGG 78538.7 SPP1 AATTCAAAAACCACAAGCAGTCCAGATTATACTCGA2879 chr4 ENST000002 GTATAATCTGGACTGCTTGTGG 37623.11 SPP1AATTCAAAAACCGAGGTGATAGTGTGGTTTACTCGA 2880 chr4 ENST000002GTAAACCACACTATCACCTCGG 37623.11 SPP1AATTCAAAAACTTCAGGGTTATGTCTATGTTCTCGA 2881 chr4 ENST000002GAACATAGACATAACCCTGAAG 37623.11 TBX21AATTCAAAAAGCCCTAACTACAGTCGTTTACCTCGA 2882 ch17 ENST000001GGTAAACGACTGTAGTTAGGGC 77694.1 TBX21AATTCAAAAACCTGTTGTGGTCCAAGTTTAACTCGA 2883 ch17 ENST000001GTTAAACTTGGACCACAACAGG 77694.1 TBX21AATTCAAAAACGCTTCCAACACGCATATCTTCTCGA 2884 ch17 ENST000001GAAGATATGCGTGTTGGAAGCG 77694.1 TBX21AATTCAAAAAACAATGTGACCCAGATGATTGCTCGA 2885 ch17 ENST000001GCAATCATCTGGGTCACATTGT 77694.1 TCAP AATTCAAAAACTTTGTAGTTTGCCCAGAGTTCTCGA2886 chr17 ENST000003 GAACTCTGGGCAAACTACAAAG 09889.2 TCAPATTCAAAAAGGCCATGGCTGCTTTGTAGTTCTCGA 2887 chr17 ENST000003GAACTACAAAGCAGCCATGGCC 09889.2 TCAP AATTCAAAAAGGTGGCTGAGATCACAAAGCACTCG2888 chr17 ENST000003 AGTGCTTTGTGATCTCAGCCACC 09889.2 TGFB1AATTCAAAAAACTGCGGATCTCTGTGTCATTCTCGA 2889 chr19 ENST000002GAATGACACAGAGATCCGCAGT 21930.5 TGFB1 AATTCAAAAACCACAACGAAATCTATGACAACTCG2890 chr19 ENST000002 AGTTGTCATAGATTTCGTTGTGG 21930.5 TGFB1AATTCAAAAACCACAACGAAATCTATGACAACTCG 2891 chr19 ENST000002AGTTGTCATAGATTTCGTTGTGG 21930.5 TGFB2AATTCAAAAAGCGGCCTATTGCTTTAGAAATCTCGA 2892 chr1 ENST000003GATTTCTAAAGCAATAGGCCGC 66930.8 TGFB2AATTCAAAAAGCTGGAGCATGCCCGTATTTACTCGA 2893 chr1 ENST000003GTAAATACGGGCATGCTCCAGC 66930.8 TGFB2AATTCAAAAATTGCTGCCTACGTCCACTTTACTCGA 2894 chr1 ENST000003GTAAAGTGGACGTAGGCAGCAA 66930.8 TGFB3AATTCAAAAACATTGCCAAACAGCGCTATATCTCGA 2895 chr14 ENST000002GATATAGCGCTGTTTGGCAATG 38682.7 TGFB3AATTCAAAAAGCTCTAGGGAATCTGGATTATCTCGA 2896 chr14 ENST000002GATAATCCAGATTCCCTAGAGC 38682.7 TGFB3 AATTCAAAAACGGAATACTATGCCAAAGAAACTCG2897 chr14 ENST000002 AGTTTCTTTGGCATAGTATTCCG 38682.7 TGFBR1AATTCAAAAAGCCTTGAGAGTAATGGCTAAACTCG 2898 chr9 ENST000003AGTTTAGCCATTACTCTCAAGGC 74994.8 TGFBR1AATTCAAAAACTCATGTTGATGGTCTATATCCTCGA 2899 chr9 ENST000003GGATATAGACCATCAACATGAG 74994.8 TGFBR1AATTCAAAAAGAAGTTGCTGTTAAGATATTCCTCGA 2900 chr9 ENST000003GGAATATCTTAACAGCAACTTC 74994.8 TGFBR2AATTCAAAAACGTTCAGAAGTCGGTTAATAACTCGA 2901 chr3 ENST000002GTTATTAACCGACTTCTGAACG 95754.9 TGFBR2AATTCAAAAACTCTAGGCTTTATCGTGTTTACTCGA 2902 chr3 ENST000002GTAAACACGATAAAGCCTAGAG 95754.9 TGFBR2AATTCAAAAACTCAGGAAATGAGATTGATTTCTCGA 2903 chr3 ENST000002GAAATCAATCTCATTTCCTGAG 95754.9 TGFBR3AATTCAAAAAGGAGTTGGTAAAGGGTTAATACTCG 2904 chr1 ENST000002AGTATTAACCCTTTACCAACTCC 12355.8 TGFBR3AATTCAAAAATAATGGATTTCCGGGAGATATCTCGA 2905 chr1 ENST000002GATATCTCCCGGAAATCCATTA 12355.8 TGFBR3AATTCAAAAACACACCCAGGGCTAGTATAAACTCG 2906 chr1 ENST000002AGTTTATACTAGCCCTGGGTGTG 12355.8 THBS1AATTCAAAAAGTAGGTTATGATGAGTTTAATCTCGA 2907 chr15 ENST000002GATTAAACTCATCATAACCTAC 60356.5 THBS1AATTCAAAAACGTGACTGTAAGATTGTAAATCTCGA 2908 chr15 ENST000002GATTTACAATCTTACAGTCACG 60356.5 THBS1AATTCAAAAAGAGATCCCTAATCATCAAATTCTCGA 2909 chr15 ENST000002GAATTTGATGATTAGGGATCTC 60356.5 THNSL2AATTCAAAAAGAGCCGATCAAGACTGTGTTTCTCGA 2910 chr2 ENST000003GAAACACAGTCTTGATCGGCTC 24166.6 THNSL2AATTCAAAAAGCTGCCATTGAGAGTGTTCAACTCGA 2911 chr2 ENST000003GTTGAACACTCTCAATGGCAGC 24166.6 THNSL2AATTCAAAAAGCTGCCATTGAGAGTGTTCAACTCGA 2912 chr2 ENST000003GTTGAACACTCTCAATGGCAGC 24166.6 THPO AATTCAAAAAGACCTCCGAGTCCTCAGTAAACTCGA2913 chr3 ENST000002 GTTTACTGAGGACTCGGAGGTC 04615.11 THPOAATTCAAAAAAGCTAGCTCTTTGGTCTATTTCTCGA 2914 chr3 ENST000002GAAATAGACCAAAGAGCTAGCT 04615.11 THPOAATTCAAAAACAACCTCCAGCCTGGATATTCCTCGA 2915 chr3 ENST000002GGAATATCCAGGCTGGAGGTTG 04615.11 TIMP1AATTCAAAAAGCACAGTGTTTCCCTGTTTATCTCGA 2916 chrX ENST000002GATAAACAGGGAAACACTGTGC 18388.8 TIMP1AATTCAAAAAGCACAGTGTTTCCCTGTTTATCTCGA 2917 chrX ENST000002GATAAACAGGGAAACACTGTGC 18388.8 TIMP1AATTCAAAAAACAGACGGCCTTCTGCAATTCCTCGA 2918 chrX ENST000002GGAATTGCAGAAGGCCGTCTGT 18388.8 TNF AATTCAAAAAGAACCCAAGCTTAGAACTTTACTCGA2919 chr6 ENST000004 GTAAAGTTCTAAGCTTGGGTTC 49264.2 TNFAATTCAAAAAGGAGCCAGCTCCCTCTATTTACTCGA 2920 chr6 ENST000004GTAAATAGAGGGAGCTGGCTCC 49264.2 TNF AATTCAAAAATGGCGTGGAGCTGAGAGATAACTCG2921 chr6 ENST000004 AGTTATCTCTCAGCTCCACGCCA 49264.2 TNFRSF4AATTCAAAAAGCACGTGGTGTAACCTCAGAACTCG 2922 chr1 ENST000003AGTTCTGAGGTTACACCACGTGC 79236.3 TNFRSF4AATTCAAAAACAGCAATAGCTCGGACGCAATCTCG 2923 chr1 ENST000003AGATTGCGTCCGAGCTATTGCTG 79236.3 TNFRSF4AATTCAAAAAGACAGCTACAAGCCTGGAGTTCTCG 2924 chr1 ENST000003AGAACTCCAGGCTTGTAGCTGTC 79236.3 TNFRSF4AATTCAAAAAGCTTCTACAACGACGTGGTCACTCGA 2925 chr1 ENST000003GTGACCACGTCGTTGTAGAAGC 79236.3 TNFRSF11AATTCAAAAATGTTTACTTGCCCGGTTTAATCTCGA 2926 chr18 ENST000005GATTAAACCGGGCAAGTAAACA 86569.2 TNFRSF11AATTCAAAAATGTACCAGTGAGAAGCATTATCTCGA 2927 chr18 ENST000005GATAATGCTTCTCACTGGTACA 86569.2 TNFRSF11AATTCAAAAATGGGACGGTGCTGTAACAAATCTCG 2928 chr18 ENST000005AGATTTGTTACAGCACCGTCCCA 86569.2 TNFRSF11AATTCAAAAAGAAAGCACTCACAGCTAATTTCTCGA 2929 chr8 ENST000002GAAATTAGCTGTGAGTGCTTTC 97350.8 TNFRSF11AATTCAAAAAGATAAATGCTTGCTGCATAAACTCGA 2930 chr8 ENST000002GTTTATGCAGCAAGCATTTATC 97350.8 TNFRSF11AATTCAAAAACCAGTGTGTGTTCATTGTAAACTCGA 2931 chr8 ENST000002GTTTACAATGAACACACACTGG 97350.8 TNFRSF1AAATTCAAAAAAGAACCAGTACCGGCATTATTCTCGA 2932 chr12 ENST000001GAATAATGCCGGTACTGGTTCT 62749.6 TNFRSF1AAATTCAAAAAGGAGCTGTTGGTGGGAATATACTCG 2933 chr12 ENST000001AGTATATTCCCACCAACAGCTCC 62749.6 TNFRSF1AAATTCAAAAACTTGAAGGAACTACTACTAAGCTCGA 2934 chr12 ENST000001GCTTAGTAGTAGTTCCTTCAAG 62749.6 TNFRSF9AATTCAAAAAGCTCCGTTTCTCTGTTGTTAACTCGA 2935 chr1 ENST000003GTTAACAACAGAGAAACGGAGC 77507.7 TNFRSF9AATTCAAAAACAAGAACACCATCCTACATAACTCG 2936 chr1 ENST000003AGTTATGTAGGATGGTGTTCTTG 77507.7 TNFRSF9AATTCAAAAACAGTCCCTGTCCTCCAAATAGCTCGA 2937 chr1 ENST000003GCTATTTGGAGGACAGGGACTG 77507.7 TNFSF9AATTCAAAAACAAGTTGGACCTTGATATTTACTCGA 2938 chr19 ENST000002GTAAATATCAAGGTCCAACTTG 45817.4 TNFSF9AATTCAAAAACTACTATGTCTTCTTTCAACTCTCGA 2939 chr19 ENST000002GAGTTGAAAGAAGACATAGTAG 45817.4 TNFSF9AATTCAAAAACCCTTCACCGAGGTCGGAATACTCGA 2940 chr19 ENST000002GTATTCCGACCTCGGTGAAGGG 45817.4 TNFSF9AATTCAAAAATGAGCTACAAAGAGGACACGACTCG 2941 chr19 ENST000002AGTCGTGTCCTCTTTGTAGCTCA 45817.4 TNFSF10AATTCAAAAAAGAAATAGTTGTTGGTCTAAACTCGA 2942 chr3 ENST000002GTTTAGACCAACAACTATTTCT 41261.6 TNFSF10AATTCAAAAAAGTTATCCTGACCCTATATTGCTCGA 2943 chr3 ENST000002GCAATATAGGGTCAGGATAACT 41261.6 TNFSF10AATTCAAAAAGACAAACAAATGGTCCAATATCTCG 2944 chr3 ENST000002AGATATTGGACCATTTGTTTGTC 41261.6 TNFSF11AATTCAAAAACTAATGGTGTACGTCACTAAACTCGA 2945 chr13 ENST000003GTTTAGTGACGTACACCATTAG 98795.6 TNFSF11AATTCAAAAACCGGATCAGGATGCAACATACCTCG 2946 chr13 ENST000003AGGTATGTTGCATCCTGATCCGG 98795.6 TNFSF11AATTCAAAAAGCAGTATATTTCTTCGTTCTTCTCGA 2947 chr13 ENST000003GAAGAACGAAGAAATATACTGC 98795.6 TNFSF12AATTCAAAAAGTATTCCCACTCTTATCTTACCTCGA 2948 chr17 ENST000002GGTAAGATAAGAGTGGGAATAC 93825.10 TNFSF12AATTCAAAAAGGGCATTGTGTTCACTGTACTCTCGA 2949 chr17 ENST000002GAGTACAGTGAACACAATGCCC 93825.10 TNFSF12AATTCAAAAACAGATGGAGGTTACACAACTTCTCGA 2950 chr17 ENST000002GAAGTTGTGTAACCTCCATCTG 93825.10 TNFSF12-AATTCAAAAACCTCACCTACTTCGGACTCTTCTCGA 2951 chr17 ENST000002GAAGAGTCCGAAGTAGGTGAGG 93826.4 TNFSF12-AATTCAAAAACTGTACTGTCAGGTGCACTTTCTCGA 2952 chr17 ENST000002GAAAGTGCACCTGACAGTACAG 93826.4 TNFSF12-AATTCAAAAAGCGCAGGCAGATGGAGGTTACCTCG 2953 chr17 ENST000002AGGTAACCTCCATCTGCCTGCGC 93826.4 TNFSF13AATTCAAAAACAGTTGCCCTCTGGTTGAGTTCTCGA 2954 chr17 ENST000003GAACTCAACCAGAGGGCAACTG 38784.8 TNFSF13AATTCAAAAAATGGCTCTGCTGACCCAACAACTCGA 2955 chr17 ENST000003GTTGTTGGGTCAGCAGAGCCAT 38784.8 TNFSF13AATTCAAAAACCCAACAAACAGAGCTGCAGACTCG 2956 chr17 ENST000003AGTCTGCAGCTCTGTTTGTTGGG 38784.8 TNFSF13BAATTCAAAAACCTGAAACACTACCCAATAATCTCGA 2957 chr13 ENST000003GATTATTGGGTAGTGTTTCAGG 75887.8 TNFSF13BAATTCAAAAACTACGCCATGGGACATCTAATCTCGA 2958 chr13 ENST000003GATTAGATGTCCCATGGCGTAG 75887.8 TNFSF13BAATTCAAAAAGTGACTTTGTTTCGATGTATTCTCGA 2959 chr13 ENST000003GAATACATCGAAACAAAGTCAC 75887.8 TNFSF14AATTCAAAAATCCTGGGAGCAGCTGATACAACTCG 2960 chr19 ENST000005AGTTGTATCAGCTGCTCCCAGGA 99359.1 TNFSF14AATTCAAAAAGACAGACCGACATCCCATTCACTCGA 2961 chr19 ENST000005GTGAATGGGATGTCGGTCTGTC 99359.1 TNFSF14AATTCAAAAAATGGGTCTGACACGTGGAGAACTCG 2962 chr19 ENST000005AGTTCTCCACGTGTCAGACCCAT 99359.1 TNFSF15AATTCAAAAAATTAAGACACTGATCACTAAACTCGA 2963 chr9 ENST000003GTTTAGTGATCAGTGTCTTAAT 74045.4 TNFSF15AATTCAAAAAGTCGGGAGACTACTTCATTTACTCGA 2964 chr9 ENST000003GTAAATGAAGTAGTCTCCCGAC 74045.4 TNFSF15AATTCAAAAAACTATAGGAGGAGAGCAAATACTCG 2965 chr9 ENST000003AGTATTTGCTCTCCTCCTATAGT 74045.4 TNFSF18AATTCAAAAACCTTCAGTTGGCTAATCTTTACTCGA 2966 chr1 ENST000004GTAAAGATTAGCCAACTGAAGG 04377.3 TNFSF18AATTCAAAAACTGAACCTCCTTGCGTGAATACTCGA 2967 chr1 ENST000004GTATTCACGCAAGGAGGTTCAG 04377.3 TNFSF18AATTCAAAAAATGATACAAACTCTAACAAACCTCG 2968 chr1 ENST000004AGGTTTGTTAGAGTTTGTATCAT 04377.3 TNFSF4AATTCAAAAAGTGGCCTCTCTGACTTACAAACTCGA 2969 chr1 ENST000002GTTTGTAAGTCAGAGAGGCCAC 81834.3 TNFSF4AATTCAAAAAGCAGAACAACTCAGTCATCATCTCGA 2970 chr1 ENST000002GATGATGACTGAGTTGTTCTGC 81834.3 TNFSF4AATTCAAAAAGCCAAGATTCGAGAGGAACAACTCG 2971 chr1 ENST000002AGTTGTTCCTCTCGAATCTTGGC 81834.3 TNFSF8AATTCAAAAAACTGTATGGTCTTGATCTATTCTCGA 2972 chr9 ENST000002GAATAGATCAAGACCATACAGT 23795.2 TNFSF8AATTCAAAAACAAACTACACAGGGTATTAAACTCG 2973 chr9 ENST000002AGTTTAATACCCTGTGTAGTTTG 23795.2 TNFSF8AATTCAAAAAGTGGATACATTCCAGTACATACTCGA 2974 chr9 ENST000002GTATGTACTGGAATGTATCCAC 23795.2 TNFSF9AATTCAAAAACAAGTTGGACCTTGATATTTACTCGA 2975 chr19 ENST000002GTAAATATCAAGGTCCAACTTG 45817.4 TNFSF9AATTCAAAAACTACTATGTCTTCTTTCAACTCTCGA 2976 chr19 ENST000002GAGTTGAAAGAAGACATAGTAG 45817.4 TNFSF9AATTCAAAAACCCTTCACCGAGGTCGGAATACTCGA 2977 chr19 ENST000002GTATTCCGACCTCGGTGAAGGG 45817.4 TRIM16AATTCAAAAAGCCGTTGTTCAGCGCAAATATCTCGA 2978 chr17 ENST000003GATATTTGCGCTGAACAACGGC 36708.11 TRIM16AATTCAAAAAGCCGTTGTTCAGCGCAAATATCTCGA 2979 chr17 ENST000003GATATTTGCGCTGAACAACGGC 36708.11 TRIM16AATTCAAAAACCGCATCAGGTGAACATCAAACTCG 2980 chr17 ENST000003AGTTTGATGTTCACCTGATGCGG 36708.11 TSLPAATTCAAAAAACTCAATGATAGCACCTAAACCTCGA 2981 chr5 ENST000003GGTTTAGGTGCTATCATTGAGT 44895.3 TSLP AATTCAAAAACGTCGCTTCAATCGACCTTTACTCGA2982 chr5 ENST000003 GTAAAGGTCGATTGAAGCGACG 44895.3 TSLPAATTCAAAAACCATCTTTATTATGGTCATATCTCGA 2983 chr5 ENST000003GATATGACCATAATAAAGATGG 44895.3 TWSG1AATTCAAAAAGACTGTGTTGGTATGTGTAATCTCGA 2984 chr18 ENST000002GATTACACATACCAACACAGTC 62120.9 TWSG1AATTCAAAAAGCGCCTTATTCCAGTGACAAACTCGA 2985 chr18 ENST000002GTTTGTCACTGGAATAAGGCGC 62120.9 TWSG1 AATTCAAAAAGAATCACTGAGCTGTAACAAACTCG2986 chr18 ENST000002 AGTTTGTTACAGCTCAGTGATTC 62120.9 TXLNAAATTCAAAAAGCACATACTGTGTGGACAATACTCGA 2987 chr1 ENST000003GTATTGTCCACACAGTATGTGC 73609.1 TXLNAAATTCAAAAATGCTGATGCAGACATTGAATACTCGA 2988 chr1 ENST000003GTATTCAATGTCTGCATCAGCA 73609.1 TXLNAAATTCAAAAAAGCGAGGTATTCACCACATTCCTCGA 2989 chr1 ENST000003GGAATGTGGTGAATACCTCGCT 73609.1 VASN AATTCAAAAAAGCTTGACTACGCCGACTTTGCTCGA2990 chr16 ENST000003 GCAAAGTCGGCGTAGTCAAGCT 04735.3 VASNAATTCAAAAAAGCCAACAGGCTGCATGAAATCTCG 2991 chr16 ENST000003AGATTTCATGCAGCCTGTTGGCT 04735.3 VASNAATTCAAAAAGAGATCCTTTCCCATTTATTCCTCGA 2992 chr16 ENST000003GGAATAAATGGGAAAGGATCTC 04735.3 VEGFA AATTCAAAAACAAGATCCGCAGACGTGTAAACTCG2993 chr6 ENST000004 AGTTTACACGTCTGCGGATCTTG 25836.6 VEGFAAATTCAAAAACAAGATCCGCAGACGTGTAAACTCG 2994 chr6 ENST000004AGTTTACACGTCTGCGGATCTTG 25836.6 VEGFAAATTCAAAAAGCGCAAGAAATCCCGGTATAACTCG 2995 chr6 ENST000004AGTTATACCGGGATTTCTTGCGC 25836.6 VSTM1AATTCAAAAAATGAATATGCGGCACTGAAAGCTCG 2996 chr19 ENST000003AGCTTTCAGTGCCGCATATTCAT 38372.6 VSTM1AATTCAAAAACATTCCCAGAATGTGACATTTCTCGA 2997 chr19 ENST000003GAAATGTCACATTCTGGGAATG 38372.6 VSTM1AATTCAAAAAGAGTGACCTATGCTGAGCTAACTCGA 2998 chr19 ENST000003GTTAGCTCAGCATAGGTCACTC 38372.6 WFIKKN1AATTCAAAAATGCGCCCTGATCAGATGTATGCTCGA 2999 chr16 ENST000003GCATACATCTGATCAGGGCGCA 19070.2 WFIKKN1AATTCAAAAAGGACGTGCTCAAGGATGACAACTCG 3000 chr16 ENST000003AGTTGTCATCCTTGAGCACGTCC 19070.2 WFIKKN1AATTCAAAAAAGTGCTGCATCAACGTGTGTGCTCGA 3001 chr16 ENST000003GCACACACGTTGATGCAGCACT 19070.2 WFIKKN2AATTCAAAAATCAAGTTCTTGGGCACCAAGTCTCGA 3002 chr17 ENST000003GACTTGGTGCCCAAGAACTTGA 11378.4 WFIKKN2AATTCAAAAATACAACCGCTGCTATATGGACCTCGA 3003 chr17 ENST000003GGTCCATATAGCAGCGGTTGTA 11378.4 WFIKKN2AATTCAAAAACACCAGCTTGCTCAGATATTCCTCGA 3004 chr17 ENST000003GGAATATCTGAGCAAGCTGGTG 11378.4 WNT1 AATTCAAAAACTGTCGAGAAACGGCGTTTATCTCGA3005 chr12 ENST000002 GATAAACGCCGTTTCTCGACAG 93549.3 WNT1AATTCAAAAAGACCTCGTCTACTTCGAGAAACTCGA 3006 chr12 ENST000002GTTTCTCGAAGTAGACGAGGTC 93549.3 WNT1 AATTCAAAAAGCCACGAGTTTGGATGTTGTACTCGA3007 chr12 ENST000002 GTACAACATCCAAACTCGTGGC 93549.3 WNT2AATTCAAAAACCACAAATGGTCCCAATTAAGCTCGA 3008 chr7 ENST000002GCTTAATTGGGACCATTTGTGG 65441.7 WNT2 AATTCAAAAATCGGGAATCTGCCTTTGTTTACTCGA3009 chr7 ENST000002 GTAAACAAAGGCAGATTCCCGA 65441.7 WNT2AATTCAAAAATTGACTATGGGATCAAATTTGCTCGA 3010 chr7 ENST000002GCAAATTTGATCCCATAGTCAA 65441.7 WNT5AAATTCAAAAACTCCCAGGACCCGCTTATTTACTCGA 3011 chr3 ENST000002GTAAATAAGCGGGTCCTGGGAG 64634.8 WNT5AAATTCAAAAACAAAGAATGCCAGTATCAATTCTCGA 3012 chr3 ENST000002GAATTGATACTGGCATTCTTTG 64634.8 WNT5AAATTCAAAAACCTGTTCAGATGTCAGAAGTACTCGA 3013 chr3 ENST000002GTACTTCTGACATCTGAACAGG 64634.8 WNT7A AATTCAAAAACATAGGAGAAGGCTCACAAATCTCG3014 chr3 ENST000002 AGATTTGTGAGCCTTCTCCTATG 85018.4 WNT7AAATTCAAAAAGGCGCAAGCATCATCTGTAACCTCGA 3015 chr3 ENST000002GGTTACAGATGATGCTTGCGCC 85018.4 WNT7A AATTCAAAAATCTTCGGGAAGGAGCTCAAAGCTCG3016 chr3 ENST000002 AGCTTTGAGCTCCTTCCCGAAGA 85018.4 XCL1AATTCAAAAAGCTGTGACAATGGCAACAATTCTCGA 3017 chr1 ENST000003GAATTGTTGCCATTGTCACAGC 67818.3 XCL1 AATTCAAAAATTCAACTTGTCTCTATAATAGCTCGA3018 chr1 ENST000003 GCTATTATAGAGACAAGTTGAA 67818.3 XCL1AATTCAAAAAAGATTCTGGCTAGTGTCTATCCTCGA 3019 chr1 ENST000003GGATAGACACTAGCCAGAATCT 67818.3 XCL2 AATTCAAAAAACTGCCAGTTAGCAGAATCAACTCG3020 chr1 ENST000003 AGTTGATTCTGCTAACTGGCAGT 67819.2 XCL2AATTCAAAAAGTAGGGAGTGAAGTCTCACATCTCG 3021 chr1 ENST000003AGATGTGAGACTTCACTCCCTAC 67819.2 XCL2 AATTCAAAAAGAAATCCAACACCAGAAATAACTCG3022 chr1 ENST000003 AGTTATTTCTGGTGTTGGATTTC 67819.2 ZFP36AATTCAAAAAGATCCGACCCTGATGAATATGCTCGA 3023 chr19 ENST000005GCATATTCATCAGGGTCGGATC 97629.1 ZFP36AATTCAAAAAATCTGTCTCCTAGAATCTTATCTCGA 3024 chr19 ENST000005GATAAGATTCTAGGAGACAGAT 97629.1 ZFP36AATTCAAAAACCCTTTATTTATGACGACTTTCTCGA 3025 chr19 ENST000005GAAAGTCGTCATAAATAAAGGG 97629.1

Example 16 Method of Making and Testing Cells Deficient in SpecificCytokine Expression Using Protein Expression Blockers(PEBL)—CAR19-GM-CSF PEBL

Inject tumor in SCID-Beige mice (3e6 Raji containing Luciferase) ifperforming in vivo CRS experiment. This should be completed 3 weeksprior to infusion of CAR-T into mice.

The following sERteps may be taken to provide CRS resistance. Aselectable marker is required to enrich for this gene modification ascytokines are secreted proteins, thus. This example describes the makingof a cell CAR19-GM-CSF PEBL, in which blockade of GM-CSF secretionmitigates risk of CRS. As those of skill in the art will recognize,certain of the steps may be conducted sequentially or out of the orderlisted below, though perhaps leading to different efficiency.

Step 1: T Cell Activation (Day 0)

Purify T cells from leukapheresis chamber using Miltenyi juman PanTisolation kit. Resuspend in media. Count cells. Determine number ofhuman T cell activation CD3/CD28 beands required to obtain 3:1 bead:cellratio. Wash beads 2× with T cell media. Dilute cells at 1.256 cells/mLin hXcyte media. Add human T cell activation CD3/CD28 beads. Aliquot 4ml/well of 1.256 cells/mL solution into 6-well plate. Incubate at 37° C.

Step 2: Transduction of T Cells with PEBL CAR (Day 1)

T cells are transduced with a CAR targeted to (i.e., that recognizes)one or more antigen or protein targets, for example with a Lentiviruscontaining a CAR construct targeting CD19, combined with the anti-GM-CSFPEBL. Expression from a polycistronic vector is preferable, allowingCD34 expression to mark both CAR and PEBL expression. However,expression can be achieved with the same viral vector expressing boththe CAR and PEBL individually, or as independent transductions withseparate vectors containing CAR and PEBL. Any other suitable method oftransduction may be used, for example, AAV, retrovirus, etc, or throughdirect insertion of the CAR PEBL complex into a targeted location of thegenome using homology directed repair and a donor vector containing theconstruct.

Step 3: Assessment of Td Efficiency (Day 10)

Take 5×10⁵ cells from each sample and analyze by flow cytometry. Washsamples with RB. Add 3 μL of anti-CD34 PE antibody. Add 5μL of CD3 APCand 2 μL of anti-FAB BV421 (detects CAR transduction). Wash. Performflow cytometry. Cells should be CD34-positive indicating expression ofCAR and PEBL from a polycistronic vector. Harvest T cells (Day 11).

Purification of CAR-T cells. CAR+ (CD34+) and GC-CSF deficient (PEBL+)cells can be enriched using a CD34-positive selection on the MiltenyiAutomacs. This enriches the GC-CSF suppressed cells and enriches CAR+cells.

Step 4: Assessment of CAR-T Activity

Inject 3×10⁷ CAR-T cells per mouse I.P. Assess serum cytokine levels.(Day 12, Day 13, Day 14). Measure serum cytokine levels using Luminexmultiplex profiling assay to check for elevations in CRS-relatedcytokines. Perform a 4-hour chromium release assay against target cells(Raji) to assess in vitro activity (Day 11).

PEBL constructs targeting GM-CSF are provided in FIG. 6 and Tables 17and 18.

TABLE 17Anti-GM-CSF PEBL Constructs (SEQ ID NOS 3071-3076, respectively)ER-Retention CD28 Leader V_(L) Linker V_(H) Domain 2a trCD34 MALPVTALLLDIELTQPPSVS GGGGS(n)n = QVQLVESGG EQKLISEEDL PLALLLHAAR VAPGQTARIS1, 2, 3, 4 GLVQPGGSLR KDEL (SEQ ID P (SEQ ID CSGDNLPGKY (SEQ LSCAASGFTFNO: 3028) NO: 1) VHWYQQKPG ID NO: 3069) SSHWMSWVR QAPVLVIYYD QAPGKGLEWSNRPSGIPERF VSNIWRGPYI SGSNSGNTAT YYADSVKGR LTISGTQAED FTISRDNSKNTEADYYCQSRT LYLQMNSLR QTTIVFGGGT AEDTAVYYC KLTVLGQ ARFQGYGGG (SEQ IDFDYWGQGTL NO: 3026) VTVSS (SEQ ID NO: 3027) MALPVTALLL DIELTQPPSVSGGGGS(n)n = QVQLVESGG (GGGGS)₄AEK PLALLLHAAR VAPGQTARIS 1, 2, 3, 4GLVQPGGSLR DEL (SEQ ID P (SEQ ID CSGDNLPGKY (SEQ LSCAASGFTF NO: 3029)NO: 1) VHWYQQKPG ID NO: 3069) SSHWMSWVR QAPVLVIYYD QAPGKGLEW SNRPSGIPERFVSNIWRGPYI SGSNSGNTAT YYADSVKGR LTISGTQAED FTISRDNSKNT EADYYCQSRTLYLQMNSLR QTTIVFGGGT AEDTAVYYC KLTVLGQ ARFQGYGGG (SEQ ID NO: FDYWGQGTL3026) VTVSS (SEQ ID NO: 3027) MALPVTALLL DIELTQPPSVS GGGGS(n)n =QVQLVESGG TTTPAPRPPTP PLALLLHAAR VAPGQTARIS 1, 2, 3, 4 GLVQPGGSLRAPTIASQPLSL P (SEQ ID CSGDNLPGKY (SEQ LSCAASGFTF RPEACRPAAG NO: 1)VHWYQQKPG ID NO: 3069) SSHWMSWVR GAVHTRGLDF QAPVLVIYYD QAPGKGLEWACDIYIWAPL SNRPSGIPERF VSNIWRGPYI AGTCGVLLLS SGSNSGNTAT YYADSVKGRLVITLYCNHR LTISGTQAED FTISRDNSKNT NLYKYKSRRS EADYYCQSRT LYLQMNSLRFEDEKKMP QTTIVFGGGT AEDTAVYYC (SEQ ID KLTVLGQ ARFQGYGGG NO: 3030)(SEQ ID NO: FDYWGQGTL 3026) VTVSS (SEQ ID NO: 3027) MALPVTALLLDIELTQPPSVS GGGGS(n)n = QVQLVESGG EQKLISEEDL GSGATNFSLL MPRGWTALCPLALLLHAAR VAPGQTARIS 1, 2, 3, 4 GLVQPGGSLR KDEL (SEQ ID KQAGDVEENLLSLLPSGFM P (SEQ ID CSGDNLPGKY (SEQ LSCAASGFTF NO: 3028) PGP (SEQ IDSLDNNGTATP NO: 1) VHWYQQKPG ID NO: 3069) SSHWMSWVR NO: 3031) ELPTQGTFSNQAPVLVIYYD QAPGKGLEW VSTNVSYQET SNRPSGIPERF VSNIWRGPYI TTPSTLGSTSLSGSNSGNTAT YYADSVKGR HPVSQHGNEA LTISGTQAED FTISRDNSKNT TTNITETTVKFEADYYCQSRT LYLQMNSLR TSTSVITSVYG QTTIVFGGGT AEDTAVYYC NTNSSVQSQT KLTVLGQARFQGYGGG SVISTVFTTPA (SEQ ID NO: FDYWGQGTL NVSTPETTLK 3026) VTVSS (SEQPSLSPGNVSD ID NO: 3027) LSTTSTSLATS PTKPYTSSSPI LSDIKAEEKCS GIREVKLTQGICLEQNKTSSC AEFKKDRGEG LARVLCGEEQ ADADAGAQV CSLLLAQSEV RPQCLLLVLANRTEISSKLQL MKKHQSDLK KLGILDFTEQ DVASHQSYSQ KTLIALVTSG ALLAVLGITGYFLMNRRSW SPI (SEQ ID NO: 3032) MALPVTALLL D1ELTQPPSVS GGGGS(n)n =QVQLVESGG (GGGGS)4AEK GSGATNFSLL MPRGWTALC PLALLLHAAR VAPGQTARIS1, 2, 3, 4 GLVQPGGSLR DEL (SEQ ED KQAGDVEEN LLSLLPSGFM P (SEQ IDCSGDNLPGKY (SEQ LSCAASGFTF NO: 3029) PGP (SEQ ID SLDNNGTATP NO: 1)VHWYQQKPG ID NO: 3069) SSHWMSWVR NO: 3031) ELPTQGTFSN QAPVLVIYYDQAPGKGLEW VSTNVSYQET SNRPSGIPERF VSNIWRGPYI TTPSTLGSTSL SGSNSGNTATYYADSVKGR HPVSQHGNEA LTISGTQAED FTISRDNSKNT TTNITETTVKF EADYYCQSRTLYLQMNSLR TSTSVITSVYG QTTIVFGGGT AEDTAVYYC NTNSSVQSQT KLTVLGQ ARFQGYGGGSVISTVFTTPA (SEQ ID NO: FDYWGQGTL NVSTPETTLK 3026) VTVSS (SEQ PSLSPGNVSDID NO: 3027) LSTTSTSLATS PTKPYTSSSPI LSDIKAEEKCS GIREVKLTQGI CLEQNKTSSCAEFKKDRGEG LARVLCGEEQ ADADAGAQV CSLLLAQSEV RPQCLLLVLA NRTEISSKLQLMKKHQSDLK KLGILDFTEQ DVASHQSYSQ KTLIALVTSG ALLAVLGITG YFLMNRRSWSPI (SEQ ID NO: 3032) MALPVTALLL D1ELTQPPSVS GGGGS(n)n = QVQLVESGGTTTPAPRPPTP GSGATNFSLL MPRGWTALC PLALLLHAAR VAPGQTARIS 1, 2, 3, 4GLVQPGGSLR APTIASQPLSL KQAGDVEEN LLSLLPSGFM P (SEQ ID CSGDNLPGKY (SEQLSCAASGFTF RPEACRPAAG PGP (SEQ ID SLDNNGTATP NO: 1) VHWYQQKPGID NO: 3069) SSHWMSWVR GAVHTRGLDF NO: 3031) ELPTQGTFSN QAPVLVIYYDQAPGKGLEW ACDIYIWAPL VSTNVSYQET SNRPSGIPERF VSNIWRGPYI AGTCGVLLLSTTPSTLGSTSL SGSNSGNTAT YYADSVKGR LVITLYCNHR HPVSQHGNEA LTISGTQAEDFTISRDNSKNT NLYKYKSRRS TTNITETTVKF EADYYCQSRT LYLQMNSLR FEDEKKMPTSTSVITSVYG QTTIVFGGGT AEDTAVYYC (SEQ ID NO: NTNSSVQSQT KLTVLGQARFQGYGGG 3030) SVISTVFTTPA (SEQ ID NO: FDYWGQGTL NVSTPETTLK 3026)VTVSS (SEQ PSLSPGNVSD ID NO: 3027) LSTTSTSLATS PTKPYTSSSPI LSDIKAEEKCSGIREVKLTQGI CLEQNKTSSC AEFKKDRGEG LARVLCGEEQ ADADAGAQV CSLLLAQSEVRPQCLLLVLA NRTEISSKLQL MKKHQSDLK KLGILDFTEQ DVASHQSYSQ KTLIALVTSGALLAVLGITG YFLMNRRSW SPI (SEQ ID NO: 3032)

TABLE 18CD19 CAR with GM-CSF PEBL Constructs (SEQ ID NOS 3077-3082, respectively)ER- CD28 Retention CD8a CD19 CD19 CD8a CD28 Co- CD8a Domain Leader V_(H)Linker V_(L) Hinge tm stim CD3z 2a Leader V_(L) Linker V_(H) and Tag 2aTag MAL DIQ GGG EVK TTT FWV RSK RVK GSG MAL DIE GGG QVQ EQK PVT MTQ GS₄LQE PAP LVV RSR FSR ATN PVT LTQ GS(n)n LVE LISE ALL TTS (SEQ SGP RPP VGGLLH SAD FSL ALL PPS = SGG EDL LPL SLS ID GLV TPA VLA SDY APA LKQ LPL VSV1, 2, GLV KDE ALL ASL NO: APS PTIA CYS MN YKQ AGD ALL APG 3, 4 QPG L LHAGDR 9) QSL SQP LLV MTP GQN VEE LHA QTA (SEQ GSL (SEQ ARP VTIS SVT LSLTVA RRP QLY NPG ARP RISC ID RLS ID (SEQ CRA CTV RPE FIIF GPT NEL P (SEQSGD NO: CAA NO: ID SQD SGV ACR WV RKH NLG (SEQ ID NLP 3069) SGF 3028)NO: 1) ISK SLP PAA (SEQ YQP RRE ID NO: 1) GKY TFS YLN DYG GGA ID YAP EYDNO: VH SHW WY VSW VHT NO: PRD VLD 3031) WY MS QQK IRQ RGL 3036) FAA KRRQQK WV PDG PPR DFA YRS GRD PGQ RQA TVK KGL CD (SEQ PEM APV PGK LLI EWL(SEQ ID GGK LVI GLE YHT GVI ID NO: PRR YYD WVS SRL WGS NO: 3037) KNP SNRNIW HSG ETT 3035) QEG PSGI RGP VPS YYN LYN PER YIY RFS SAL ELQ FSG YADGSG KSR KDK SNS SVK SGT LTII MAE GNT GRF DYS KDN AYS ATL TISR LTIS SKSEIG TISG DNS NLE QVF MK TQA KNT QED LKM GER EDE LYL IAT NSL RRG ADY QMYFC QTD KGH YCQ NSL QQG DTA DGL SRT RAE NTL IYY YQG QTT DTA PYT CAK LSTIVF VYY FGG HYY ATK GGG CAR GTK YGG DTY TKL FQG LEIT SYA DAL TVL YGG RADMD HM GQ GFD AAP YW QAL (SEQ YW TVSI GQG PPR ID GQG FPPS TSV (SEQ NO:TLV SN TVS ID 3026) TVS (SEQ S NO: S ID (SEQ 3038) (SEQ NO: ID ID 3033)NO: NO: 3034) 3027) MAL DIQ GGG EVK TIT FWV RSK RVK GSG MAL DIE GGG QVQ(GG PVT MTQ GS₄ LQE PAP LVV RSR FSR ATN PVT LTQ GS(n)n LVE GGS)₄ ALL rrs(SEQ SGP RPP VGG LLH SAD FSL ALL PPS = SGG AE LPL SLS ID GLV TPA VLA SDYAPA LKQ LPL VSV 1, 2, GLV KDE ALL ASL NO: APS PTIA CYS MN YKQ AGD ALLAPG 3, 4 QPG L LHA GDR 9) QSL SQP LLV MTP GQN VEE LHA QTA (SEQ GSL (SEQARP VTIS SVT LSL TVA RRP QLY NPG ARP RISC ID RLS ID (SEQ CRA CTV RPEFIIF GPT NEL P (SEQ SGD NO: CAA NO: ID SQD SGV ACR WV RKH NLG (SEQ IDNLP 3069) SGF 3029) NO: 1) ISK SLP PAA (SEQ YQP RRE ID NO: 1) GKY TFSYLN DYG GGA ID YAP EYD NO: VH SHW WY VSW VHT NO: PRD VLD 3031) WY MS QQKIRQ RGL 3036) FAA KRR QQK WV PDG PPR DFA YRS GRD PGQ RQA TVK KGL CD (SEQPEM APV PGK LLI EWL (SEQ ID GGK LVI GLE YHT GVI ID NO: PRR YYD WVS SRLWGS NO: 3037) KNP SNR NIW HSG ETT 3035) QEG PSGI RGP VPS YYN LYN PER YIYRFS SAL ELQ FSG YAD GSG KSR KDK SNS SVK SGT LTII MAE GNT GRF DYS KDN AYSATL TISR LTIS SKS EIG TISG DNS NLE QVF MK TQA KNT QED LKM GER EDE LYLIAT NSL RRG ADY QM YFC QTD KGH YCQ NSL QQG DTA DGL SRT RAE NTL IYY YQGQTT DTA PYT CAK LST IVF VYY FGG HYY ATK GGG CAR GTK YGG DTY TKL FQG LEITSYA DAL TVL YGG RAD MD HM GQ GFD AAP YW QAL (SEQ YW TVSI GQG PPR ID GQGFPPS TSV (SEQ NO: TLV SN TVS ID 3026) TVS (SEQ S NO: S ID (SEQ 3038)(SEQ NO: ID ID 3033) NO: NO: 3034) 3027) MAL DIQ GGG EVK TIT FWV RSK RVKGSG MAL DIE GGG QVQ TTT PVT MTQ GS₄ LQE PAP LVV RSR FSR ATN PVT LTQGS(n)n LVE PAP ALL rrs (SEQ SGP RPP VGG LLH SAD FSL ALL PPS = SGG RPPLPL SLS ID GLV TPA VLA SDY APA LKQ LPL VSV 1, 2, GLV TPA ALL ASL NO: APSPTIA CYS MN YKQ AGD ALL APG 3, 4 QPG PTIA LHA GDR 9) QSL SQP LLV MTP GQNVEE LHA QTA (SEQ GSL SQP ARP VTIS SVT LSL TVA RRP QLY NPG ARP RISC IDRLS LSL (SEQ CRA CTV RPE FIIF GPT NEL P (SEQ SGD NO: CAA RPE ID SQD SGVACR WV RKH NLG (SEQ ID NLP 3069) SGF ACR NO: 1) ISK SLP PAA (SEQ YQP RREID NO: 1) GKY TFS PAA YLN DYG GGA ID YAP EYD NO: VH SHW GGA WY VSW VHTNO: PRD VLD 3031) WY MS VHT QQK IRQ RGL 3036) FAA KRR QQK WV RGL PDG PPRDFA YRS GRD PGQ RQA DFA TVK KGL CD (SEQ PEM APV PGK CDI LLI EWL (SEQ IDGGK LVI GLE YIW YHT GVI ID NO: PRR YYD WVS APL SRL WGS NO: 3037) KNP SNRNIW AGT HSG ETT 3035) QEG PSGI RGP CGV VPS YYN LYN PER YIY LLL RFS SALELQ FSG YAD SLVI GSG KSR KDK SNS SVK TLY SGT LTII MAE GNT GRF CNH DYSKDN AYS ATL TISR RNL LTIS SKS EIG TISG DNS YKY NLE QVF MK TQA KNT KSRQED LKM GER EDE LYL RSFI IAT NSL RRG ADY QM DEK YFC QTD KGH YCQ NSL KMPQQG DTA DGL SRT RAE (SEQ NTL IYY YQG QTT DTA D PYT CAK LST IVF VYY NO:FGG HYY ATK GGG CAR 3030) GTK YGG DTY TKL FQG LEIT SYA DAL TVL YGG RADMD HM GQ GFD AAP YW QAL (SEQ YW TVSI GQG PPR ID GQG FPPS TSV (SEQ NO:TLV SN TVS ID 3026) TVS (SEQ S NO: S ID (SEQ 3038) (SEQ NO: ID ID 3033)NO: NO: 3034) 3027) MAL DIQ GGG EVK TIT FWV RSK RVK GSG MAL DIE GGG QVQEDL FSL TAL PVT MTQ GS₄ LQE PAP LVV RSR FSR ATN PVT LTQ GS(n)n LVE KDELKQ CLL ALL rrs (SEQ SGP RPP VGG LLH SAD FSL ALL PPS = SGG L AGD SLL LPLSLS ID GLV TPA VLA SDY APA LKQ LPL VSV 1, 2, GLV (SEQ VEE PSG ALL ASLNO: APS PTIA CYS MN YKQ AGD ALL APG 3, 4 QPG ID NPG FMS LHA GDR 9) QSLSQP LLV MTP GQN VEE LHA QTA (SEQ GSL NO: P LDN ARP VTIS SVT LSL TVA RRPQLY NPG ARP RISC ID RLS 3028) (SEQ NGT (SEQ CRA CTV RPE FIIF GPT NEL P(SEQ SGD NO: CAA ID ATP ID SQD SGV ACR WV RKH NLG (SEQ ID NLP 3069) SGFNO: ELP NO: 1) ISK SLP PAA (SEQ YQP RRE ID NO: 1) GKY TFS 3031) TQG YLNDYG GGA ID YAP EYD NO: VH SHW TFS WY VSW VHT NO: PRD VLD 3031) WY MS NVSQQK IRQ RGL 3036) FAA KRR QQK WV TNV PDG PPR DFA YRS GRD PGQ RQA SYQ TVKKGL CD (SEQ PEM APV PGK ETT LLI EWL (SEQ ID GGK LVI GLE TPS YHT GVI IDNO: PRR YYD WVS TLG SRL WGS NO: 3037) KNP SNR NIW STS HSG ETT 3035) QEGPSGI RGP LHP VPS YYN LYN PER YIY VSQ RFS SAL ELQ FSG YAD HGN GSG KSR KDKSNS SVK EAT SGT LTII MAE GNT GRF TNI DYS KDN AYS ATL TISR TET LTIS SKSEIG TISG DNS TVK NLE QVF MK TQA KNT FTS QED LKM GER EDE LYL TSVI IAT NSLRRG ADY QM TSV YFC QTD KGH YCQ NSL YGN QQG DTA DGL SRT RAE TNS NTL IYYYQG QTT DTA SVQ PYT CAK LST IVF VYY SQT FGG HYY ATK GGG CAR SVIS GTK YGGDTY TKL FQG TVF LEIT SYA DAL TVL YGG TIP RAD MD HM GQ GFD ANV AAP YW QAL(SEQ YW STP TVSI GQG PPR ID GQG ETT FPPS TSV (SEQ NO: TLV LKP SN TVS ID3026) TVS SLS (SEQ S NO: S PGN ID (SEQ 3038) (SEQ VSD NO: ID ID LST3033) NO: NO: TST 3034) 3027) SLA TSP TKP YTS SSPI LSDI KAE IKC SGI REVKLT QGI CLE QNK TSS CAE FKK DRG EGL ARV LCG EEQ ADA DAD AQV CSL LLA QSEVRP QCL LLV LAN RTEI SSK LQL MK KHQ SDL KKL GIL DFT EQD VAS HQS YSQ KTLIAL VTS GAL LAV LGI TGY FLM NRR SWS PI (SEQ ID NO: 10) MAL DIQ GGG EVKTIT FWV RSK RVK GSG MAL DIE GGG QVQ (GG FSL TAL PVT MTQ GS₄ LQE PAP LVVRSR FSR ATN PVT LTQ GS(n)n LVE GGS)₄ LKQ CLL ALL rrs (SEQ SGP RPP VGGLLH SAD FSL ALL PPS = SGG AE AGD SLL LPL SLS ID GLV TPA VLA SDY APA LKQLPL VSV 1, 2, GLV KDE VEE PSG ALL ASL NO: APS PTIA CYS MN YKQ AGD ALLAPG 3, 4 QPG L NPG FMS LHA GDR 9) QSL SQP LLV MTP GQN VEE LHA QTA (SEQGSL (SEQ P LDN ARP VTIS SVT LSL TVA RRP QLY NPG ARP RISC ID RLS ID (SEQNGT (SEQ CRA CTV RPE FIIF GPT NEL P (SEQ SGD NO: CAA NO: ID ATP ID SQDSGV ACR WV RKH NLG (SEQ ID NLP 3069) SGF 3029) NO: ELP NO: 1) ISK SLPPAA (SEQ YQP RRE ID NO: 1) GKY TFS 3031) TQG YLN DYG GGA ID YAP EYD NO:VH SHW TFS WY VSW VHT NO: PRD VLD 3031) WY MS NVS QQK IRQ RGL 3036) FAAKRR QQK WV TNV PDG PPR DFA YRS GRD PGQ RQA SYQ TVK KGL CD (SEQ PEM APVPGK ETT LLI EWL (SEQ ID GGK LVI GLE TPS YHT GVI ID NO: PRR YYD WVS TLGSRL WGS NO: 3037) KNP SNR NIW STS HSG ETT 3035) QEG PSGI RGP LHP VPS YYNLYN PER YIY VSQ RFS SAL ELQ FSG YAD HGN GSG KSR KDK SNS SVK EAT SGT LTIIMAE GNT GRF TNI DYS KDN AYS ATL TISR TET LTIS SKS EIG TISG DNS TVK NLEQVF MK TQA KNT FTS QED LKM GER EDE LYL TSVI IAT NSL RRG ADY QM TSV YFCQTD KGH YCQ NSL YGN QQG DTA DGL SRT RAE TNS NTL IYY YQG QTT DTA SVQ PYTCAK LST IVF VYY SQT FGG HYY ATK GGG CAR SVIS GTK YGG DTY TKL FQG TVFLEIT SYA DAL TVL YGG TIP RAD MD HM GQ GFD ANV AAP YW QAL (SEQ YW STPTVSI GQG PPR ID GQG ETT FPPS TSV (SEQ NO: TLV LKP SN TVS ID 3026) TVSSLS (SEQ S NO: S PGN ID (SEQ 3038) (SEQ VSD NO: ID ID LST 3033) NO: NO:TST 3034) 3027) SLA TSP TKP YTS SSPI LSDI KAE IKC SGI REV KLT QGI CLEQNK TSS CAE FKK DRG EGL ARV LCG EEQ ADA DAD AQV CSL LLA QSE VRP QCL LLVLAN RTEI SSK LQL MK KHQ SDL KKL GIL DFT EQD VAS HQS YSQ KTL IAL VTS GALLAV LGI TGY FLM NRR SWS PI (SEQ ID NO: 10) MAL DIQ GGG EVK TIT FWV RSKRVK GSG MAL DIE GGG QVQ TTT FSL TAL PVT MTQ GS₄ LQE PAP LVV RSR FSR ATNPVT LTQ GS(n)n LVE PAP LKQ CLL ALL rrs (SEQ SGP RPP VGG LLH SAD FSL ALLPPS = SGG RPP AGD SLL LPL SLS ID GLV TPA VLA SDY APA LKQ LPL VSV 1, 2,GLV TPA VEE PSG ALL ASL NO: APS PTIA CYS MN YKQ AGD ALL APG 3, 4 QPGPTIA NPG FMS LHA GDR 9) QSL SQP LLV MTP GQN VEE LHA QTA (SEQ GSL SQP PLDN ARP VTIS SVT LSL TVA RRP QLY NPG ARP RISC ID RLS LSL (SEQ NGT (SEQCRA CTV RPE FIIF GPT NEL P (SEQ SGD NO: CAA RPE ID ATP ID SQD SGV ACR WVRKH NLG (SEQ ID NLP 3069) SGF ACR NO: ELP NO: 1) ISK SLP PAA (SEQ YQPRRE ID NO: 1) GKY TFS PAA 3031) TQG YLN DYG GGA ID YAP EYD NO: VH SHWGGA TFS WY VSW VHT NO: PRD VLD 3031) WY MS VHT NVS QQK IRQ RGL 3036) FAAKRR QQK WV RGL TNV PDG PPR DFA YRS GRD PGQ RQA DFA SYQ TVK KGL CD (SEQPEM APV PGK CDI ETT LLI EWL (SEQ ID GGK LVI GLE YIW TPS YHT GVI ID NO:PRR YYD WVS APL TLG SRL WGS NO: 3037) KNP SNR NIW AGT STS HSG ETT 3035)QEG PSGI RGP CGV LHP VPS YYN LYN PER YIY LLL VSQ RFS SAL ELQ FSG YADSLVI HGN GSG KSR KDK SNS SVK TLY EAT SGT LTII MAE GNT GRF CNH TNI DYSKDN AYS ATL TISR RNL TET LTIS SKS EIG TISG DNS YKY TVK NLE QVF MK TQAKNT KSR FTS QED LKM GER EDE LYL RSFI TSVI IAT NSL RRG ADY QM DEK TSV YFCQTD KGH YCQ NSL KMP YGN QQG DTA DGL SRT RAE (SEQ TNS NTL IYY YQG QTT DTAD SVQ PYT CAK LST IVF VYY NO: SQT FGG HYY ATK GGG CAR 3030) SVIS GTK YGGDTY TKL FQG TVF LEIT SYA DAL TVL YGG TIP RAD MD HM GQ GFD ANV AAP YW QAL(SEQ YW STP TVSI GQG PPR ID GQG ETT FPPS TSV (SEQ NO: TLV LKP SN TVS ID3026) TVS SLS (SEQ S NO: S PGN ID (SEQ 3038) (SEQ VSD NO: ID ID LST3033) NO: NO: TST 3034) 3027) SLA TSP TKP YTS SSPI LSDI KAE IKC SGI REVKLT QGI CLE QNK TSS CAE FKK DRG EGL ARV LCG EEQ ADA DAD AQV CSL LLA QSEVRP QCL LLV LAN RTEI SSK LQL MK KHQ SDL KKL GIL DFT EQD VAS HQS YSQ KTLIAL VTS GAL LAV LGI TGY FLM NRR SWS PI (SEQ ID NO: 10)

Example 17 In Vitro CRS Assay for Testing Efficacy of Inducing CRS AfterDeletion of GM-CSF in CART19

Cell lines: CD19 positive B-ALL cell line RAMOS was used to evaluate CRSin an in vitro assay. Prior to assay, RAMOS cells were stablytransfected with GFP using lentiviral transduction and cultured in RPMI+10% FBS+Pen/Strep.

Isolation of normal donor monocytes and T cells: Primary human T cellsand monocytes were isolated from normal healthy human donors. T cellcells were isolated from PBMC using CD4+CD8+ selection (Miltenyi Biotec)and monocytes were separated using Miltenyi biotec classical MonocyteIsolation beads according to the manufactures protocol.

T cell culture and CAR-T gene editing: T cells were subsequentlyresuspended at a concentration of 1×10⁶ cells/mL in Xcyte mediasupplemented with 50 U/mL IL-2 and 10 ng/ml IL-15 in the presence ofanti-CD3/CD28 beads (Bead to cell ratio 3:1). Twenty-four hours afterinitial stimulation, T cells were transfected with lentiviral vectorencoding the CD19 CAR construct in the presence of polybrene (finalconc. 6 μg/ml). Stimulatory beads were removed on day 2. CART19 cellswere suspended at 4×10⁶ T cells were electroporated in 100 μl buffer P3with 15 μg spCas9 mRNA (Trilink CA.) and 20 μg of GM-CSF gRNA (Trilink)using a nucleofector 4D, program EO-115. Control CAR19 T cells wereelectroporated without GM-CSF gRNA. T-cells were subsequently evaluatedat day 6 for CD34 (bicistronic marker of CAR-T) and intracellular GM-CSFexpression using flowcytometry prior to co-culture assay.

Production of monocyte lineage cells: For iDC generation, monocytes(1×10⁶) were plated in 6 mLs of RPMI 1640 supplemented with supplementedwith 0.1 mmol/L MEM Non-Essential Amino Acids, 2 mmol/L L-glutamine, 100units/mL penicillin, 100 μg/mL streptomycin (Life Technologies) and 10%fetal calf serum (cR10). cR10 was subsequently supplemented with 0.2μg/mL human IL-4 (Peptotec) and 0.2 μg/mL GM-CSF (Peptotec).

For macrophage and activated macrophage generation cR10 was supplementedwith 10% human AB serum instead of fetal calf serum (hR10). Foractivated macrophages hR10 medium was supplemented with 30 ng/ml of LPS.On day 4 cytokines and LPS were replenished. Macrophages, activatedmacrophages and iDC were harvested using 2 mmol/L EDTA (immaturedendritic cells) on day 6 post-isolation. Twenty-four hours later, cellswere harvested with 2 mmol/L EDTA and stained with CD45, CD80 and CD86to confirm immature DC and mature DC differentiation.

Co-culture assay: CAR-T cells were combined at the following ratios in200 ul per 96 well: 12.5K UCART-19 (with or with-out GM-CSF KO), Target,50K Ramos cells (CD19+) and monocyte derived cells, 1K iDC or 5Kmacrophages or 5K activated macrophages.

Co-cultures were subsequently incubated for at 37° C. and 100 ul ofassay supernatant was collected at 24 hr and 48 hr for cytokineanalysis.

Measurement of Cytokine Levels

Cytokine concentration determination from culture supernatants wasperformed using IL-6 ELISA plate (R&D systems). Prior to analysissupernatant's were centrifuged at 300 g for 10 mins at 4° C. andsubsequently diluted 1:10 in assay calibrator diluent. Measurements wereperformed using standard product protocols.

GM-CSF deficient CART19 induced significantly lower it-6 expressionacross the different monocyte lineages. FIGS. 8 and 10

Example 18 In Vitro CRS Assay for Testing Efficacy of Inducing CRS afterDeletion of GM-CSF in T Cells

Isolation of normal donor monocytes and T cells: Primary human T cellsand monocytes were isolated from normal healthy human donors. T cellcells were isolated from PBMC using CD4+CD8+ selection (Miltenyi Biotec)and monocytes were separated using Miltenyi Biotec classical MonocyteIsolation beads according to the manufactures protocol.

T cell culture and gene editing: T cells were subsequently resuspendedat a concentration of 106 cells/mL in Xcyte media supplemented with 50U/mL IL-2 and 10 ng/ml IL-15 in the presence of anti-CD3/CD28 beads(Bead to cell ratio 3:1) (Life Technologies, catalog #111.32D).Twenty-four hours after initial stimulation. Stimulatory beads wereremoved on day 2. 4×10⁶ T cells were electroporated in 100 μl buffer P3with 15 μg spCas9 mRNA (Trilink CA.) and 20 μg of TRAC gRNA (Trilink)using a nucleofector 4D, program EO-115. Control CAR19 T cells wereelectroporated without GM-CSF gRNA. T-cells were subsequently evaluatedat day 6 for GM-CSF expression prior to co-culture assay usingflowcytometry.

Production of monocyte lineage cells: For iDC generation, monocytes(1×10⁶) were plated in 6 mLs of RPMI 1640 supplemented with supplementedwith 0.1 mmol/L MEM Non-Essential Amino Acids, 2 mmol/L L-glutamine, 100units/mL penicillin, 100 μg/mL streptomycin (Life Technologies) and 10%fetal calf serum (cR10). cR10 was subsequently supplemented with 0.2μg/mL human IL-4 (Peptotec) and 0.2 μg/mL GM-CSF (Peptotec). On day 4cytokines and LPS were replenished. iDC were harvested using 2 mmol/LEDTA (immature dendritic cells) on day 6 post-isolation.

Co-culture assay: T cells were combined at the following ratios in 200ul per 96 well: 12.5K T cells (with or with-out GM-CSF KO), 50Kanti-CD3/CD28 beads and 1K iDC Co-cultures were subsequently incubatedfor at 37° C. and 100 ul of assay supernatant was collected at 24 hr and48 hr for cytokine analysis.

Measurement of cytokine levels: Cytokine concentration determinationfrom culture supernatants was performed using IL-6 ELISA plate (R&Dsystems). Prior to analysis supernatants were centrifuged at 300×g for10 mins at 4° C. and subsequently diluted 1:10 in assay calibratordiluent. Measurements were performed using standard product protocols.

Deletion of GM-CSF reduced IL-6 production >3-fold at 24 hrs (FIGS. 7and 8) and >4-fold at 48 hrs (FIGS. 9 and 10) relative to non-edited Tcells.

GM-CSF deficient T cells induced significantly lower IL-6 expressionacross the different monocyte lineages.

Example 19 Method for Making and Testing a Genome-Edited CAR-T CellDeficient at Inducing CRS by Insertion of Selectable Marker into GeneEdited Locus

Inject primary B-ALL (2×10⁶) in NSG mice if performing an in vivo CRSexperiment. This should be completed 3 weeks prior to infusion of CAR-Tinto mice.

The following steps may be taken to provide a genome-edited,CRS-resistant, CAR-T cells. This example describes the making of aCD19CARTΔGMCSFΔCD3ε mutant IL-7R T cell, in which the deletion of GM-CSFmitigates risk of CRS, deletion of CD3e prevent TCR signaling and GvHDand the mutant IL-7R enhances proliferation of the CAR-T sufficiently toinduce CRS in this model. Sequences encoding a mutant, constitutivelyactive IL-7R sequence can be found in Table 19, or found in the art. Asthose of skill in the art will recognize, certain of the steps may beconducted sequentially or out of the order listed below, though perhapsleading to different efficiency.

Step 1: T Cell Activation (Day 0)

Purify T cells from a leukapheresis chamber using a Miltenyi human PanTisolation kit. Resuspend in media. Count cells. Determine the number ofhuman T cell activation CD3/CD28 beads required to obtain a 3:1bead:cell ratio. Wash beads 2× with T cell media. Dilute cells at 1.256cells/mL in hXcyte media. Add human T cell activation CD3/CD28 beads.Aliquot 4 mL/well of 1.256 cell/mL solution into a 6 well plate.Incubate cells at 37° C.

Step 2: T Cell Transduction (Day 1)

CAR-T cells may then be transduced with one or more CARs targeted to(i.e., that recognizes) one or more targets, for example with alentivirus containing a CAR construct. Any other suitable method oftransduction may be used.

Step 3: CRISPR (Day 2)

In a CRS-resistant CAR-T cell, cytokine/chemokine/transcription factorgenes or transcription factors may be deleted to prevent secretion offactors that induce secretion of cytokines from myeloid cells. Deletionmay be accomplished by electroporating with Cas9 mRNA and gRNA againstthe target(s). Other techniques, however, could be used to suppressexpression of the target. These include other genome editing techniquessuch as TALENs, RNA interference, and eliciting of internal binding ofthe antigen to prevent cell surface expression. Examples of gRNAs thatmay be used include those shown in Tables 8-10, and others known in theart.

Nuecleofection Sample ID gRNA#1 gRNA#2 Cas9 Buffer P3 UCART19 20 μg 20μg 15 μg Cas9 100 μl gGM-CSF gCD3ε mRNA

Cells are harvested, isolated, and purified, for example using magneticselection with a labelled antibody-coated magnetic beads that bind to acell-specific protein (available from, e.g., Miltenyi Biotec). For Tcells, anti-CD3/CD28 beads could be used. Other purification techniquesare known in the art and could be used.

TABLE 19 Sequences for Constitutively Expressing IL-7R Truc- Truc- CD28Trunc- ated  ated  CD8a CD19 CD19 CD8a CD28 Co- ated IL-7R IL-7 IL-7RLeader V_(L) Linker  V_(H) Hinge tm stim CD3z 2a CD34 ECD TMD ICDDescription MALP DIQM GGGG EVKL TTTPA FWVL RSKR RVKF GSGA MPRG YREGLLTCP KKRI IL7R VTAL TQTTS S₄ QESG PRPPT VVVG SRLL SRSA TNFSL WTAL ANDFTISILS KPIV with L5 LLPLA SLSAS (SEQ PGLV PAPTI GVLA HSDY DAPA LKQACLLSL VVTF FFSVA WPSL and L6 LLLH LGDR ID NO: APSQS ASQP CYSL MNMT YKQGGDVE LPSGF NTSH LLVIL PDHK elbows AARP VTISC 9) LSVT LSLRP LVTV PRRPQNQL ENPG MSLD LQKK ACVL KTLE with (SEQ RASQ CTVS EACR AFIIF GPTR YNELP (SEQ NNGT YVKV W HLCK CPT ID DISKY GVSL PAAG WV KHYQ NLGR ID NO: ATPELLMHD (SEQ KPRK trans- NO: 1) LNWY PDYG GAVH (SEQ PYAPP REEY 3031) PTQGVAYR ID NLNV membrane QQKP VSWI TRGL ID NO: RDFA DVLD TFSN QEKD NO:SFNPE T- DGTV RQPP DFAC 3036) AYRS KRRG VSTN ENKW 3045) SFLDC ALL KLLIYRKGL D (SEQ RDPE VSYQ THVN QIHR mutation HTSR EWLG (SEQ ID NO: MGGKETTTP LSSTK VDDI insertion LHSG VIWG ID NO: 3037) PRRK STLGS LTLL QARDonly VPSRF SETTY 3035) NPQE TSLHP QRKL EVEG SGSGS YNSA GLYN VSQH QPAAFLQD GTDY LKSR ELQK GNEA MYEI TFPQ SLTIS LTIIK DKMA TTNIT KVRSI QLEESNLEQ DNSK EAYS ETTV PDHY EKQR EDIAT SQVF EIGM KFTST FKGF LGGD YFCQ LKMNKGER SVITS WSEW VQSP QGNT SLQT RRGK VYGN SPSYY NCPSE LPYTF DDTAI GHDGTNSS FRTPE DVVIT GGGT YYCA LYQG VQSQ INNSS PESFG KLEIT KHYY LSTAT TSVISGEMD RDSSL RADA YGGS KDTY TVFTT PI TCLA APTV YAMD DALH PANV (SEQ GNVSSIFPPS YWGQ MQAL STPET ID ACDA SN GTSV PPR TLKPS NO: PILSS (SEQ TVSS(SEQ LSPG 3040) SRSLD ID (SEQ ID NO: NVSD CRES NO: ID 3038) LSTTS GKNG3033) NO: TSLAT PHVY 3034) SPTKP QDLL YTSSS LSLGT PILSDI TNSTL KAEIKPPPFS CSGIR LQSGI EVKL LTLNP TQGIC VAQG LEQN QPILT KTSSC SLGS AEFK NQEEKDRG AYVT EGLA MSSF RVLC YQNQ GEEQ (SEQ ADAD ID AGAQ NO: VCSL 3047) LLAQSEVRP QCLL LVLA NRTEI SSKL QLMK KHQS DLKK LG (SEQ ID NO: 3039) MALP DIQMGGGG EVKL TTTPA FWVL RSKR RVKF GSGA MPRG YREG LLTCP KKRI IL7R VTAL TQTTSS₄ QESG PRPPT VVVG SRLL SRSA TNFSL WTAL ANDF TISILS KPIV with L5 LLPLASLSAS (SEQ PGLV PAPTI GVLA HSDY DAPA LKQA CLLSL VVTF FFSVA WPSL and L6LLLH LGDR ID NO: APSQS ASQP CYSL MNMT YKQG GDVE LPSGF NTSH LLVIL PDHKelbows AARP VTISC 9) LSVT LSLRP LVTV PRRP QNQL ENPG MSLD LQKK ACVL KTLEwith (SEQ RASQ CTVS EACR AFIIF GPTR YNEL P (SEQ NNGT YVKV W HLCK CPT IDDISKY GVSL PAAG WV KHYQ NLGR ID NO: ATPEL LMHD (SEQ KPRK trans- NO: 1)LNWY PDYG GAVH (SEQ PYAPP REEY 3031) PTQG VAYR ID NLNV membrane QQKPVSWI TRGL ID NO: RDFA DVLD TFSN QEKD NO: SFNPE T- DGTV RQPP DFAC 3036)AYRS KRRG VSTN ENKW 3045) SFLDC ALL KLLIY RKGL D (SEQ RDPE VSYQ THVNQIHR mutation HTSR EWLG (SEQ ID NO: MGGK ETTTP LSCT VDDI insertion LHSGVIWG ID NO: 3037) PRRK STLGS KLTL QARD and S185C VPSRF SETTY 3035) NPQETSLHP LQRK EVEG B-ALL SGSGS YNSA GLYN VSQH LQPA FLQD mutation GTDY LKSRELQK GNEA AMYE TFPQ SLTIS LTIIK DKMA TTNIT IKVRS QLEES NLEQ DNSK EAYSETTV IPDHY EKQR EDIAT SQVF EIGM KFTST FKGF LGGD YFCQ LKMN KGER SVITSWSEW VQSP QGNT SLQT RRGK VYGN SPSYY NCPSE LPYTF DDTAI GHDG TNSS FRTPEDVVIT GGGT YYCA LYQG VQSQ INNSS PESFG KLEIT KHYY LSTAT TSVIS GEMD RDSSLRADA YGGS KDTY TVFTT PI TCLA APTV YAMD DALH PANV (SEQ GNVS SIFPPS YWGQMQAL STPET ID ACDA SN GTSV PPR TLKPS NO: PILSS (SEQ TVSS (SEQ LSPG 3041)SRSLD ID (SEQ ID NO: NVSD CRES NO: ID 3038) LSTTS GKNG 3033) NO: TSLATPHVY 3034) SPTKP QDLL YTSSS LSLGT PILSDI TNSTL KAEIK PPPFS CSGIR LQSGIEVKL LTLNP TQGIC VAQG LEQN QPILT KTSSC SLGS AEFK NQEE KDRG AYVT EGLAMSSF RVLC YQNQ GEEQ (SEQ ADAD ID AGAQ NO: VCSL 3047) LLAQ SEVRP QCLLLVLA NRTEI SSKL QLMK KHQS DLKK LG (SEQ ID NO: 3039) MALP DIQM GGGG EVKLTTTPA FWVL RSKR RVKF GSGA MPRG YREG LLTISI KKRI IL7R VTAL TQTTS S₄ QESGPRPPT VVVG SRLL SRSA TNFSL WTAL ANDF LSFFS KPIV with L5 LLPLA SLSAS (SEQPGLV PAPTI GVLA HSDY DAPA LKQA CLLSL VVTF VALL WPSL and L6 LLLH LGDRID NO: APSQS ASQP CYSL MNMT YKQG GDVE LPSGF NTSH VILAC PDHK elbows AARPVTISC 9) LSVT LSLRP LVTV PRRP QNQL ENPG MSLD LQKK VLW KTLE with (SEQRASQ CTVS EACR AFIIF GPTR YNEL P (SEQ NNGT YVKV (SEQ HLCK S185C ID DISKYGVSL PAAG WV KHYQ NLGR ID NO: ATPEL LMHD ID KPRK B-ALL NO: 1) LNWY PDYGGAVH (SEQ PYAPP REEY 3031) PTQG VAYR NO: NLNV mutation QQKP VSWI TRGLID NO: RDFA DVLD TFSN QEKD 3046) SFNPE only DGTV RQPP DFAC 3036) AYRSKRRG VSTN ENKW SFLDC KLLIY RKGL D (SEQ RDPE VSYQ THVN QIHR HTSR EWLG(SEQ ID NO: MGGK ETTTP LSCT VDDI LHSG VIWG ID NO: 3037) PRRK STLGS KLTLQARD VPSRF SETTY 3035) NPQE TSLHP LQRK EVEG SGSGS YNSA GLYN VSQH LQPAFLQD GTDY LKSR ELQK GNEA AMYE TFPQ SLTIS LTIIK DKMA TTNIT IKVRS QLEESNLEQ DNSK EAYS ETTV IPDHY EKQR EDIAT SQVF EIGM KFTST FKGF LGGD YFCQ LKMNKGER SVITS WSEW VQSP QGNT SLQT RRGK VYGN SPSYY NCPSE LPYTF DDTAI GHDGTNSS FRTPE DVVIT GGGT YYCA LYQG VQSQ INNSS PESFG KLEIT KHYY LSTAT TSVISGEMD RDSSL RADA YGGS KDTY TVFTT PI TCLA APTV YAMD DALH PANV (SEQ GNVSSIFPPS YWGQ MQAL STPET ID ACDA SN GTSV PPR TLKPS NO: PILSS (SEQ TVSS(SEQ LSPG 3041) SRSLD ID (SEQ ID NO: NVSD CRES NO: ID 3038) LSTTS GKNG3033) NO: TSLAT PHVY 3034) SPTKP QDLL YTSSS LSLGT PILSDI TNSTL KAEIKPPPFS CSGIR LQSGI EVKL LTLNP TQGIC VAQG LEQN QPILT KTSSC SLGS AEFK NQEEKDRG AYVT EGLA MSSF RVLC YQNQ GEEQ (SEQ ADAD ID AGAQ NO: VCSL 3047) LLAQSEVRP QCLL LVLA NRTEI SSKL QLMK KHQS DLKK LG (SEQ ID NO: 3039) MALP DIQMGGGG EVKL TTTPA FWVL RSKR RVKF GSGA MPRG YREG LLTISI KKRI IL7R VTALTQTTS S₄ QESG PRPPT VVVG SRLL SRSA TNFSL WTAL ANDF LSFFS KPIV with L5LLPLA SLSAS (SEQ PGLV PAPTI GVLA HSDY DAPA LKQA CLLSL VVTF VALL WPSLand L6 LLLH LGDR ID NO: APSQS ASQP CYSL MNMT YKQG GDVE LPSGF NTSH VILACPDHK elbows AARP VTISC 9) LSVT LSLRP LVTV PRRP QNQL ENPG MSLD LQKK VLWKTLE WT (SEQ RASQ CTVS EACR AFIIF GPTR YNEL P (SEQ NNGT YVKV (SEQ HLCKID DISKY GVSL PAAG WV KHYQ NLGR ID NO: ATPEL LMHD ID KPRK NO: 1) LNWYPDYG GAVH (SEQ PYAPP REEY 3031) PTQG VAYR NO: NLNV QQKP VSWI TRGL ID NO:RDFA DVLD TFSN QEKD 3046) SFNPE DGTV RQPP DFAC 3036) AYRS KRRG VSTN ENKWSFLDC KLLIY RKGL D (SEQ RDPE VSYQ THVN QIHR HTSR EWLG (SEQ ID NO: MGGKETTTP LSSTK VDDI LHSG VIWG ID NO: 3037) PRRK STLGS LTLL QARD VPSRF SETTY3035) NPQE TSLHP QRKL EVEG SGSGS YNSA GLYN VSQH QPAA FLQD GTDY LKSR ELQKGNEA MYEI TFPQ SLTIS LTIIK DKMA TTNIT KVRSI QLEES NLEQ DNSK EAYS ETTVPDHY EKQR EDIAT SQVF EIGM KFTST FKGF LGGD YFCQ LKMN KGER SVITS WSEW VQSPQGNT SLQT RRGK VYGN SPSYY NCPSE LPYTF DDTAI GHDG TNSS FRTPE DVVIT GGGTYYCA LYQG VQSQ INNSS PESFG KLEIT KHYY LSTAT TSVIS GEMD RDSSL RADA YGGSKDTY TVFTT PI TCLA APTV YAMD DALH PANV (SEQ GNVS SIFPPS YWGQ MQAL STPETID ACDA SN GTSV PPR TLKPS NO: PILSS (SEQ TVSS (SEQ LSPG 3040) SRSLD ID(SEQ ID NO: NVSD CRES NO: ID 3038) LSTTS GKNG 3033) NO: TSLAT PHVY 3034)SPTKP QDLL YTSSS LSLGT PILSDI TNSTL KAEIK PPPFS CSGIR LQSGI EVKL LTLNPTQGIC VAQG LEQN QPILT KTSSC SLGS AEFK NQEE KDRG AYVT EGLA MSSF RVLC YQNQGEEQ (SEQ ADAD ID AGAQ NO: VCSL 3047) LLAQ SEVRP QCLL LVLA NRTEI SSKLQLMK KHQS DLKK LG (SEQ ID NO: 3039) MALP DIQM GGGG EVKL TTTPA FWVL RSKRRVKF GSGA MPRG VNLS LLTCP KKRI IL7R VTAL TQTTS S₄ QESG PRPPT VVVG SRLLSRSA TNFSL WTAL STKLT TISILS KPIV with L6 LLPLA SLSAS (SEQ PGLV PAPTIGVLA HSDY DAPA LKQA CLLSL LLQR FFSVA WPSL elbow LLLH LGDR ID NO: APSQSASQP CYSL MNMT YKQG GDVE LPSGF KLQP LLVIL PDHK only AARP VTISC 9) LSVTLSLRP LVTV PRRP QNQL ENPG MSLD AAMY ACVL KTLE with (SEQ RASQ CTVS EACRAFIIF GPTR YNEL P (SEQ NNGT EIKVR W HLCK CPT ID DISKY GVSL PAAG WV KHYQNLGR ID NO: ATPEL SIPDH (SEQ KPRK trans- NO: 1) LNWY PDYG GAVH (SEQPYAPP REEY 3031) PTQG YFKG ID NLNV membrane QQKP VSWI TRGL ID NO: RDFADVLD TFSN FWSE NO: SFNPE T- DGTV RQPP DFAC 3036) AYRS KRRG VSTN WSPS3045) SFLDC ALL KLLIY RKGL D (SEQ RDPE VSYQ YYFR QIHR mutation HTSR EWLG(SEQ ID NO: MGGK ETTTP TPEIN VDDI insertion LHSG VIWG ID NO: 3037) PRRKSTLGS NSSG QARD only VPSRF SETTY 3035) NPQE TSLHP EMDPI EVEG SGSGS YNSAGLYN VSQH (SEQ FLQD GTDY LKSR ELQK GNEA ID TFPQ SLTIS LTIIK DKMA TTNITNO: QLEES NLEQ DNSK EAYS ETTV 3042) EKQR EDIAT SQVF EIGM KFTST LGGD YFCQLKMN KGER SVITS VQSP QGNT SLQT RRGK VYGN NCPSE LPYTF DDTAI GHDG TNSSDVVIT GGGT YYCA LYQG VQSQ PESFG KLEIT KHYY LSTAT TSVIS RDSSL RADA YGGSKDTY TVFTT TCLA APTV YAMD DALH PANV GNVS SIFPPS YWGQ MQAL STPET ACDA SNGTSV PPR TLKPS PILSS (SEQ TVSS (SEQ LSPG SRSLD ID (SEQ ID NO: NVSD CRESNO: ID 3038) LSTTS GKNG 3033) NO: TSLAT PHVY 3034) SPTKP QDLL YTSSSLSLGT PILSDI TNSTL KAEIK PPPFS CSGIR LQSGI EVKL LTLNP TQGIC VAQG LEQNQPILT KTSSC SLGS AEFK NQEE KDRG AYVT EGLA MSSF RVLC YQNQ GEEQ (SEQ ADADID AGAQ NO: VCSL 3047) LLAQ SEVRP QCLL LVLA NRTEI SSKL QLMK KHQS DLKK LG(SEQ ID NO: 3039) MALP DIQM GGGG EVKL TTTPA FWVL RSKR RVKF GSGA MPRGVNLS LLTCP KKRI IL7R VTAL TQTTS S₄ QESG PRPPT VVVG SRLL SRSA TNFSL WTALCTKL TISILS KPIV with L6 LLPLA SLSAS (SEQ PGLV PAPTI GVLA HSDY DAPA LKQACLLSL TLLQ FFSVA WPSL elbows LLLH LGDR ID NO: APSQS ASQP CYSL MNMT YKQGGDVE LPSGF RKLQ LLVIL PDHK with AARP VTISC 9) LSVT LSLRP LVTV PRRP QNQLENPG MSLD PAAM ACVL KTLE CPT (SEQ RASQ CTVS EACR AFIIF GPTR YNEL P (SEQNNGT YEIKV W HLCK trans- ID DISKY GVSL PAAG WV KHYQ NLGR ID NO: ATPELRSIPD (SEQ KPRK membrane NO: 1) LNWY PDYG GAVH (SEQ PYAPP REEY 3031)PTQG HYFK ID NLNV T- QQKP VSWI TRGL ID NO: RDFA DVLD TFSN GFWS NO: SFNPEALL DGTV RQPP DFAC 3036) AYRS KRRG VSTN EWSP 3045) SFLDC mutation KLLIYRKGL D (SEQ RDPE VSYQ SYYF QIHR insertion HTSR EWLG (SEQ ID NO: MGGKETTTP RTPEI VDDI and S185C LHSG VIWG ID NO: 3037) PRRK STLGS NNSS QARDB-ALL VPSRF SETTY 3035) NPQE TSLHP GEMD EVEG mutation SGSGS YNSA GLYNVSQH PI FLQD GTDY LKSR ELQK GNEA (SEQ TFPQ SLTIS LTIIK DKMA TTNIT IDQLEES NLEQ DNSK EAYS ETTV NO: EKQR EDIAT SQVF EIGM KFTST 3043) LGGD YFCQLKMN KGER SVITS VQSP QGNT SLQT RRGK VYGN NCPSE LPYTF DDTAI GHDG TNSSDVVIT GGGT YYCA LYQG VQSQ PESFG KLEIT KHYY LSTAT TSVIS RDSSL RADA YGGSKDTY TVFTT TCLA APTV YAMD DALH PANV GNVS SIFPPS YWGQ MQAL STPET ACDA SNGTSV PPR TLKPS PILSS (SEQ TVSS (SEQ LSPG SRSLD ID (SEQ ID NO: NVSD CRESNO: ID 3038) LSTTS GKNG 3033) NO: TSLAT PHVY 3034) SPTKP QDLL YTSSSLSLGT PILSDI TNSTL KAEIK PPPFS CSGIR LQSGI EVKL LTLNP TQGIC VAQG LEQNQPILT KTSSC SLGS AEFK NQEE KDRG AYVT EGLA MSSF RVLC YQNQ GEEQ (SEQ ADADID AGAQ NO: VCSL 3047) LLAQ SEVRP QCLL LVLA NRTEI SSKL QLMK KHQS DLKK LG(SEQ ID NO: 3039) MALP DIQM GGGG EVKL TTTPA FWVL RSKR RVKF GSGA MPRGVNLS LLTISI KKRI IL7R VTAL TQTTS S₄ QESG PRPPT VVVG SRLL SRSA TNFSL WTALCTKL LSFFS KPIV with L6 LLPLA SLSAS (SEQ PGLV PAPTI GVLA HSDY DAPA LKQACLLSL TLLQ VALL WPSL elbows LLLH LGDR ID NO: APSQS ASQP CYSL MNMT YKQGGDVE LPSGF RKLQ VILAC PDHK with AARP VTISC 9) LSVT LSLRP LVTV PRRP QNQLENPG MSLD PAAM VLW KTLE S185C (SEQ RASQ CTVS EACR AFIIF GPTR YNEL P (SEQNNGT YEIKV (SEQ HLCK B-ALL ID DISKY GVSL PAAG WV KHYQ NLGR ID NO: ATPELRSIPD ID KPRK mutation NO: 1) LNWY PDYG GAVH (SEQ PYAPP REEY 3031) PTQGHYFK NO: NLNV only QQKP VSWI TRGL ID NO: RDFA DVLD TFSN GFWS 3046) SFNPEDGTV RQPP DFAC 3036) AYRS KRRG VSTN EWSP SFLDC KLLIY RKGL D (SEQ RDPEVSYQ SYYF QIHR HTSR EWLG (SEQ ID NO: MGGK ETTTP RTPEI VDDI LHSG VIWGID NO: 3037) PRRK STLGS NNSS QARD VPSRF SETTY 3035) NPQE TSLHP GEMD EVEGSGSGS YNSA GLYN VSQH PI FLQD GTDY LKSR ELQK GNEA (SEQ TFPQ SLTIS LTIIKDKMA TTNIT ID QLEES NLEQ DNSK EAYS ETTV NO: EKQR EDIAT SQVF EIGM KFTST3043) LGGD YFCQ LKMN KGER SVITS VQSP QGNT SLQT RRGK VYGN NCPSE LPYTFDDTAI GHDG TNSS DVVIT GGGT YYCA LYQG VQSQ PESFG KLEIT KHYY LSTAT TSVISRDSSL RADA YGGS KDTY TVFTT TCLA APTV YAMD DALH PANV GNVS SIFPPS YWGQMQAL STPET ACDA SN GTSV PPR TLKPS PILSS (SEQ TVSS (SEQ LSPG SRSLD ID(SEQ ID NO: NVSD CRES NO: ID 3038) LSTTS GKNG 3033) NO: TSLAT PHVY 3034)SPTKP QDLL YTSSS LSLGT PILSDI TNSTL KAEIK PPPFS CSGIR LQSGI EVKL LTLNPTQGIC VAQG LEQN QPILT KTSSC SLGS AEFK NQEE KDRG AYVT EGLA MSSF RVLC YQNQGEEQ (SEQ ADAD ID AGAQ NO: VCSL 3047) LLAQ SEVRP QCLL LVLA NRTEI SSKLQLMK KHQS DLKK LG (SEQ ID NO: 3039) MALP DIQM GGGG EVKL TTTPA FWVL RSKRRVKF GSGA MPRG VNLS LLTISI KKRI IL7R VTAL TQTTS S₄ QESG PRPPT VVVG SRLLSRSA TNFSL WTAL STKLT LSFFS KPIV with L6 LLPLA SLSAS (SEQ PGLV PAPTIGVLA HSDY DAPA LKQA CLLSL LLQR VALL WPSL elbows LLLH LGDR ID NO: APSQSASQP CYSL MNMT YKQG GDVE LPSGF KLQP VILAC PDHK WT AARP VTISC 9) LSVTLSLRP LVTV PRRP QNQL ENPG MSLD AAMY VLW KTLE (SEQ RASQ CTVS EACR AFIIFGPTR YNEL P (SEQ NNGT EIKVR (SEQ HLCK ID DISKY GVSL PAAG WV KHYQ NLGRID NO: ATPEL SIPDH ID KPRK NO: 1) LNWY PDYG GAVH (SEQ PYAPP REEY 3031)PTQG YFKG NO: NLNV QQKP VSWI TRGL ID NO: RDFA DVLD TFSN FWSE 3046) SFNPEDGTV RQPP DFAC 3036) AYRS KRRG VSTN WSPS SFLDC KLLIY RKGL D (SEQ RDPEVSYQ YYFR QIHR HTSR EWLG (SEQ ID NO: MGGK ETTTP TPEIN VDDI LHSG VIWGID NO: 3037) PRRK STLGS NSSG QARD VPSRF SETTY 3035) NPQE TSLHP EMDPIEVEG SGSGS YNSA GLYN VSQH (SEQ FLQD GTDY LKSR ELQK GNEA ID TFPQ SLTISLTIIK DKMA TTNIT NO: QLEES NLEQ DNSK EAYS ETTV 3042) EKQR EDIAT SQVFEIGM KFTST LGGD YFCQ LKMN KGER SVITS VQSP QGNT SLQT RRGK VYGN NCPSELPYTF DDTAI GHDG TNSS DVVIT GGGT YYCA LYQG VQSQ PESFG KLEIT KHYY LSTATTSVIS RDSSL RADA YGGS KDTY TVFTT TCLA APTV YAMD DALH PANV GNVS SIFPPSYWGQ MQAL STPET ACDA SN GTSV PPR TLKPS PILSS (SEQ TVSS (SEQ LSPG SRSLDID (SEQ ID NO: NVSD CRES NO: ID 3038) LSTTS GKNG 3033) NO: TSLAT PHVY3034) SPTKP QDLL YTSSS LSLGT PILSDI TNSTL KAEIK PPPFS CSGIR LQSGI EVKLLTLNP TQGIC VAQG LEQN QPILT KTSSC SLGS AEFK NQEE KDRG AYVT EGLA MSSFRVLC YQNQ GEEQ (SEQ ADAD ID AGAQ NO: VCSL 3047) LLAQ SEVRP QCLL LVLANRTEI SSKL QLMK KHQS DLKK LG (SEQ ID NO: 3039) MALP DIQM GGGG EVKL TTTPAFWVL RSKR RVKF GSGA MPRG PEINN LLTCP KKRI IL-7R VTAL TQTTS S₄ QESG PRPPTVVVG SRLL SRSA TNFSL WTAL SSGE TISILS KPIV with LLPLA SLSAS (SEQ PGLVPAPTI GVLA HSDY DAPA LKQA CLLSL MDPI FFSVA WPSL CPT T LLLH LGDR ID NO:APSQS ASQP CYSL MNMT YKQG GDVE LPSGF (SEQ LLVIL PDHK ALL AARP VTISC 9)LSVT LSLRP LVTV PRRP QNQL ENPG MSLD ID ACVL KTLE mutation (SEQ RASQ CTVSEACR AFIIF GPTR YNEL P (SEQ NNGT NO: W HLCK Lacking ID DISKY GVSL PAAGWV KHYQ NLGR ID NO: ATPEL 3044) (SEQ KPRK elbows NO: 1) LNWY PDYG GAVH(SEQ PYAPP REEY 3031) PTQG ID NLNV and QQKP VSWI TRGL ID NO: RDFA DVLDTFSN NO: SFNPE WSEW DGTV RQPP DFAC 3036) AYRS KRRG VSTN 3045) SFLDCS (SEQ KLLIY RKGL D (SEQ RDPE VSYQ QIHR ID NO: HTSR EWLG (SEQ ID NO:MGGK ETTTP VDDI 3070) LHSG VIWG ID NO: 3037) PRRK STLGS QARD motif VPSRFSETTY 3035) NPQE TSLHP EVEG (sugar SGSGS YNSA GLYN VSQH FLQD bridge)GTDY LKSR ELQK GNEA TFPQ SLTIS LTIIK DKMA TTNIT QLEES NLEQ DNSK EAYSETTV EKQR EDIAT SQVF EIGM KFTST LGGD YFCQ LKMN KGER SVITS VQSP QGNT SLQTRRGK VYGN NCPSE LPYTF DDTAI GHDG TNSS DVVIT GGGT YYCA LYQG VQSQ PESFGKLEIT KHYY LSTAT TSVIS RDSSL RADA YGGS KDTY TVFTT TCLA APTV YAMD DALHPANV GNVS SIFPPS YWGQ MQAL STPET ACDA SN GTSV PPR TLKPS PILSS (SEQ TVSS(SEQ LSPG SRSLD ID (SEQ ID NO: NVSD CRES NO: ID 3038) LSTTS GKNG 3033)NO: TSLAT PHVY 3034) SPTKP QDLL YTSSS LSLGT PILSDI TNSTL KAEIK PPPFSCSGIR LQSGI EVKL LTLNP TQGIC VAQG LEQN QPILT KTSSC SLGS AEFK NQEE KDRGAYVT EGLA MSSF RVLC YQNQ GEEQ (SEQ ADAD ID AGAQ NO: VCSL 3047) LLAQSEVRP QCLL LVLA NRTEI SSKL QLMK KHQS DLKK LG (SEQ ID NO: 3039)

Protocol—Nucleofection Using Nucleofector 4D:

Perform nucleofection protocol as described above (Example 6), using 20μg of each gRNA (gGM-CSF and gCD3ε) to each tube of 15 μg Cas9 mRNA.

Step 4: Assessment of CRISPR Activity and Td Efficiency (Day 10)

Take 5×10⁵ cells from each sample and analyze by flow cytometry. Washsamples with RB. Add 5 μl of CD3 APC and 2 μl of anti-FAB BV421 (detectsCAR transduction). Wash. Perform Flow cytometry. Cells should beCD3ε-negative, CD34-positive and FAB+. Harvest T cells (Day 11).

Purification of CAR-T cells. TCR negative cells can be purified usingTCRa/b negative selection to remove TCR positive cells.

Step 5: Assessment of CAR-T Activity In Vivo

Inject 5×10⁶ CAR-T per mouse I.V. Assess serum cytokine levels (Day +1,+2, +3 +4, +5, +10, +15). Measure serum cytokine levels using Luminexmultiplex cytokine profiling assay to check for elevations in CRSrelated cytokines. Perform a 4-hr chromium release assay against targetscells (Raji) to assess in vitro activity (Day 11). Monitor efficacy oftumor clearance using flow cytometry of blood to detect hCD45, CD19+cells.

A modified gRNA protocol for T cell CRISPR and CAR-T transduction ofUCART19 is provided below.

Day 0—T Cell Activation:

Purify T cells from a leukapheresis chamber using a Miltenyi human PanTisolation kit. Resuspend in media. Count cells. Determine the number ofhuman T cell activation CD3/CD28 beads required to obtain a 3:1bead:cell ratio. Wash beads 2× with T cell media. Dilute cells at 1.256cells/mL in hXcyte media. Add human T cell activation CD3/CD28 beads

T cells may then be transduced with one or more CARs targeted to (i.e.,that recognizes) one or more targets, for example with a lentiviruscontaining a CAR construct. Any other suitable method of transductionmay be used.

Day 2: 4×10⁶ cells per reaction are used. EO-115—100 μl transfectionvolume is programmed, and the entire supplement added to theNucleofector™ Solution P3. Cell culture plates are prepared by fillingappropriate number of wells with desired volume of recommended culturemedia (2 ml in 6 well plate) and pre-incubating/equilibrating plates ina humidified 37° C./5% CO₂ incubator. Beads are magnetically removed(twice to ensure complete removal), then cells counted and cell densitydetermined. The required number of cells are centrifuged at 90×g for 10minutes at room temperature, the supernatant removed completely. Cellsare then resuspended in PBS (1 ml) and transferred to a microcentrifugetube, and the required number of cells centrifuged at 90×g for 10minutes at room temperature. The supernatant is removed completely, andthe cell pellet resuspended carefully in complete room temperature 4DNucleofector™ Solution P3, 4×10⁶ per 100 μl). Twenty μg of gRNA (gGM-CSFand gTRAC) are added to each tube of 15 μg Cas9 mRNA. Then 100 μl ofcells is added to each tube of Cas9/gRNA, gently mixed and everythingtransferred into the Nucleocuvette™. The cuvette is gently tapped toremove bubbles. Electroporation is carried out using program (Human Tcell stim EO-115). After run completion, the NucleocuvetteTM iscarefully removed from the vessel from the retainer using a specializedtool. Cells are resuspended with pre-warmed medium. The media is thentaken up from destination well, added to cuvette, and gently pipetted upand down two to three times. This is then transferred to well. Thisprocedure is repeated with media from same well and incubated at 37° C.

Day 5: Assessment of CRISPR activity and Td efficiency. Samples of cellsmay then be assessed for transduction efficiency by taking a 5×10⁵ cellsfrom each sample and analyzing by flow cytometry. Samples are fixpermeablised and anlaysed by FACS for CD3, CD34 and intracellularGM-CSF.

Assessment of Genetic Deletion.

To assess genetic deletion of GM-CSF and TRAC, 5×10⁵ cells are harvestedfrom each sample and their DNA extracted. Gene editing efficiency isassessed using target sequencing of the target loci using TIDE-analysisor deep sequencing.

Day 11

Bleed mice and measure tumor burden.

CD3 deplete T cells and inject into mice.

Inject mice with 5×10⁶ CAR+ T cells/mouse.

Mouse groups are provided in Table 20 below:

Mice are then bled on days 0, 1, 2, 3, 5, 7, 14, and 21 for FACS andplasma measurements, weighed, and body temperature is determined.

The panel for detecting specific markers of the CAR-T cells is asfollows:

TABLE 20 Sample Gene T cell ID editing Tumor source CAR-T CAR-T A — 2 ×10⁶/mouse — — B TRAC 2 × 10⁶/mouse PanT CAR19 + 5 × 10⁶/ CD34 mouse CTRAC + 2 × 10⁶/mouse PanT CAR19 CD34 5 × 10⁶/ GM-CSF mouse D TRAC 2 ×10⁶/mouse PanT CAR19 + 5 × 10⁶/ IL7r + CD34 mouse E TRAC + 2 × 10⁶/mousePanT CAR19 + 5 × 10⁶/ GM-CSF IL7r + CD34 mouse Attune-CAR-T in vivopanel-CRS Titer 50 μl blood Bandpass or 500K Detector (nm) AntigenColour Product # in 100 μl BL1 530/30 BL2 695/40 7aad 7AAd 1 ul RL1670/14 CD19 APC BD555415 2 ul RL2 720/30 RL3 780/60 CD4 APC-H7 BD5601581 ul VL1 450/40 mCD45 BV421 BD 563890 1 ul VL2 525/50 CD8 BV510 BD5632564 ul VL3 610/20 VL4 660/20 CD3 BV650 BD 563852 2 ul VL5 710/50 VL6780/60 hCD45 BV785 BD 563716 1 ul YL1 585/16 CD34 PE BD Pool PE 2 ul YL2620/15 YL3 780/60

Cytokine analysis and assessment of CRS is assed using Millipore luminexmultiplex cytokine analysis.

Sequences for preparation of a vector as described herein include, butare not limited to, the following:

-Left ITR of vector for insertion of CD34 into GM-CSF locusSEQ ID NO: 3048CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCT-Left Homology Arm of vector for insertion of CD34 into GM-CSF locusSEQ ID NO: 3049cctgagatggatgcagccacagccctggagccagcctgaagctcctggtgtcttctgggggctacatataggagtgtagtccgaacctcagaggggcaaacctgctctgcagagggaatcaaggttcacataaccagagaggggagtcactcaggaaggtggctccagagccaagagtcagactctgggtcccgacttgacccagccacaccccctctgaagcttgctgagagtggctgcagtctcgctgctggatgtgcacatggtggtcattccctctgctcacaggggcaggggtcccccottactggactgaggttgccccctgctccaggtcctgggtgggagcccatgtgaactgtcagtggggcaggtctgtgagagctcccctcacactcaagtctctcacagtggccagagaagaggaaggctggagtcagaatgaggcaccagggcgggcatagcctgcccaaaggcccctgggattacaggcaggatggggagccctatctaagtgtctcccacgccccaccccagccattccaggccaggaagtccaaactgtgcccctcagagggagggggcagcctcaggcccattcagactgcccagggagggctggagagccctcaggaaggcgggtgggtgggctgtcggttcttggaaaggttcattaatgaaaacccccaagcctgaccacctagggaaaaggctcaccgttcccatgtgtggctgataagggccaggagattccacagttcaggtagttcccccgcctccctggcattttgtggtcaccattaatcatttcctctgtgtatttaagagctatttgccagtgagcccaGTACACAGAGAGAAAGGCTAAAGTTCTCTGGAGGATGTGGCTGCAGAGCCTGCTGCTCTTGGGCACTGTGGCCTGCAGCATCTCTGCACCCGCCCGCTCGCCCAGCCCCAGCACGCAGCCCTGGGAGCATGTGAATGCCATCCAGGAGGCCC -EFS promotor of vector for insertion of CD34 into GM-CSF locusSEQ ID NO: 3050GGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGATCCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGG-trCD34 of vector for insertion of CD34 into GM-CSF locusSEQ ID NO: 3051atgccgcggggctggaccgcgctttgcttgctgagtttgctgccttctgggttcatgagtcttgacaacaacggtactgctaccccagagttacctacccagggaacattttcaaatgtttctacaaatgtatcctaccaagaaactacaacacctagtaccottggaagtaccagcctgcaccctgtgtctcaacatggcaatgaggccacaacaaacatcacagaaacgacagtcaaattcacatctacctctgtgataacctcagtttatggaaacacaaactatctgtccagtcacagacctctgtaatcagcacagtgttcaccaccccagccaacgtttcaactccagagacaaccttgaagcctagcctgtcacctggaaatgtttcagacctttcaaccactagcactagccttgcaacatctcccactaaaccctatacatcatcttctcctatcctaagtgacatcaaggcagaaatcaaatgttcaggcatcagagaagtgaaattgactcagggcatctgcctggagcaaaataagacctccagctgtgcggagtttaagaaggacaggggagagggcctggcccgagtgctgtgtggggaggagcaggctgatgctgatgctggggcccaggtatgctccctgctccttgcccagtctgaggtgaggcctcagtgtctactgctggtcttggccaacagaacagaaatttccagcaaactccaacttatgaaaaagcaccaatctgacctgaaaaagctggggatcctagatttcactgagcaagatgttgcaagccaccagagctattcccaaaagaccctgattgcactggtcacctcgggagccctgctggctgtcttgggcatcactggctatttcctgatgaatcgccgcagctggagccccatttaa-hGMB Poly A of vector for insertion of CD34 into GM-CSF locusSEQ ID NO: 3052ACGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTTCTGATTTTGTAGGTAACCACGTGCGGACCGA-RHA of vector for insertion of CD34 into GM-CSF locus SEQ ID NO: 3053CGTCTCCTGAACCTGAGTAGAGACACTGCTGCTGAGATGgtaagtgagagaatgtgggcctgtgcctaggccacccagctggcccctgactggccacgcctgtcagcttgataacatgacattttccttttctacagAATGAAACAGTAGAAGTCATCTCAGAAATGTTTGACCTCCAGgtaagatgcttctctctgacatagctttccagaagcccctgccctggggtggaggtggggactccattttagatggcaccacacagggttgtccactttctctccagtcagctggctgcaggaggagggggtagcaactgggtgctcaagaggctgctggccgtgccectatggcagtcacatgagctcctttatcagctgageggccatgggcagacctagcattcaatggccaggagtcaccaggggacaggtggtaaagtgggggtcacttcatgagacaggagctgtgggtttggggcgctcactgtgccccgagaccaagtcctgttgagacagtgctgactacagagaggcacagaggggtttcaggaacaacccttgcccacccagcaggtccaggtgaggccccaccccectctccctgaatgatggggtgagagtcacctccttccctaaggctgggctcctctccaggtgccgctgagggtggcctgggcggggcagtgagaagggcaggttcgtgcctgccatggacagggcagggtctatgactggacccagcctgtgcccctcccaagccctactcctgggggctgggggcagcagcaaaaaggagtggtggagagttcttgtaccactgtgggcacttggccactgctcaccgacgaacgacattttccacagGAGCCGACCTGCCTACAGACCCGCCTGGAGCTGTACAAGCAGGGCCTGCGGGGCAGCCTCACCAAGCTCAAGGGCCCCTTGACCATGATGGCCAGCCACTACAAGCAGCACTGCCCTCCAACCCCGgtgagtgc-Right ITR of vector for insertion of CD34 into GM-CSF locusSEQ ID NO: 51AGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGG-Complete sequence of vector for insertion of CD34 into GM-CSF locusSEQ ID NO: 3054CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTcctgagatggatgcagccacagccctggagccagcctgaagctcctggtgtcttctgggggctacatataggagtgtagtccgaacctcagaggggcaaacctgctctgcagagggaatcaaggttcacataaccagagaggggagtcactcaggaaggtggctccagagccaagagtcagactctgggtcccgacttgacccagccacaccccctctgaagcttgctgagagtggctgcagtctcgctgctggatgtgcacatggtggtcattccctctgctcacaggggcaggggtccccccttactggactgaggttgccccctgctccaggtcctgggtgggagcccatgtgaactgtcagtggggcaggtctgtgagagctcccctcacactcaagtctctcacagtggccagagaagaggaaggctggagtcagaatgaggcaccagggcgggcatagcctgcccaaaggcccctgggattacaggcaggatggggagccctatctaagtgtctcccacgccccaccccagccattccaggccaggaagtccaaactgtgcccctcagagggagggggcagcctcaggcccattcagactgcccagggagggctggagagccctcaggaaggcgggtgggtgggctgtcggttcttggaaaggttcattaatgaaaacccccaagcctgaccacctagggaaaaggctcaccgttcccatgtgtggctgataagggccaggagattccacagttcaggtagttcccccgcctccctggcattttgtggtcaccattaatcatttcctctgtgtatttaagagctcttttgccagtgagcccaGTACACAGAGAGAAAGGCTAAAGTTCTCTGGAGGATGTGGCTGCAGAGCCTGCTGCTCTTGGGCACTGTGGCCTGCAGCATCTCTGCACCCGCCCGCTCGCCCAGCCCCAGCACGCAGCCCTGGGAGCATGTGAATGCCATCCAGGAGGCCCGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGATCCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGatgccgcggggctggaccgcgctttgcttgctgagtttgctgccttctgggttcatgagtcttgacaacaacggtactgctaccccagagttacctacccagggaacattttcaaatgtttctacaaatgtatcctaccaagaaactacaacacctagtacccttggaagtaccagcctgcaccctgtgtctcaacatggcaatgaggccacaacaaacatcacagaaacgacagtcaaattcacatctacctctgtgataacctcagtttatggaaacacaaactcttctgtccagtcacagacctctgtaatcagcacagtgttcaccaccccagccaacgtttcaactccagagacaaccttgaagcctagcctgtcacctggaaatgtttcagacctttcaaccactagcactagccttgcaacatctcccactaaaccctatacatcatcttctcctatcctaagtgacatcaaggcagaaatcaaatgttcaggcatcagagaagtgaaattgactcagggcatctgcctggagcaaaataagacctccagctgtgcggagtttaagaaggacaggggagagggcctggcccgagtgctgtgtggggaggagcaggctgatgctgatgctggggcccaggtatgctccctgctccttgcccagtctgaggtgaggcctcagtgtctactgctggtcttggccaacagaacagaaatttccagcaaactccaacttatgaaaaagcaccaatctgacctgaaaaagctggggatcctagatttcactgagcaagatgttgcaagccaccagagctattcccaaaagaccctgattgcactggtcacctcgggagccctgctggctgtcttgggcatcactggctatttcctgatgaatcgccgcagctggagccccatttaaACGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTTCTGATTTTGTAGGTAACCACGTGCGGACCGACGTCTCCTGAACCTGAGTAGAGACACTGCTGCTGAGATGgtaagtgagagaatgtgggcctgtgcctaggccacccagctggcccctgactggccacgcctgtcagcttgataacatgacattttccttttctacagAATGAAACAGTAGAAGTCATCTCAGAAATGTTTGACCTCCAGgtaagatgatctctctgacatagattccagaagcccctgccctggggtggaggtggggactccattttagatggcaccacacagggttgtccactttctctccagtcagctggctgcaggaggagggggtagcaactgggtgctcaagaggctgctggccgtgcccctatggcagtcacatgagctcctttatcagctgagcggccatgggcagacctagcattcaatggccaggagtcaccaggggacaggtggtaaagtgggggtcacttcatgagacaggagctgtgggtttggggcgctcactgtgccccgagaccaagtcctgttgagacagtgctgactacagagaggcacagaggggtttcaggaacaacccttgcccacccagcaggtccaggtgaggccccacccccctctccctgaatgatggggtgagagtcacctccttccctaaggctgggctcctctccaggtgccgctgagggtggcctgggcggggcagtgagaagggcaggttcgtgcctgccatggacagggcagggtctatgactggacccagcctgtgcccctcccaagccctactcctgggggctgggggcagcagcaaaaaggagtggtggagagttcttgtaccactgtgggcacttggccactgctcaccgacgaacgacattttccacagGAGCCGACCTGCCTACAGACCCGCCTGGAGCTGTACAAGCAGGGCCTGCGGGGCAGCCTCACCAAGCTCAAGGGCCCCTTGACCATGATGGCCAGCCACTACAAGCAGCACTGCCCTCCAACCCCGgtgagtgcAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCG AGCGCGCAGCTGCCTGCAGG-left ITR of donor construct for inserting GFP into CD3ϵ locusSEQ ID NO: 3048CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCT-cloning remnants of donor construct for inserting GFP into CD3ϵ locusSEQ ID NO: 3055 GCGGCCGCATCGATTGaattc-CD3 L homology arm of donor construct for inserting GFP into CD3ϵ locusSEQ ID NO: 3056AGGTAAGTCCACGAATCAGTGATTCAGTGGTGTGGAGAGCTTTATTTCTGAGAAGGCCAGTAGCGCTCCCTTCTGACAAGCAAATCTAAGACCTGGATGACAGATGACTTCCTGCATTTGGTTGGTTCTTTTGTCATTCATATCTATCTGTAATACAGTTCTGGCTAATTTAAGAGGATAAGCTTGAAGACCTCTGGAATTTTTCGGCTTTAGGACTTTAAGGCTTTCTGAGCTTCAGTAGATCTAGATCTAGGAGCTCATGCTGGTATATTCTGAATCCGATGTATCTGAGTTACATCTATGAGCTACTTAATAAATATATCTATGAGCTAAATCTCATAGGCTAAGCATGAACCTCACCTCCAAGACTCGGGGTTCCTAAATGGATGAGACCCTCTTTGGGAAGTCTTGTGGGCAGTGTCTAATTCCACTAGAAAAGTTTTACCTACAATTTAAACTTAAACCATGATATTTTCTTACTGCTGTTTCCTTTTTTCATTTTCAGGTGGTATTACACAGACACGTGAGTTTATTGGTCTTTTATTTATGCCCTGTCTGAGGATGCAGATTGGTGGGTAGATGAGAAGGAACTGATTGAGAGAGATTAACCCCAAGAACTGATATCTTCCCAGCATTGCATTCTCAACTCCATTTTAGAAAGGTTCCAAATAGGGACTTCTGTGGGTTTTTCTTTACATCCATCTTACCCTTCCCAAGTCCCCATGTCCCTGCGTAAACCCTAAAGCCACCTCTCAAAAGGTTCTCTAGTTCCCTTCAAGGTTCTCTAGTTCCCTTCATTCCACATATCTCCTCTTCCACACCCTCTAGCCAGTAGAGCTCCCTTCTGACAAGCAAGTCTAAGATCTAGATGACAGATGACTTCCTGCATTTGGGTGGTTCTTTTGTCACTAATTTGCCTTTTCTAAAATTGTCCTGGTTTCTTCTGCCAATTTCCCTTCTTTCTCCCCAGCATATAAAGTCTCCATCTCTGGAACCACA-CAR7 of donor construct for inserting GFP into CD3ϵ locusSEQ ID NO: 3057atggccttaccagtgaccgccttgctcctgccgctggccttgctgctccacgccgccaggccggatatccagatgacacagactacatcctccctgtctgcctctctgggagacagagtcaccatcagttgcagtgcaagtcagggcattagcaattatttaaactggtatcagcagaaaccagatggaactgttaaactcctgatctattacacatcaagtttacactcaggagtcccatcaaggttcagtggcagtgggtctgggacagattattctctcaccatcagcaacctggaacctgaagatattgccacttattattgtcagcagtatagcaagcttccgtacacgttcggaggggggaccaagctggaaataaaacgtggtggtggtggttctggtggtggtggttctggcggcggcggctccggtggtggtggatccgaggtgcaactggtggagtctgggggaggcttagtgaagcctggggggtccctgaaactctcctgtgcagcctctggactcactttcagtagctatgccatgtcttgggttcgccagactccagagaagaggctggagtgggtcgcatccattagtagtggtggtttcacctactatccagacagtgtgaagggccgattcaccatctccagagataatgccaggaacatcctgtatctgcaaatgagcagtctgaggtctgaggacacggccatgtattactgtgcaagagacgaggtacgggggtacctcgatgtctggggcgcagggaccacggtcaccgtttcccctaggGCTAGCaccacgacgccagcgccgcgaccaccaacaccggcgcccaccatcgcgtcgcagcccctgtccctgcgcccagaggcgtgccggccagcggcggggggcgcagtgcacacgagggggctggacttcgcctgtgatttttgggtgctggtggtggttggtggagtcctggcttgctatagcttgctagtaacagtggcctttattattttctgggtgaggagtaagaggagcaggctcctgcacagtgactacatgaacatgactccccgccgccccgggcccacccgcaagcattaccagccctatgccccaccacgcgacttcgcagcctatcgctccagagtgaagttcagcaggagcgcagacgcccccgcgtacaagcagggccagaaccagctctataacgagctcaatctaggacgaagagaggagtacgatgttttggacaagagacgtggccgggaccctgagatggggggaaagccgagaaggaagaaccctcaggaaggcctgtacaatgaactgcagaaagataagatggcggaggcctacagtgagattgggatgaaaggcgagcgccggaggggcaaggggcacgatggcctttaccagggtctcagtacagccaccaaggacacctacgacgcccttcacatgcaggccctgccccctcgcCGGACCGATggaagcggagctactaacttcagcctgctgaagcaggctggagacgtggaggagaaccctggacctgtttctgaagccatgccgcggggctggaccgcgctttgcttgctgagtttgctgccttctgggttcatgagtatgacaacaacggtactgctaccccagagttacctacccagggaacattttcaaatgtttctacaaatgtatcctaccaagaaactacaacacctagtacccttggaagtaccagcctgcaccctgtgtctcaacatggcaatgaggccacaacaaacatcacagaaacgacagtcaaattcacatctacctctgtgataacctcagtttatggaaacacaaactcttctgtccagtcacagacctctgtaatcagcacagtgttcaccaccccagccaacgtttcaactccagagacaaccttgaagcctagcctgtcacctggaaatgtttcagacctttcaaccactagcactagccttgcaacatctcccactaaaccctatacatcatcttctcctatcctaagtgacatcaaggcagaaatcaaatgttcaggcatcagagaagtgaaattgactcagggcatctgcctggagcaaaataagacctccagctgtgcggagtttaagaaggacaggggagagggcctggcccgagtgctgtgtggggaggagcaggctgatgctgatgctggggcccaggtatgctccctgctccttgcccagtctgaggtgaggcctcagtgtctactgctggtcttggccaacagaacagaaatttccagcaaactccaacttatgaaaaagcaccaatctgacctgaaaaagctggggatcctagatttcactgagcaagatgttgcaagccaccagagctattcccaaaagaccctgattgcactggtcacctcgggagccctgctggctgtcttgggcatcactggctatttcctgatgaatcgccgcagctggagccccatttaa-GFP of donor construct for inserting into CD3ϵ locus SEQ ID NO: 3058ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA-hGMB poly A of donor construct for inserting GFP into CD3ϵ locusSEQ ID NO: 3059ACGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTTCTGATTTTGTAGGTAACCAC-CD3e R homology ARM of donor construct for inserting GFP into CD3ϵlocus SEQ ID NO: 3060aGTAtaatattgacatgccctcagtatcctggatctgaaatactatggcaacacaatgataaaaacataggcggtgatgaggatgataaaaacataggcagtgatgaggatcacctgtcactgaaggaattttcagaattggagcaaagtggttattatgtctgctaccccagaggaagcaaaccagaagatgcgaacttttatctctacctgagggcaagagtgtgtgagaactgcatggagatggatgtgatgtcggtggccacaattgtcatagtggacatctgcatcactgggggcttgctgctgctggtttactactggagcaagaatagaaaggccaaggccaagcctgtgacacgaggagcgggtgctggcggcaggcaaaggggacaaaacaaggagaggccaccacctgttcccaacccagactatgagcccatccggaaaggccagcgggacctgtattctggcctgaatcagagacgcatctgaccctctggagaacactgcctcccgctggcccaggtctcctctccagtccccctgcgactccctgtttcctgggctagtcttggaccccacgagagagaatcgttcctcagcctcatggtgaactcgcgccctccagcctgatcccccgctccctcctccctgccttctctgctggtacccagtcctaaaatattgctgcttcctcttcctttgaagcatcatcagtagtcacaccctcacagctggcctgccctcttgccaggatatttatttgtgctattcactcccttccctttggatgtaacttctccgttcagttccctccttttcttgcatgtaagttgtcccccatcccaaagtattccatctacttttctatcgccgtccccttttgcagccctctctggggatggactgggtaaatgttgacagaggccctgccccgttcacagatcctggccctgagccagccctgtgctcctccctcccccaacactccctaccaacc-cloning remnants of donor construct for inserting GFP into CD3ϵ locusSEQ ID NO: 3061 GCGgacCGAGCGGCCGC-right ITR of donor construct for inserting GFP into CD3ϵ locusSEQ ID NO: 3062AGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGG-cloning remnants of donor construct for inserting GFP into CDR locusSEQ ID NO: 3063CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTGCGGCCGCATCGATTGaattcAGGTAAGTCCACGAATCAGTGATTCAGTGGTGTGGAGAGCTTTATTTCTGAGAAGGCCAGTAGCGCTCCCTTCTGACAAGCAAATCTAAGACCTGGATGACAGATGACTTCCTGCATTTGGTTGGTTCTTTTGTCATTCATATCTATCTGTAATACAGTTCTGGCTAATTTAAGAGGATAAGCTTGAAGACCTCTGGAATTTTTCGGCTTTAGGACTTTAAGGCTTTCTGAGCTTCAGTAGATCTAGATCTAGGAGCTCATGCTGGTATATTCTGAATCCGATGTATCTGAGTTACATCTATGAGCTACTTAATAAATATATCTATGAGCTAAATCTCATAGGCTAAGCATGAACCTCACCTCCAAGACTCGGGGTTCCTAAATGGATGAGACCCTCTTTGGGAAGTCTTGTGGGCAGTGTCTAATTCCACTAGAAAAGTTTTACCTACAATTTAAACTTAAACCATGATATTTTCTTACTGCTGTTTCCTTTTTTCATTTTCAGGTGGTATTACACAGACACGTGAGTTTATTGGTCTTTTATTTATGCCCTGTCTGAGGATGCAGATTGGTGGGTAGATGAGAAGGAACTGATTGAGAGAGATTAACCCCAAGAACTGATATCTTCCCAGCATTGCATTCTCAACTCCATTTTAGAAAGGTTCCAAATAGGGACTTCTGTGGGTTTTTCTTTACATCCATCTTACCCTTCCCAAGTCCCCATGTCCCTGCGTAAACCCTAAAGCCACCTCTCAAAAGGTTCTCTAGTTCCCTTCAAGGTTCTCTAGTTCCCTTCATTCCACATATCTCCTCTTCCACACCCTCTAGCCAGTAGAGCTCCCTTCTGACAAGCAAGTCTAAGATCTAGATGACAGATGACTTCCTGCATTTGGGTGGTTCTTTTGTCACTAATTTGCCTTTTCTAAAATTGTCCTGGTTTCTTCTGCCAATTTCCCTTCTTTCTCCCCAGCATATAAAGTCTCCATCTCTGGAACCACAATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAACGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTTCTGATTTTGTAGGTAACCACaGTAtaatattgacatgccctcagtatcctggatctgaaatactatggcaacacaatgataaaaacataggcggtgatgaggatgataaaaacataggcagtgatgaggatcacctgtcactgaaggaattttcagaattggagcaaagtggttattatgtctgctaccccagaggaagcaaaccagaagatgcgaacttttatctctacctgagggcaagagtgtgtgagaactgcatggagatggatgtgatgtcggtggccacaattgtcatagtggacatctgcatcactgggggcttgctgctgctggtttactactggagcaagaatagaaaggccaaggccaagcctgtgacacgaggagcgggtgctggcggcaggcaaaggggacaaaacaaggagaggccaccacctgttcccaacccagactatgagcccatccggaaaggccagcgggacctgtattctggcctgaatcagagacgcatctgaccctctggagaacactgcctcccgctggcccaggtctcctctccagtccccctgcgactccctgtttcctgggctagtcttggaccccacgagagagaatcgttcctcagcctcatggtgaactcgcgccctccagcctgatcccccgctccctcctccctgccttctctgctggtacccagtcctaaaatattgctgcttcctcttcctttgaagcatcatcagtagtcacaccctcacagctggcctgccctcttgccaggatatttatttgtgctattcactcccttccattggatgtaacttctccgttcagttccctccttttcttgcatgtaagttgtcccccatcccaaagtattccatctacttttctatcgccgtccccttttgcagccctctctggggatggactgggtaaatgttgacagaggccctgccccgttcacagatcctggccctgagccagccctgtgctcctccctcccccaacactccctaccaaccGCGgacCGAGCGGCCGCAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGG-complete sequence of vector for insertion of GFP into CD3e locusSEQ ID NO: 3064CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTGCGGCCGCATCGATTGaattcAGGTAAGTCCACGAATCAGTGATTCAGTGGTGTGGAGAGCTTTATTTCTGAGAAGGCCAGTAGCGCTCCCTTCTGACAAGCAAATCTAAGACCTGGATGACAGATGACTTCCTGCATTTGGTTGGTTCTTTTGTCATTCATATCTATCTGTAATACAGTTCTGGCTAATTTAAGAGGATAAGCTTGAAGACCTCTGGAATTTTTCGGCTTTAGGACTTTAAGGCTTTCTGAGCTTCAGTAGATCTAGATCTAGGAGCTCATGCTGGTATATTCTGAATCCGATGTATCTGAGTTACATCTATGAGCTACTTAATAAATATATCTATGAGCTAAATCTCATAGGCTAAGCATGAACCTCACCTCCAAGACTCGGGGTTCCTAAATGGATGAGACCCTCTTTGGGAAGTCTTGTGGGCAGTGTCTAATTCCACTAGAAAAGTTTTACCTACAATTTAAACTTAAACCATGATATTTTCTTACTGCTGTTTCCTTTTTTCATTTTCAGGTGGTATTACACAGACACGTGAGTTTATTGGTCTTTTATTTATGCCCTGTCTGAGGATGCAGATTGGTGGGTAGATGAGAAGGAACTGATTGAGAGAGATTAACCCCAAGAACTGATATCTTCCCAGCATTGCATTCTCAACTCCATTTTAGAAAGGTTCCAAATAGGGACTTCTGTGGGTTTTTCTTTACATCCATCTTACCCTTCCCAAGTCCCCATGTCCCTGCGTAAACCCTAAAGCCACCTCTCAAAAGGTTCTCTAGTTCCCTTCAAGGTTCTCTAGTTCCCTTCATTCCACATATCTCCTCTTCCACACCCTCTAGCCAGTAGAGCTCCCTTCTGACAAGCAAGTCTAAGATCTAGATGACAGATGACTTCCTGCATTTGGGTGGTTCTTTTGTCACTAATTTGCCTTTTCTAAAATTGTCCTGGTTTCTTCTGCCAATTTCCCTTCTTTCTCCCCAGCATATAAAGTCTCCATCTCTGGAACCACAatggccttaccagtgaccgccttgctcctgccgctggccttgctgctccacgccgccaggccggatatccagatgacacagactacatcctccctgtctgcctctctgggagacagagtcaccatcagttgcagtgcaagtcagggcattagcaattatttaaactggtatcagcagaaaccagatggaactgttaaactcctgatctattacacatcaagtttacactcaggagtcccatcaaggttcagtggcagtgggtctgggacagattattctctcaccatcagcaacctggaacctgaagatattgccacttattattgtcagcagtatagcaagcttccgtacacgttcggaggggggaccaagctggaaataaaacgtggtggtggtggttctggtggtggtggttctggcggcggcggctccggtggtggtggatccgaggtgcaactggtggagtctgggggaggcttagtgaagcctggggggtccctgaaactctcctgtgcagcctctggactcactttcagtagctatgccatgtcttgggttcgccagactccagagaagaggctggagtgggtcgcatccattagtagtggtggtttcacctactatccagacagtgtgaagggccgattcaccatctccagagataatgccaggaacatcctgtatctgcaaatgagcagtctgaggtctgaggacacggccatgtattactgtgcaagagacgaggtacgggggtacctcgatgtctggggcgcagggaccacggtcaccgtttcccctaggGCTAGCaccacgacgccagcgccgcgaccaccaacaccggcgcccaccatcgcgtcgcagcccctgtccctgcgcccagaggcgtgccggccagcggcggggggcgcagtgcacacgagggggctggacttcgcctgtgatttttgggtgctggtggtggttggtggagtcctggcttgctatagcttgctagtaacagtggcctttattattttctgggtgaggagtaagaggagcaggctcctgcacagtgactacatgaacatgactccccgccgccccgggcccacccgcaagcattaccagccctatgccccaccacgcgacttcgcagcctatcgctccagagtgaagttcagcaggagcgcagacgcccccgcgtacaagcagggccagaaccagctctataacgagctcaatctaggacgaagagaggagtacgatgttttggacaagagacgtggccgggaccctgagatggggggaaagccgagaaggaagaaccctcaggaaggcctgtacaatgaactgcagaaagataagatggcggaggcctacagtgagattgggatgaaaggcgagcgccggaggggcaaggggcacgatggcctttaccagggtctcagtacagccaccaaggacacctacgacgcccttcacatgcaggccctgccccctcgcCGGACCGATggaagcggagctactaacttcagcctgctgaagcaggctggagacgtggaggagaaccctggacctgtttctgaagccatgccgcggggctggaccgcgctttgcttgctgagtttgctgccttctgggttcatgagtcttgacaacaacggtactgctaccccagagttacctacccagggaacattttcaaatgtttctacaaatgtatcctaccaagaaactacaacacctagtacccttggaagtaccagcctgcaccctgtgtctcaacatggcaatgaggccacaacaaacatcacagaaacgacagtcaaattcacatctacctctgtgataacctcagtttatggaaacacaaactcttctgtccagtcacagacctctgtaatcagcacagtgttcaccaccccagccaacgtttcaactccagagacaaccttgaagcctagcctgtcacctggaaatgtttcagacctttcaaccactagcactagccttgcaacatctcccactaaaccctatacatcatcttctcctatcctaagtgacatcaaggcagaaatcaaatgttcaggcatcagagaagtgaaattgactcagggcatctgcctggagcaaaataagacctccagctgtgcggagtttaagaaggacaggggagagggcctggcccgagtgctgtgtggggaggagcaggctgatgctgatgctggggcccaggtatgctccctgctccttgcccagtctgaggtgaggcctcagtgtctactgctggtcttggccaacagaacagaaatttccagcaaactccaacttatgaaaaagcaccaatctgacctgaaaaagctggggatcctagatttcactgagcaagatgttgcaagccaccagagctattcccaaaagaccctgattgcactggtcacctcgggagccctgctggctgtcttgggcatcactggctatttcctgatgaatcgccgcagctggagccccatttaaACGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTTCTGATTTTGTAGGTAACCACaGTAtaatattgacatgccctcagtatcctggatctgaaatactatggcaacacaatgataaaaacataggcggtgatgaggatgataaaaacataggcagtgatgaggatcacctgtcactgaaggaattttcagaattggagcaaagtggttattatgtctgctaccccagaggaagcaaaccagaagatgcgaacttttatctctacctgagggcaagagtgtgtgagaactgcatggagatggatgtgatgtcggtggccacaattgtcatagtggacatctgcatcactgggggcttgctgctgctggtttactactggagcaagaatagaaaggccaaggccaagcctgtgacacgaggagcgggtgctggcggcaggcaaaggggacaaaacaaggagaggccaccacctgttcccaacccagactatgagcccatccggaaaggccagcgggacctgtattctggcctgaatcagagacgcatctgaccctctggagaacactgcctcccgctggcccaggtctcctctccagtccccctgcgactccctgtttcctgggctagtcttggaccccacgagagagaatcgttcctcagcctcatggtgaactcgcgccctccagcctgatcccccgctccctcctccctgccttctctgctggtacccagtcctaaaatattgctgcttcctcttcctttgaagcatcatcagtagtcacaccctcacagctggcctgccctcttgccaggatatttatttgtgctattcactcccttccctttggatgtaacttctccgttcagttccctccttttcttgcatgtaagttgtcccccatcccaaagtattccatctacttttctatcgccgtccccttttgcagccctctctggggatggactgggtaaatgttgacagaggccctgccccgttcacagatcctggccctgagccagccctgtgctcctccctcccccaacactccctaccaaccGCGgacCGAGCGGCCGCAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGG

All references, patents or applications, U.S. or foreign, cited in theapplication are hereby incorporated by reference as if written herein intheir entireties. Where any inconsistencies arise, material literallydisclosed herein controls.

From the foregoing description, one skilled in the art can easilyascertain the essential characteristics of this invention, and withoutdeparting from the spirit and scope thereof, can make various changesand modifications of the invention to adapt it to various usages andconditions.

E 0.172 0.17 0.073 0.075 0.085 0.084 0.492 0.557 0.42 0.18 0.247 0.19450 [Test] 0.046 0.045 0.044 0.046 0.045 0.045 0.05 0.053 0.05 0.0480.048 0.047 540 [Ref] 0.698 0.691 0.161 0.161 0.222 0.216 2.46 2.7962.054 0.735 1.107 0.794 Pathlength 0.171 0.17 0.073 0.075 0.085 0.0840.496 0.558 0.42 0.181 0.249 0.19 450 0.046 0.046 0.045 0.047 0.0450.045 0.05 0.053 0.051 0.048 0.049 0.047 540 0.245 0.246 0.454 0.4680.383 0.389 0.202 0.2 0.204 0.246 0.225 0.239 Corrected [450] 0.0660.066 0.277 0.291 0.204 0.209 0.02 0.019 0.025 0.066 0.044 0.059Corrected [540] F 0.127 0.124 0.07 0.074 0.075 0.072 0.148 0.143 0.1280.102 0.115 0.121 450 [Test] 0.044 0.045 0.043 0.047 0.046 0.044 0.0550.057 0.045 0.045 0.051 0.048 540 [Ref] 0.458 0.436 0.147 0.15 0.1620.157 0.516 0.479 0.463 0.316 0.353 0.406 Pathlength 0.127 0.124 0.070.074 0.075 0.072 0.147 0.144 0.129 0.102 0.116 0.12 450 0.045 0.0450.044 0.047 0.046 0.044 0.055 0.057 0.045 0.045 0.052 0.048 540 0.2770.283 0.475 0.493 0.465 0.462 0.286 0.3 0.278 0.323 0.328 0.296Corrected [450] 0.097 0.104 0.297 0.314 0.285 0.283 0.106 0.119 0.0970.144 0.147 0.119 Corrected [540] G 0.098 0.1 0.078 0.073 0.104 0.1220.143 0.169 0.144 0.125 0.134 0.131 450 [Test] 0.044 0.044 0.046 0.0440.045 0.05 0.049 0.049 0.05 0.05 0.045 0.046 540 [Ref] 0.301 0.313 0.1790.161 0.326 0.398 0.523 0.667 0.523 0.415 0.493 0.469 Pathlength 0.0990.101 0.078 0.073 0.103 0.122 0.144 0.169 0.144 0.125 0.133 0.13 4500.044 0.044 0.046 0.044 0.045 0.05 0.05 0.049 0.05 0.05 0.045 0.045 5400.328 0.322 0.437 0.452 0.317 0.306 0.275 0.254 0.275 0.301 0.269 0.277Corrected [450] 0.148 0.142 0.259 0.272 0.138 0.127 0.095 0.074 0.0960.12 0.091 0.096 Corrected [540] H 0.082 0.087 0.113 0.12 0.074 0.0810.165 0.169 0.15 0.103 0.122 0.119 450 [Test] 0.047 0.051 0.049 0.0470.047 0.053 0.055 0.059 0.045 0.044 0.046 0.044 540 [Ref] 0.197 0.1970.356 0.406 0.15 0.157 0.611 0.607 0.579 0.329 0.422 0.412 Pathlength0.082 0.087 0.113 0.12 0.074 0.081 0.165 0.169 0.15 0.103 0.122 0.118450 0.047 0.052 0.049 0.047 0.047 0.053 0.055 0.06 0.046 0.044 0.0460.045 540 0.415 0.443 0.316 0.296 0.493 0.516 0.27 0.279 0.259 0.3140.289 0.288 Corrected [450] 0.236 0.263 0.137 0.117 0.311 0.338 0.090.098 0.079 0.134 0.11 0.109 Corrected [540]

1. A chimeric antigen receptor (CAR)-bearing immune effector cell thatis deficient in a cytokine or in a chemokine or in a transcriptionfactor that is involved in cytokine release syndrome.
 2. The cell asrecited in claim 1, wherein the cytokine or chemokine or transcriptionfactor deficiency is effected by deletion or suppression of a geneencoding the cytokine or chemokine or transcription factor, or bysuppression of a gene transcript of the cytokine or chemokine ortranscription factor gene.
 3. The cell as recited in claim 2, whereinthe deletion or suppression of the gene encoding the cytokine orchemokine or transcription factor is effected by inserting the CAR intoa locus of the cytokine or chemokine or transcription factor gene, orwherein the suppression of the gene transcript of the cytokine orchemokine or transcription factor is effected by transfection of one ormore types of small interfering RNAs (siRNA) or by transduction of oneor more types of short hairpin RNAs (shRNA).
 4. The cell as recited inclaim 3, wherein the CAR is part of a construct that also includes aselectable marker chosen from a green fluorescence (GFP) gene, a YFPgene, a tCD34 gene, or a tEGFR gene. 5.-6. (canceled)
 7. The cell asrecited in claim 1, wherein deletion or suppression is effected usingCRISPR, Cas9-CRISPR, Transcription Activator-like Effector Nucleases(TALENs), Zinc Finger Nucleases (ZFNs), or Clustered RegularlyInterspaced Short Palindromic Repeats (CRISPR).
 8. (canceled)
 9. Thecell as recited in claim 7, wherein the Cas9 is delivered into the cellas mRNA or protein, and/or wherein a guide RNA (gRNA) targeting the geneto be deleted or suppressed is delivered contemporaneously with theCas9. 10.-15. (canceled)
 16. The cell of claim 2, wherein: the cellexpresses at least one CAR that is inserted into a locus of the geneencoding the cytokine or chemokine or transcription factor; the geneencoding the cytokine or chemokine or transcription factor is deleted orsuppressed by a method chosen from Transcription Activator-like EffectorNucleases (TALENs), Zinc Finger Nucleases (ZFNs), and ClusteredRegularly Interspaces Short Palindromic Repeats (CRISPR) editing; thecytokine or chemokine or transcription factor is suppressed byexpression of an scFv with an endoplasmic reticulum (ER) binding tetherto bind the cytokine or chemokine in the ER and prevent secretion; thecytokine or chemokine or transcription factor gene transcript issuppressed by transfection of small interfering RNAs (siRNAs); thecytokine or chemokine or transcription factor gene transcript issuppressed by transduction of short hairpin RNAs (shRNAs); or the genethat is deleted or suppressed is a T cell surface receptor that isintegrated into CAR-T cell signaling.
 17. The cell as recited in claim1, wherein the cell is chosen from a chimeric antigen receptor T cell(CAR-T), a CAR-bearing iNKT cell (iNKT-CAR), and a CAR-bearing naturalkiller (NK) cell (NK-CAR), or a CAR-bearing macrophage.
 18. (canceled)19. The cell as recited in claim 17, wherein the cell is a dual ortandem CAR-T or iNKT-CAR or CAR-bearing macrophage. 20.-23. (canceled)24. The cell as recited in claim 1, wherein the cytokine or chemokine ortranscription factor contributes to the development of cytokine releasesyndrome and is selected from among those recited in Table
 10. 25.(canceled)
 26. The cell as recited in claim 24, wherein the cytokine orchemokine or transcription factor is produced by T cells that activateor localize myeloid cells, or is a T cell surface receptor gene thatactivates myeloid or CAR-T cells. 27.-28. (canceled)
 29. The cell asrecited in claim 1, wherein the cytokine or chemokine or transcriptionfactor drives T cell/CAR-T cell differentiation, or wherein the cytokineor chemokine is a transcription factor that drives T cell/CAT-T celldifferentiation.
 30. (canceled)
 31. The cell as recited in claim 1,wherein the cytokine or chemokine or transcription factor is chosen fromMCP1 (CCL2), MCP-2, GM-CSF, G-CSF, M-CSF, Il-4, and IFNγ.
 32. (canceled)33. The cell as recited in claim 31, wherein the cell is a GM-CSFdeficient CAR-T cell or a GM-CSF deficient iNKT-CAR cell. 34.-36.(canceled)
 37. The cell as recited in claim 1, wherein the chimericantigen receptor(s) specifically binds at least one antigen expressed ona malignant cell, a malignant T cell, a malignant B cell, a malignantmesothelial cell, or a malignant plasma cell.
 38. The cell as recited inclaim 37, wherein the at least one antigen expressed on a malignant cellis chosen from BCMA, CS1, CD38, CD138, CD19, CD33, CD123, CD371, CD117,CD135, Tim-3, CD5, CD7, CD2, CD4, CD3, CD79A, CD79B, APRIL, CD56, andCD1a; or wherein the at least one antigen expressed on a malignant Tcell is chosen from CD2, CD3ε, CD4, CD5, CD7, TCRA, and TCRβ; or whereinthe at least one antigen expressed on a malignant B cell is chosen fromCD19, CD20, CD21, CD22, CD23, CD24, CD25, CD27, CD38, and CD45; orwherein the at least one antigen expressed on a malignant mesothelialcell is mesothelin; or wherein the at least one antigen expressed on amalignant plasma cell is chosen from BCMA, CS1, CD38, and CD19. 39.-47.(canceled)
 48. The cell as recited in claim 37, wherein the chimericantigen receptor expresses the extracellular portion of the APRILprotein, the ligand for BCMA and TACI, effectively co-targeting bothBCMA and TACI.
 49. (canceled)
 50. The cell as recited in claim 1,wherein endogenous T cell receptor mediated signaling is negligible inthe cell.
 51. The cell as recited in claim 50, wherein the cell does notinduce alloreactivity, graft-versus-host disease, or fratricide. 52.(canceled)
 53. A method of treatment of cancer in a patient, which has areduced incidence of cytokine release syndrome and/or CAR-T associatedneuropathy, comprising the administration of cells as recited inclaim
 1. 54. The method as recited in claim 53, wherein the cancer is ahematologic malignancy chosen from a T-cell malignancy, multiplemyeloma, or acute myeloid leukemia (AML), or a solid tumor chosen fromcervical cancer, pancreatic cancer, ovarian cancer, mesothelioma, orlung cancer.
 55. (canceled)
 56. The method as recited in claim 54,wherein the T cell malignancy is T-cell acute lymphoblastic leukemia(T-ALL), or non-Hodgkin's lymphoma. 57.-61. (canceled)
 61. A method ofprevention or reduction of cytokine release syndrome or CAR-T associatedneuropathy in a patient being treated for cancer and receiving chimericantigen receptor T cell (CAR-T), CAR-bearing iNKT cell (iNKT-CAR),CAR-bearing natural killer (NK) cell (NK-CAR), or CAR-bearing macrophage(CAR-macrophage) immunotherapy, comprising the administration of cellsas recited in claim 1 as the immunotherapy.
 62. (canceled)
 63. Themethod as recited in claim 62, wherein the cancer is a hematologicmalignancy chosen from T-cell malignancy, multiple myeloma, or AML, or asolid tumor chosen from cervical cancer, pancreatic cancer, ovariancancer, mesothelioma, or lung cancer.
 64. (canceled)
 65. The method asrecited in claim 64, wherein the T cell malignancy is T-cell acutelymphoblastic leukemia (T-ALL) or non-Hodgkin's lymphoma. 66.-73.(canceled)
 74. A method of making a CAR-T (immune effector) cell thatdoes not cause or contribute to CRS or CAR-T-associated neuropathy (CAN)comprising deleting or suppressing a cytokine or chemokine ortranscription factor gene, wherein deleting or suppressing the cytokineor chemokine or transcription factor gene does not reduce CAR-Tcell-mediated killing.
 75. (canceled)
 76. The method as recited in claim74, wherein the deletion or suppression is effected by inserting the CARinto a locus of the cytokine or chemokine or transcription factor gene,by suppression of the cytokine or chemokine or transcription factor genetranscript by transduction of one or more types of short hairpin RNAs(shRNA), or by transducing a construct encoding a protein expressionblocker (PEBL).
 77. The method as recited in claim 74, wherein the CARis part of a construct that also includes a selectable marker chosenfrom a green fluorescence (GFP) gene, a YFP gene, a tCD34 gene, or atEGFR gene.
 78. (canceled)
 79. The method of claim 74, wherein theinsertion of a CAR with a selectable marker into the cytokine orchemokine or transcription factor gene allows a single-step purificationof TCR-negative cells or CAR+ cytokine negative cells.
 80. (canceled)81. The method as recited in claim 74, wherein the deletion orsuppression is effected using Transcription Activator-like EffectorNucleases (TALENs), Zinc Finger Nucleases (ZFNs), Clustered RegularlyInterspaced Short Palindromic Repeats (CRISPR), or Cas9-CRISPR. 82.-83.(canceled)
 84. The method as recited in claim 81, wherein the Cas9 isdelivered into the cell as mRNA or protein and/or wherein a guide RNA(gRNA) targeting the gene to be deleted or suppressed is deliveredcontemporaneously with the Cas9. 85.-90. (canceled)
 91. The method ofclaim 76, wherein the construct encodes an antibody-derived single-chainvariable fragment specific for the cytokine, chemokine or transcriptionfactor gene. 92.-94. (canceled)